

**CUMULATIVE
SUPPLEMENT 9
SEPTEMBER 2004**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

24th EDITION

**Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs**

2004

Prepared By
Office of Generic Drugs
Center for Drug Evaluation and Research
Food and Drug Administration

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

24th EDITION

Cumulative Supplement 9

September 2004

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION	iii
1.1 How to Use the Cumulative Supplement	iii
1.2 Applicant Name Changes.....	iv
1.3 Ribavirin 200mg Oral Capsule.....	v
1.4 Levothyroxine Sodium.....	v
1.5 Availability of the Edition.....	vi
1.6 Report of Counts for the Prescription Drug Product List	vii
1.7 Cumulative Supplement Change Legend	viii
 DRUG PRODUCT LISTS	
Prescription Drug Product List.....	1-1
OTC Drug Product List.....	2-1
Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List.....	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution	5-1
 PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms.....	B-1

Please Note:

The 24th Edition of the Orange Book will be the last paper version. All the components of the paper Orange Book are and have been available on the Internet since 1997. Refer to the Introduction 1.3, Availability of the Edition, for specific locations. Additional details will be made available in future Cumulative Supplement publications.

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

24th EDITION

CUMULATIVE SUPPLEMENT 9
September 2004

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 24th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research and products that have never been marketed, are for exportation, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 23rd Edition List will then be added to the "Discontinued Drug Product List" appearing in the 24th Edition. The current edition Section 2. How To Use The Drug Product Lists describes the layout and usage of the List.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section A, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity Data are indicated by the symbol >ADD> to the left of the line on which new information exists. The >ADD> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

1.2 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section

APPLICANT NAME CHANGES

FORMER APPLICANT NAME
(FORMER ABBREVIATED NAME)

NEW APPLICANT NAME
(NEW ABBREVIATED NAME)

BERLEX
(BERLEX)
BERLEX LABORATORIES INC
(BERLEX LABS)
BERLEX LABORATORIES INC SUB SCHERING AG
(BERLEX)
AMERSHAM HEALTH
(AMERSHAM)

BERLEX INC
(BERLEX INC)
BERLEX INC
(BERLEX INC)
BERLEX INC
(BERLEX INC)
GE HEALTHCARE
(GE HEALTHCARE)

PUREPAC PHARMACEUTICAL COMPANY DIVISION
OF PUREPAC INC
(PUREPAC PHARM)

PUREPAC INC
(PUREPAC PHARM)

1.3 RIBAVIRIN 200MG ORAL CAPSULE

The footnote for Ribavirin 200MG capsule product 001 was inadvertently omitted from the 24th Edition. The footnote: Indicated for use and comarketed with interferon alfa-2b, recombinant (Intron A), as Rebetron Combination Therapy.

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets.

Levo-T (Alara NDA 021342) and Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbott NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210) and Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King/Jones Pharma NDA 021301) tablets.

Novothyrox (Genpharm NDA 021292) requires further investigation and review to establish therapeutic equivalence to corresponding strengths of any other levothyroxine sodium drug products and is rated BX.

Thyro-Tabs (Lloyd NDA 021116) requires further investigation and review to establish therapeutic equivalence to corresponding strengths of any other levothyroxine sodium drug products and is rated BX.

Levolet (Vintage NDA 021137) requires further investigation and review to establish therapeutic equivalence to corresponding strengths of any other levothyroxine sodium drug products and is rated BX.

The chart outlines TE codes for all 0.025mg products with other products being similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Potency	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	76187	001
LEVOXYL	JONES PHARMA	0.025MG	AB1	21301	001
SYNTHROID	ABBOTT	0.025MG	AB2	21402	001

Trade Name	Applicant	Potency	TE Code	Appl No	Product No
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	76187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	21342	001
LEVOXYL	JONES PHARMA	0.025MG	AB3	21301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	21342	001
UNITHROID	STEVENS J	0.025MG	AB3	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	76187	001
NOVOTHYROX	GENPHARM	0.025MG	BX	21292	001
THYRO-TABS	LLOYD	0.025MG	BX	21116	001
LEVOLET	VINTAGE PHARMS	0.025MG	BX	21137	001

1.5 AVAILABILITY OF THE EDITION

The 24th Edition of the Orange Book and its monthly cumulative supplements are available by subscription from the Government Printing Office:

Superintendent of Documents
Government Printing Office
P.O. Box 371954
Pittsburgh, PA 15250-7954

The telephone number to charge your subscription is 202-512-1800 or toll free 866-512-1800. The cost is \$110.00 annually. A GPO Orange Book Subscription form is provided at the end of each cumulative supplement.

The Approved Drug Products with Therapeutic Equivalence Evaluation (Orange Book) and related drug information is also available on the Internet at the Food and Drug Administration, Center for Drug Evaluation and Research, Drug Info page.

The Electronic Orange Book Query (EOB) is at <http://www.fda.gov/cder/ob>. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder or applicant number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product. The data is updated concurrently with the publication of the monthly cumulative supplements.

The Internet version of the Orange Book annual edition is at <http://www.fda.gov/cder/orange/adp.htm>.

The Internet version of the monthly supplement is at <http://www.fda.gov/cder/orange/supplement/cspreface.htm>.

There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/cder/orange/obreadme.htm>. The drug product text files are zipped into zipobtxt.exe.

The files are updated concurrently with the publication of the monthly cumulative supplements. Appendix A and Appendix B text files of the paper annual Orange Book are updated quarterly.

The 24th annual edition of the 2003 Orange Book Patent and Exclusivity List is at <http://www.fda.gov/cder/orange/24bookpub.pdf>.

The current year Patent and Exclusivity cumulative supplement list that denotes the current month additions is at <http://www.fda.gov/cder/orange/supplement/patents.pdf>.

The Patent Term Extension and new Patents, Docket Number *95S-0117, is at <http://www.fda.gov/cder/orange/docket.pdf>. It is updated approximately weekly. Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from Program Support Center Forms Download Website, <http://forms/psc.gov/forms/FDA/fda.html>

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2003) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2003</u>	<u>MAR 2004</u>	<u>JUN 2004</u>	<u>SEP 2004</u>
DRUG PRODUCTS LISTED	10665	10668	10702	10822
SINGLE SOURCE	2423 (22.7%)	2404 (22.5%)	2385 (22.3%)	2385 (22.0%)
MULTISOURCE	8134 (76.3%)	8156 (76.5%)	8209 (76.7%)	8329 (77.0%)
THERAPEUTICALLY EQUIVALENT	7856 (73.7%)	7885 (73.9%)	7995 (74.7%)	8116 (75.0%)
NOT THERAPEUTICALLY EQUIVALENT	278 (2.6%)	271 (2.5%)	214 (2.0%)	213 (2.0%)
EXCEPTIONS ¹	108 (1.0%)	108 (1.0%)	108 (1.0%)	108 (1.0%)
NEW MOLECULAR ENTITIES APPROVED	6	3	1	1
NUMBER OF APPLICANTS	601	586	602	605

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Approval number, product number, and approval date. The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.

CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.
WDAG	Withdrawn. The applicant holder has notified the FDA in writing that the product is no longer being marketed resulting in the product approval being withdrawn by mutual agreement. The product will be listed in the Discontinued Section.
WDRP	Withdrawn. The application approval has been withdrawn for failure to provide Annual Reports. The product will be moved to the Discontinued Section in the next edition.

PRESCRIPTION DRUG PRODUCT LIST - 24TH EDITION

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2004

i-1

ABACAVIR SULFATE; LAMIVUDINE

TABLET; ORAL

EPZICOM

+ SMITHKLINE BEECHAM EQ 600MG BASE;300MG N21652 001 Aug 02, 2004 Aug NEWA

ACAMPROSATE CALCIUM

TABLET, DELAYED RELEASE; ORAL

CAMPRAL

>A> + FOREST LABS 333MG N21431 001 Jul 29, 2004 Sep CAHN

>D> + LIPHA 333MG N21431 001 Jul 29, 2004 Sep CAHN

+ 333MG N21431 001 Jul 29, 2004 Jul NEWA

ACETAMINOPHEN; BUTALBITAL

CAPSULE; ORAL

PHRENILIN FORTE

AB + VALEANT 650MG;50MG N88831 001 Jun 19, 1985 Aug CAHN

TABLET; ORAL

PHRENILIN

AB + VALEANT 325MG;50MG N87811 001 Jun 19, 1985 Aug CAHN

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE

AB ANABOLIC LABS 325MG;50MG;40MG;30MG N76560 001 Jun 10, 2004 Jun NEWA

PHRENILIN WITH CAFFEINE AND CODEINE

AB VALEANT 325MG;50MG;40MG;30MG N74911 001 Aug 22, 2001 Aug CAHN

ACETAMINOPHEN; CODEINE PHOSPHATE

SUSPENSION; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

AA + AMARIN PHARMS 120MG/5ML;12MG/5ML N86024 001 Apr CRLD

AA + VALEANT 120MG/5ML;12MG/5ML N86024 001 Aug CAHN

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

@ MUTUAL PHARM 300MG;15MG N85795 001 Aug CAHN

@ 300MG;30MG N85794 001 Aug CAHN

@ 300MG;60MG N89673 001 Feb 10, 1988 Aug DISC

ACETAMINOPHEN W/ CODEINE

@ MUTUAL PHARM 300MG;60MG N87653 001 Apr 13, 1982 Aug CAHN

ACETAMINOPHEN; HYDROCODONE BITARTRATE

CAPSULE; ORAL

ACETAMINOPHEN AND HYDROCODONE BITARTRATE

@ CENT PHARMS 500MG;5MG N88898 001 Mar 27, 1985 Aug DISC

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

+ MIKART 300MG;10MG N40556 001 Jun 23, 2004 Jun NEWA

AA MUTUAL PHARM 500MG;5MG N40236 001 Sep 25, 1997 Aug CAHN

AA 650MG;7.5MG N40240 002 Nov 26, 1997 Aug CAHN

AA 650MG;10MG N40240 001 Nov 26, 1997 Aug CAHN

AA 750MG;7.5MG N40236 002 Sep 25, 1997 Aug CAHN

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL

OXYCODONE AND ACETAMINOPHEN

AA	MUTUAL PHARM	500MG;5MG	N40219 001	Jan 22, 1998	Aug	CAHN
----	--------------	-----------	------------	--------------	-----	------

TABLET; ORAL

OXYCODONE AND ACETAMINOPHEN

AA	MALLINCKRODT	325MG;7.5MG	N40545 001	Jun 30, 2004	Jun	NEWA
AA		325MG;10MG	N40545 002	Jun 30, 2004	Jun	NEWA
AA		500MG;7.5MG	N40550 001	Jun 30, 2004	Jun	NEWA
AA		650MG;10MG	N40550 002	Jun 30, 2004	Jun	NEWA

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL

DARVOCET A500

AB	AAIPHARMA	500MG;100MG	N76429 001	Sep 10, 2003	May	CRLD
		500MG;100MG	N76429 001	Sep 10, 2003	Jun	CFTG

PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN

	@ MUTUAL PHARM	325MG;50MG	N70115 001	Jun 12, 1985	Aug	CAHN
	@	650MG;100MG	N70116 001	Jun 12, 1985	Aug	CAHN
AB		650MG;100MG	N70615 001	Mar 21, 1986	Aug	CAHN
AB		650MG;100MG	N70771 001	Mar 21, 1986	Aug	CAHN
AB		650MG;100MG	N70775 001	Mar 21, 1986	Aug	CAHN
AB	VINTAGE PHARMS	325MG;100MG	N76743 001	May 07, 2004	May	NEWA
AB		500MG;100MG	N76750 001	Jun 28, 2004	Jun	NEWA

ACETAZOLAMIDE SODIUM

INJECTABLE; INJECTION

ACETAZOLAMIDE SODIUM

AP	HOSPIRA	EQ 500MG BASE/VIAL	N40108 001	Oct 30, 1995	May	CAHN
----	---------	--------------------	------------	--------------	-----	------

ACETIC ACID, GLACIAL

SOLUTION; IRRIGATION, URETHRAL

ACETIC ACID 0.25% IN PLASTIC CONTAINER

AT	HOSPIRA	250MG/100ML	N17656 001		May	CAHN
----	---------	-------------	------------	--	-----	------

ACETYLCYSTEINE

INJECTABLE; INTRAVENOUS

ACETADOTE

	+ CUMBERLAND PHARMS	6GM /30ML(200MG/ML)	N21539 001	Jan 23, 2004	Jan	NEWA
--	---------------------	---------------------	------------	--------------	-----	------

SOLUTION; INHALATION, ORAL

ACETYLCYSTEINE

AN	HOSPIRA	10%	N73664 001	Aug 30, 1994	May	CAHN
AN		20%	N74037 001	Aug 30, 1994	May	CAHN

ACITRETIN

CAPSULE; ORAL

SORIATANE

	CONNETICS	10MG	N19821 001	Oct 28, 1996	Mar	CAHN
	+	25MG	N19821 002	Oct 28, 1996	Mar	CAHN

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

ACYCLOVIR SODIUM

AP	HOSPIRA	EQ 500MG BASE/VIAL	N74663 001	Apr 22, 1997	May	CAHN
AP		EQ 500MG BASE/VIAL	N74758 001	Apr 22, 1997	May	CAHN

INJECTABLE; INJECTION

	ACYCLOVIR SODIUM								
AP	HOSPIRA	EQ 1GM BASE/VIAL	N74663	002	Apr 22, 1997	May	CAHN		
AP		EQ 1GM BASE/VIAL	N74758	002	Apr 22, 1997	May	CAHN		
AP	MAYNE PHARMA USA	EQ 50MG BASE/ML	N75065	001	Feb 25, 1999	Apr	CAHN		

ADENOSINE

INJECTABLE; INJECTION

	ADENOCARD								
AP	+ FUJISAWA HLTHCARE	3MG/ML	N19937	002	Oct 30, 1989	Jun	CFTG		
	ADENOSINE								
AP	BAXTER HLTHCARE	3MG/ML	N76500	001	Jun 16, 2004	Jun	NEWA		
AP		3MG/ML	N76501	001	Jun 16, 2004	Jun	NEWA		
AP	BEDFORD	3MG/ML	N76404	001	Jun 16, 2004	Jun	NEWA		
AP	SICOR PHARMS	3MG/ML	N76564	001	Jun 16, 2004	Jun	NEWA		

ALATROFLOXACIN MESYLATE

INJECTABLE; INJECTION

TROVAN PRESERVATIVE FREE

	@ PFIZER	EQ 200MG BASE/VIAL	N20760	001	Dec 18, 1997	Jun	DISC		
	@	EQ 300MG BASE/VIAL	N20760	002	Dec 18, 1997	Jun	DISC		

ALBUMIN IODINATED I-125 SERUM

INJECTABLE; INJECTION

JEANATOPE

	ISO TEX	100UCI/10ML(100CI/ML)	N17836	003	Jun 08, 2004	Jun	NEWA		
		500uCi/0.5ML	N17836	001		Jun	CMFD		
+		1,000uCi/ML	N17836	002		Jun	CMFD		
	RADIOIODINATED SERUM ALBUMIN (HUMAN) IHSA I 125								
	@ MALLINCKRODT	10uCi/ML	N17844	001		Jun	DISC		

ALBUTEROL SULFATE

SOLUTION; INHALATION

ACCUNEB

AN	+ DEY	EQ 0.042% BASE	N20949	001	Apr 30, 2001	Jun	CFTG		
	ALBUTEROL SULFATE								
AN	+ BAUSCH AND LOMB	EQ 0.083% BASE	N75358	001	Mar 29, 2000	Jun	CRLD		
AN	+	EQ 0.5% BASE	N75050	001	Jun 18, 1998	Jun	CRLD		
AN	NEPHRON	EQ 0.042% BASE	N76355	001	Jun 28, 2004	Jun	NEWA		
	PROVENTIL								
	@ SCHERING	EQ 0.083% BASE	N19243	002	Jan 14, 1987	Jun	DISC		
	@	EQ 0.5% BASE	N19243	001	Jan 14, 1987	Jun	DISC		

SYRUP; ORAL

ALBUTEROL SULFATE

>D>	AA	TEVA	EQ 2MG BASE/5ML	N73419	001	Mar 30, 1992	Sep	CRLD	
>A>	AA	+	EQ 2MG BASE/5ML	N73419	001	Mar 30, 1992	Sep	CRLD	

TABLET, EXTENDED RELEASE; ORAL

ALBUTEROL SULFATE

+	PLIVA	EQ 4MG BASE	N76130	002	Sep 26, 2002	Jan	CRLD		
+		EQ 8MG BASE	N76130	003	Sep 26, 2002	Jan	CRLD		
	VOLMAX								
	@ MURO	EQ 4MG BASE	N19604	002	Dec 23, 1992	Jan	DISC		
	@	EQ 8MG BASE	N19604	001	Dec 23, 1992	Jan	DISC		

ALCLOMETASONE DIPROPIONATE

OINTMENT; TOPICAL

ACLOVATE

AB	+	GLAXOSMITHKLINE	0.05%	N18702 001	Dec 14, 1982	Jul	CFTG
		ALCLOMETASONE DIPROPIONATE					
AB		TARO	0.05%	N76730 001	Jul 29, 2004	Jul	NEWA

ALCOHOL; DEXTROSE

INJECTABLE; INJECTION

ALCOHOL 5% IN D5-W

AP		HOSPIRA	5ML/100ML;5GM/100ML	N83263 001		May	CAHN
----	--	---------	---------------------	------------	--	-----	------

ALFENTANIL HYDROCHLORIDE

INJECTABLE; INJECTION

ALFENTANIL

AP		HOSPIRA	EQ 0.5MG BASE/ML	N75221 001	Oct 28, 1999	May	CAHN
----	--	---------	------------------	------------	--------------	-----	------

ALLOPURINOL

TABLET; ORAL

ALLOPURINOL

@ MUTUAL PHARM

@

			100MG	N70466 001	Dec 24, 1985	Aug	CAHN
			300MG	N70467 001	Dec 24, 1985	Aug	CAHN

ALLOPURINOL SODIUM

INJECTABLE; INJECTION

ALLOPURINOL SODIUM

AP		BEDFORD LABS	EQ 500MG BASE/VIAL	N76870 001	Aug 26, 2004	Aug	NEWA
		ALOPRIM					
	+	NABI	EQ 500MG BASE/VIAL	N20298 001	May 17, 1996	Jun	CAHN
AP	+		EQ 500MG BASE/VIAL	N20298 001	May 17, 1996	Aug	CFTG

ALMOTRIPTAN MALATE

TABLET; ORAL

AXERT

ORTHO MCNEIL PHARM

+

			EQ 6.25MG BASE	N21001 001	May 07, 2001	Jul	CAHN
			EQ 12.5MG BASE	N21001 002	May 07, 2001	Jul	CAHN

AMANTADINE HYDROCHLORIDE

SYRUP; ORAL

AMANTADINE HCL

SILARX

>A>	AA		50MG/5ML	N76352 001	Sep 10, 2004	Sep	NEWA
-----	----	--	----------	------------	--------------	-----	------

AMIKACIN SULFATE

INJECTABLE; INJECTION

AMIKACIN SULFATE

@ BAXTER HLTHCARE

@

			EQ 50MG BASE/ML	N63274 001	May 18, 1992	Aug	CAHN
			EQ 250MG BASE/ML	N63275 001	May 18, 1992	Aug	CAHN
AP		HOSPIRA	EQ 50MG BASE/ML	N63263 001	Nov 30, 1994	May	CAHN
			EQ 62.5MG BASE/ML	N63283 001	Oct 31, 1994	May	CAHN
AP			EQ 250MG BASE/ML	N63264 001	Nov 30, 1994	May	CAHN
AP			EQ 250MG BASE/ML	N64098 001	Jun 26, 1995	May	CAHN
		@	EQ 250MG BASE/ML	N64099 001	Jun 20, 1995	May	CAHN
		AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
		HOSPIRA	EQ 500MG BASE/100ML	N64146 001	Apr 02, 1997	May	CAHN

AMINO ACIDS

INJECTABLE; INJECTION

AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE

HOSPIRA	5.2% (5.2GM/100ML)	N18901 001	Apr 06, 1984	Aug	CAHN
AMINOSYN 10%					
HOSPIRA	10% (10GM/100ML)	N17673 003		May	CAHN
AMINOSYN 10% (PH6)					
HOSPIRA	10% (10GM/100ML)	N17673 008	Nov 18, 1985	May	CAHN
AMINOSYN 3.5%					
HOSPIRA	3.5% (3.5GM/100ML)	N17789 004		May	CAHN
AMINOSYN 5%					
HOSPIRA	5% (5GM/100ML)	N17673 001		May	CAHN
AMINOSYN 7%					
@ HOSPIRA	7% (7GM/100ML)	N17673 002		May	CAHN
AMINOSYN 7% (PH6)					
HOSPIRA	7% (7GM/100ML)	N17673 006	Nov 18, 1985	May	CAHN
AMINOSYN 8.5%					
@ HOSPIRA	8.5% (8.5GM/100ML)	N17673 004		May	CAHN
AMINOSYN 8.5% (PH6)					
HOSPIRA	8.5% (8.5GM/100ML)	N17673 007	Nov 18, 1985	May	CAHN
AMINOSYN II 10%					
HOSPIRA	10% (10GM/100ML)	N19438 005	Apr 03, 1986	May	CAHN
AMINOSYN II 10% IN PLASTIC CONTAINER					
HOSPIRA	10% (10GM/100ML)	N20015 001	Dec 19, 1991	May	CAHN
AMINOSYN II 15% IN PLASTIC CONTAINER					
HOSPIRA	15% (15GM/100ML)	N20041 001	Dec 19, 1991	May	CAHN
AMINOSYN II 3.5%					
@ HOSPIRA	3.5% (3.5GM/100ML)	N19438 001	Apr 03, 1986	May	CAHN
AMINOSYN II 5%					
@ HOSPIRA	5% (5GM/100ML)	N19438 002	Apr 03, 1986	May	CAHN
AMINOSYN II 7%					
HOSPIRA	7% (7GM/100ML)	N19438 003	Apr 03, 1986	May	CAHN
AMINOSYN II 8.5%					
HOSPIRA	8.5% (8.5GM/100ML)	N19438 004	Apr 03, 1986	May	CAHN
AMINOSYN-HBC 7%					
HOSPIRA	7% (7GM/100ML)	N19374 001	Jul 12, 1985	May	CAHN
AMINOSYN-HF 8%					
HOSPIRA	8% (8GM/100ML)	N20345 001	Apr 04, 1996	May	CAHN
AMINOSYN-PF 10%					
HOSPIRA	10% (10GM/100ML)	N19492 002	Oct 17, 1986	May	CAHN
AMINOSYN-PF 7%					
HOSPIRA	7% (7GM/100ML)	N19398 001	Sep 06, 1985	May	CAHN
AMINOSYN-RE 5.2%					
HOSPIRA	5.2% (5.2GM/100ML)	N18429 001		May	CAHN
NEOPHAM 6.4%					
@ HOSPIRA	6.4% (6.4GM/100ML)	N18792 001	Jan 17, 1984	Aug	CAHN
NOVAMINE 11.4%					
HOSPIRA	11.4% (11.4GM/100ML)	N17957 003	Aug 09, 1982	Aug	CAHN
NOVAMINE 15%					
HOSPIRA	15% (15GM/100ML)	N17957 004	Nov 28, 1986	Aug	CAHN
NOVAMINE 8.5%					
@ HOSPIRA	8.5% (8.5GM/100ML)	N17957 002	Aug 09, 1982	Aug	CAHN

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER

HOSPIRA	3.5%;36.8MG/100ML;25GM/100ML;51MG /100ML;22.4MG/100ML;261MG/100ML;2 05MG/100ML	N19683 001	Nov 07, 1988	May	CAHN
---------	--	------------	--------------	-----	------

AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER

HOSPIRA	4.25%;36.8MG/100ML;20GM/100ML;51M G/100ML;22.4MG/100ML;261MG/100ML; 205MG/100ML	N19683 002	Nov 07, 1988	May	CAHN
---------	---	------------	--------------	-----	------

AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER

HOSPIRA	4.25%;36.8MG/100ML;25GM/100ML;51M G/100ML;22.4MG/100ML;261MG/100ML; 205MG/100ML	N19683 003	Nov 07, 1988	May	CAHN
---------	---	------------	--------------	-----	------

AMINOSYN II 5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER

@ HOSPIRA	5%;36.8MG/100ML;25GM/100ML;51MG/1 00ML;22.4MG/100ML;261MG/100ML;205 MG/100ML	N19683 004	Nov 07, 1988	May	CAHN
-----------	--	------------	--------------	-----	------

AMINO ACIDS; DEXTROSE

INJECTABLE; INJECTION

AMINOSYN II 3.5% IN DEXTROSE 25% IN PLASTIC CONTAINER

HOSPIRA	3.5%;25GM/100ML	N19681 001	Nov 01, 1988	May	CAHN
---------	-----------------	------------	--------------	-----	------

AMINOSYN II 3.5% IN DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA	3.5%;5GM/100ML	N19681 002	Nov 01, 1988	May	CAHN
---------	----------------	------------	--------------	-----	------

AMINOSYN II 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER

HOSPIRA	4.25%;10GM/100ML	N19681 004	Nov 01, 1988	May	CAHN
---------	------------------	------------	--------------	-----	------

AMINOSYN II 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER

HOSPIRA	4.25%;20GM/100ML	N19681 005	Nov 01, 1988	May	CAHN
---------	------------------	------------	--------------	-----	------

AMINOSYN II 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER

HOSPIRA	4.25%;25GM/100ML	N19681 003	Nov 01, 1988	May	CAHN
---------	------------------	------------	--------------	-----	------

AMINOSYN II 5% IN DEXTROSE 25% IN PLASTIC CONTAINER

HOSPIRA	5%;25GM/100ML	N19681 006	Nov 01, 1988	May	CAHN
---------	---------------	------------	--------------	-----	------

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM ACETATE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN II 4.25% W/ ELECT AND ADJUSTED PHOSPHATE IN DEXTROSE 10% IN PLASTIC CONTAINER

@ HOSPIRA	4.25%;10GM/100ML;51MG/100ML;176.5 MG/100ML;22.4MG/100ML;104.5MG/100 ML;205MG/100ML	N19682 003	Nov 01, 1988	May	CAHN
-----------	--	------------	--------------	-----	------

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INJECTION

AMINOSYN II 3.5% M IN DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA	3.5%;5GM/100ML;30MG/100ML;97MG/10 0ML;120MG/100ML;49.3MG/100ML	N19682 001	Nov 01, 1988	May	CAHN
---------	---	------------	--------------	-----	------

AMINOSYN II 4.25% M IN DEXTROSE 10% IN PLASTIC CONTAINER

HOSPIRA	4.25%;5GM/100ML;30MG/100ML;97MG/1 00ML;120MG/100ML;49.3MG/100ML	N19682 002	Nov 01, 1988	May	CAHN
---------	--	------------	--------------	-----	------

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN 3.5% M

HOSPIRA	3.5%;21MG/100ML;40MG/100ML;128MG/ 100ML;234MG/100ML	N17789 003		May	CAHN
---------	--	------------	--	-----	------

AMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN 3.5% M

@ HOSPIRA	3.5%;21MG/100ML;128MG/100ML;234MG/100ML	N17789 005	May	CAHN
-----------	---	------------	-----	------

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATE

INJECTABLE; INJECTION

VEINAMINE 8%

@ HOSPIRA	8%;61MG/100ML;211MG/100ML;56MG/100ML;388MG/100ML	N17957 001	Aug	CAHN
-----------	--	------------	-----	------

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN II 10% W/ ELECTROLYTES

HOSPIRA	10%;102MG/100ML;45MG/100ML;522MG/100ML;410MG/100ML	N19437 004	Apr 03, 1986	May	CAHN
---------	--	------------	--------------	-----	------

AMINOSYN II 7% W/ ELECTROLYTES

@ HOSPIRA	7%;102MG/100ML;45MG/100ML;522MG/100ML;410MG/100ML	N19437 006	Apr 03, 1986	May	CAHN
-----------	---	------------	--------------	-----	------

AMINOSYN II 8.5% W/ ELECTROLYTES

HOSPIRA	8.5%;102MG/100ML;45MG/100ML;522MG/100ML;410MG/100ML	N19437 005	Apr 03, 1986	May	CAHN
---------	---	------------	--------------	-----	------

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INJECTION

AMINOSYN II 3.5% M

@ HOSPIRA	3.5%;30MG/100ML;97MG/100ML;120MG/100ML;49MG/100ML	N19437 007	Apr 03, 1986	May	CAHN
-----------	---	------------	--------------	-----	------

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN 7% W/ ELECTROLYTES

HOSPIRA	7%;102MG/100ML;522MG/100ML;410MG/100ML	N17789 002	May	CAHN
---------	--	------------	-----	------

AMINOSYN 8.5% W/ ELECTROLYTES

HOSPIRA	8.5%;102MG/100ML;522MG/100ML;410MG/100ML	N17673 005	May	CAHN
---------	--	------------	-----	------

AMINOCAPROIC ACID

INJECTABLE; INJECTION

AMINOCAPROIC ACID

AP	HOSPIRA	250MG/ML	N70888 001	Jun 16, 1988	May	CAHN
----	---------	----------	------------	--------------	-----	------

AMINOCAPROIC ACID IN PLASTIC CONTAINER

AP	HOSPIRA	250MG/ML	N70010 001	Mar 09, 1987	May	CAHN
----	---------	----------	------------	--------------	-----	------

AMINOPHYLLINE

INJECTABLE; INJECTION

AMINOPHYLLINE

AP	HOSPIRA	25MG/ML	N87242 001	Oct 26, 1983	May	CAHN
----	---------	---------	------------	--------------	-----	------

AP	+	25MG/ML	N87601 001	Jul 23, 1982	May	CAHN
----	---	---------	------------	--------------	-----	------

AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%

+	HOSPIRA	100MG/100ML	N88147 002	May 03, 1983	May	CAHN
---	---------	-------------	------------	--------------	-----	------

+		200MG/100ML	N88147 003	May 03, 1983	May	CAHN
---	--	-------------	------------	--------------	-----	------

AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

@	HOSPIRA	100MG/100ML	N18924 001	Dec 12, 1984	May	CAHN
---	---------	-------------	------------	--------------	-----	------

@		200MG/100ML	N18924 002	Dec 12, 1984	May	CAHN
---	--	-------------	------------	--------------	-----	------

@		400MG/100ML	N18924 003	Dec 12, 1984	May	CAHN
---	--	-------------	------------	--------------	-----	------

INJECTABLE; INJECTION

AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

@ HOSPIRA 500MG/100ML N18924 004 Dec 12, 1984 May CAHN

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION

AMIODARONE HCL

AF HOSPIRA 50MG/ML N75955 001 Oct 18, 2002 May CAHN

AMIODARONE HYDROCHLORIDE

AF INTL MEDICATION SYS 50MG/ML N21594 001 Feb 04, 2004 Feb NEWA

TABLET; ORAL

AMIODARONE HCL

@ TARO 400MG N76362 001 Nov 29, 2002 Jul DISC

AMITRIPTYLINE HYDROCHLORIDE

>D> INJECTABLE; INJECTION

>D> ELAVIL

>D> + ASTRAZENECA 10MG/ML N12704 001 Sep DISC

>A> @ 10MG/ML N12704 001 Sep DISC

TABLET; ORAL

AMITRIPTYLINE HCL

@ MUTUAL PHARM 10MG N85744 001 Aug CAHN

@ 25MG N85627 001 Aug CAHN

@ 50MG N85745 001 Aug CAHN

@ 75MG N85743 001 Aug CAHN

@ 100MG N85742 002 May 11, 1982 Aug CAHN

@ 150MG N89423 001 Feb 17, 1987 Aug CAHN

ELAVIL

@ ASTRAZENECA 10MG N12703 001 Jul DISC

@ 25MG N12703 003 Jul DISC

@ 50MG N12703 004 Jul DISC

@ 75MG N12703 005 Jul DISC

@ 100MG N12703 006 Jul DISC

@ 150MG N12703 007 Jul DISC

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET; ORAL

CHLORDIAZEPOXIDE AND AMITRIPTYLINE HCL

@ MUTUAL PHARM EQ 12.5MG BASE;5MG N70765 001 Dec 10, 1986 Aug CAHN

@ EQ 25MG BASE;10MG N70766 001 Dec 10, 1986 Aug CAHN

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL

PERPHENAZINE AND AMITRIPTYLINE HCL

@ MUTUAL PHARM 10MG;2MG N71077 001 Nov 12, 1986 Aug CAHN

@ 10MG;4MG N71078 001 Nov 12, 1986 Aug CAHN

@ 25MG;2MG N70297 001 Nov 12, 1986 Aug CAHN

@ 25MG;4MG N71079 001 Nov 12, 1986 Aug CAHN

AMLEXANOX

>A> PATCH; TOPICAL

>A> AMLEXANOX

>A> + ACCESS PHARMS 2MG N21727 001 Sep 29, 2004 Sep NEWA

AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM

TABLET; ORAL

CADUET

PFIZER

EQ 2.5MG BASE;EQ 10MG BASE	N21540 009	Jul 29, 2004	Aug	NEWA
EQ 2.5MG BASE;EQ 20MG BASE	N21540 010	Jul 29, 2004	Aug	NEWA
EQ 2.5MG BASE;EQ 40MG BASE	N21540 011	Jul 29, 2004	Aug	NEWA
EQ 5MG BASE;EQ 10MG BASE	N21540 001	Jan 30, 2004	Jan	NEWA
EQ 5MG BASE;EQ 20MG BASE	N21540 002	Jan 30, 2004	Jan	NEWA
EQ 5MG BASE;EQ 40MG BASE	N21540 003	Jan 30, 2004	Jan	NEWA
EQ 5MG BASE;EQ 80MG BASE	N21540 004	Jan 30, 2004	Jan	NEWA
EQ 10MG BASE;EQ 10MG BASE	N21540 005	Jan 30, 2004	Jan	NEWA
EQ 10MG BASE;EQ 20MG BASE	N21540 006	Jan 30, 2004	Jan	NEWA
EQ 10MG BASE;EQ 40MG BASE	N21540 007	Jan 30, 2004	Jan	NEWA
EQ 10MG BASE;EQ 80MG BASE	N21540 008	Jan 30, 2004	Jan	NEWA

+

AMLODIPINE MALEATE

TABLET; ORAL

AMVAZ

@ DR REDDYS LABS INC

2.5MG

N21435 001 Oct 31, 2003 Mar DISC

@

5MG

N21435 002 Oct 31, 2003 Mar DISC

@

10MG

N21435 003 Oct 31, 2003 Mar DISC

AMMONIUM CHLORIDE

INJECTABLE; INJECTION

AMMONIUM CHLORIDE IN PLASTIC CONTAINER

+ HOSPIRA

5MEQ/ML

N88366 001 Jun 13, 1984 May CAHN

AMMONIUM LACTATE

LOTION; TOPICAL

AMMONIUM LACTATE

AB

CLAY PARK

EQ 12% BASE

N75570 001 Jun 23, 2004 Jun NEWA

AB

TARO

EQ 12% BASE

N76216 001 May 28, 2004 May NEWA

AMOXICILLIN

TABLET, CHEWABLE; ORAL

AMOXIL

@ GLAXOSMITHKLINE

125MG

N50542 002

Aug DISC

@

250MG

N50542 001

Aug DISC

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB

TEVA

200MG/5ML;EQ 28.5MG BASE/5ML

N65089 001 May 25, 2004 May NEWA

AB

400MG/5ML;EQ 57MG BASE/5ML

N65089 002 May 25, 2004 May NEWA

AB

600MG/5ML;EQ 42.9MG BASE/5ML

N65162 001 Mar 12, 2004 Mar NEWA

AUGMENTIN ES-600

AB

+ GLAXOSMITHKLINE

600MG/5ML;EQ 42.9MG BASE/5ML

N50755 001 Jun 22, 2001 Mar CFTG

TABLET, EXTENDED RELEASE; ORAL

AUGMENTIN XR

>D>

+ GLAXOSMITHKLINE

1GM;62.5MG

N50785 001 Sep 25, 2002 Sep CPOT

>A>

+

1GM;EQ 62.5MG BASE

N50785 001 Sep 25, 2002 Sep CPOT

AMPICILLIN SODIUM

INJECTABLE; INJECTION

AMPICILLIN SODIUM

AP	IBI	EQ 2GM BASE/VIAL	N62797 002	Jul 12, 1993	Aug	CMFD
AP	+ SANDOZ	EQ 125MG BASE/VIAL	N61395 001		Jun	CAHN
AP	+	EQ 250MG BASE/VIAL	N61395 002		Jun	CAHN
AP	+	EQ 500MG BASE/VIAL	N61395 003		Jun	CAHN
AP	+	EQ 1GM BASE/VIAL	N61395 004		Jun	CAHN
AP	+	EQ 2GM BASE/VIAL	N61395 005		Jun	CAHN
AP	+	EQ 10GM BASE/VIAL	N61395 006		Jun	CAHN

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE; INJECTION

AMPICILLIN AND SULBACTAM

AP	BAXTER HLTHCARE	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	N65074 001	Mar 19, 2002	Aug	CAHN
AP		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	N65074 002	Mar 19, 2002	Aug	CAHN
AP		EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL	N65076 001	Mar 19, 2002	Aug	CARN

APOMORPHINE HYDROCHLORIDE

INJECTABLE; SUBCUTANEOUS

APOKYN

	BERTEK	20MG/2ML (10MG/ML)	N21264 001	Apr 20, 2004	Apr	NEWA
+	"	30MG/3ML (10MG/ML)	N21264 002	Apr 20, 2004	Apr	NEWA
	MYLAN BERTEK	20MG/2ML (10MG/ML)	N21264 001	Apr 20, 2004	Aug	CAHN
+		30MG/3ML (10MG/ML)	N21264 002	Apr 20, 2004	Aug	CAHN

ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID;
NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

INJECTABLE; IV (INFUSION)

INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE)

+	SABEX 2002	80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.1 4MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG /VIAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL	N21646 001	Jan 29, 2004	Jan	NEWA
---	------------	---	------------	--------------	-----	------

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID;
NIACINAMIDE; PHYTONADIONE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE
HYDROCHLORIDE; VITAMIN A; VITAMIN E

FOR SOLUTION; IV (INFUSION)

M.V.I. PEDIATRIC

+	MAYNE PHARMA USA	80MG/VIAL;0.02MG/VIAL;0.001MG/VIA L;5MG/VIAL;0.01MG/VIAL;0.14MG/VIA L;17MG/VIAL;0.2MG/VIAL;1MG/VIAL;1 .4MG/VIAL;EQ 1.2MG BASE/VIAL;0.7MG/VIAL;7MG/VIAL	N18920 001	Sep 21, 2000	Apr	CAHN
---	------------------	--	------------	--------------	-----	------

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID;
NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE;
VITAMIN A; VITAMIN E

INJECTABLE; INJECTION

M.V.I.-12

+	MAYNE PHARMA USA	10MG/ML;0.006MG/ML;0.5UGM/ML;1.5M G/ML;20 IU/ML;0.04MG/ML;4MG/ML;0.4MG/ML;0 .36MG/ML;0.3MG/ML;330 UNITS/ML;1 IU/ML	N08809 004	Aug 08, 1985	Apr	CAHN
---	------------------	--	------------	--------------	-----	------

INJECTABLE; INJECTION

M.V.I.-12 (WITHOUT VITAMIN K)

>A> + MAYNE PHARMA USA 20MG/ML;0.006MG/ML;0.05UGM/ML;1.5 MG/ML;0.0005MG/ML;0.06MG/ML;4MG/ML;0.6MG/ML;0.36MG/ML;0.6MG/ML;0.1 MG/ML;1MG/ML N08809 006 Sep 09, 2004 Sep NEWA

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E; VITAMIN K

INJECTABLE; IV (INFUSION)

M.V.I. ADULT

+ AAIPHARMA LLC 200MG/VIAL;0.06MG/VIAL;0.005MG/VIAL;15MG/VIAL;0.005MG/VIAL;0.6MG/VIAL;40MG/VIAL;6MG/VIAL;3.6MG/VIAL;6MG/VIAL;1MG/VIAL;10MG/VIAL;0.15 MG/VIAL N21625 001 Jan 30, 2004 Jan NEWA

+ MAYNE PHARMA USA 200MG/VIAL;0.06MG/VIAL;0.005MG/VIAL;15MG/VIAL;0.005MG/VIAL;0.6MG/VIAL;40MG/VIAL;6MG/VIAL;3.6MG/VIAL;6MG/VIAL;1MG/VIAL;10MG/VIAL;0.15 MG/VIAL N21625 001 Jan 30, 2004 Apr CAHN

M.V.I. ADULT (PHARMACY BULK PACKAGE)

+ AAIPHARMA LLC 200MG/5ML;0.06MG/5ML;0.005MG/5ML;15MG/5ML;0.005MG/5ML;0.6MG/5ML;40 MG/5ML;6MG/5ML;3.6MG/5ML;6MG/5ML;1MG/5ML;10MG/5ML;0.15MG/5ML N21643 001 Feb 18, 2004 Feb NEWA

+ MAYNE PHARMA USA 200MG/5ML;0.06MG/5ML;0.005MG/5ML;15MG/5ML;0.005MG/5ML;0.6MG/5ML;40 MG/5ML;6MG/5ML;3.6MG/5ML;6MG/5ML;1MG/5ML;10MG/5ML;0.15MG/5ML N21643 001 Feb 18, 2004 Apr CAHN

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION

M.V.I.-12

+ MAYNE PHARMA USA 20MG/ML;0.006MG/ML;0.05UGM/ML;1.5 G/ML;20 IU/ML;0.6MG/ML;4MG/ML;0.4MG/ML;0.36MG/ML;0.6MG/ML;330 UNITS/ML;1 IU/ML N08809 005 Apr 22, 2004 May NEWA

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PHYTONADIONE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A PALMITATE; VITAMIN E

INJECTABLE; INJECTION

VITAPED

Q HOSPIRA

80MG/VIAL;0.02MG/VIAL;0.001MG/VIAL;400 IU/10ML;0.14MG/VIAL;17MG/VIAL;5MG/VIAL;0.2MG/10ML;1MG/VIAL;1.4MG/VIAL;1.2MG/VIAL;EQ 2,300 UNITS BASE/10ML;7 IU/10ML N20176 001 Dec 29, 1993 Aug CAHN

ASPIRIN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE; ORAL

SYNALGOS-DC

>A> + LEITNER PHARMS 356.4MG;30MG;16MG N11483 004 Sep 06, 1983 Sep CAHN

>D> + WOMEN FIRST HLTHCARE 356.4MG;30MG;16MG N11483 004 Sep 06, 1983 Sep CAHN

ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

DARVON COMPOUND

B AAIPHARMA LLC

389MG;32.4MG;32MG N10996 006 Mar 08, 1983 Jun DISC

ASPIRIN; MEPROBAMATE

TABLET; ORAL
EQUAGESIC

>A>	+	LEITNER PHARMS	325MG;200MG	N11702 003	Dec 29, 1983	Sep	CAHN
>D>	+	WOMEN FIRST HLTHCARE	325MG;200MG	N11702 003	Dec 29, 1983	Sep	CAHN

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

TABLET; ORAL
OXYCODONE AND ASPIRIN

AA		MUTUAL PHARM	325MG;4.5MG;0.38MG	N40260 001	Jul 17, 1998	Aug	CAHN
AA			325MG;4.5MG;0.38MG	N87794 001	May 26, 1982	Aug	CAHN

ATENOLOL

TABLET; ORAL
ATENOLOL

AB		ABLE	25MG	N76907 001	Jul 30, 2004	Jul	NEWA
AB			50MG	N76907 002	Jul 30, 2004	Jul	NEWA
AB			100MG	N76907 003	Jul 30, 2004	Jul	NEWA
AB		TEVA	25MG	N74056 003	Jul 19, 2004	Jul	NEWA

ATRACURIUM BESYLATE

INJECTABLE; INJECTION
ATRACURIUM BESYLATE

AP		BAXTER HLTHCARE	10MG/ML	N74824 001	Sep 30, 1997	Aug	CAHN
AP		HOSPIRA	10MG/ML	N74632 001	Dec 23, 1996	May	CAHN
		ATRACURIUM BESYLATE PRESERVATIVE FREE					
		@ BAXTER HLTHCARE	10MG/ML	N74825 001	Sep 30, 1997	Aug	CAHN
AP		HOSPIRA	10MG/ML	N74633 001	Dec 23, 1996	May	CAHN
AP			10MG/ML	N74639 001	Mar 25, 1997	May	CAHN
		TRACRIUM					
AP	+	HOSPIRA	10MG/ML	N18831 002	Jun 20, 1985	May	CAHN
		TRACRIUM PRESERVATIVE FREE					
AP	+	HOSPIRA	10MG/ML	N18831 001	Nov 23, 1983	May	CAHN

ATROPINE

INJECTABLE; INJECTION
ATROPEN

>A>	+	MERIDIAN MEDCL TECHN	EQ 0.25MG SULFATE/0.3ML	N17106 004	Sep 17, 2004	Sep	NEWA
-----	---	----------------------	-------------------------	------------	--------------	-----	------

ATROPINE SULFATE

INJECTABLE; IM-IV-SC
ATROPINE SULFATE ANSYR ELASTIC SYRINGE

		HOSPIRA	0.05MG/ML	N21146 002	Jul 09, 2001	May	CAHN
	+		0.1MG/ML	N21146 001	Jul 09, 2001	May	CAHN

ATROPINE SULFATE; DIFENOXIN HYDROCHLORIDE

TABLET; ORAL
MOTOFEN

	+	VALEANT	0.025MG;1MG	N17744 002		May	CAHN
		MOTOFEN HALF-STRENGTH					
		@ VALEANT	0.025MG;0.5MG	N17744 001		May	CAHN

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET; ORAL

DIPHENOXYLATE HCL AND ATROPINE SULFATE
@ MUTUAL PHARM 0.025MG;2.5MG

N85506 001 Aug CAHN

AZACITIDINE

INJECTABLE; SUBCUTANEOUS

VIDAZA

+ PHARMION 100MG/VIAL

N50794 001 May 19, 2004 May NEWA

AZATADINE MALEATE

TABLET; ORAL

OPTIMINE

@ SCHERING 1MG

N17601 001 May DISC

AZATADINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

TRINALIN

@ SCHERING 1MG;120MG

N18506 001 Mar 23, 1982 May DISC

AZATHIOPRINE SODIUM

INJECTABLE; INJECTION

AZATHIOPRINE SODIUM

+ BEDFORD EQ 100MG BASE/VIAL

N74419 001 Mar 31, 1995 May CRLD

IMURAN

@ PROMETHEUS LABS EQ 100MG BASE/VIAL

N17391 001 May DISC

AZITHROMYCIN

CAPSULE; ORAL

ZITHROMAX

@ PFIZER EQ 250MG BASE

N50670 001 Nov 01, 1991 Mar DISC

AZTREONAM

INJECTABLE; INJECTION

AZACTAM

+ BRISTOL MYERS SQUIBB 500MG/VIAL

N50580 001 Dec 31, 1986 Jul CMFD

+ 1GM/VIAL

N50580 002 Dec 31, 1986 Jul CMFD

+ 2GM/VIAL

N50580 003 Dec 31, 1986 Jul CMFD

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

CORTISPORIN

AT MONARCH PHARMS 400 UNITS/GM;1%;EQ 3.5MG
BASE/GM;10,000 UNITS/GM

N50416 002 Mar CRLD

NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE

AT + BAUSCH AND LOMB 400 UNITS/GM;1%;EQ 3.5MG
BASE/GM;10,000 UNITS/GM

N64068 001 Oct 30, 1995 Mar CRLD

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATE AND BACITRACIN ZINC

AT AKORN 400 UNITS/GM;EQ 3.5MG
BASE/GM;10,000 UNITS/GM

N65088 001 Feb 06, 2004 Feb NEWA

NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC

AT + BAUSCH AND LOMB 400 UNITS/GM;EQ 3.5MG
BASE/GM;10,000 UNITS/GM

N64064 001 Oct 30, 1995 Mar CRLD

OINTMENT; OPHTHALMIC
NEOSPORIN

AT	MONARCH PHARMS	400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N50417 001		Mar	CRLD
----	----------------	--	------------	--	-----	------

BACITRACIN ZINC; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
BACITRACIN ZINC AND POLYMYXIN B SULFATE

AT	+ BAUSCH AND LOMB	500 UNITS/GM;10,000 UNITS/GM	N64046 001	Jan 26, 1995	Mar	CRLD
----	-------------------	------------------------------	------------	--------------	-----	------

POLYSPORIN

AT	MONARCH PHARMS	500 UNITS/GM;10,000 UNITS/GM	N61229 001		Mar	CRLD
----	----------------	------------------------------	------------	--	-----	------

BECLOMETHASONE DIPROPIONATE

AEROSOL, METERED; INHALATION

VANCERIL

+	SCHERING	0.042MG/INH	N17573 001		Jun	CTEC
---	----------	-------------	------------	--	-----	------

VANCERIL DOUBLE STRENGTH

@	SCHERING	0.084MG/INH	N20486 001	Dec 24, 1996	Jun	DISC
---	----------	-------------	------------	--------------	-----	------

BECLOMETHASONE DIPROPIONATE MONOHYDRATE

SPRAY, METERED; NASAL

BECONASE AQ

+	GLAXOSMITHKLINE	EQ 0.042MG DIPROP/SPRAY	N19389 001	Jul 27, 1987	Jun	CTEC
---	-----------------	-------------------------	------------	--------------	-----	------

VANCENASE AQ

@	SCHERING	EQ 0.042MG DIPROP/SPRAY	N19589 001	Dec 23, 1987	Jun	DISC
---	----------	-------------------------	------------	--------------	-----	------

BENAZEPRIL HYDROCHLORIDE

TABLET; ORAL

BENAZEPRIL HCL

AB	ANDRX PHARMS	5MG	N76267 001	Feb 11, 2004	Feb	NEWA
AB		10MG	N76267 002	Feb 11, 2004	Feb	NEWA
AB		20MG	N76267 003	Feb 11, 2004	Feb	NEWA
AB		40MG	N76267 004	Feb 11, 2004	Feb	NEWA
AB	EON	5MG	N76402 001	Feb 11, 2004	Feb	NEWA
AB		10MG	N76402 002	Feb 11, 2004	Feb	NEWA
AB		20MG	N76402 003	Feb 11, 2004	Feb	NEWA
AB		40MG	N76402 004	Feb 11, 2004	Feb	NEWA
AB	GENPHARM	5MG	N76476 001	Feb 11, 2004	Feb	NEWA
AB		10MG	N76476 002	Feb 11, 2004	Feb	NEWA
AB		20MG	N76476 003	Feb 11, 2004	Feb	NEWA
AB		40MG	N76476 004	Feb 11, 2004	Feb	NEWA
AB	IVAX PHARMS	5MG	N76333 001	Feb 11, 2004	Feb	NEWA
AB		10MG	N76333 002	Feb 11, 2004	Feb	NEWA
AB		20MG	N76333 003	Feb 11, 2004	Feb	NEWA
AB		40MG	N76333 004	Feb 11, 2004	Feb	NEWA
AB	KV PHARM	5MG	N76118 001	Feb 11, 2004	Feb	NEWA
AB		10MG	N76118 002	Feb 11, 2004	Feb	NEWA
AB		20MG	N76118 003	Feb 11, 2004	Feb	NEWA
AB		40MG	N76118 004	Feb 11, 2004	Feb	NEWA
AB	MYLAN	5MG	N76430 001	Feb 11, 2004	Feb	NEWA
AB		10MG	N76430 002	Feb 11, 2004	Feb	NEWA
AB		20MG	N76430 003	Feb 11, 2004	Feb	NEWA
AB		40MG	N76430 004	Feb 11, 2004	Feb	NEWA
AB	RANBAXY	5MG	N76344 001	Feb 11, 2004	Feb	NEWA
AB		10MG	N76344 002	Feb 11, 2004	Feb	NEWA
AB		20MG	N76344 003	Feb 11, 2004	Feb	NEWA
AB		40MG	N76344 004	Feb 11, 2004	Feb	NEWA

TABLET; ORAL		BENAZEPRIL HCL	
AB	TEVA	5MG	N76211 001 Feb 11, 2004 Feb NEWA
AB		10MG	N76211 002 Feb 11, 2004 Feb NEWA
AB		20MG	N76211 003 Feb 11, 2004 Feb NEWA
AB		40MG	N76211 004 Feb 11, 2004 Feb NEWA
LOTENSIN		NOVARTIS	
AB		5MG	N19851 001 Jun 25, 1991 Feb CFTG
AB		10MG	N19851 002 Jun 25, 1991 Feb CFTG
AB		20MG	N19851 003 Jun 25, 1991 Feb CFTG
AB	+	40MG	N19851 004 Jun 25, 1991 Feb CFTG

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL		BENAZEPRIL HCL AND HYDROCHLOROTHIAZIDE	
AB	ANDRX PHARMS	5MG; 6.25MG	N76342 001 Feb 11, 2004 Feb NEWA
AB		10MG; 12.5MG	N76342 002 Feb 11, 2004 Feb NEWA
AB		20MG; 12.5MG	N76342 003 Feb 11, 2004 Feb NEWA
AB		20MG; 25MG	N76342 004 Feb 11, 2004 Feb NEWA
AB	EON	5MG; 6.25MG	N76631 001 Feb 11, 2004 Feb NEWA
AB		10MG; 12.5MG	N76631 002 Feb 11, 2004 Feb NEWA
AB		20MG; 12.5MG	N76631 003 Feb 11, 2004 Feb NEWA
AB		20MG; 25MG	N76631 004 Feb 11, 2004 Feb NEWA
AB	GENPHARM	5MG; 6.25MG	N76612 001 Feb 11, 2004 Feb NEWA
AB		10MG; 12.5MG	N76612 002 Feb 11, 2004 Feb NEWA
AB		20MG; 12.5MG	N76612 003 Feb 11, 2004 Feb NEWA
AB		20MG; 25MG	N76612 004 Feb 11, 2004 Feb NEWA
AB	IVAX PHARMS	5MG; 6.25MG	N76348 001 Feb 11, 2004 Feb NEWA
AB		10MG; 12.5MG	N76348 002 Feb 11, 2004 Feb NEWA
AB		20MG; 12.5MG	N76348 003 Feb 11, 2004 Feb NEWA
AB		20MG; 25MG	N76348 004 Feb 11, 2004 Feb NEWA
AB	MYLAN	5MG; 6.25MG	N76688 001 Feb 11, 2004 Feb NEWA
AB		10MG; 12.5MG	N76688 002 Feb 11, 2004 Feb NEWA
AB		20MG; 12.5MG	N76688 003 Feb 11, 2004 Feb NEWA
AB		20MG; 25MG	N76688 004 Feb 11, 2004 Feb NEWA
LOTENSIN HCT		NOVARTIS	
AB		5MG; 6.25MG	N20033 001 May 19, 1992 Feb CFTG
AB		10MG; 12.5MG	N20033 002 May 19, 1992 Feb CFTG
AB		20MG; 12.5MG	N20033 004 May 19, 1992 Feb CFTG
AB	+	20MG; 25MG	N20033 003 May 19, 1992 Feb CFTG

BENZOYL PEROXIDE; ERYTHROMYCIN

GEL; TOPICAL		BENZAMYCIN		
AB	+	DERMIK LABS	5%; 3%	N50557 001 Oct 26, 1984 Mar CFTG
ERYTHROMYCIN AND BENZOYL PEROXIDE		ATRIX		
AB			5%; 3%	N65112 001 Mar 29, 2004 Mar NEWA

BETAMETHASONE DIPROPIONATE

CREAM, AUGMENTED; TOPICAL		BETAMETHASONE DIPROPIONATE		
AB		ATRIX	EQ 0.05% BASE	N76603 001 Jan 23, 2004 Jan NEWA

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

LOTION; TOPICAL

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

AB	TARO	EQ 0.05% BASE;1%	N76493 001	Jul 28, 2004	Jul	NEWA
AB	+ SCHERING PLOUGH RES	EQ 0.05% BASE;1%	N20010 001	Dec 08, 2000	Jul	CFTG

BETAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

BETAMETHASONE SODIUM PHOSPHATE

	@ STERIS	EQ 3MG BASE/ML	N85738 001		Feb	DISC
	CELESTONE					
	@ SCHERING	EQ 3MG BASE/ML	N17561 001		Feb	DISC

BETHANECHOL CHLORIDE

INJECTABLE; INJECTION

URECHOLINE

	@ ODYSSEY PHARMS	5MG/ML	N06536 001		Jun	CAHN
--	------------------	--------	------------	--	-----	------

TABLET; ORAL

BETHANECHOL CHLORIDE

AA	ABLE	5MG	N40492 001	Jul 27, 2004	Jul	NEWA
AA		10MG	N40483 001	Jul 27, 2004	Jul	NEWA
AA		25MG	N40485 001	Jul 27, 2004	Jul	NEWA
AA		50MG	N40509 001	Jul 27, 2004	Jul	NEWA
	DUVOID					
AA	WELLSPRING PHARM	10MG	N86262 001		Jul	CMFD
AA		25MG	N86263 001		Jul	CMFD
	URECHOLINE					
	@ ODYSSEY PHARMS	5MG	N06536 003		Jun	CAHN
	@	10MG	N06536 002		Jun	CAHN
	@	25MG	N06536 004		Jun	CAHN
	@	50MG	N06536 005		Jun	CAHN

BISACODYL; POLYETHYLENE GLYCOL; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION; TABLET, DELAYED RELEASE; ORAL

HALFLYTELY

+	BRAINTREE	5MG;210GM;0.74GM;2.86GM;5.6GM	N21551 001	May 10, 2004	May	NEWA
---	-----------	-------------------------------	------------	--------------	-----	------

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION

BRETYLIUM TOSYLATE

	@ HOSPIRA	50MG/ML	N19033 001	Apr 29, 1986	Jun	DISC
AP	+	50MG/ML	N19033 001	Apr 29, 1986	May	CAHN
AP	+	INTL MEDICATION	N70119 001	Apr 29, 1986	Jun	CRLO
	BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER					
AP	+	HOSPIRA	N19008 002	Apr 29, 1986	May	CAHN
AP	+	400MG/100ML	N19008 003	Apr 29, 1986	May	CAHN
	@	800MG/100ML	N19008 001	Apr 29, 1986	May	CAHN
	BRETYLIUM TOSYLATE IN PLASTIC CONTAINER					
AP	+	HOSPIRA	N19030 001	Apr 29, 1986	May	CAHN

BRIMONIDINE TARTRATE

SOLUTION/DROPS; OPHTHALMIC

BRIMONIDINE TARTRATE

>A>	AT	IVAX PHARMS	0.2%	N76372 001	Sep 10, 2004	Sep	NEWA
-----	----	-------------	------	------------	--------------	-----	------

BROMOCRIPTINE MESYLATE

TABLET; ORAL

BROMOCRIPTINE MESYLATE

>A>	AB	MYLAN	EQ 2.5MG BASE	N76962 001	Sep 24, 2004	Sep	NEWA
-----	----	-------	---------------	------------	--------------	-----	------

BUMETANIDE

INJECTABLE; INJECTION

BUMETANIDE

AF		HOSPIRA	0.25MG/ML	N74160 001	Oct 30, 1997	May	CAHN
AF			0.25MG/ML	N74332 001	Oct 31, 1994	May	CAHN

BUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

BUPIVACAINE HCL

AP		HOSPIRA	0.25%	N18053 002		May	CAHN
AP			0.25%	N70583 001	Feb 17, 1987	May	CAHN
AP			0.25%	N70586 001	Mar 03, 1987	May	CAHN
AP			0.25%	N70590 001	Feb 17, 1987	May	CAHN
AP			0.5%	N18053 001		May	CAHN
AP			0.5%	N70584 001	Feb 17, 1986	May	CAHN
AP			0.5%	N70597 001	Mar 03, 1987	May	CAHN
AP			0.5%	N70609 001	Mar 03, 1987	May	CAHN
AP			0.75%	N18053 003		May	CAHN
AP			0.75%	N70585 001	Mar 03, 1987	May	CAHN
AP			0.75%	N70587 001	Mar 03, 1987	May	CAHN

BUPIVACAINE HCL KIT

@ HOSPIRA

0.075%

N19978 001 Sep 03, 1992 May CAHN

@

0.114%

N19978 002 Sep 03, 1992 May CAHN

@

0.23%

N19978 003 Sep 03, 1992 May CAHN

MARCAINE HCL

AP	+	HOSPIRA	0.25%	N16964 001		May	CAHN
AP	+		0.5%	N16964 006		May	CAHN

MARCAINE HCL PRESERVATIVE FREE

AP	+	HOSPIRA	0.25%	N16964 012		May	CAHN
AP	+		0.5%	N16964 005		May	CAHN
AP	+		0.75%	N16964 009		May	CAHN

INJECTABLE; SPINAL

BUPIVACAINE

AP		HOSPIRA	0.75%	N71810 001	Dec 11, 1987	May	CAHN
----	--	---------	-------	------------	--------------	-----	------

MARCAINE

AP	+	HOSPIRA	0.75%	N18692 001	May 04, 1984	May	CAHN
----	---	---------	-------	------------	--------------	-----	------

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE

INJECTABLE; INJECTION

BUPIVACAINE HCL AND EPINEPHRINE

+		HOSPIRA	0.25%;0.005MG/ML	N71165 001	Jun 16, 1988	May	CAHN
			0.25%;0.005MG/ML	N71166 001	Jun 16, 1988	May	CAHN
			0.25%;0.005MG/ML	N71167 001	Jun 16, 1988	May	CAHN
+			0.5%;0.005MG/ML	N71168 001	Jun 16, 1988	May	CAHN
			0.5%;0.005MG/ML	N71169 001	Jun 16, 1988	May	CAHN
			0.5%;0.005MG/ML	N71170 001	Jun 16, 1988	May	CAHN
+			0.75%;0.005MG/ML	N71171 001	Jun 16, 1988	May	CAHN

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

MARCAINE HCL W/ EPINEPHRINE

AP	+	HOSPIRA	0.25%;0.0091MG/ML	N16964 004		May	CAHN
AP	+		0.5%;0.0091MG/ML	N16964 008		May	CAHN
MARCAINE HCL W/ EPINEPHRINE PRESERVATIVE FREE							
AP	+	HOSPIRA	0.25%;0.0091MG/ML	N16964 013		May	CAHN
AP	+		0.5%;0.0091MG/ML	N16964 007		May	CAHN
AP	+		0.75%;0.0091MG/ML	N16964 010		May	CAHN

BUPRENORPHINE HYDROCHLORIDE

INJECTABLE; INJECTION

BUPRENORPHINE HCL

AP		HOSPIRA	EQ 0.3MG BASE/ML	N74137 001	Jun 03, 1996	May	CAHN
----	--	---------	------------------	------------	--------------	-----	------

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

BUPROPION HCL

AB1		EON	100MG	N75932 001	Nov 25, 2003	May	CFTG
AB			150MG	N75932 002	Mar 22, 2004	Mar	NEWA
AB1			150MG	N75932 002	Mar 22, 2004	May	CTEC
AB1		IMPAX LABS	100MG	N75913 001	Jan 28, 2004	May	CTEC
AB			100MG	N75913 001	Jan 28, 2004	Jan	NEWA
AB			150MG	N75913 002	Mar 22, 2004	Mar	NEWA
AB1			150MG	N75913 002	Mar 22, 2004	May	CTEC
AB2			150MG	N75914 001	May 27, 2004	May	NEWA
WELLBUTRIN SR							
AB1		GLAXOSMITHKLINE	100MG	N20358 002	Oct 04, 1996	May	CTEC
AB1	+		150MG	N20358 003	Oct 04, 1996	Jun	CTEC
AB	+		150MG	N20358 003	Oct 04, 1996	Mar	CFTG
AB	+		150MG	N20358 003	Oct 04, 1996	May	CTEC
ZYSAN							
AB2	+	GLAXOSMITHKLINE	150MG	N20711 003	May 14, 1997	Jun	CTEC
AB	+		150MG	N20711 003	May 14, 1997	May	CFTG

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL

BUSPIRONE HCL

AB		TEVA	30MG	N75022 004	Mar 25, 2004	Mar	NEWA
----	--	------	------	------------	--------------	-----	------

BUTORPHANOL TARTRATE

INJECTABLE; INJECTION

BUTORPHANOL TARTRATE

AP		HOSPIRA	1MG/ML	N75559 001	Mar 20, 2000	May	CAHN
AP			2MG/ML	N75559 002	Mar 20, 2000	May	CAHN
BUTORPHANOL TARTRATE PRESERVATIVE FREE							
AP		HOSPIRA	1MG/ML	N74620 001	Jan 22, 1997	May	CAHN
AP			1MG/ML	N74626 001	Jan 23, 1997	May	CAHN
AP			2MG/ML	N74620 002	Jan 22, 1997	May	CAHN
AP			2MG/ML	N74626 002	Jan 23, 1997	May	CAHN

CAFFEINE CITRATE

SOLUTION; INTRAVENOUS, ORAL

CAFICIT

>D>	+	MEAD JOHNSON	EQ 10MG BASE/ML	N20793 001	Sep 21, 1999	Sep	CPOT
-----	---	--------------	-----------------	------------	--------------	-----	------

SOLUTION; INTRAVENOUS, ORAL

CAPCIT

>A> + MEAD JOHNSON EQ 30MG BASE/3ML (EQ 10MG BASE/ML) N20793 001 Sep 21, 1999 Sep CPOT

SOLUTION; ORAL

CAPCIT

>A> + MEAD JOHNSON EQ 30MG BASE/3ML (EQ 10MG BASE/ML) N20793 002 Apr 12, 2000 Sep NEWA

CAFFEINE; ERGOTAMINE TARTRATE

TABLET; ORAL

ERCATAB

>D> + SANDOZ 100MG;1MG N84294 001 Sep CFTG

>A> AB + 100MG;1MG N84294 001 Sep CFTG

>A> ERGOTAMINE TARTRATE AND CAFFEINE

>A> AB WEST WARD 100MG;1MG N40510 001 Sep 17, 2004 Sep NEWA

CALCITRIOL

INJECTABLE; INJECTION

CALCITRIOL

AP MAYNE PHARMA USA 0.001MG/ML N75816 001 Jan 16, 2004 Jan NEWA

AP 0.002MG/ML N75816 002 Jan 16, 2004 Jan NEWA

CALCIUM CHLORIDE

INJECTABLE; INJECTION

CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER

+ HOSPIRA 100MG/ML N21117 001 Jan 28, 2000 May CARN

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5% AND RINGER'S IN PLASTIC CONTAINER

AP HOSPIRA 33MG/100ML;5GM/100ML;30MG/100ML;8 60MG/100ML N18254 001 May CARN

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP HOSPIRA 20MG/100ML;5GM/100ML;30MG/100ML;6 00MG/100ML;310MG/100ML N17608 001 May CARN

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

@ HOSPIRA 20MG/100ML;5GM/100ML;104MG/100ML; 600MG/100ML;310MG/100ML N19685 005 Oct 17, 1988 May CARN

@ 20MG/100ML;5GM/100ML;179MG/100ML; 600MG/100ML;310MG/100ML N19685 006 Oct 17, 1988 May CARN

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

@ HOSPIRA 20MG/100ML;5GM/100ML;254MG/100ML; 600MG/100ML;310MG/100ML N19685 007 Oct 17, 1988 May CARN

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP HOSPIRA 20MG/100ML;5GM/100ML;179MG/100ML; 600MG/100ML;310MG/100ML N19685 002 Oct 17, 1988 May CARN

AP 20MG/100ML;5GM/100ML;328MG/100ML; 600MG/100ML;310MG/100ML N19685 008 Oct 17, 1988 May CARN

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

@ HOSPIRA 20MG/100ML;5GM/100ML;254MG/100ML; 600MG/100ML;310MG/100ML N19685 003 Oct 17, 1988 May CARN

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP HOSPIRA 20MG/100ML;5GM/100ML;328MG/100ML; 600MG/100ML;310MG/100ML N19685 004 Oct 17, 1988 May CARN

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

@ HOSPIRA 20MG/100ML;5GM/100ML;104MG/100ML; 600MG/100ML;310MG/100ML N19685 001 Oct 17, 1988 May CARN

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

TPN ELECTROLYTES IN PLASTIC CONTAINER

HOSPIRA	16.5MG/ML; 25.4MG/ML; 74.6MG/ML; 121 MG/ML; 16.1MG/ML	N18895 001	Jul 20, 1984	May	CAHN
---------	--	------------	--------------	-----	------

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

SOLUTION; PERFUSION, CARDIAC

PLEGISOL IN PLASTIC CONTAINER

AT +	HOSPIRA	17.6MG/100ML; 325.3MG/100ML; 119.3M G/100ML; 643MG/100ML	N18608 001	Feb 26, 1982	May	CAHN
------	---------	---	------------	--------------	-----	------

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

RINGER'S IN PLASTIC CONTAINER

AP	HOSPIRA	33MG/100ML; 30MG/100ML; 860MG/100ML	N18251 001		May	CAHN
----	---------	-------------------------------------	------------	--	-----	------

SOLUTION; IRRIGATION

RINGER'S IN PLASTIC CONTAINER

AT	HOSPIRA	33MG/100ML; 30MG/100ML; 860MG/100ML	N17635 001		May	CAHN
----	---------	-------------------------------------	------------	--	-----	------

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

LACTATED RINGER'S IN PLASTIC CONTAINER

AP	HOSPIRA	20MG/100ML; 30MG/100ML; 600MG/100ML ; 310MG/100ML	N17641 001		May	CAHN
----	---------	--	------------	--	-----	------

SOLUTION; IRRIGATION

LACTATED RINGER'S IN PLASTIC CONTAINER

AT	HOSPIRA	20MG/100ML; 30MG/100ML; 600MG/100ML ; 310MG/100ML	N19416 001	Jan 17, 1986	May	CAHN
----	---------	--	------------	--------------	-----	------

CAPTOPRIL

TABLET; ORAL

CAPTOPRIL

AB	DURAMED PHARMS BARR	12.5MG	N74477 001	Feb 13, 1996	May	CAHN
AB		25MG	N74477 002	Feb 13, 1996	May	CAHN
AB		50MG	N74477 003	Feb 13, 1996	May	CAHN
AB		100MG	N74477 004	Feb 13, 1996	May	CAHN
AB	KALI LABS	12.5MG	N74477 001	Feb 13, 1996	Aug	CAHN
AB		25MG	N74477 002	Feb 13, 1996	Aug	CAHN
AB		50MG	N74477 003	Feb 13, 1996	Jul	CAHN
AB		100MG	N74477 004	Feb 13, 1996	Aug	CAHN

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE; ORAL

CARBATROL

	SHIRE PHARM	100MG	N20712 003	Sep 30, 1997	Mar	CRLD
		200MG	N20712 001	Sep 30, 1997	Mar	CRLD

SUSPENSION; ORAL

TERIL

>A>	AB	TARO	100MG/5ML	N76729 001	Sep 20, 2004	Sep	NEWA
-----	----	------	-----------	------------	--------------	-----	------

CARBIDOPA; LEVODOPA

TABLET, EXTENDED RELEASE; ORAL

CARBIDOPA AND LEVODOPA

AB	IMPAX LABS	25MG/100MG	N76521 001	May 14, 2004	May	NEWA
AB		50MG; 200MG	N76521 002	May 14, 2004	May	NEWA
AB	KV PHARM	50MG; 200MG	N76663 001	Jun 24, 2004	Jun	NEWA

TABLET, EXTENDED RELEASE; ORAL							
CARBIDOPA AND LEVODOPA							
AB	TORPHARM	25MG;100MG		N76212 001	Jun 16, 2004	Jun	NEWA
AB		50MG;200MG		N76212 002	Jun 16, 2004	Jun	NEWA
TABLET, ORALLY DISINTEGRATING; ORAL							
PARCOPA							
	SCHWARZ PHARMA	10MG;100MG		N76699 001	Aug 27, 2004	Aug	NEWA
		25MG;100MG		N76699 002	Aug 27, 2004	Aug	NEWA
+		25MG;250MG		N76699 003	Aug 27, 2004	Aug	NEWA
<u>CARBOPLATIN</u>							
INJECTABLE; IV (INFUSION)							
PARAPLATIN							
+	BRISTOL MYERS SQUIBB	EQ 600MG /60ML(10MG/ML)		N20452 004	Jan 15, 2004	Jan	NEWA
<u>CARTEOLOL HYDROCHLORIDE</u>							
TABLET; ORAL							
CARTROL							
	@ ABBOTT	2.5MG		N19204 001	Dec 28, 1988	Jun	DISC
	@	5MG		N19204 002	Dec 28, 1988	Jun	DISC
<u>CEFACTOR</u>							
CAPSULE; ORAL							
CEFACTOR							
AB	CARLSBAD	EQ 250MG BASE		N65146 001	Jan 22, 2004	Jan	NEWA
AB		EQ 500MG BASE		N65146 002	Jan 22, 2004	Jan	NEWA
FOR SUSPENSION; ORAL							
CECLOR							
AB	CEPH INTL	EQ 125MG BASE/5ML		N62206 001		May	CAHN
AB		EQ 187MG BASE/5ML		N62206 003	Apr 20, 1988	May	CAHN
AB		EQ 250MG BASE/5ML		N62206 002		May	CAHN
AB	+	EQ 375MG BASE/5ML		N62206 004	Apr 20, 1988	May	CAHN
TABLET, EXTENDED RELEASE; ORAL							
CECLOR CD							
	@ LILLY	EQ 500MG BASE		N50673 002	Jun 28, 1996	Jun	DISC
CEFACTOR							
AB	+	IVAX PHARMS	EQ 500MG BASE	N65057 001	Jan 05, 2001	Jun	CRLD
<u>CEFAMANDOLE NAFATE</u>							
INJECTABLE; INJECTION							
MANDOL							
	@ LILLY	EQ 1GM BASE/VIAL		N50504 002		Jul	DISC
	@	EQ 2GM BASE/VIAL		N50504 003		Jul	DISC
<u>CEFAZOLIN SODIUM</u>							
INJECTABLE; INJECTION							
CEFAZOLIN SODIUM							
	@ MARSAM PHARMS LLC	EQ 250MG BASE/VIAL		N62988 001	Dec 29, 1989	Jun	DISC
	@	EQ 500MG BASE/VIAL		N62988 002	Dec 29, 1989	Jun	DISC
	@	EQ 1GM BASE/VIAL		N62988 003	Dec 29, 1989	Jun	DISC
	@	EQ 5GM BASE/VIAL		N62989 001	Dec 29, 1989	Jun	DISC
	@	EQ 10GM BASE/VIAL		N62989 002	Dec 29, 1989	Jun	DISC
	@	EQ 20GM BASE/VIAL		N62989 003	Dec 29, 1989	Jun	DISC
KEFZOL							
	@ LILLY	EQ 250MG BASE/VIAL		N61773 001		Jun	DISC
	@	EQ 500MG BASE/VIAL		N61773 002		Jun	DISC

INJECTABLE; INJECTION

KEFZOL

@ LILLY

EQ 1GM BASE/VIAL

N61773 003

Jun DISC

@

EQ 10GM BASE/VIAL

N61773 004

Jun DISC

@

EQ 20GM BASE/VIAL

N61773 005 Sep 08, 1987 Jun DISC

CEFDINIR

FOR SUSPENSION; ORAL

OMNICEF

ABBOTT

125MG/5ML

N50749 001 Dec 04, 1997 Jul CRLD

+

250MG/5ML

N50749 002 Jul 29, 2004 Jul NEWA

CEFIXIME

SUSPENSION; ORAL

SUPRAX

+ LUPIN

100MG/5ML

N65129 001 Feb 23, 2004 Feb NEWA

TABLET; ORAL

SUPRAX

+ LUPIN

400MG

N65130 001 Feb 12, 2004 Feb NEWA

CEFOTAXIME SODIUM

INJECTABLE; INJECTION

CEFOTAXIME AND DEXTROSE 2.4% IN PLASTIC CONTAINER

+ B BRAUN

EQ 2GM BASE

N50792 001 Jul 29, 2004 Jul NEWA

CEFOTAXIME AND DEXTROSE 3.9% IN PLASTIC CONTAINER

+ B BRAUN

EQ 1GM BASE

N50792 002 Jul 29, 2004 Jul NEWA

CEFTAZIDIME

INJECTABLE; INJECTION

CEFTAZIDIME

AP ACS DOBFAR

500MG/VIAL

N62640 001 Nov 20, 1985 Apr CTNA

AP

1GM/VIAL

N62640 002 Nov 20, 1985 Apr CTNA

AP

2GM/VIAL

N62640 003 Nov 20, 1985 Apr CTNA

TAZICEF

AP HOSPIRA

500MG/VIAL

N62662 001 Mar 06, 1986 May CAHN

AP

1GM/VIAL

N62662 002 Mar 06, 1986 May CAHN

AP

1GM/VIAL

N64032 001 Oct 31, 1993 May CAHN

AP

2GM/VIAL

N62662 003 Mar 06, 1986 May CAHN

AP

2GM/VIAL

N64032 002 Oct 31, 1993 May CAHN

AP

6GM/VIAL

N62662 004 Mar 06, 1986 May CAHN

TAZIDIME

@ LILLY

1GM/VIAL

N62655 001 Nov 20, 1985 Apr DISC

@

2GM/VIAL

N62655 002 Nov 20, 1985 Apr DISC

CEFTIBUTEN DIHYDRATE

CAPSULE; ORAL

CEDAX

>D> + BIOVAIL

EQ 400MG BASE

N50685 002 Dec 20, 1995 Sep CAHN

>A> + SHIONOGI

EQ 400MG BASE

N50685 002 Dec 20, 1995 Sep CAHN

FOR SUSPENSION; ORAL

CEDAX

>D> BIOVAIL

EQ 90MG BASE/5ML

N50686 001 Dec 20, 1995 Sep CAHN

>D> +

EQ 180MG BASE/5ML

N50686 002 Dec 20, 1995 Sep CAHN

>A> SHIONOGI

EQ 90MG BASE/5ML

N50686 001 Dec 20, 1995 Sep CAHN

>A> +

EQ 180MG BASE/5ML

N50686 002 Dec 20, 1995 Sep CAHN

CEFUROXIME AXETIL

TABLET; ORAL

CEFUROXIME AXETIL

AB	SANDOZ	EQ 250MG BASE	N65126 001	Oct 28, 2003	Aug	CAHN
AB		EQ 500MG BASE	N65126 002	Oct 28, 2003	Aug	CAHN

CEFUROXIME SODIUM

INJECTABLE; IM-IV

CEFUROXIME

AB	HIKMA FARMACEUTICA	EQ 750MG BASE/VIAL	N65048 001	Jan 09, 2004	Jan	NEWA
	KEFUROX					
	@ LILLY	EQ 750MG BASE/VIAL	N62591 001	Jan 10, 1986	Jun	DISC

INJECTABLE; INJECTION

CEFUROXIME

AP	HIKMA FARMACEUTICA	EQ 1.5GM BASE/VIAL	N65048 002	Jan 09, 2004	Jan	NEWA
AP		EQ 7.5GM BASE/VIAL	N65046 001	Jan 09, 2004	Jan	NEWA
	KEFUROX					
	@ LILLY	EQ 1.5GM BASE/VIAL	N62591 002	Jan 10, 1986	Jun	DISC
	@	EQ 1.5GM BASE/VIAL	N62592 002	Jan 10, 1986	Jun	DISC
	@	EQ 7.5GM BASE/VIAL	N62591 003	Dec 17, 1987	Jun	DISC

INJECTABLE; INTRAVENOUS

KEFUROX

@ LILLY

EQ 750MG BASE/VIAL N62592 001 Jan 10, 1986 Jun DISC

>D> CELLULOSE SODIUM PHOSPHATE

>D> POWDER; ORAL

>D> CALCIBIND

>D>	+	MISSION PHARMA	300GM/BOT	N18757 003	Oct 16, 1984	Sep	DISC
>A>		@	300GM/BOT	N18757 003	Oct 16, 1984	Sep	DISC

CEPHALEXIN

CAPSULE; ORAL

KEFLEX

AB	ADVANCIS PHARM	EQ 250MG BASE	N50405 002		Jun	CAHN
AB	+	EQ 500MG BASE	N50405 003		Jun	CAHN

FOR SUSPENSION; ORAL

KEFLEX

@ ADVANCIS PHARM

@

@

EQ 100MG BASE/ML	N50406 003	Jun	CAHN
EQ 125MG BASE/5ML	N50406 001	Jun	CAHN
EQ 250MG BASE/5ML	N50406 002	Jun	CAHN

TABLET; ORAL

KEFLET

@ LILLY

EQ 250MG BASE N50440 003 Feb 26, 1987 Jun DISC

CEPHALEXIN HYDROCHLORIDE

TABLET; ORAL

KEFTAB

@ LILLY

EQ 500MG BASE N50614 002 Oct 29, 1987 Jul DISC

CETIRIZINE HYDROCHLORIDE

TABLET, CHEWABLE; ORAL

ZYRTEC

PFIZER

+

5MG	N21621 001	Mar 16, 2004	Mar	NEWA
10MG	N21621 002	Mar 16, 2004	Mar	NEWA

CEVIMELINE HYDROCHLORIDE

CAPSULE; ORAL
EVOXAC

+ DAIICHI EQ 30MG BASE N20989 002 Jan 11, 2000 Jun CAHN

CHLORDIAZEPOXIDE HYDROCHLORIDE

INJECTABLE; INJECTION
LIBRIUM

@ VALEANT PHARM INTL 100MG/AMP N12301 001 Jun DISC

CHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL
CHLORHEXIDINE GLUCONATE

AT MORTON GROVE 0.12% N75006 001 Mar 03, 2004 Mar NEWA

CHLOROPROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
CHLOROPROCAINE HCL

AP HOSPIRA 2% N87447 001 Apr 16, 1982 May CAHN

AE 3% N87446 001 Apr 16, 1982 May CAHN

AP NESACAINE
ASTRAZENECA 2% N09435 002 Jun CTEC

CHLOROTHIAZIDE

>D> SUSPENSION; ORAL

>D> DIURIL

>D> + MERCK 250MG/5ML N11870 001 Sep DISC

>A> @ 250MG/5ML N11870 001 Sep DISC

TABLET; ORAL
CHLOROTHIAZIDE

>D> AB MYLAN 250MG N84388 001 Sep CRLD

>A> AB + 250MG N84388 001 Sep CRLD

>D> DIURIL

>D> AB MERCK 250MG N11145 004 Sep DISC

>A> @ 250MG N11145 004 Sep DISC

>D> AB + 500MG N11145 002 Sep DISC

>A> @ 500MG N11145 002 Sep DISC

CHLORPHENIRAMINE MALEATE

TABLET; ORAL
CHLORPHENIRAMINE MALEATE

@ MUTUAL PHARM 4MG N80700 001 Aug CAHN

CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL
CODEPREX

+ CELLTECH PHARMS EQ 4MG MALEATE/5ML;EQ 20MG
BASE/5ML N21369 001 Jun 21, 2004 Jun NEWA

CHLORTHALIDONE

TABLET; ORAL
CHLORTHALIDONE

@ MUTUAL PHARM 25MG N87292 001 Aug CAHN

@ 50MG N87293 001 Aug CAHN

CHORIOGONADOTROPIN ALFA

INJECTABLE; INJECTION

OVIDREL

@ SERONO INC

0.25MG/VIAL

N21149 001 Sep 20, 2000 May DISC

INJECTABLE; SUBCUTANEOUS

OVIDREL

+ SERONO INC

EQ 0.25MG /0.5ML

N21149 002 Oct 06, 2003 Apr CPOT

CHROMIC CHLORIDE

INJECTABLE; INJECTION

CHROMIC CHLORIDE IN PLASTIC CONTAINER

+ HOSPIRA

EQ 0.004MG CHROMIUM/ML

N18961 001 Jun 26, 1986 May CAHN

CICLOPIROX

SUSPENSION; TOPICAL

CICLOPIROX

AB ALTANA

0.77%

N76422 001 Aug 06, 2004 Aug NEWA

LOPROX

AT + MEDICIS

0.77%

N19824 001 Dec 30, 1988 Aug CFTG

CIMETIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

CIMETIDINE HCL

AP HOSPIRA

EQ 300MG BASE/2ML

N74296 001 Mar 28, 1997 May CAHN

AP

EQ 300MG BASE/2ML

N74344 001 Jan 31, 1995 May CAHN

AP

EQ 300MG BASE/2ML

N74345 001 Jan 31, 1995 May CAHN

AP

EQ 300MG BASE/2ML

N74412 001 Mar 28, 1997 May CAHN

AP

EQ 300MG BASE/2ML

N74422 001 Jan 31, 1995 May CAHN

CIMETIDINE HCL IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP HOSPIRA

EQ 6MG BASE/ML

N74269 001 Dec 27, 1994 May CAHN

+

EQ 90MG BASE/100ML

N74468 005 Dec 29, 1994 May CAHN

+

EQ 120MG BASE/100ML

N74468 006 Dec 29, 1994 May CAHN

+

EQ 180MG BASE/100ML

N74468 003 Dec 29, 1994 May CAHN

+

EQ 240MG BASE/100ML

N74468 004 Dec 29, 1994 May CAHN

+

EQ 360MG BASE/100ML

N74468 001 Dec 29, 1994 May CAHN

+

EQ 480MG BASE/100ML

N74468 002 Dec 29, 1994 May CAHN

CINACALCET HYDROCHLORIDE

TABLET; ORAL

SENSIPAR

AMGEN

EQ 30MG BASE

N21688 001 Mar 08, 2004 Mar NEWA

EQ 60MG BASE

N21688 002 Mar 08, 2004 Mar NEWA

+

EQ 90MG BASE

N21688 003 Mar 08, 2004 Mar NEWA

CIPROFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

CILOXAN

>D> + ALCON

EQ 0.3% BASE

N19992 001 Dec 31, 1990 Sep CFTG

>A> AT +

EQ 0.3% BASE

N19992 001 Dec 31, 1990 Sep CFTG

CIPROFLOXACIN

AT BAUSCH AND LOMB

EQ 0.3% BASE

N76754 001 Jun 09, 2004 Jun NEWA

AT NOVEX

EQ 0.3% BASE

N75928 001 Jun 09, 2004 Jun NEWA

TABLET; ORAL

CIPRO

AB BAYER PHARMS

EQ 100MG BASE

N19537 001 Apr 08, 1996 Jun CFTG

TABLET; ORAL

CIPRO

AB	BAYER PHARMS	EQ 250MG BASE	N19537 002	Oct 22, 1987	Jun	CFTG
AB		EQ 500MG BASE	N19537 003	Oct 22, 1987	Jun	CFTG
AB	+	EQ 750MG BASE	N19537 004	Oct 22, 1987	Jun	CFTG

CIPROFLOXACIN

AB	BARR	EQ 250MG BASE	N74124 001	Jun 09, 2004	Jun	NEWA	
AB		EQ 500MG BASE	N74124 002	Jun 09, 2004	Jun	NEWA	
AB		EQ 750MG BASE	N74124 003	Jun 09, 2004	Jun	NEWA	
AB	COBALT	EQ 250MG BASE	N76794 002	Jun 09, 2004	Jun	NEWA	
AB		EQ 500MG BASE	N76794 003	Jun 09, 2004	Jun	NEWA	
AB		EQ 750MG BASE	N76794 004	Jun 09, 2004	Jun	NEWA	
AB	DR REDDYS LABS LTD	EQ 100MG BASE	N75593 002	Jun 09, 2004	Jun	NEWA	
AB		EQ 250MG BASE	N75593 003	Jun 09, 2004	Jun	NEWA	
AB		EQ 500MG BASE	N75593 004	Jun 09, 2004	Jun	NEWA	
AB		EQ 750MG BASE	N75593 001	Jun 09, 2004	Jun	NEWA	
AB	EON	EQ 250MG BASE	N76593 002	Jun 09, 2004	Jun	NEWA	
AB		EQ 500MG BASE	N76593 003	Jun 09, 2004	Jun	NEWA	
AB		EQ 750MG BASE	N76593 004	Jun 09, 2004	Jun	NEWA	
AB	GENPHARM	EQ 250MG BASE	N75817 002	Jun 09, 2004	Jun	NEWA	
AB		EQ 500MG BASE	N75817 003	Jun 09, 2004	Jun	NEWA	
AB		EQ 750MG BASE	N75817 004	Jun 09, 2004	Jun	NEWA	
AB	HIKMA	EQ 250MG BASE	N76558 002	Jun 09, 2004	Jun	NEWA	
AB		EQ 500MG BASE	N76558 003	Jun 09, 2004	Jun	NEWA	
AB		EQ 750MG BASE	N76558 004	Jun 09, 2004	Jun	NEWA	
AB	IVAX PHARMS	EQ 250MG BASE	N76089 002	Jun 09, 2004	Jun	NEWA	
AB		EQ 500MG BASE	N76089 003	Jun 09, 2004	Jun	NEWA	
AB		EQ 750MG BASE	N76089 004	Jun 09, 2004	Jun	NEWA	
AB	MARTEC	EQ 250MG BASE	N76138 001	Jun 09, 2004	Jun	NEWA	
AB		EQ 500MG BASE	N76138 002	Jun 09, 2004	Jun	NEWA	
AB		EQ 750MG BASE	N76138 003	Jun 09, 2004	Jun	NEWA	
AB	MYLAN	EQ 250MG BASE	N75685 002	Jun 09, 2004	Jun	NEWA	
AB		EQ 500MG BASE	N75685 003	Jun 09, 2004	Jun	NEWA	
AB		EQ 750MG BASE	N75685 001	Jun 09, 2004	Jun	NEWA	
AB	RANBAXY	EQ 250MG BASE	N75747 001	Jun 09, 2004	Jun	NEWA	
AB		EQ 500MG BASE	N75747 002	Jun 09, 2004	Jun	NEWA	
AB		EQ 750MG BASE	N75747 003	Jun 09, 2004	Jun	NEWA	
AB	SANDOZ	EQ 250MG BASE	N75939 002	Jun 09, 2004	Jun	NEWA	
AB		EQ 500MG BASE	N75939 003	Jun 09, 2004	Jun	NEWA	
AB		EQ 750MG BASE	N75939 004	Jun 09, 2004	Jun	NEWA	
AB	TEVA	EQ 250MG BASE	N76136 001	Jun 09, 2004	Jun	NEWA	
AB		EQ 500MG BASE	N76136 002	Jun 09, 2004	Jun	NEWA	
AB		EQ 750MG BASE	N76136 003	Jun 09, 2004	Jun	NEWA	
>A>	AB	UNIQUE PHARM LABS	EQ 250MG BASE	N76639 001	Sep 10, 2004	Sep	NEWA
>A>	AB		EQ 500MG BASE	N76639 002	Sep 10, 2004	Sep	NEWA
>A>	AB		EQ 750MG BASE	N76639 003	Sep 10, 2004	Sep	NEWA

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

CIPRO XR

+	BAYER PHARMS	425.2MG;EQ 574.9MG BASE	N21473 002	Aug 28, 2003	Feb	CDFR
---	--------------	-------------------------	------------	--------------	-----	------

CITRIC ACID; MAGNESIUM OXIDE; SODIUM CARBONATE

SOLUTION; IRRIGATION

UROLOGIC G IN PLASTIC CONTAINER

AT	HOSPIRA	3.24GM/100ML;380MG/100ML;430MG/100ML	N18904 001	May 27, 1983	May	CAHN
----	---------	--------------------------------------	------------	--------------	-----	------

CLADRIBINE

INJECTABLE; INJECTION

CLADRIBINE

AP AM PHARM 1MG/ML N76571 001 Apr 22, 2004 Apr NEWA

CLARITHROMYCIN

TABLET, EXTENDED RELEASE; ORAL

BIAXIN XL

AB + ABBOTT 500MG N50775 001 Mar 03, 2000 Jun CFTG

CLARITHROMYCIN

AB ANDRX PHARMS 500MG N65145 001 Jun 24, 2004 Jun NEWA

TABLET; ORAL

BIAXIN

AB + ABBOTT 250MG N50662 001 Oct 31, 1991 May CFTG

AB + 500MG N50662 002 Oct 31, 1991 May CFTG

CLARITHROMYCIN

>A> AB RANBAXY 250MG N65174 001 Sep 24, 2004 Sep NEWA

>A> AB 500MG N65174 002 Sep 24, 2004 Sep NEWA

AB ROXANE 250MG N65178 002 May 25, 2004 May NEWA

AB 500MG N65178 001 May 25, 2004 May NEWA

CLEMASTINE FUMARATE

TABLET; ORAL

CLEMASTINE FUMARATE

AB + TEVA 2.68MG N73283 001 Jan 31, 1992 Mar CRLD

TAVIST

@ NOVARTIS 2.68MG N17661 001 Mar DISC

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL

CLINDAMYCIN HCL

AB COREPHARMA EQ 150MG BASE N65194 001 Mar 22, 2004 Mar NEWA

AB EQ 300MG BASE N65194 002 Mar 22, 2004 Mar NEWA

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION; ORAL

CLEOCIN

+ PHARMACIA AND UPJOHN EQ 75MG BASE/5ML N62644 001 Apr 07, 1986 May CRLD

CLINDAMYCIN PHOSPHATE

INJECTABLE; INJECTION

CLINDAMYCIN PHOSPHATE

@ BAXTER HLTHCARE EQ 150MG BASE/ML N62953 001 Apr 21, 1988 Aug CAHN

>A> AP BEDFORD EQ 150MG BASE/ML N65206 001 Sep 24, 2004 Sep NEWA

AP HOSPIRA EQ 150MG BASE/ML N62800 001 Jul 24, 1987 May CAHN

AP EQ 150MG BASE/ML N62801 001 Jul 24, 1987 May CAHN

@ EQ 150MG BASE/ML N62943 001 Sep 29, 1986 May CAHN

SOLUTION; TOPICAL

CLINDAMYCIN PHOSPHATE

AT TARO PHARM INDS EQ 1% BASE N65184 001 Mar 31, 2004 Mar NEWA

CLOBETASOL PROPIONATE

SHAMPOO; TOPICAL

CLOBEX

+ GALDERMA LABS 0.05% N21644 001 Feb 05, 2004 Feb NEWA

CLONIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

DURACLON

AAIPHARMA

0.1MG/ML

N20615 001 Oct 02, 1996 Jun CRLD

+

0.5MG/ML

N20615 002 Apr 27, 1999 Jun NEWA

TABLET; ORAL

CLONIDINE HCL

AB

MUTUAL PHARM

0.1MG

N70925 001 Sep 04, 1987 Aug CAHN

@

0.2MG

N70924 001 Sep 04, 1987 Aug CAHN

@

0.3MG

N70923 001 Sep 04, 1987 Aug CAHN

CLORAZEPATE DIPOTASSIUM

CAPSULE; ORAL

CLORAZEPATE DIPOTASSIUM

@ SANDOZ

7.5MG

N72220 001 Aug 26, 1988 Aug DISC

TABLET; ORAL

CLORAZEPATE DIPOTASSIUM

>A> AB

RANBAXY

3.75MG

N76911 001 Sep 29, 2004 Sep NEWA

>A> AB

7.5MG

N76911 002 Sep 29, 2004 Sep NEWA

>A> AB

15MG

N76911 003 Sep 29, 2004 Sep NEWA

CLOTRIMAZOLE

TROCHE/LOZENGE; ORAL

CLOTRIMAZOLE

AB

ROXANE

10MG

N76387 001 Jul 29, 2004 Jul NEWA

MYCELEX

AB

+

BAYER PHARMS

10MG

N18713 001 Jun 17, 1983 Jul CFTG

CLOZAPINE

TABLET, ORALLY DISINTEGRATING; ORAL

FAZACLO

ALAMO PHARMS

25MG

N21590 001 Feb 10, 2004 Feb NEWA

+

100MG

N21590 002 Feb 10, 2004 Feb NEWA

FAZACLO ODT

ALAMO PHARMS

25MG

N21590 001 Feb 10, 2004 Jul CTNA

+

100MG

N21590 002 Feb 10, 2004 Jul CTNA

COLISTIMETHATE SODIUM

INJECTABLE; INJECTION

COLISTIMETHATE

AP

PADDOCK

EQ 150MG BASE/VIAL

N65177 001 Mar 19, 2004 Mar NEWA

CROMOLYN SODIUM

AEROSOL, METERED; INHALATION

INTAL

+

KING PHARMS

0.8MG/INH

N18887 001 Dec 05, 1985 Jan CAHN

SOLUTION; INHALATION

INTAL

AN

+

KING PHARMS

10MG/ML

N18596 001 May 28, 1982 Jan CAHN

CUPRIC CHLORIDE

INJECTABLE; INJECTION

CUPRIC CHLORIDE IN PLASTIC CONTAINER

+

HOSPIRA

EQ 0.4MG COPPER/ML

N18960 001 Jun 26, 1986 May CAHN

CYANOCOBALAMIN

INJECTABLE; INJECTION

CYANOCOBALAMIN

>D>	AP	BIONICHE ANIM HLTH	1MG/ML	N40451 001	Sep 23, 2003	Sep	CAHN
	AP		1MG/ML	N40451 001	Sep 23, 2003	Apr	CAHN
>A>	AP	BIONICHE PHARMA	1MG/ML	N40451 001	Sep 23, 2003	Sep	CAHN

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL

CYCLOBENZAPRINE HCL

AB		MUTUAL PHARM	10MG	N73541 001	May 23, 1995	Aug	CAHN
----	--	--------------	------	------------	--------------	-----	------

CYCLOSPORINE

SOLUTION; ORAL

CYCLOSPORINE

>D>	AB	ABBOTT	100MG/ML	N65025 001	Mar 03, 2000	Sep	CTEC
>A>	AB1		100MG/ML	N65025 001	Mar 03, 2000	Sep	CTEC
>A>	AB2	MORTON GROVE	100MG/ML	N65133 001	Sep 17, 2004	Sep	NEWA
>D>	AB	PLIVA	100MG/ML	N65054 001	Dec 18, 2001	Sep	CTEC
>A>	AB1		100MG/ML	N65054 001	Dec 18, 2001	Sep	CTEC
		NEORAL					
>D>	AB	+ NOVARTIS	100MG/ML	N50716 001	Jul 14, 1995	Sep	CTEC
>A>	AB1	+	100MG/ML	N50716 001	Jul 14, 1995	Sep	CTEC
		SANDIMMUNE					
>D>	BX	+ NOVARTIS	100MG/ML	N50574 001	Nov 14, 1983	Sep	CFTG
>A>	AB2	+	100MG/ML	N50574 001	Nov 14, 1983	Sep	CFTG

CYPROHEPTADINE HYDROCHLORIDE

SYRUP; ORAL

CYPROHEPTADINE HCL

+	ALPHARMA	2MG/5ML	N86833 001			Aug	CRLD
	PERIACTIN						
	@ MERCK	2MG/5ML	N13220 002			Aug	DISC

CYSTEINE HYDROCHLORIDE

INJECTABLE; INJECTION

CYSTEINE HCL

@	HOSPIRA	7.25%	N19523 001	Oct 22, 1986	Aug	CAHN
---	---------	-------	------------	--------------	-----	------

CYTARABINE

INJECTABLE; INJECTION

CYTARABINE

AP		AM PHARM	100MG/ML	N76512 001	Jan 15, 2004	Jan	NEWA
AP	+	MAYNE PHARMA USA	100MG/ML	N75383 001	Nov 22, 1999	Jan	CFTG

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

DAUNORUBICIN HCL

AP		BIGMAR BIOREN PHARMS	EQ 20MG BASE/VIAL	N65000 001	May 25, 1999	Jul	CAHN
----	--	----------------------	-------------------	------------	--------------	-----	------

DEFEROXAMINE MESYLATE

INJECTABLE; INJECTION

DEFEROXAMINE MESYLATE

AP		ABBOTT	500MG/VIAL	N76019 001	Mar 17, 2004	Mar	NEWA
AP			2GM/VIAL	N76019 002	Mar 17, 2004	Mar	NEWA

INJECTABLE; INJECTION

DEFEROXAMINE MESYLATE

AP	HOSPIRA	500MG/VIAL	N76019 001	Mar 17, 2004	May	CAHN
AP		2GM/VIAL	N76019 002	Mar 17, 2004	May	CAHN
DESFERAL						
AP	+ NOVARTIS	500MG/VIAL	N16267 001		Mar	CFTG
AP	+	2GM/VIAL	N16267 002	May 25, 2000	Mar	CFTG

DEMECLOCYCLINE HYDROCHLORIDE

TABLET; ORAL

DECLOMYCIN

AB	ESP PHARMA	150MG	N50261 002		Mar	CFTG
AB	+	300MG	N50261 003		Mar	CFTG

DEMECLOCYCLINE HCL

AB	IMPAX LABS	150MG	N65094 001	Mar 22, 2004	Mar	NEWA
AB		300MG	N65094 002	Mar 22, 2004	Mar	NEWA

DESERPIDINE; METHYLCLOTHIAZIDE

TABLET; ORAL

ENDURONYL

@ ABBOTT

0.25MG;5MG

N12775 001

Jun DISC

ENDURONYL FORTE

@ ABBOTT

0.5MG;5MG

N12775 002

Jun DISC

DESIRUDIN

INJECTABLE; SUBCUTANEOUS

I PRIVASK

+ CANYON

15MG/VIAL

N21271 001

Apr 04, 2003 Apr CAHN

DESLORATADINE

SYRUP; ORAL

CLARINEX

+ SCHERING

0.5MG/ML

N21300 001

Sep 01, 2004 Sep NEWA

>A>
>A>
>A>

DESMOPRESSIN ACETATE

INJECTABLE; INJECTION

DESMOPRESSIN ACETATE

AF	HOSPIRA	0.004MG/ML	N75220 001	Aug 28, 2000	May	CAHN
----	---------	------------	------------	--------------	-----	------

SPRAY, METERED; NASAL

STIMATE

>D>	+ AVENTIS BEHRING	0.15MG/SPRAY	N20355 001	Mar 07, 1994	Sep	CAHN
>A>	+ ZLB BEHRING	0.15MG/SPRAY	N20355 001	Mar 07, 1994	Sep	CAHN

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-28

CYCLESSA

AB	+ ORGANON USA INC	0.1MG, 0.125MG, 0.15MG; 0.025MG, 0.025MG, 0.025MG	N21090 001	Dec 20, 2000	Feb	CFTG
----	-------------------	---	------------	--------------	-----	------

VELIVET

AB	DURAMED PHARMS BARR	0.1MG, 0.125MG, 0.15MG; 0.025MG, 0.025MG, 0.025MG	N76455 001	Feb 24, 2004	Feb	NEWA
----	---------------------	---	------------	--------------	-----	------

DESOXIMETASONE

CREAM; TOPICAL

TOPICORT

AB	+ TARO PHARMS NORTH	0.25%	N17856 001		Jun	CAHN
----	---------------------	-------	------------	--	-----	------

CREAM; TOPICAL

Code	Manufacturer	Strength	NDA Number	Effective Date	Approval Date	Status
AB +	TARO PHARMS NORTH	0.05%	N18309 001		Jun	CAHN
GEL; TOPICAL						
AB +	TARO PHARMS NORTH	0.05%	N18586 001	Mar 29, 1982	Jun	CAHN
OINTMENT; TOPICAL						
AB +	TARO PHARMS NORTH	0.05%	N18594 001	Jan 17, 1985	Jun	CAHN
AB +		0.25%	N18763 001	Sep 30, 1983	Jun	CAHN

DEXAMETHASONE

TABLET; ORAL

DEXAMETHASONE

@ MUTUAL PHARM

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

DEXAMETHASONE SODIUM PHOSPHATE

SOLUTION/DROPS; OPHTHALMIC, OTIC

DECADRON

>D>	AT +	MERCK	EQ 0.1% PHOSPHATE	N11984 001	Sep	DISC
>A>		@	EQ 0.1% PHOSPHATE	N11984 001	Sep	DISC

DEXAMETHASONE SODIUM PHOSPHATE

>D>	AT	ALCON UNIVERSAL	EQ 0.1% PHOSPHATE	N88771 001	Jan 16, 1985	Sep	CRLD
>A>	AT +		EQ 0.1% PHOSPHATE	N88771 001	Jan 16, 1985	Sep	CRLD

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION/DROPS; OPHTHALMIC

DEXACIDIN

@ NOVARTIS

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

DEXMEDETOMIDINE

INJECTABLE; INJECTION

PRECEDEX

+ HOSPIRA EQ 100UGM BASE/ML

N21038 001 Dec 17, 1999 May CAHN

DEXRAZOXANE HYDROCHLORIDE

INJECTABLE; INJECTION

DEXRAZOXANE

>A>	AP	BEDFORD	EQ 250MG BASE/VIAL	N76068 001	Sep 28, 2004	Sep	NEWA
>A>	AP		EQ 500MG BASE/VIAL	N76068 002	Sep 28, 2004	Sep	NEWA

ZINECARD

>D>	+	PHARMACIA AND UPJOHN	EQ 250MG BASE/VIAL	N20212 001	May 26, 1995	Sep	CFTG
>A>	AP +		EQ 250MG BASE/VIAL	N20212 001	May 26, 1995	Sep	CFTG
>D>	+		EQ 500MG BASE/VIAL	N20212 002	May 26, 1995	Sep	CFTG
>A>	AP +		EQ 500MG BASE/VIAL	N20212 002	May 26, 1995	Sep	CFTG

DEXTROAMPHETAMINE SULFATECAPSULE, EXTENDED RELEASE; ORAL
DEXTROAMPHETAMINE SULFATE

AB	ABLE	5MG	N76814 001	Aug 25, 2004	Aug	NEWA
AB		10MG	N76814 002	Aug 25, 2004	Aug	NEWA
AB		15MG	N76814 003	Aug 25, 2004	Aug	NEWA

DEXTROSE

INJECTABLE; INJECTION

AP	DEXTROSE 10% IN PLASTIC CONTAINER HOSPIRA	10GM/100ML	N18080 001		May	CAHN
	DEXTROSE 2.5% IN PLASTIC CONTAINER @ B BRAUN	2.5GM/100ML	N18358 001		May	DISC
AP	DEXTROSE 20% IN PLASTIC CONTAINER HOSPIRA	20GM/100ML	N18564 001	Mar 23, 1982	May	CAHN
	DEXTROSE 25% HOSPIRA	250MG/ML	N19445 002	Nov 23, 1998	May	CAHN
AP	DEXTROSE 30% IN PLASTIC CONTAINER HOSPIRA	30GM/100ML	N19345 001	Jan 26, 1985	May	CAHN
AP	DEXTROSE 40% IN PLASTIC CONTAINER HOSPIRA	40GM/100ML	N18562 001	Mar 23, 1982	May	CAHN
AP	DEXTROSE 5% IN PLASTIC CONTAINER HOSPIRA	50MG/ML	N16367 002		May	CAHN
AP		50MG/ML	N19222 001	Jul 13, 1984	May	CAHN
AP		5GM/100ML	N19466 001	Jul 15, 1985	May	CAHN
AP		5GM/100ML	N19479 001	Sep 17, 1985	May	CAHN
	DEXTROSE 50% IN PLASTIC CONTAINER @ HOSPIRA	500MG/ML	N19445 001	Jun 03, 1986	May	CAHN
AP		50GM/100ML	N18563 001	Mar 23, 1982	May	CAHN
AP		50GM/100ML	N19894 001	Dec 26, 1989	May	CAHN
AP	DEXTROSE 60% IN PLASTIC CONTAINER HOSPIRA	60GM/100ML	N19346 001	Jan 25, 1985	May	CAHN
AP	DEXTROSE 70% IN PLASTIC CONTAINER HOSPIRA	70GM/100ML	N18561 001	Mar 23, 1982	May	CAHN
AP		70GM/100ML	N19893 001	Dec 26, 1989	May	CAHN

DEXTROSE; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

	NORMOSOL-M AND DEXTROSE 5% IN PLASTIC CONTAINER HOSPIRA	5GM/100ML; 21MG/100ML; 128MG/100ML; 234MG/100ML	N17610 001		May	CAHN
--	--	--	------------	--	-----	------

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE

INJECTABLE; INJECTION

	ISOLYTE P W/ DEXTROSE 5% IN PLASTIC CONTAINER @ B BRAUN	5GM/100ML; 31MG/100ML; 130MG/100ML; 26MG/100ML; 320MG/100ML	N19025 001	Dec 27, 1984	May	DISC
--	--	--	------------	--------------	-----	------

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS

INJECTABLE; INJECTION

	IONOSOL B AND DEXTROSE 5% IN PLASTIC CONTAINER HOSPIRA	5GM/100ML; 53MG/100ML; 100MG/100ML; 100MG/100ML; 180MG/100ML; 280MG/100 ML; 16MG/100ML	N19515 001	May 08, 1986	May	CAHN
--	---	--	------------	--------------	-----	------

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS

INJECTABLE; INJECTION

IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA	5GM/100ML;30MG/100ML;141MG/100ML; 15MG/100ML;260MG/100ML;25MG/100ML	N19513 001	May 08, 1986	May	CAHN
---------	--	------------	--------------	-----	------

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER

@ B BRAUN	5GM/100ML;30MG/100ML;97MG/100ML;2 20MG/100ML;140MG/100ML	N18273 001		May	DISC
-----------	---	------------	--	-----	------

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION

NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA	5GM/100ML;30MG/100ML;37MG/100ML;2 22MG/100ML;525MG/100ML;502MG/100M L	N17609 001		May	CAHN
---------	---	------------	--	-----	------

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA	5GM/100ML;149MG/100ML	N18371 001		May	CAHN
---------	-----------------------	------------	--	-----	------

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	HOSPIRA	5GM/100ML;224MG/100ML	N18371 003		May	CAHN
----	---------	-----------------------	------------	--	-----	------

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA	5GM/100ML;298MG/100ML	N18371 002		May	CAHN
---------	-----------------------	------------	--	-----	------

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM LACTATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS

INJECTABLE; INJECTION

IONOSOL T AND DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA	5GM/100ML;111MG/100ML;256MG/100ML ;146MG/100ML;207MG/100ML	N19514 001	May 08, 1986	May	CAHN
---------	---	------------	--------------	-----	------

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

ISOLYTE M W/ DEXTROSE 5% IN PLASTIC CONTAINER

@ B BRAUN	5GM/100ML;150MG/100ML;130MG/100ML ;280MG/100ML;91MG/100ML	N18270 001		May	DISC
-----------	--	------------	--	-----	------

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

HOSPIRA	5GM/100ML;74.5MG/100ML;225MG/100M L	N18365 002	Jul 05, 1983	May	CAHN
---------	--	------------	--------------	-----	------

	5GM/100ML;149MG/100ML;225MG/100ML	N18365 006	Mar 28, 1988	May	CAHN
--	-----------------------------------	------------	--------------	-----	------

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

HOSPIRA	5GM/100ML;74.5MG/100ML;300MG/100M L	N18876 001	Jan 17, 1986	May	CAHN
---------	--	------------	--------------	-----	------

	5GM/100ML;149MG/100ML;300MG/100ML	N18876 006	Mar 28, 1988	May	CAHN
--	-----------------------------------	------------	--------------	-----	------

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	HOSPIRA	5GM/100ML;74.5MG/100ML;450MG/100M L	N18362 005	Mar 28, 1988	May	CAHN
----	---------	--	------------	--------------	-----	------

AP		5GM/100ML;74.5MG/100ML;450MG/100M L	N18362 009	Jul 05, 1983	May	CAHN
----	--	--	------------	--------------	-----	------

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	HOSPIRA	5GM/100ML;74.5MG/100ML;900MG/100M L	N19691 002	Mar 24, 1988	May	CAHN
----	---------	--	------------	--------------	-----	------

INJECTABLE; INJECTION

AP	POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER HOSPIRA	5GM/100ML;149MG/100ML;900MG/100ML	N19691 004	Mar 24, 1988	May	CAHN
	POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER HOSPIRA	5GM/100ML;224MG/100ML;225MG/100ML	N18365 008	Mar 28, 1988	May	CAHN
	POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER HOSPIRA	5GM/100ML;224MG/100ML;300MG/100ML	N18876 007	Mar 28, 1988	May	CAHN
AP	POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER HOSPIRA	5GM/100ML;224MG/100ML;450MG/100ML	N18362 006	Mar 28, 1988	May	CAHN
AP	POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER HOSPIRA	5GM/100ML;224MG/100ML;900MG/100ML	N19691 006	Mar 24, 1988	May	CAHN
	POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER HOSPIRA	5GM/100ML;149MG/100ML;225MG/100ML	N18365 001		May	CAHN
		5GM/100ML;298MG/100ML;225MG/100ML	N18365 009	Mar 28, 1988	May	CAHN
	POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER HOSPIRA	5GM/100ML;298MG/100ML;300MG/100ML	N18876 008	Mar 28, 1988	May	CAHN
AP	POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER HOSPIRA	5GM/100ML;149MG/100ML;450MG/100ML	N18362 010	Jul 05, 1983	May	CAHN
AP		5GM/100ML;298MG/100ML;450MG/100ML	N18362 007	Mar 28, 1988	May	CAHN
AP	POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER HOSPIRA	5GM/100ML;149MG/100ML;900MG/100ML	N19691 005	Mar 24, 1988	May	CAHN
AP		5GM/100ML;298MG/100ML;900MG/100ML	N19691 008	Mar 24, 1988	May	CAHN
	POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER HOSPIRA	5GM/100ML;149MG/100ML;300MG/100ML	N18876 002	Jan 17, 1986	May	CAHN
	POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER HOSPIRA	5GM/100ML;224MG/100ML;225MG/100ML	N18365 003	Jul 05, 1983	May	CAHN
	POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER HOSPIRA	5GM/100ML;224MG/100ML;300MG/100ML	N18876 003	Jan 17, 1986	May	CAHN
AP	POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER HOSPIRA	5GM/100ML;224MG/100ML;450MG/100ML	N18362 002		May	CAHN
AP	POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER HOSPIRA	5GM/100ML;224MG/100ML;900MG/100ML	N19691 007	Mar 24, 1988	May	CAHN
	POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER HOSPIRA	5GM/100ML;298MG/100ML;225MG/100ML	N18365 004	Jul 05, 1983	May	CAHN
	POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER HOSPIRA	5GM/100ML;298MG/100ML;300MG/100ML	N18876 004	Mar 28, 1988	May	CAHN
AP	POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER HOSPIRA	5GM/100ML;298MG/100ML;450MG/100ML	N18362 003		May	CAHN
AP	POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER HOSPIRA	5GM/100ML;298MG/100ML;900MG/100ML	N19691 009	Mar 24, 1988	May	CAHN
	POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER HOSPIRA	5GM/100ML;74.5MG/100ML;225MG/100ML	N18365 005	Mar 28, 1988	May	CAHN
		5GM/100ML;149MG/100ML;225MG/100ML	N18365 007	Mar 28, 1988	May	CAHN
	POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER HOSPIRA	5GM/100ML;74.5MG/100ML;300MG/100ML	N18876 005	Mar 28, 1988	May	CAHN
		5GM/100ML;149MG/100ML;300MG/100ML	N18876 009	Mar 28, 1988	May	CAHN
AP	POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER HOSPIRA	5GM/100ML;74.5MG/100ML;450MG/100ML	N18362 008	Mar 28, 1988	May	CAHN
AP		5GM/100ML;149MG/100ML;450MG/100ML	N18362 004	Mar 28, 1988	May	CAHN
AP	POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER HOSPIRA	5GM/100ML;74.5MG/100ML;900MG/100ML	N19691 001	Mar 24, 1988	May	CAHN
AP		5GM/100ML;149MG/100ML;900MG/100ML	N19691 003	Mar 24, 1988	May	CAHN

DICLOXACILLIN SODIUM

	CAPSULE; ORAL						
	DICLOXACILLIN SODIUM						
	SANDOZ	EQ 125MG BASE	N61454	002		Mar	CAHN
AB		EQ 250MG BASE	N61454	001		Mar	CAHN
AB	+	EQ 500MG BASE	N61454	003		Mar	CAHN

DICYCLOMINE HYDROCHLORIDE

	CAPSULE; ORAL						
	DICYCLOMINE HCL						
	@ MUTUAL PHARM	10MG	N84505	001	Oct 21, 1986	Aug	CAHN
	TABLET; ORAL						
	DICYCLOMINE HCL						
	@ MUTUAL PHARM	20MG	N84600	001	Jul 29, 1985	Aug	CAHN

DIDANOSINE

	FOR SOLUTION; ORAL						
	VIDEX						
+	BRISTOL MYERS SQUIBB	10MG/ML	N20156	001	Oct 09, 1991	Jun	CRLD
	@	100MG/PACKET	N20155	003	Oct 09, 1991	Jun	DISC
	@	167MG/PACKET	N20155	004	Oct 09, 1991	Jun	DISC
	@	250MG/PACKET	N20155	005	Oct 09, 1991	Jun	DISC
	TABLET, CHEWABLE; ORAL						
	VIDEX						
	BRISTOL MYERS SQUIBB	25MG	N20154	002	Oct 09, 1991	Jul	CRLD
+		200MG	N20154	006	Oct 28, 1999	Jul	CRLD

DIENESTROL

	CREAM; VAGINAL						
	DIENESTROL						
	@ ORTHO MCNEIL PHARM	0.01%	N06110	005		Jul	CAHN

DIGOXIN

	ELIXIR; ORAL						
	DIGOXIN						
+	ROXANE	0.05MG/ML	N21648	001	Aug 26, 2004	Aug	NEWA
	INJECTABLE; INJECTION						
	DIGOXIN						
AP	BAXTER HLTHCARE	0.25MG/ML	N83391	001		Aug	CAHN
AP	HOSPIRA	0.25MG/ML	N40093	001	May 16, 1996	May	CAHN
AP		0.25MG/ML	N40206	001	Aug 28, 1998	May	CAHN
	DIGOXIN PEDIATRIC						
AP	HOSPIRA	0.1MG/ML	N40092	001	Apr 25, 1996	May	CAHN

DILTIAZEM HYDROCHLORIDE

	CAPSULE, EXTENDED RELEASE; ORAL						
	CARDIZEM SR						
	@ AVENTIS PHARMS	60MG	N19471	001	Jan 23, 1989	Jun	DISC
	@	90MG	N19471	002	Jan 23, 1989	Jun	DISC
	@	120MG	N19471	003	Jan 23, 1989	Jun	DISC
	DILT-CD						
AB3	TORPHARM	120MG	N76151	001	May 20, 2004	May	NEWA
AB3		180MG	N76151	002	May 20, 2004	May	NEWA
AB3		240MG	N76151	003	May 20, 2004	May	NEWA
AB3		300MG	N76151	004	May 20, 2004	May	NEWA

CAPSULE, EXTENDED RELEASE; ORAL

DILTIAZEM HCL

	@ BIOVAIL	60MG	N74845 001	Sep 15, 1999	Jun	DISC
	@	90MG	N74845 002	Sep 15, 1999	Jun	DISC
	@	120MG	N74845 003	Sep 15, 1999	Jun	DISC
+	MYLAN	60MG	N74910 001	May 02, 1997	Jun	CRLD
+		90MG	N74910 002	May 02, 1997	Jun	CRLD
+		120MG	N74910 003	May 02, 1997	Jun	CRLD
	@ TEVA	60MG	N74079 001	Nov 30, 1993	Jun	DISC
	@	90MG	N74079 002	Nov 30, 1993	Jun	DISC
	@	120MG	N74079 003	Nov 30, 1993	Jun	DISC

INJECTABLE; INJECTION

DILTIAZEM HCL

AP	HOSPIRA	5MG/ML	N74941 001	Apr 15, 1998	May	CAHN
AP		5MG/ML	N75004 001	Feb 16, 2000	May	CAHN
AP		100MG/VIAL	N75853 001	Dec 17, 2002	May	CAHN

TABLET, EXTENDED RELEASE; ORAL

CARDIZEM LA

	BIOVAIL	120MG	N21392 001	Feb 06, 2003	Jan	CRLD
		180MG	N21392 002	Feb 06, 2003	Jan	CRLD
		240MG	N21392 003	Feb 06, 2003	Jan	CRLD
		300MG	N21392 004	Feb 06, 2003	Jan	CRLD
		360MG	N21392 005	Feb 06, 2003	Jan	CRLD

DIMENHYDRINATE

INJECTABLE; INJECTION

DIMENHYDRINATE

AP	AM PHARM	50MG/ML	N40519 001	Jun 23, 2004	Jun	NEWA
AP	+ STERIS	50MG/ML	N80615 001		Jun	CFTG

DIMYRISTOYL LECITHIN; PERFLEXANE

INJECTABLE; INTRAVENOUS

IMAGENT

+	IMCOR PH	0.92MG/VIAL;0.092MG/VIAL	N21191 001	May 31, 2002	Feb	CAHN
---	----------	--------------------------	------------	--------------	-----	------

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL

DIPHENHYDRAMINE HCL

AA	MUTUAL PHARM	25MG	N84506 001		Aug	CAHN
----	--------------	------	------------	--	-----	------

INJECTABLE; INJECTION

DIPHENHYDRAMINE HCL

AP	HOSPIRA	50MG/ML	N40140 001	Nov 20, 1998	May	CAHN
----	---------	---------	------------	--------------	-----	------

DIPYRIDAMOLE

INJECTABLE; INJECTION

DIPYRIDAMOLE

AP	BAXTER HLTHCARE	5MG/ML	N74521 001	Oct 18, 1996	Aug	CAHN
AP	HOSPIRA	5MG/ML	N74601 001	Dec 19, 1997	May	CAHN

DIRITHROMYCIN

TABLET, DELAYED RELEASE; ORAL

DYNABAC

	@ LILLY RES LABS	250MG	N50678 001	Jun 19, 1995	Jul	DISC
--	------------------	-------	------------	--------------	-----	------

DISOPYRAMIDE PHOSPHATE

CAPSULE; ORAL

DISOPYRAMIDE PHOSPHATE

@ MUTUAL PHARM	EQ 100MG BASE	N70351 001	Dec 17, 1985	Aug	CAHN
@	EQ 150MG BASE	N70352 001	Dec 17, 1985	Aug	CAHN

DISULFIRAM

TABLET; ORAL

ANTABUSE

@ ODYSSEY PHARMS	250MG	N07883 003		Jun	CAHN
@	500MG	N07883 002		Jun	CAHN

DIVALPROEX SODIUM

TABLET, DELAYED RELEASE; ORAL

DEPAKOTE

ABBOTT

EQ 125MG VALPROIC ACID	N18723 003	Oct 26, 1984	Jan	CRLD
EQ 250MG VALPROIC ACID	N18723 001	Mar 10, 1983	Jan	CRLD

DOBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOBUTAMINE HCL

AP	HOSPIRA	EQ 12.5MG BASE/ML	N74086 001	Nov 29, 1993	May	CAHN	
AP		EQ 12.5MG BASE/ML	N74292 001	Feb 16, 1995	May	CAHN	
AP		EQ 1.25GM BASE/100ML	N74634 001	Sep 27, 1996	May	CAHN	
		DOBUTAMINE HCL IN DEXTROSE 5%					
AP	+	HOSPIRA	EQ 50MG BASE/100ML	N20269 001	Oct 19, 1993	May	CAHN
AP	+		EQ 100MG BASE/100ML	N20269 002	Oct 19, 1993	May	CAHN
AP	+		EQ 200MG BASE/100ML	N20269 003	Oct 19, 1993	May	CAHN
		DOBUTAMINE HCL IN DEXTROSE 5% IN PLASTIC CONTAINER					
AP	+	HOSPIRA	EQ 50MG BASE/100ML	N20201 003	Oct 19, 1993	May	CAHN
AP	+		EQ 100MG BASE/100ML	N20201 002	Oct 19, 1993	May	CAHN
AP	+		EQ 200MG BASE/100ML	N20201 001	Oct 19, 1993	May	CAHN
AP	+		EQ 400MG BASE/100ML	N20201 006	Jul 07, 1994	May	CAHN
		DOBUTREX					
	@ LILLY	EQ 12.5MG BASE/ML	N17820 002		Jun	DISC	

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOPAMINE HCL

AP	+	HOSPIRA	40MG/ML	N18132 001		May	CAHN
AP			40MG/ML	N74403 001	May 23, 1996	May	CAHN
AP	+		80MG/100ML	N18132 002	Feb 04, 1982	May	CAHN
AP	+		80MG/ML	N18132 004	Jul 09, 1982	May	CAHN
AP	+		160MG/100ML	N18132 003	Feb 04, 1982	May	CAHN
		DOPAMINE HCL IN DEXTROSE 5%					
	@ HOSPIRA	1.6MG/ML	N20542 001	Aug 30, 1995	Jun	DISC	
AP	+	1.6MG/ML	N20542 001	Aug 30, 1995	May	CAHN	
		DOPAMINE HCL IN DEXTROSE 5% IN PLASTIC CONTAINER					
AP	+	HOSPIRA	80MG/100ML	N18826 001	Sep 30, 1983	May	CAHN
AP	+		160MG/100ML	N18826 002	Sep 30, 1983	May	CAHN
AP	+		320MG/100ML	N18826 003	Sep 30, 1983	May	CAHN

DOXAZOSIN MESYLATE

TABLET; ORAL

DOXAZOSIN MESYLATE

AB	CLONMEL HLTHCARE	EQ 1MG BASE	N76161 001	Jun 10, 2004	Jun	NEWA
AB		EQ 2MG BASE	N76161 002	Jun 10, 2004	Jun	NEWA
AB		EQ 4MG BASE	N76161 003	Jun 10, 2004	Jun	NEWA
AB		EQ 8MG BASE	N76161 004	Jun 10, 2004	Jun	NEWA

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL

DOXEPIN HCL

	@ MUTUAL PHARM	EQ 25MG BASE	N71502 001	Feb 18, 1988	Aug	CAHN
	@	EQ 50MG BASE	N71653 001	Feb 18, 1988	Aug	CAHN
	@	EQ 75MG BASE	N71654 001	Feb 18, 1988	Aug	CAHN
	@	EQ 100MG BASE	N71521 001	Feb 18, 1988	Aug	CAHN
>D>	AB SANDOZ	EQ 25MG BASE	N70827 001	May 15, 1986	Sep	DISC
>A>	@	EQ 25MG BASE	N70827 001	May 15, 1986	Sep	DISC
>D>	AB	EQ 50MG BASE	N70828 001	May 15, 1986	Sep	DISC
>A>	@	EQ 50MG BASE	N70828 001	May 15, 1986	Sep	DISC
>D>	AB	EQ 100MG BASE	N71562 001	Mar 02, 1987	Sep	DISC
>A>	@	EQ 100MG BASE	N71562 001	Mar 02, 1987	Sep	DISC

CONCENTRATE; ORAL

DOXEPIN HCL

AA	PHARM ASSOC	EQ 10MG BASE/ML	N75924 001	Jan 15, 2004	Jan	NEWA
----	-------------	-----------------	------------	--------------	-----	------

CREAM; TOPICAL

ZONALON

+	BIOGLAN PHARMS CORP	5%	N20126 001	Apr 01, 1994	Aug	CAHN
---	---------------------	----	------------	--------------	-----	------

DOXERCALCIFEROL

CAPSULE; ORAL

HECTOROL

BONE CARE

		0.5UGM	N20862 002	Apr 23, 2004	Apr	NEWA
--	--	--------	------------	--------------	-----	------

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

ADRIAMYCIN RDF

@ PHARMACIA AND UPJOHN

@

@

		10MG/VIAL	N50467 001		Jun	DISC
		20MG/VIAL	N50467 003	May 20, 1985	Jun	DISC
		50MG/VIAL	N50467 002		Jun	DISC

DOXYCYCLINE

CAPSULE; ORAL

DOXYCYCLINE

AB	WATSON LABS	EQ 50MG BASE	N65041 001	Apr 28, 2000	Apr	CAHN
AB		EQ 100MG BASE	N65041 002	Apr 28, 2000	Apr	CAHN

DOXYCYCLINE HYCLATE

CAPSULE, COATED PELLETS; ORAL

DORYX

FH FAULDING CO LTD

AB	+		N50582 002	Aug 13, 2001	Jul	CAHN
----	---	--	------------	--------------	-----	------

CAPSULE; ORAL

DOXYCYCLINE HYCLATE

@ MUTUAL PHARM

@

		EQ 50MG BASE	N62418 001	Jan 28, 1983	Aug	CAHN
		EQ 100MG BASE	N62418 002	Jan 28, 1983	Aug	CAHN

	CAPSULE; ORAL						
	DOXYCYCLINE HYCLATE						
AB	WATSON LABS	EQ 50MG BASE	N61717 001		Apr	CAHN	
AB		EQ 100MG BASE	N61717 002		Apr	CAHN	
	TABLET; ORAL						
	DOXYCYCLINE HYCLATE						
	@ MUTUAL PHARM	EQ 100MG BASE	N62391 001	Sep 30, 1982	Aug	CAHN	
	<u>DROPERIDOL</u>						
	INJECTABLE; INJECTION						
	DROPERIDOL						
AP	HOSPIRA	2.5MG/ML	N71981 001	Feb 29, 1988	May	CAHN	
AP		2.5MG/ML	N72272 001	Aug 31, 1995	May	CAHN	
>D>	<u>DROPERIDOL; FENTANYL CITRATE</u>						
>D>	INJECTABLE; INJECTION						
>D>	FENTANYL CITRATE AND DROPERIDOL						
>D>	+	HOSPIRA	2.5MG/ML;EQ 0.05MG BASE/ML	N71982 001	May 04, 1988	Sep	DISC
>A>	@		2.5MG/ML;EQ 0.05MG BASE/ML	N71982 001	May 04, 1988	Sep	DISC
	+		2.5MG/ML;EQ 0.05MG BASE/ML	N71982 001	May 04, 1988	May	CAHN
	<u>DULOXETINE HYDROCHLORIDE</u>						
>A>	CAPSULE, DELAYED REL PELLETS; ORAL						
>A>	CYMBALTA						
>A>	LILLY	EQ 20MG BASE	N21733 001	Sep 03, 2004	Sep	NEWA	
>A>		EQ 30MG BASE	N21733 002	Sep 03, 2004	Sep	NEWA	
>A>	+	EQ 60MG BASE	N21733 004	Sep 03, 2004	Sep	NEWA	
	CAPSULE; ORAL						
	CYMBALTA						
	LILLY	EQ 20MG BASE	N21427 001	Aug 03, 2004	Aug	NEWA	
		EQ 30MG BASE	N21427 002	Aug 03, 2004	Aug	NEWA	
	+	EQ 60MG BASE	N21427 004	Aug 03, 2004	Aug	NEWA	
	<u>ECONAZOLE NITRATE</u>						
	CREAM; TOPICAL						
	ECONAZOLE NITRATE						
AB	CLAY PARK	1%	N76479 001	Jun 23, 2004	Jun	NEWA	
	<u>EDETATE DISODIUM</u>						
	INJECTABLE; INJECTION						
	EDETATE DISODIUM						
>D>	AP	STERIS	150MG/ML	N80391 001		Sep	DISC
>A>	@		150MG/ML	N80391 001		Sep	DISC
	ENDRATE						
AP	+	HOSPIRA	150MG/ML	N11355 001		May	CAHN
	<u>EDROPHONIUM CHLORIDE</u>						
	INJECTABLE; INJECTION						
	EDROPHONIUM CHLORIDE						
AP	HOSPIRA	10MG/ML	N40131 001	Feb 24, 1998	May	CAHN	
	<u>EFAVIRENZ</u>						
	TABLET; ORAL						
	SUSTIVA						
	@ BRISTOL MYERS SQUIBB	300MG	N21360 001	Feb 01, 2002	Jun	DISC	

EFLORNITHINE HYDROCHLORIDE

CREAM; TOPICAL

VANIQA

+ SKINMEDICA 13.9% N21145 001 Jul 27, 2000 Jul CAHN

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

TRUVADA

+ GILEAD 200MG;300MG N21752 001 Aug 02, 2004 Aug NEWA

ENALAPRILAT

INJECTABLE; INJECTION

ENALAPRILAT

AP HOSPIRA 1.25MG/ML N75456 001 Aug 22, 2000 May CAHN

AP 1.25MG/ML N75458 001 Aug 22, 2000 May CAHN

EPINEPHRINE

INJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS

EPINEPHRINE

+ HOLLISTER STIER LABS EQ 0.15MG /DELIVERY N20800 002 May 28, 2004 May NEWA

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HCL AND EPINEPHRINE

AP HOSPIRA 0.005MG/ML;0.5% N89635 001 Jun 21, 1988 May CAHN

AP 0.005MG/ML;1% N89649 001 Jun 21, 1988 May CAHN

AP 0.005MG/ML;1.5% N88571 001 Sep 13, 1985 May CAHN

AP 0.005MG/ML;1.5% N89645 001 Jun 21, 1988 May CAHN

AP 0.005MG/ML;1.5% N89650 001 Jun 21, 1988 May CAHN

AP 0.005MG/ML;2% N89651 001 Jun 21, 1988 May CAHN

AP 0.01MG/ML;1% N89644 001 Jun 21, 1988 May CAHN

AP 0.01MG/ML;2% N89646 001 Jun 21, 1988 May CAHN

PATCH; IONTOPHORESIS

LIDOSITE TOPICAL SYSTEM KIT

+ VYTERIS 1.05MG/PATCH;100MG/PATCH N21504 001 May 06, 2004 May NEWA

SOLUTION; IONTOPHORESIS

IONTOCAINE

+ IOMED 0.01MG/ML;2% N20530 001 Dec 21, 1995 May MAGC

ERGOLOID MESYLATES

TABLET; ORAL

ERGOLOID MESYLATES

@ MUTUAL PHARM

1MG

N88891 001 Nov 01, 1985 Aug CAHN

TABLET; SUBLINGUAL

ERGOLOID MESYLATES

@ MUTUAL PHARM

0.5MG

N87407 001 Aug CAHN

@

1MG

N87552 001 Aug CAHN

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS; ORAL

ERYC

AB WARNER CHILCOTT 250MG N62338 001 Jan CMFD

GEL; TOPICAL

ERYGEL

AT + MERZ PHARMS 2% N50617 001 Oct 21, 1987 Jul CAHN

OINTMENT; OPHTHALMIC								
ERYTHROMYCIN								
AT	+ FOUGERA	0.5%		N62447 001	Sep 26, 1983	Jul	CRLD	
	ILOTYCIN							
	@ DISTA	0.5%		N50368 001		Jul	DISC	
SOLUTION; TOPICAL								
C-SOLVE-2								
	@ BIOGLAN PHARMA	2%		N62468 001	Jul 03, 1985	Jun	DISC	
<u>ERYTHROMYCIN ESTOLATE</u>								
SUSPENSION; ORAL								
ERYTHROMYCIN ESTOLATE								
	ALPHARMA	EQ 125MG BASE/5ML		N62353 001	Nov 18, 1982	Jan	CTEC	
	+	EQ 250MG BASE/5ML		N62409 001	Dec 16, 1982	Jan	CRLD	
	ILOSONE							
	@ LILLY	EQ 125MG BASE/5ML		N50010 001		Jan	DISC	
	@	EQ 250MG BASE/5ML		N50010 002		Jan	DISC	
<u>ERYTHROMYCIN LACTOBIONATE</u>								
INJECTABLE; INJECTION								
ERYTHROCIN								
AP	+ HOSPIRA	EQ 500MG BASE/VIAL		N50182 002		May	CAHN	
AP		EQ 500MG BASE/VIAL		N50609 001	Sep 24, 1986	May	CAHN	
AP		EQ 500MG BASE/VIAL		N62638 001	Oct 31, 1986	May	CAHN	
AP	+	EQ 1GM BASE/VIAL		N50182 003		May	CAHN	
AP		EQ 1GM BASE/VIAL		N50609 002	Sep 24, 1986	May	CAHN	
AP		EQ 1GM BASE/VIAL		N62638 002	Oct 31, 1986	May	CAHN	
<u>ESCITALOPRAM OXALATE</u>								
TABLET; ORAL								
LEXAPRO								
	FOREST LABS	5MG		N21323 001	Aug 14, 2002	Apr	CMFD	
<u>ESMOLOL HYDROCHLORIDE</u>								
INJECTABLE; INJECTION								
BREVIBLOC								
AP	+ BAXTER HLTHCARE CORP	10MG/ML		N19386 006	Feb 25, 2003	Aug	CFTG	
ESMOLOL HCL								
AP	BEDFORD LABS	10MG/ML		N76323 001	Aug 10, 2004	Aug	NEWA	
<u>ESTRADIOL</u>								
FILM, EXTENDED RELEASE; TRANSDERMAL								
MENOSTAR								
	+ BERLEX LABS	0.014MG/24HR		N21674 001	Jun 08, 2004	Jun	NEWA	
VIVELLE								
AB1	+ NOVARTIS	0.025MG/24HR		N20323 005	Aug 16, 2000	Jul	CTEC	
	@	0.0375MG/24HR		N20323 001	Oct 28, 1994	Jul	DISC	
	@	0.075MG/24HR		N20323 003	Oct 28, 1994	Jul	DISC	
VIVELLE-DOT								
AB1	NOVARTIS	0.025MG/24HR		N20538 009	May 03, 2002	Jul	NEWA	
BX		0.0375MG/24HR		N20538 005	Jan 08, 1999	Jul	CTEC	
BX		0.075MG/24HR		N20538 007	Jan 08, 1999	Jul	CTEC	
GEL, METERED; TOPICAL								
ESTROGEL								
	+ SOLVAY	0.06%		N21166 002	Feb 09, 2004	Aug	CRLD	
		0.06%		N21166 002	Feb 09, 2004	Feb	NEWA	

GEL; TOPICAL

ESTROGEL

@ SOLVAY

0.06%

N21166 001 Feb 09, 2004 Aug DISC

0.06%

N21166 001 Feb 09, 2004 Feb NEWA

+

0.06%

N21166 001 Feb 09, 2004 Mar CRLD

ESTRADIOL ACETATE

INSERT, EXTENDED RELEASE; VAGINAL

FEMRING

GALEN LTD

EQ 0.05MG BASE/24HR

N21367 001 Mar 20, 2003 May CPOT

+

EQ 0.1MG BASE/24HR

N21367 002 Mar 20, 2003 May CPOT

TABLET; ORAL

FEMTRACE

WARNER CHILCOTT

0.45MG

N21633 001 Aug 20, 2004 Aug NEWA

0.9MG

N21633 002 Aug 20, 2004 Aug NEWA

+

1.8MG

N21633 003 Aug 20, 2004 Aug NEWA

ESTROGENS, CONJUGATED

TABLET; ORAL

PREMARIN

@ WYETH PHARMS INC

2.5MG

N04782 002 May DISC

ESTROGENS, CONJUGATED SYNTHETIC A

TABLET; ORAL

CENESTIN

DURAMED

0.45MG

N20992 005 Feb 05, 2004 Feb NEWA

ESTROGENS, CONJUGATED SYNTHETIC B

TABLET; ORAL

ENJUVIA

DURAMED

0.625MG

N21443 003 May 10, 2004 May NEWA

@

0.625MG

N21443 003 May 10, 2004 Jul DISC

+

1.25MG

N21443 004 May 10, 2004 May NEWA

@

1.25MG

N21443 004 May 10, 2004 Jul DISC

ETHAMBUTOL HYDROCHLORIDE

TABLET; ORAL

MYAMBUTOL

@ ELAN PHARMS

100MG

N16320 001 Feb CAHN

@

200MG

N16320 002 Feb CAHN

@

400MG

N16320 003 Feb CAHN

@

500MG

N16320 004 Feb CAHN

AB

STAT TRADE

100MG

N16320 001 May CMFD

@

200MG

N16320 002 May CAHN

AB

400MG

N16320 003 May CMFD

@

500MG

N16320 004 May CAHN

ETHINYL ESTRADIOL

TABLET; ORAL

ESTINYL

@ SCHERING

0.02MG

N05292 001 Apr DISC

@

0.05MG

N05292 002 Apr DISC

@

0.5MG

N05292 003 Apr DISC

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL							
PREVEN EMERGENCY CONTRACEPTIVE KIT							
+	DURAMED	0.05MG;0.25MG	N20946	001	Sep 01, 1998	Feb	CAHN
	@	0.05MG;0.25MG	N20946	001	Sep 01, 1998	Jul	DISC
TABLET; ORAL-21							
ALESSE							
	@ WYETH PHARMS INC	0.02MG;0.1MG	N20683	001	Mar 27, 1997	Aug	DISC
AVIANE-21							
+	DURAMED PHARMS BARR	0.02MG;0.1MG	N75796	002	Apr 30, 2001	Aug	CRLD
LEVLITE							
AB2	+ BERLEX	0.02MG;0.1MG	N20860	001	Jul 13, 1998	May	CTEC
TABLET; ORAL-28							
ALESSE							
AB1	+ WYETH PHARMS INC	0.02MG;0.1MG	N20683	002	Mar 27, 1997	Jul	CRLD
LESSINA-28							
AB2	BARR	0.02MG;0.1MG	N75803	002	Mar 20, 2002	May	CTEC
LEVLITE							
AB2	BERLEX	0.02MG;0.1MG	N20860	002	Jul 13, 1998	May	CTEC
AB2	+	0.02MG;0.1MG	N20860	002	Jul 13, 1998	Jul	CRLD
TRIPHASIL-28							
	@ WYETH PHARMS INC	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG	N19190	001	Nov 01, 1984	Aug	DISC

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21							
BALZIVA-21							
AB	BARR	0.035MG;0.4MG	N76198	001	Apr 22, 2004	Apr	NEWA
OVCON-35							
AB	+ WARNER CHILCOTT	0.035MG;0.4MG	N18127	001		Apr	CFTG
TABLET; ORAL-28							
ARANELLE							
>A>	AB	0.035MG,0.035MG,0.035MG;0.5MG,1MG,0.5MG	N76783	001	Sep 29, 2004	Sep	NEWA
BALZIVA-28							
AB	BARR	0.035MG;0.4MG	N76238	001	Apr 22, 2004	Apr	NEWA
ORTHO-NOVUM 1/35-28							
AB	+ ORTHO MCNEIL PHARM	0.035MG;1MG	N17919	002		Mar	CRLD
OVCON-35							
AB	+ WARNER CHILCOTT	0.035MG;0.4MG	N17716	001		Apr	CFTG
TRI-NORINYL 28-DAY							
>D>	+	0.035MG,0.035MG,0.035MG;0.5MG,1MG,0.5MG	N18977	002	Apr 13, 1984	Sep	CFTG
>A>	AB	0.035MG,0.035MG,0.035MG;0.5MG,1MG,0.5MG	N18977	002	Apr 13, 1984	Sep	CFTG

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL							
FEMHRT							
+	WARNER CHILCOTT	0.005MG;1MG	N21065	002	Oct 15, 1999	Aug	CAHN
TABLET; ORAL-21							
ESTROSTEP 21							
	@ WARNER CHILCOTT	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	N20130	001	Oct 09, 1996	Aug	CAHN
LOESTRIN 21 1.5/30							
AB	+ WARNER CHILCOTT	0.03MG;1.5MG	N17875	001		Aug	CAHN
LOESTRIN 21 1/20							
AB	+ WARNER CHILCOTT	0.02MG;1MG	N17876	001		Aug	CAHN

TABLET; ORAL-28

ESTROSTEP FE

	+	WARNER CHILCOTT	0.02MG, 0.03MG, 0.035MG; 1MG, 1MG, 1MG	N20130 002	Oct 09, 1996	Aug	CAHN
		LOESTRIN FE 1.5/30					
AB	+	WARNER CHILCOTT	0.03MG; 1.5MG	N17355 001		Aug	CAHN
		LOESTRIN FE 1/20					
AB	+	WARNER CHILCOTT	0.02MG; 1MG	N17354 001		Aug	CAHN

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET; ORAL-28

ORTHO TRI-CYCLEN LO

	+	ORTHO MCNEIL PHARM	0.025MG, 0.025MG, 0.25MG; 0.18MG, 0.215MG, 0.25MG	N21241 001	Aug 22, 2002	Jun	CAHN
		PREVIFEM					
AB		ANDRX PHARMS	0.035MG; 0.25MG	N76334 001	Jan 09, 2004	Jan	NEWA
		TRI-PREVIFEM					
AB		ANDRX PHARMS	0.035MG, 0.035MG, 0.035MG; 0.18MG, 0.215MG, 0.25MG	N76335 001	Mar 26, 2004	Mar	NEWA

ETHINYL ESTRADIOL; NORGESTREL

TABLET; ORAL-21

LO/OVRAL

		@ WYETH PHARMS INC	0.03MG; 0.3MG	N17612 001		Aug	DISC
		LOW-OGESTREL-21					
AB	+	WATSON LABS	0.03MG; 0.3MG	N75288 001	Jul 28, 1999	Aug	CRLD
		OGESTREL 0.5/50-21					
	+	WATSON LABS	0.05MG; 0.5MG	N75406 001	Dec 15, 1999	Aug	CRLD
		OVRAL					
		@ WYETH PHARMS INC	0.05MG; 0.5MG	N16672 001		Aug	DISC
		TABLET; ORAL-28					
		OGESTREL 0.5/50-28					
AB	+	WATSON LABS	0.05MG; 0.5MG	N75406 002	Dec 15, 1999	Aug	CRLD

ETIDRONATE DISODIUM

INJECTABLE; INJECTION

DIDRONEL

@ MGI PHARMA INC

50MG/ML

N19545 001 Apr 20, 1987 Jun DISC

ETODOLAC

TABLET, EXTENDED RELEASE; ORAL

LODINE XL

AB		WYETH PHARMS INC	400MG	N20584 001	Oct 25, 1996	May	CRLD
AB			500MG	N20584 003	Jan 20, 1998	May	CRLD
AB	+		500MG	N20584 003	Jan 20, 1998	Jul	CRLD
		@	600MG	N20584 002	Oct 25, 1996	Jul	DISC

ETOMIDATE

INJECTABLE; INJECTION

AMIDATE

AP	+	HOSPIRA	2MG/ML	N18227 001	Sep 07, 1982	May	CAHN
----	---	---------	--------	------------	--------------	-----	------

ETOPOSIDE

INJECTABLE; INJECTION

ETOPOSIDE

AP		HOSPIRA	20MG/ML	N74320 001	Aug 30, 1995	May	CAHN
AP			20MG/ML	N74351 001	Aug 30, 1995	May	CAHN

EZETIMIBE; SIMVASTATIN

TABLET; ORAL

VYTORIN

MSP SINGAPORE

10MG;10MG

N21687 001 Jul 23, 2004 Jul NEWA

10MG;20MG

N21687 002 Jul 23, 2004 Jul NEWA

10MG;40MG

N21687 003 Jul 23, 2004 Jul NEWA

+

10MG;80MG

N21687 004 Jul 23, 2004 Jul NEWA

FAMOTIDINE

INJECTABLE; INJECTION

FAMOTIDINE

AP HOSPIRA

10MG/ML

N75870 001 Nov 23, 2001 May CAHN

AP HOSPIRA

10MG/ML

N75905 001 Nov 23, 2001 May CAHN

>A> TABLET, ORALLY DISINTEGRATING; ORAL

>A> FLUXID

>A> SCHWARZ PHARMA

20MG

N21712 001 Sep 24, 2004 Sep NEWA

>A> +

40MG

N21712 002 Sep 24, 2004 Sep NEWA

FENOLDOPAM MESYLATE

INJECTABLE; INJECTION

CORLOPAM

AP + HOSPIRA

EQ 10MG BASE/ML

N19922 001 Sep 23, 1997 May CAHN

FENTANYL

FILM, EXTENDED RELEASE; TRANSDERMAL

DURAGESIC

+ ALZA

0.6MG/24HR

N19813 004 Aug 07, 1990 Jul CTEC

1.2MG/24HR

N19813 003 Aug 07, 1990 Jul CTEC

1.8MG/24HR

N19813 002 Aug 07, 1990 Jul CTEC

2.4MG/24HR

N19813 001 Aug 07, 1990 Jul CTEC

FENTANYL CITRATE

INJECTABLE; INJECTION

FENTANYL CITRATE

AP HOSPIRA

EQ 0.05MG BASE/ML

N19115 001 Jan 12, 1985 May CAHN

FENTANYL CITRATE PRESERVATIVE FREE

AP HOSPIRA

EQ 0.05MG BASE/ML

N72786 001 Sep 24, 1991 May CAHN

TROCHE/LOZENGE; ORAL

ACTIQ

CEPHALON

EQ 0.2MG BASE

N20747 001 Nov 04, 1998 Feb CAHN

>D> EQ 0.4MG BASE

N20747 002 Nov 04, 1998 Sep CRLD

>A> + EQ 0.4MG BASE

N20747 002 Nov 04, 1998 Sep CRLD

EQ 0.4MG BASE

N20747 002 Nov 04, 1998 Feb CAHN

EQ 0.6MG BASE

N20747 003 Nov 04, 1998 Feb CAHN

EQ 0.8MG BASE

N20747 004 Nov 04, 1998 Feb CAHN

EQ 1.2MG BASE

N20747 005 Nov 04, 1998 Feb CAHN

>D> + EQ 1.6MG BASE

N20747 006 Nov 04, 1998 Sep CRLD

>A> EQ 1.6MG BASE

N20747 006 Nov 04, 1998 Sep CRLD

+ EQ 1.6MG BASE

N20747 006 Nov 04, 1998 Feb CAHN

FLUCONAZOLE

FOR SUSPENSION; ORAL

DIFLUCAN

AB PFIZER

50MG/5ML

N20090 001 Dec 23, 1993 Jul CFTG

AB +

200MG/5ML

N20090 002 Dec 23, 1993 Jul CFTG

FOR SUSPENSION; ORAL

FLUCONAZOLE

AB	RANBAXY	50MG/5ML	N76332 001	Jul 29, 2004	Jul	NEWA
AB		200MG/5ML	N76332 002	Jul 29, 2004	Jul	NEWA
AB	ROXANE	50MG/5ML	N76246 001	Jul 29, 2004	Jul	NEWA
AB		200MG/5ML	N76246 002	Jul 29, 2004	Jul	NEWA

INJECTABLE; INJECTION

DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	+ PFIZER	200MG/100ML	N19950 003	Sep 29, 1992	Jul	CFTG
----	----------	-------------	------------	--------------	-----	------

DIFLUCAN IN SODIUM CHLORIDE 0.9%

AP	+ PFIZER	200MG/100ML	N19950 001	Jan 29, 1990	Jul	CFTG
----	----------	-------------	------------	--------------	-----	------

DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	+ PFIZER	200MG/100ML	N19950 002	Jan 29, 1990	Jul	CFTG
----	----------	-------------	------------	--------------	-----	------

FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	HOSPIRA	200MG/100ML	N76304 001	Jul 29, 2004	Jul	NEWA
----	---------	-------------	------------	--------------	-----	------

FLUCONAZOLE IN SODIUM CHLORIDE 0.9%

AP	AM PHARM PARTNERS	200MG/100ML	N76145 001	Jul 29, 2004	Jul	NEWA
----	-------------------	-------------	------------	--------------	-----	------

AP	BEDFORD	200MG/100ML	N76087 001	Jul 29, 2004	Jul	NEWA
----	---------	-------------	------------	--------------	-----	------

AP	SICOR PHARMS	200MG/100ML	N76653 001	Jul 29, 2004	Jul	NEWA
----	--------------	-------------	------------	--------------	-----	------

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	200MG/100ML	N76766 001	Jul 29, 2004	Jul	NEWA
----	-----------------	-------------	------------	--------------	-----	------

AP	HOSPIRA	200MG/100ML	N76303 001	Jul 29, 2004	Jul	NEWA
----	---------	-------------	------------	--------------	-----	------

AP	MAYNE PHARMA USA	200MG/100ML	N76617 001	Jul 29, 2004	Aug	CRLD
----	------------------	-------------	------------	--------------	-----	------

AP	+	200MG/100ML	N76617 001	Jul 29, 2004	Jul	NEWA
----	---	-------------	------------	--------------	-----	------

TABLET; ORAL

DIFLUCAN

AB	PFIZER	50MG	N19949 001	Jan 29, 1990	Jul	CFTG
----	--------	------	------------	--------------	-----	------

AB		100MG	N19949 002	Jan 29, 1990	Jul	CFTG
----	--	-------	------------	--------------	-----	------

AB		150MG	N19949 004	Jun 30, 1994	Jul	CFTG
----	--	-------	------------	--------------	-----	------

AB	+	200MG	N19949 003	Jan 29, 1990	Jul	CFTG
----	---	-------	------------	--------------	-----	------

FLUCONAZOLE

AB	DR REDDYS LABS INC	50MG	N76658 001	Jul 29, 2004	Jul	NEWA
----	--------------------	------	------------	--------------	-----	------

AB		100MG	N76658 002	Jul 29, 2004	Jul	NEWA
----	--	-------	------------	--------------	-----	------

AB		150MG	N76658 003	Jul 29, 2004	Jul	NEWA
----	--	-------	------------	--------------	-----	------

AB		200MG	N76658 004	Jul 29, 2004	Jul	NEWA
----	--	-------	------------	--------------	-----	------

AB	GEDEON RICHTER USA	50MG	N76432 001	Jul 29, 2004	Jul	NEWA
----	--------------------	------	------------	--------------	-----	------

AB		100MG	N76432 002	Jul 29, 2004	Jul	NEWA
----	--	-------	------------	--------------	-----	------

AB		150MG	N76432 003	Jul 29, 2004	Jul	NEWA
----	--	-------	------------	--------------	-----	------

AB		200MG	N76432 004	Jul 29, 2004	Jul	NEWA
----	--	-------	------------	--------------	-----	------

AB	GENPHARM	50MG	N76042 001	Jul 29, 2004	Jul	NEWA
----	----------	------	------------	--------------	-----	------

AB		100MG	N76042 002	Jul 29, 2004	Jul	NEWA
----	--	-------	------------	--------------	-----	------

AB		150MG	N76042 003	Jul 29, 2004	Jul	NEWA
----	--	-------	------------	--------------	-----	------

AB		200MG	N76042 004	Jul 29, 2004	Jul	NEWA
----	--	-------	------------	--------------	-----	------

AB	IVAX PHARMS	50MG	N76077 001	Jul 29, 2004	Jul	NEWA
----	-------------	------	------------	--------------	-----	------

AB		100MG	N76077 002	Jul 29, 2004	Jul	NEWA
----	--	-------	------------	--------------	-----	------

AB		150MG	N76077 003	Jul 29, 2004	Jul	NEWA
----	--	-------	------------	--------------	-----	------

AB		200MG	N76077 004	Jul 29, 2004	Jul	NEWA
----	--	-------	------------	--------------	-----	------

AB	MYLAN	50MG	N76351 001	Jul 29, 2004	Jul	NEWA
----	-------	------	------------	--------------	-----	------

AB		100MG	N76351 002	Jul 29, 2004	Jul	NEWA
----	--	-------	------------	--------------	-----	------

AB		150MG	N76351 003	Jul 29, 2004	Jul	NEWA
----	--	-------	------------	--------------	-----	------

AB		200MG	N76351 004	Jul 29, 2004	Jul	NEWA
----	--	-------	------------	--------------	-----	------

AB	PLIVA	50MG	N76424 001	Jul 29, 2004	Jul	NEWA
----	-------	------	------------	--------------	-----	------

AB		100MG	N76424 002	Jul 29, 2004	Jul	NEWA
----	--	-------	------------	--------------	-----	------

AB		150MG	N76424 003	Jul 29, 2004	Jul	NEWA
----	--	-------	------------	--------------	-----	------

AB		200MG	N76424 004	Jul 29, 2004	Jul	NEWA
----	--	-------	------------	--------------	-----	------

AB	RANBAXY	50MG	N76386 001	Jul 29, 2004	Jul	NEWA
----	---------	------	------------	--------------	-----	------

AB		100MG	N76386 002	Jul 29, 2004	Jul	NEWA
----	--	-------	------------	--------------	-----	------

TABLET; ORAL

FLUCONAZOLE

AB	RANBAXY	150MG	N76386 003	Jul 29, 2004	Jul	NEWA
AB		200MG	N76386 004	Jul 29, 2004	Jul	NEWA
AB	ROXANE	50MG	N76213 001	Jul 29, 2004	Jul	NEWA
AB		100MG	N76213 002	Jul 29, 2004	Jul	NEWA
AB		150MG	N76213 003	Jul 29, 2004	Jul	NEWA
AB		200MG	N76213 004	Jul 29, 2004	Jul	NEWA
AB	SANDOZ	50MG	N76086 001	Jul 29, 2004	Jul	NEWA
AB		100MG	N76086 002	Jul 29, 2004	Jul	NEWA
AB		150MG	N76086 003	Jul 29, 2004	Jul	NEWA
AB		200MG	N76086 004	Jul 29, 2004	Jul	NEWA
AB	TARO	50MG	N76507 001	Jul 29, 2004	Jul	NEWA
AB		100MG	N76507 002	Jul 29, 2004	Jul	NEWA
AB		150MG	N76507 003	Jul 29, 2004	Jul	NEWA
AB		200MG	N76507 004	Jul 29, 2004	Jul	NEWA
AB	TEVA	50MG	N74681 001	Jul 29, 2004	Jul	NEWA
AB		100MG	N74681 002	Jul 29, 2004	Jul	NEWA
AB		150MG	N74681 003	Jul 29, 2004	Jul	NEWA
AB		200MG	N74681 004	Jul 29, 2004	Jul	NEWA
AB	TORPHARM	50MG	N76665 001	Jul 29, 2004	Jul	NEWA
AB		100MG	N76665 002	Jul 29, 2004	Jul	NEWA
AB		150MG	N76665 003	Jul 29, 2004	Jul	NEWA
AB		200MG	N76665 004	Jul 29, 2004	Jul	NEWA

FLUDARABINE PHOSPHATE

INJECTABLE; INJECTION

FLUDARABINE PHOSPHATE

+	GENSIA SICOR PHARMS	50MG/2ML (25MG/ML)	N76661 001	Apr 28, 2004	Apr	NEWA
---	---------------------	--------------------	------------	--------------	-----	------

FLUDEOXYGLUCOSE, F-18

INJECTABLE; INJECTION

FLUDEOXYGLUCOSE F 18

@ DOWNSTATE CLINCL 4-90mCi/ML

N20306 002 Sep 25, 2001 May DISC

INJECTABLE; INTRAVENOUS

FLUDEOXYGLUCOSE F 18

+	WEILL MEDCL COLL	10-100mCi/ML	N21768 001	Aug 05, 2004	Aug	NEWA
---	------------------	--------------	------------	--------------	-----	------

N21768 001 Aug 05, 2004 Aug NEWA

FLUNISOLIDE

SPRAY, METERED; NASAL

FLUNISOLIDE

+	BAUSCH AND LOMB	0.025MG/SPRAY	N74805 001	Feb 20, 2002	Jun	CRLD
---	-----------------	---------------	------------	--------------	-----	------

N74805 001 Feb 20, 2002 Jun CRLD

NASALIDE

@ IVAX RES 0.025MG/SPRAY

N18148 001 Jun DISC

FLUOCINONIDE

CREAM; TOPICAL

FLUOCINONIDE EMULSIFIED BASE

AB2	ALTANA	0.05%	N76586 001	Jun 23, 2004	Jun	NEWA
-----	--------	-------	------------	--------------	-----	------

FLUOROURACIL

INJECTABLE; INJECTION

FLUOROURACIL

AP	BIGMAR BIOREN PHARMS	50MG/ML	N40291 001	Mar 24, 1999	Jul	CAHN
----	----------------------	---------	------------	--------------	-----	------

AP		50MG/ML	N40379 001	Nov 15, 2000	Jul	CAHN
----	--	---------	------------	--------------	-----	------

FLUOXETINE HYDROCHLORIDE

	CAPSULE; ORAL						
	FLUOXETINE						
>A>	AB	IVAX PHARMS	EQ 40MG BASE	N75245 003	Sep 28, 2004	Sep	NEWA
	SOLUTION; ORAL						
	FLUOXETINE HCL						
AA		PAR PHARM	EQ 20MG BASE/5ML	N76458 001	May 14, 2004	May	NEWA
	TABLET; ORAL						
	FLUOXETINE						
AB		IVAX PHARMS	EQ 40MG BASE	N75865 003	Aug 30, 2004	Aug	NEWA
	FLUOXETINE HCL						
AB		IVAX PHARMS	EQ 10MG BASE	N75865 001	Feb 28, 2002	Aug	CAHN

FLUPHENAZINE DECANOATE

	INJECTABLE; INJECTION						
	FLUPHENAZINE DECANOATE						
		@ MAYNE PHARMA USA	25MG/ML	N74966 001	Apr 16, 1998	Apr	CAHN

FLUPHENAZINE HYDROCHLORIDE

	CONCENTRATE; ORAL						
	PERMITIL						
		@ SCHERING	5MG/ML	N16008 001		Jun	DISC

FLURAZEPAM HYDROCHLORIDE

	CAPSULE; ORAL						
	FLURAZEPAM HCL						
		@ MUTUAL PHARM	15MG	N70454 001	Aug 04, 1986	Aug	CAHN
		@	30MG	N70455 001	Aug 04, 1986	Aug	CAHN

FLUTICASONE PROPIONATE

	AEROSOL, METERED; INHALATION						
	FLOVENT HFA						
		GLAXOSMITHKLINE	0.044MG/INH	N21433 003	May 14, 2004	May	NEWA
			0.11MG/INH	N21433 002	May 14, 2004	May	NEWA
		+	0.22MG/INH	N21433 001	May 14, 2004	May	NEWA
	CREAM; TOPICAL						
	CUTIVATE						
AB	+	GLAXOSMITHKLINE	0.05%	N19958 001	Dec 18, 1990	May	CFTG
	FLUTICASONE PROPIONATE						
AB		ALTANA	0.05%	N76451 001	May 14, 2004	May	NEWA
AB		ATRIX	0.05%	N76633 001	May 14, 2004	May	NEWA
AB		CLAY PARK	0.05%	N76793 001	May 14, 2004	May	NEWA
>A>	AB	KV PHARM	0.05%	N76865 001	Sep 10, 2004	Sep	NEWA
	OINTMENT; TOPICAL						
	CUTIVATE						
AB	+	GLAXOSMITHKLINE	0.005%	N19957 001	Dec 14, 1990	May	CFTG
	FLUTICASONE PROPIONATE						
AB		ALTANA	0.005%	N76300 001	May 14, 2004	May	NEWA
AB		CLAY PARK	0.005%	N76668 001	May 14, 2004	May	NEWA

FOLLITROPIN ALFA/BETA

	INJECTABLE; IM-SC						
	FOLLISTIM						
BX		ORGANON USA INC	75 IU/VIAL	N20582 001	Sep 29, 1997	Mar	CDFR
		@	75 IU/VIAL	N20582 001	Sep 29, 1997	Aug	DISC

INJECTABLE; IM-SC

FOLLISTIM

	+	ORGANON USA INC	75 IU/VIAL	N20582 001	Sep 29, 1997	Jun	CTEC
BX			150 IU/VIAL	N20582 002	Sep 29, 1997	Mar	CDFR
	+		150 IU/VIAL	N20582 002	Sep 29, 1997	Jun	CTEC
	@		150 IU/VIAL	N20582 002	Sep 29, 1997	Aug	DISC

INJECTABLE; SUBCUTANEOUS

FOLLISTIM AQ

		ORGANON USA INC	300 IU/0.525ML	N21211 001	Mar 23, 2004	Mar	NEWA
	+		600 IU/0.885ML	N21211 002	Mar 23, 2004	Mar	NEWA

GONAL-F

SERONO INC

			37.5 IU/VIAL	N21765 001	Mar 25, 2004	Mar	NEWA
	@		37.5 IU/VIAL	N21765 001	Mar 25, 2004	May	DISC
BX			75 IU/VIAL	N20378 001	Sep 29, 1997	Mar	CDFR
	@		75 IU/VIAL	N20378 001	Sep 29, 1997	Jun	DISC
			75 IU/VIAL	N21765 002	Mar 25, 2004	Mar	NEWA
	+		75 IU/VIAL	N21765 002	Mar 25, 2004	Jun	CRLD
BX			150 IU/VIAL	N20378 002	Sep 29, 1997	Mar	CDFR
	@		150 IU/VIAL	N20378 002	Sep 29, 1997	Jun	DISC
	+		150 IU/VIAL	N21765 003	Mar 25, 2004	Mar	NEWA
	@		150 IU/VIAL	N21765 003	Mar 25, 2004	May	DISC
			450 IU/VIAL	N20378 005	Mar 26, 2004	Mar	NEWA
	+		1,050 IU/VIAL	N20378 004	Feb 28, 2001	Apr	CPOT
	+		1,200 IU/VIAL	N20378 004	Feb 28, 2001	Mar	CAIN

GONAL-F RFE PEN

SERONO INC

			300 IU/0.5ML	N21684 001	May 25, 2004	May	NEWA
			450 IU/0.75ML	N21684 002	May 25, 2004	May	NEWA
	+		900 IU/1.5ML	N21684 003	May 25, 2004	May	NEWA

FOMIVIRSEN SODIUM

INJECTABLE; INJECTION

VITRAVENE PRESERVATIVE FREE

	+	NOVARTIS	6.6MG/ML	N20961 001	Aug 26, 1998	Jan	CAHN
--	---	----------	----------	------------	--------------	-----	------

FONDAPARINUX SODIUM

INJECTABLE; SUBCUTANEOUS

ARIXTRA

	+	FONDA BV	5MG/0.4ML	N21345 002	May 28, 2004	May	NEWA
	+		7.5MG/0.6ML	N21345 003	May 28, 2004	May	NEWA
	+		10MG/0.8ML	N21345 004	May 28, 2004	May	NEWA
	+	GLAXOSMITHKLINE	2.5MG/0.5ML	N21345 001	Dec 07, 2001	Aug	CAHN
	+		5MG/0.4ML	N21345 002	May 28, 2004	Aug	CAHN
	+		7.5MG/0.6ML	N21345 003	May 28, 2004	Aug	CAHN
	+		10MG/0.8ML	N21345 004	May 28, 2004	Aug	CAHN

FOSINOPRIL SODIUM

TABLET; ORAL

FOSINOPRIL SODIUM

AB		EON	10MG	N76483 001	Apr 23, 2004	Apr	NEWA
AB			20MG	N76483 002	Apr 23, 2004	Apr	NEWA
AB			40MG	N76483 003	Apr 23, 2004	Apr	NEWA
AB		RANBAXY	10MG	N76580 001	Apr 23, 2004	Apr	NEWA
AB			20MG	N76580 002	Apr 23, 2004	Apr	NEWA
AB			40MG	N76580 003	Apr 23, 2004	Apr	NEWA

FROVATRIPTAN SUCCINATE

TABLET; ORAL

FROVA

+	ENDO PHARMS	EQ 2.5MG BASE	N21006 001	Nov 08, 2001	Aug	CAHN
+	VERNALIS	EQ 2.5MG BASE	N21006 001	Nov 08, 2001	May	CAHN

FUROSEMIDE

INJECTABLE; INJECTION

FUROSEMIDE

AP	HOSPIRA	10MG/ML	N18667 001	May 28, 1982	May	CAHN
AP		10MG/ML	N70578 001	Jul 08, 1987	May	CAHN
AP		10MG/ML	N72080 001	Aug 13, 1991	May	CAHN
AP		10MG/ML	N74337 001	Oct 31, 1994	May	CAHN
AP		10MG/ML	N75241 001	May 28, 1999	May	CAHN

TABLET; ORAL

FUROSEMIDE

	@ MUTUAL PHARM	20MG	N70043 001	Sep 26, 1985	Aug	CAHN
	@	40MG	N18790 001	Nov 29, 1983	Aug	CAHN
	@	80MG	N70100 001	Jan 26, 1988	Aug	CAHN
AB	VINTAGE PHARMS	20MG	N76796 001	Mar 26, 2004	Mar	NEWA
AB		40MG	N76796 002	Mar 26, 2004	Mar	NEWA
AB		80MG	N76796 003	Mar 26, 2004	Mar	NEWA
>D>	AB WATSON LABS	40MG	N70413 001	Feb 26, 1986	Sep	DISC
>A>	@	40MG	N70413 001	Feb 26, 1986	Sep	DISC

GABAPENTIN

TABLET; ORAL

GABAPENTIN

	IVAX PHARMS	100MG	N76017 001	Apr 28, 2004	Apr	NEWA
		300MG	N76017 002	Apr 28, 2004	Apr	NEWA
		400MG	N76017 003	Apr 28, 2004	Apr	NEWA

GANIRELIX ACETATE

INJECTABLE; INJECTION

GANIRELIX ACETATE INJECTION

+	ORGANON USA INC	EQ 250UGM BASE/0.5ML	N21057 001	Jul 29, 1999	Jun	CTNA
---	-----------------	----------------------	------------	--------------	-----	------

GATIFLOXACIN

SUSPENSION; ORAL

TEQUIN

+	BRISTOL MYERS SQUIBB	200MG/5ML	N21678 001	Aug 27, 2004	Aug	NEWA
---	----------------------	-----------	------------	--------------	-----	------

GEMIFLOXACIN MESYLATE

TABLET; ORAL

FACTIVE

+	OSCIENT	EQ 320MG BASE	N21158 001	Apr 04, 2003	Apr	CAHN
---	---------	---------------	------------	--------------	-----	------

GENTAMICIN SULFATE

INJECTABLE; INJECTION

GENTAMICIN SULFATE

AP	HOSPIRA	EQ 10MG BASE/ML	N62420 001	Aug 15, 1983	May	CAHN
AP		EQ 10MG BASE/ML	N62612 004	Feb 20, 1986	May	CAHN
AP		EQ 40MG BASE/ML	N62420 002	Aug 15, 1983	May	CAHN
	GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
AP	HOSPIRA	EQ 1.2MG BASE/ML	N62414 001	Aug 15, 1983	May	CAHN

INJECTABLE; INJECTION

GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	@ HOSPIRA	EQ 1.2MG BASE/ML	N62588 001	Jan 06, 1986	May	CAHN
AP		EQ 1.4MG BASE/ML	N62414 002	Aug 15, 1983	May	CAHN
	@	EQ 1.4MG BASE/ML	N62588 002	Jan 06, 1986	May	CAHN
AP		EQ 1.6MG BASE/ML	N62414 003	Aug 15, 1983	May	CAHN
	@	EQ 1.6MG BASE/ML	N62588 003	Jan 06, 1986	May	CAHN
AP		EQ 1.8MG BASE/ML	N62414 004	Aug 15, 1983	May	CAHN
	@	EQ 1.8MG BASE/ML	N62588 004	Jan 06, 1986	May	CAHN
AP		EQ 2MG BASE/ML	N62414 005	Aug 15, 1983	May	CAHN
	@	EQ 2MG BASE/ML	N62588 005	Jan 06, 1986	May	CAHN
AP		EQ 60MG BASE/100ML	N62414 006	Aug 15, 1983	May	CAHN
	@	EQ 60MG BASE/100ML	N62588 006	Jan 06, 1986	May	CAHN
AP		EQ 70MG BASE/100ML	N62414 007	Aug 15, 1983	May	CAHN
	@	EQ 70MG BASE/100ML	N62588 007	Jan 06, 1986	May	CAHN
AP		EQ 80MG BASE/100ML	N62414 008	Aug 15, 1983	May	CAHN
	@	EQ 80MG BASE/100ML	N62588 008	Jan 06, 1986	May	CAHN
AP		EQ 90MG BASE/100ML	N62414 009	Aug 15, 1983	May	CAHN
	@	EQ 90MG BASE/100ML	N62588 009	Jan 06, 1986	May	CAHN
AP		EQ 100MG BASE/100ML	N62414 010	Aug 15, 1983	May	CAHN
	@	EQ 100MG BASE/100ML	N62588 010	Jan 06, 1986	May	CAHN

OINTMENT; OPHTHALMIC

GENTAMICIN SULFATE

AT	+ AKORN	EQ 0.3% BASE	N64093 001	Aug 31, 1995	Jul	CFTG
AT	ALTANA	EQ 0.3% BASE	N65024 001	Jul 30, 2004	Jul	NEWA

SOLUTION/DROPS; OPHTHALMIC

GARAMYCIN

AT	+ SCHERING	EQ 0.3% BASE	N50039 002		Jan	CDFR
----	------------	--------------	------------	--	-----	------

GENTAMICIN SULFATE

AT	ALTANA	EQ 3% BASE	N65121 001	Jan 30, 2004	Jan	NEWA
----	--------	------------	------------	--------------	-----	------

GLIPIZIDE

TABLET; ORAL

GLIPIZIDE

AB	KALI LABS	5MG	N74550 001	Sep 11, 1997	Aug	CAHN
AB		10MG	N74550 002	Sep 11, 1997	Aug	CAHN

>D> GLUTAMINE

>D> FOR SOLUTION; ORAL

>D> NUTRESTORE

>D>	+ NUTRITIONAL RESTART	5GM/PACKET	N21667 001	Jun 10, 2004	Sep	DISC
>A>	@	5GM/PACKET	N21667 001	Jun 10, 2004	Sep	DISC
	+	5GM/PACKET	N21667 001	Jun 10, 2004	Jul	CMS2

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLUCOVANCE

AB	BRISTOL MYERS SQUIBB	1.25MG;250MG	N21178 001	Jul 31, 2000	Feb	CFTG
AB		2.5MG;500MG	N21178 002	Jul 31, 2000	Feb	CFTG
AB	+	5MG;500MG	N21178 003	Jul 31, 2000	Feb	CFTG

GLYBURIDE AND METFORMIN HCL

AB	IVAX PHARMS	1.25MG;250MG	N76345 001	Feb 18, 2004	Feb	NEWA
AB		2.5MG;500MG	N76345 002	Feb 18, 2004	Feb	NEWA
AB		5MG;500MG	N76345 003	Feb 18, 2004	Feb	NEWA

GLYCINE

SOLUTION; IRRIGATION

GLYCINE 1.5% IN PLASTIC CONTAINER

AT	HOSPIRA	1.5GM/100ML	N17633 001	May	CAHN
AT		1.5GM/100ML	N18315 001	May	CAHN

GLYCOPYRROLATE

INJECTABLE; INJECTION

GLYCOPYRROLATE

@	HOSPIRA	0.2MG/ML	N89393 001	Jun 15, 1988	May	CAHN
---	---------	----------	------------	--------------	-----	------

GONADORELIN HYDROCHLORIDE

INJECTABLE; INJECTION

FACTREL

@	BAXTER HLTHCARE CORP	EQ 0.1MG BASE/VIAL	N18123 001	Sep 30, 1982	Jun	DISC
---	----------------------	--------------------	------------	--------------	-----	------

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION

KYTRIL

>A>	+	ROCHE	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	N20239 003	Sep 17, 2004	Sep	NEWA
>A>	+		EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N20239 004	Mar 11, 1994	Sep	NEWA
>D>	+		EQ 1MG BASE/ML	N20239 002	Mar 11, 1994	Sep	CPOT
>A>	+		EQ 4MG BASE/4ML (EQ 1MG BASE /ML)	N20239 002	Mar 11, 1994	Sep	CPOT

GRISEOFULVIN, MICROCRYSTALLINE

TABLET; ORAL

FULVICIN-U/F

>D>	AB	SCHERING	250MG	N60569 002		Sep	CRLD
>A>	AB	+	250MG	N60569 002		Sep	CRLD

GRISEOFULVIN, ULTRAMICROCRYSTALLINE

TABLET; ORAL

FULVICIN P/G

@	SCHERING	125MG	N61996 001		Jun	DISC
---	----------	-------	------------	--	-----	------

@		250MG	N61996 002		Jun	DISC
---	--	-------	------------	--	-----	------

FULVICIN P/G 165

@	SCHERING	165MG	N61996 003	Apr 06, 1982	Jun	DISC
---	----------	-------	------------	--------------	-----	------

FULVICIN P/G 330

@	SCHERING	330MG	N61996 004	Apr 06, 1982	Jun	DISC
---	----------	-------	------------	--------------	-----	------

GRIS-PEG

>D>	AB	PEDINOL	125MG	N50475 001		Sep	CTEC
>A>			125MG	N50475 001		Sep	CTEC
	+		250MG	N50475 002		Jun	CRLD

HALAZEPAM

TABLET; ORAL

PAXIPAM

@	SCHERING	20MG	N17736 003		Apr	DISC
---	----------	------	------------	--	-----	------

@		40MG	N17736 004		Apr	DISC
---	--	------	------------	--	-----	------

HALOPERIDOL

TABLET; ORAL

HALOPERIDOL

@	MUTUAL PHARM	0.5MG	N71156 001	Jan 02, 1987	Aug	CAHN
---	--------------	-------	------------	--------------	-----	------

@		1MG	N71157 001	Jan 02, 1987	Aug	CAHN
---	--	-----	------------	--------------	-----	------

TABLET; ORAL

HALOPERIDOL

@	MUTUAL PHARM	2MG	N71172 001	Jan 02, 1987	Aug	CAHN
@		5MG	N71212 001	Jan 07, 1988	Aug	CAHN
@		10MG	N71173 001	Jan 07, 1988	Aug	CAHN
@		20MG	N71177 001	Jan 07, 1988	Aug	CAHN

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION

HALOPERIDOL DECANOATE

@	MAYNE PHARMA USA	EQ 50MG BASE/ML	N75176 001	Feb 09, 2000	Apr	CAHN
@		EQ 100MG BASE/ML	N75176 002	Feb 09, 2000	Apr	CAHN

HALOPERIDOL LACTATE

INJECTABLE; INJECTION

HALOPERIDOL

AP	APOTEX	EQ 5MG BASE/ML	N76774 001	Aug 25, 2004	Aug	NEWA
AP		EQ 5MG BASE/ML	N76791 001	Aug 25, 2004	Aug	NEWA
AP		EQ 5MG BASE/ML	N76828 001	Aug 25, 2004	Aug	NEWA
>A>	SABEX 2002	EQ 5MG BASE/ML	N76464 001	Sep 29, 2004	Sep	NEWA

HALOTHANE

LIQUID; INHALATION

HALOTHANE

AN	+	HOSPIRA	99.99%	N83254 001	May	CAHN
----	---	---------	--------	------------	-----	------

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN LOCK FLUSH

AP		HOSPIRA	10 UNITS/ML	N05264 001	May	CAHN	
AP			10 UNITS/ML	N40082 001	Feb 28, 1995	May	CAHN
AP			10 UNITS/ML	N88097 001	Apr 28, 1983	May	CAHN
AP			10 UNITS/ML	N88346 001	May 18, 1983	May	CAHN
		@	100 UNITS/ML	N05264 010	May	CAHN	
AP			100 UNITS/ML	N40082 002	Feb 28, 1995	May	CAHN
AP			100 UNITS/ML	N88098 001	Apr 28, 1983	May	CAHN
AP			100 UNITS/ML	N88347 001	May 18, 1983	May	CAHN
			HEPARIN LOCK FLUSH IN PLASTIC CONTAINER				
AP		HOSPIRA	10 UNITS/ML	N05264 015	May 21, 1985	May	CAHN
AP			100 UNITS/ML	N05264 016	May 21, 1985	May	CAHN
			HEPARIN SODIUM				
AP	+	HOSPIRA	2,500 UNITS/ML	N88099 001	Apr 28, 1983	May	CAHN
		@	2,500 UNITS/ML	N88099 001	Apr 28, 1983	Aug	DISC
AP			5,000 UNITS/ML	N88100 001	Apr 28, 1983	May	CAHN
		@	10,000 UNITS/ML	N40095 001	Jul 26, 1996	May	CAHN
		@	10,000 UNITS/ML	N05521 002	Jun	DISC	
>D>	AP	MARSAM PHARMS LLC	1,000 UNITS/ML	N40007 001	Jun 07, 1996	Sep	DISC
>A>		@	1,000 UNITS/ML	N40007 001	Jun 07, 1996	Sep	DISC

HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP		HOSPIRA	200 UNITS/100ML	N18916 010	Jun 23, 1989	May	CAHN	
			HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5%					
		@	HOSPIRA	10,000 UNITS/100ML	N18911 006	Jan 30, 1985	May	CAHN
			HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER					
AP		HOSPIRA	10,000 UNITS/100ML	N19339 003	Mar 27, 1985	May	CAHN	
			HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.45%					
		@	HOSPIRA	10,000 UNITS/100ML	N18911 001	Jan 30, 1985	May	CAHN
		@		10,000 UNITS/100ML	N18916 005	Jan 31, 1984	May	CAHN

INJECTABLE; INJECTION

	HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.9%						
	@ HOSPIRA	10,000 UNITS/100ML	N18911 003	Jan 30, 1985	May	CAHN	
	@	10,000 UNITS/100ML	N18916 002	Jan 31, 1984	May	CAHN	
	HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5%						
	@ HOSPIRA	5,000 UNITS/100ML	N18911 007	Jan 30, 1985	May	CAHN	
	HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER						
	HOSPIRA	5,000 UNITS/100ML	N19339 001	Mar 27, 1985	May	CAHN	
	HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER						
	HOSPIRA	5,000 UNITS/100ML	N18916 006	Jan 31, 1984	May	CAHN	
	HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.9%						
	@ HOSPIRA	5,000 UNITS/100ML	N18911 005	Jan 30, 1985	May	CAHN	
	@	5,000 UNITS/100ML	N18916 003	Jan 31, 1984	May	CAHN	
	HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
AP	HOSPIRA	200 UNITS/100ML	N18916 011	Jun 23, 1989	May	CAHN	
	HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER						
AP	HOSPIRA	4,000 UNITS/100ML	N19805 001	Jan 25, 1989	May	CAHN	
	HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5%						
	@ HOSPIRA	5,000 UNITS/100ML	N18911 009	Jan 30, 1985	May	CAHN	
	@	10,000 UNITS/100ML	N18911 008	Jan 30, 1985	May	CAHN	
	HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER						
AP	HOSPIRA	5,000 UNITS/100ML	N19339 004	Mar 27, 1985	May	CAHN	
AP		5,000 UNITS/100ML	N19805 002	Jan 25, 1989	May	CAHN	
AP		10,000 UNITS/100ML	N19339 002	Mar 27, 1985	May	CAHN	
	HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER						
	HOSPIRA	5,000 UNITS/100ML	N18916 007	Jan 31, 1984	May	CAHN	
		10,000 UNITS/100ML	N18916 008	Jan 31, 1984	May	CAHN	
	HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9%						
	@ HOSPIRA	5,000 UNITS/100ML	N18911 004	Jan 30, 1985	May	CAHN	
	HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
	@ HOSPIRA	5,000 UNITS/100ML	N18916 009	Jan 31, 1984	May	CAHN	
	HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.45%						
	@ HOSPIRA	100 UNITS/ML	N18911 002	Jan 30, 1985	May	CAHN	
	@	100 UNITS/ML	N18916 004	Jan 31, 1984	May	CAHN	
	HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9%						
	@ HOSPIRA	1,000 UNITS/100ML	N18916 001	Jan 31, 1984	May	CAHN	
	HEPARIN SODIUM PRESERVATIVE FREE						
	+ HOSPIRA	2,000 UNITS/ML	N05264 013	Apr 07, 1986	May	CAHN	
AP	+	2,500 UNITS/ML	N05264 014	Apr 07, 1986	May	CAHN	
AP	+	10,000 UNITS/ML	N89522 001	May 04, 1987	May	CAHN	
>D>	AP	MARSAM PHARMS LLC	1,000 UNITS/ML	N89464 001	Jun 03, 1986	Sep	DISC
>A>	@		1,000 UNITS/ML	N89464 001	Jun 03, 1986	Sep	DISC
	PANHEPRIN						
	@ HOSPIRA	1,000 UNITS/ML	N05264 004		May	CAHN	
	@	5,000 UNITS/ML	N05264 006		May	CAHN	
	@	10,000 UNITS/ML	N05264 007		May	CAHN	
	@	20,000 UNITS/ML	N05264 008		May	CAHN	
	@	40,000 UNITS/ML	N05264 009		May	CAHN	

HYALURONIDASE

INJECTABLE; INJECTION

VITRASE

	+ ISTA PHARMS	6,200 UNITS/VIAL	N21640 001	May 05, 2004	May	NEWA	
--	---------------	------------------	------------	--------------	-----	------	--

HYDRALAZINE HYDROCHLORIDE

TABLET; ORAL

HYDRALAZINE HCL

@	MUTUAL PHARM	10MG	N88728 001	Apr 11, 1985	Aug	CAHN
@		25MG	N84106 002		Aug	CAHN
@		50MG	N84107 002		Aug	CAHN
@		100MG	N88729 001	Apr 11, 1985	Aug	CAHN

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

RESERPINE, HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE

@	MUTUAL PHARM	25MG;15MG;0.1MG	N88570 001	Apr 10, 1984	Aug	CAHN
---	--------------	-----------------	------------	--------------	-----	------

HYDROCHLOROTHIAZIDE

TABLET; ORAL

HYDROCHLOROTHIAZIDE

@	MUTUAL PHARM	25MG	N83972 001		Aug	CAHN
@		50MG	N83972 002		Aug	CAHN
@		100MG	N83972 003		Aug	CAHN

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET; ORAL

LOPRESSOR HCT

AB	NOVARTIS	25MG;50MG	N18303 001	Dec 31, 1984	Aug	CFTG
AB		25MG;100MG	N18303 002	Dec 31, 1984	Aug	CFTG
AB	+	50MG;100MG	N18303 003	Dec 31, 1984	Aug	CFTG

METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE

AB	MYLAN	25MG;50MG	N76792 001	Aug 20, 2004	Aug	NEWA
AB		25MG;100MG	N76792 002	Aug 20, 2004	Aug	NEWA
AB		50MG;100MG	N76792 003	Aug 20, 2004	Aug	NEWA

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

ACCURETIC

AB	PFIZER PHARMS	12.5MG;EQ 10MG BASE	N20125 001	Dec 28, 1999	Mar	CFTG
AB		12.5MG;EQ 20MG BASE	N20125 002	Dec 28, 1999	Mar	CFTG
AB	+	25MG;EQ 20MG BASE	N20125 003	Dec 28, 1999	Mar	CFTG

QUINARETIC

AB	AMIDE PHARM	12.5MG;EQ 10MG BASE	N76374 001	Mar 31, 2004	Mar	NEWA
AB		12.5MG;EQ 20MG BASE	N76374 002	Mar 31, 2004	Mar	NEWA
AB		25MG;EQ 20MG BASE	N76374 003	Mar 31, 2004	Mar	NEWA

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET; ORAL

SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE

AB	MUTUAL PHARM	25MG;25MG	N87267 001		Aug	CAHN
----	--------------	-----------	------------	--	-----	------

HYDROCHLOROTHIAZIDE; TELMISARTAN

TABLET; ORAL

MICARDIS HCT

	BOEHRINGER INGELHEIM	12.5MG;80MG	N21162 002	Nov 17, 2000	May	CRLD
+		25MG;80MG	N21162 003	Apr 19, 2004	May	NEWA

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET; ORAL

HYDROCODONE BITARTRATE AND IBUPROFEN

+ INTERPHARM 5MG;200MG N76642 002 Mar 18, 2004 Mar NEWA

HYDROCORTISONE

CREAM; TOPICAL

HYDROCORTISONE

AT VINTAGE PHARMS 2.5% N40503 001 Mar 12, 2004 Mar NEWA

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

AEROSOL, METERED; TOPICAL

HYDROCORTISONE ACETATE 1% AND PRAMOXINE HCL 1%

BX BOCA PHARMA 1%;1% N89440 001 May 17, 1988 Apr CAHN

HYDROCORTISONE BUTYRATE

SOLUTION; TOPICAL

HYDROCORTISONE BUTYRATE

AT TARO PHARM INDS 0.1% N76364 001 Jan 14, 2004 Jan NEWA

LOCOID

AT + FERNDAL LABS 0.1% N19116 001 Feb 25, 1987 Jan CFTG

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION

A-HYDROCORT

AP HOSPIRA EQ 100MG BASE/VIAL N85929 001 May CAHN

AP EQ 250MG BASE/VIAL N85930 001 May CAHN

AP EQ 500MG BASE/VIAL N85931 001 May CAHN

AP EQ 1GM BASE/VIAL N85932 001 May CAHN

HYDROMORPHONE HYDROCHLORIDE

>A> CAPSULE, EXTENDED RELEASE; ORAL

>A> PALLADONE

>A> PURDUE PHARMA LP 12MG N21044 001 Sep 24, 2004 Sep NEWA

>A> + 16MG N21044 002 Sep 24, 2004 Sep NEWA

>A> 24MG N21044 003 Sep 24, 2004 Sep NEWA

>A> 32MG N21044 004 Sep 24, 2004 Sep NEWA

INJECTABLE; INJECTION

HYDROMORPHONE HCL

AP HOSPIRA 10MG/ML N74598 001 Jun 19, 1997 May CAHN

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDROXYZINE HCL

AP HOSPIRA 25MG/ML N87416 001 May CAHN

@ 50MG/ML N86821 001 May CAHN

AP 50MG/ML N87546 001 May CAHN

TABLET; ORAL

HYDROXYZINE HCL

AB ABLE 10MG N40559 001 Jul 22, 2004 Jul NEWA

AB 25MG N40562 001 Jul 22, 2004 Jul NEWA

AB 50MG N40563 001 Jul 22, 2004 Jul NEWA

@ MUTUAL PHARM 10MG N88409 001 Nov 15, 1983 Aug CAHN

@ 25MG N87857 001 Apr 18, 1983 Aug CAHN

@ 50MG N87860 001 Apr 18, 1983 Aug CAHN

TABLET; ORAL
HYDROXYZINE HCL
@ MUTUAL PHARM

100MG

N87862 001 Apr 18, 1983 Aug CAHN

IBUPROFEN

SUSPENSION; ORAL
IBUPROFEN
PERRIGO R AND D

100MG/5ML

N76925 001 Sep 23, 2004 Sep NEWA

TABLET; ORAL
IBUPROFEN
@ MUTUAL PHARM

400MG

N70079 001 Jul 24, 1985 Aug CAHN

@

600MG

N70080 001 Jul 24, 1985 Aug CAHN

@

800MG

N71448 001 Feb 18, 1987 Aug CAHN

IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION
IDARUBICIN HCL

+ GENZIA SICOR PHARMS 5MG/VIAL

N65037 003 May 01, 2002 Feb CTEC

INAMRINONE LACTATE

INJECTABLE; INJECTION
AMRINONE

AP + HOSPIRA EQ 5MG BASE/ML

N74616 001 Aug 03, 1998 May CAHN

INDOMETHACIN

CAPSULE; ORAL
INDOMETHACIN
@ MUTUAL PHARM
@

25MG

N70067 001 Oct 03, 1986 Aug CAHN

50MG

N70068 001 Oct 03, 1986 Aug CAHN

INSULIN ASPART RECOMBINANT

INJECTABLE; SUBCUTANEOUS
NOVOLOG

+ NOVO NORDISK 100 UNITS/ML

N20986 001 Jun 07, 2000 May CAIN

INSULIN GLARGINE RECOMBINANT

INJECTABLE; INJECTION
LANTUS

+ AVENTIS PHARMS 100 UNITS/ML

N21081 001 Apr 20, 2000 May CAIN

INSULIN GLULISINE RECOMBINANT

INJECTABLE; SUBCUTANEOUS
APIDRA

+ AVENTIS PHARMS 100 UNITS/ML

N21629 001 Apr 16, 2004 Apr NEWA

@

100 UNITS/ML

N21629 001 Apr 16, 2004 Jun DISC

INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT

INJECTABLE; INJECTION
HUMALOG MIX 50/50

+ LILLY 50 UNITS/ML;50 UNITS/ML

N21018 001 Dec 22, 1999 May CAIN

HUMALOG MIX 75/25

+ LILLY 75 UNITS/ML;25 UNITS/ML

N21017 001 Dec 22, 1999 May CAIN

INSULIN LISPRO RECOMBINANT

INJECTABLE; INJECTION

HUMALOG

+ LILLY 100 UNITS/ML N20563 001 Jun 14, 1996 May CAIN

HUMALOG PEN

+ LILLY 100 UNITS/ML N20563 002 Aug 06, 1998 May CAIN

IODIXANOL

INJECTABLE; INJECTION

VISIPAQUE 270

GE HEALTHCARE 55% N20808 001 Aug 29, 1997 Jun CMFD

VISIPAQUE 320

GE HEALTHCARE 65.2% N20808 002 Aug 29, 1997 Jun CMFD

IOPAMIDOL

INJECTABLE; INJECTION

IOPAMIDOL-200

AP HOSPIRA 41% N74898 001 Dec 30, 1997 May CAHN

IOPAMIDOL-200 IN PLASTIC CONTAINER

AP HOSPIRA 41% N74636 001 Dec 30, 1997 May CAHN

IOPAMIDOL-250

AP HOSPIRA 51% N74898 002 Dec 30, 1997 May CAHN

AP 51% N75005 001 Feb 24, 1998 May CAHN

IOPAMIDOL-250 IN PLASTIC CONTAINER

AP HOSPIRA 51% N74636 002 Dec 30, 1997 May CAHN

IOPAMIDOL-300

AP HOSPIRA 61% N74898 003 Dec 30, 1997 May CAHN

AP 61% N75005 002 Feb 24, 1998 May CAHN

IOPAMIDOL-300 IN PLASTIC CONTAINER

AP HOSPIRA 61% N74636 003 Dec 30, 1997 May CAHN

AP 61% N74637 001 Apr 03, 1997 May CAHN

IOPAMIDOL-370

AP HOSPIRA 76% N74898 004 Dec 30, 1997 May CAHN

AP 76% N75005 003 Feb 24, 1998 May CAHN

IOPAMIDOL-370 IN PLASTIC CONTAINER

AP HOSPIRA 76% N74636 004 Dec 30, 1997 May CAHN

IOPANOIC ACID

TABLET; ORAL

TELEPAQUE

@ GE HEALTHCARE 500MG N08032 001 May DISC

IOPROMIDE

INJECTABLE; INJECTION

ULTRAVIST (PHARMACY BULK)

+ BERLEX 49.9% N21425 003 Mar 12, 2004 Mar NEWA

+ 62.3% N21425 001 Sep 20, 2002 Mar CPOT

+ 76.9% N21425 002 Sep 20, 2002 Mar CPOT

IOTHALAMATE MEGLUMINE; IOTHALAMATE SODIUM

INJECTABLE; INJECTION

VASCORAY

@ MALLINCKRODT 52%;26% N16783 001 Jun DISC

IPRATROPIUM BROMIDESOLUTION; INHALATION
IPRATROPIUM BROMIDE

AN HOLOPACK INTL 0.02% N75693 001 Jan 26, 2001 Apr CAHN

ISOFLURANELIQUID; INHALATION
ISOFLURANE

AN HOSPIRA 99.9% N74097 001 Jan 25, 1993 May CAHN

ISONIAZIDINJECTABLE; INJECTION
NYDRAZID

+ SANDOZ 100MG/ML

N08662 001 Feb CAHN

TABLET; ORAL

ISONIAZID

@ MUTUAL PHARM 100MG

N80136 001 Aug CAHN

AA 300MG N83633 001 Aug CAHN

ISOPROTERENOL HYDROCHLORIDE

INJECTABLE; INJECTION

ISOPROTERENOL HCL

HOSPIRA 0.02MG/ML

N83283 001 May CAHN

AP 0.2MG/ML N83346 001 May CAHN

ISUPREL

AP + HOSPIRA 0.2MG/ML N10515 001 May CAHN

ISOSORBIDE DINITRATE

TABLET; ORAL

ISOSORBIDE DINITRATE

@ MUTUAL PHARM 5MG

N86166 002 Sep 19, 1986 Aug CAHN

@ 10MG

N86169 001 Sep 19, 1986 Aug CAHN

@ 20MG

N86167 001 Sep 19, 1986 Aug CAHN

@ 30MG

N87564 001 Sep 18, 1986 Aug CAHN

TABLET; SUBLINGUAL

ISOSORBIDE DINITRATE

@ MUTUAL PHARM 2.5MG

N84204 001 Sep 18, 1986 Aug CAHN

@ 5MG

N86168 001 Sep 18, 1986 Aug CAHN

@ 10MG

N87545 001 Sep 18, 1986 Aug CAHN

ISOSORBIDE MONONITRATE

TABLET, EXTENDED RELEASE; ORAL

IMDUR

AB SCHERING PLOUGH 30MG N20225 001 Aug 12, 1993 Apr CRLD

AB 60MG N20225 002 Aug 12, 1993 Apr CRLD

ITRACONAZOLE

CAPSULE; ORAL

ITRACONAZOLE

AB EON 100MG N76104 001 May 28, 2004 May NEWA

SPORANOX

AB + JANSSEN PHARMA 100MG N20083 001 Sep 11, 1992 May CFTG

KETAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

KETAMINE HCL

AP	HOSPIRA	EQ 50MG BASE/ML	N74549 001	Jun 27, 1996	May	CAHN
AP		EQ 100MG BASE/ML	N74549 002	Jun 27, 1996	May	CAHN

KETOCONAZOLE

CREAM; TOPICAL

KETOCONAZOLE

AB	ALTANA	2%	N76294 001	Apr 28, 2004	Apr	NEWA
AB	+ TEVA	2%	N75581 001	Apr 25, 2000	Apr	CRLD
	NIZORAL					
	@ JANSSEN PHARMA	2%	N19084 001	Dec 31, 1985	Apr	DISC

SHAMPOO; TOPICAL

KETOCONAZOLE

AB	CLAY PARK	2%	N76419 001	Jan 07, 2004	Jan	NEWA
AB	+ MCNEIL CONS SPECT	2%	N19927 001	Aug 31, 1990	Jan	CFTG

SUSPENSION; ORAL

NIZORAL

@ JANSSEN PHARMA

100MG/5ML

N70767 001 Nov 07, 1986 Jul CAHN

TABLET; ORAL

NIZORAL

AB	+ JANSSEN PHARMA	200MG	N18533 001		Jul	CAHN
----	------------------	-------	------------	--	-----	------

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION

KETOROLAC TROMETHAMINE

AP	AMPHASTAR PHARM	15MG/ML	N76209 001	Jul 21, 2004	Jul	NEWA
AP		30MG/ML	N76209 002	Jul 21, 2004	Jul	NEWA
AP	APOTEX	15MG/ML	N76722 001	Jul 27, 2004	Jul	NEWA
AP		30MG/ML	N76722 002	Jul 27, 2004	Jul	NEWA
AP	BAXTER HLTHCARE	15MG/ML	N75772 001	Jul 21, 2004	Jul	NEWA
AP		30MG/ML	N75772 002	Jul 21, 2004	Jul	NEWA
AP	+ BEDFORD	15MG/ML	N75222 001	Apr 26, 1999	Jan	CRLD
AP	+ @ HOSPIRA	15MG/ML	N74801 001	Jun 05, 1997	May	CAHN
AP		15MG/ML	N74802 001	Jun 05, 1997	May	CAHN
AP		15MG/ML	N74993 001	Jan 27, 1999	May	CAHN
	@	30MG/ML	N74801 002	Jun 05, 1997	May	CAHN
AP		30MG/ML	N74802 002	Jun 05, 1997	May	CAHN
AP		30MG/ML	N74993 002	Jan 27, 1999	May	CARN
	TORADOL					
	@ ROCHE PALO	15MG/ML	N19698 001	Nov 30, 1989	Jan	DISC
	@	30MG/ML	N19698 002	Nov 30, 1989	Jan	DISC

KETOTIFEN FUMARATE

SOLUTION/DROPS; OPHTHALMIC

ZADITOR

+	NOVARTIS	EQ 0.025% BASE	N21066 001	Jul 02, 1999	Feb	CAHN
---	----------	----------------	------------	--------------	-----	------

LABETALOL HYDROCHLORIDE

INJECTABLE; INJECTION

LABETALOL HCL

AP	HOSPIRA	5MG/ML	N75239 001	Nov 29, 1999	May	CAHN
----	---------	--------	------------	--------------	-----	------

INJECTABLE; INJECTION

LABETALOL HCL

AP	HOSPIRA	5MG/ML	N75240 001	Nov 29, 1999	May	CAHN
>D>	NORMODYNE					
>D>	AP + SCHERING	5MG/ML	N18686 001	Aug 01, 1984	Sep	DISC
>A>	@	5MG/ML	N18686 001	Aug 01, 1984	Sep	DISC
TABLET; ORAL						
>D>	NORMODYNE					
>D>	AB SCHERING	100MG	N18687 001	Aug 31, 1987	Sep	DISC
>A>	@	100MG	N18687 001	Aug 31, 1987	Sep	DISC
>D>	AB	200MG	N18687 002	Aug 01, 1984	Sep	DISC
>A>	@	200MG	N18687 002	Aug 01, 1984	Sep	DISC
>D>	AB +	300MG	N18687 003	Aug 01, 1984	Sep	DISC
>A>	@	300MG	N18687 003	Aug 01, 1984	Sep	DISC
TRANDATE						
>D>	AB PROMETHEUS LABS	300MG	N18716 003	Aug 01, 1984	Sep	CRLD
>A>	AB +	300MG	N18716 003	Aug 01, 1984	Sep	CRLD

LAMIVUDINE

TABLET; ORAL

EPIVIR

	GLAXOSMITHKLINE	150MG	N20564 001	Nov 17, 1995	May	CRLD
+		300MG	N20564 003	Jun 24, 2002	May	CRLD

LAMOTRIGINE

TABLET; ORAL

LAMICTAL

+	GLAXOSMITHKLINE	25MG	N20241 005	Dec 27, 1994	Apr	CRLD
		200MG	N20241 003	Dec 27, 1994	Apr	CRLD

LANSOPRAZOLE

FOR SUSPENSION, DELAYED RELEASE; ORAL

PREVACID

	TAP PHARM	15MG/PACKET	N21281 001	May 03, 2001	Jul	CDFR
+		30MG/PACKET	N21281 002	May 03, 2001	Jul	CDFR

INJECTABLE; INTRAVENOUS

PREVACID IV

+	TAP PHARM	30MG/VIAL	N21566 001	May 27, 2004	May	NEWA
---	-----------	-----------	------------	--------------	-----	------

TABLET, DELAYED RELEASE, ORALLY DISINTEGRATING; ORAL

PREVACID

	TAP PHARM	15MG	N21428 001	Aug 30, 2002	Jul	CDFR
+		30MG	N21428 002	Aug 30, 2002	Jul	CDFR

LEFLUNOMIDE

TABLET; ORAL

ARAVA

+	AVENTIS PHARMS	100MG	N20905 003	Sep 10, 1998	Jul	CMFD
---	----------------	-------	------------	--------------	-----	------

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION

LEUCOVORIN CALCIUM

@ PHARMACHEMIE USA EQ 100MG BASE/VIAL

N89915 001 Apr 17, 1997 Aug DISC

LEUCOVORIN CALCIUM PRESERVATIVE FREE

AP	BIGMAR BIOREN PHARMS	EQ 200MG BASE/VIAL	N40258 001	Feb 26, 1999	Jul	CAHN	
+		EQ 500MG BASE/VIAL	N40286 001	Feb 26, 1999	Jul	CAHN	
AP	+	HOSPIRA	EQ 10MG BASE/ML	N40147 001	Jun 25, 1997	May	CAHN

LEVOBUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CHIROCAINE

@	PURDUE PHARMA LP	EQ 2.5MG BASE/ML	N20997 001	Aug 05, 1999	May	DISC
@		EQ 5MG BASE/ML	N20997 002	Aug 05, 1999	May	DISC
@		EQ 7.5MG BASE/ML	N20997 003	Aug 05, 1999	May	DISC

LEVOCABASTINE HYDROCHLORIDE

SUSPENSION/DROPS; OPHTHALMIC

LIVOSTIN

+	NOVARTIS	EQ 0.05% BASE	N20219 001	Nov 10, 1993	Feb	CAHN
---	----------	---------------	------------	--------------	-----	------

LEVOCARNITINE

SOLUTION; ORAL

CARNITOR

AA	+	SIGMA TAU	1GM/10ML	N19257 001	Apr 10, 1986	Aug	CFTG
----	---	-----------	----------	------------	--------------	-----	------

LEVOCARNITINE

AA		LYNE	1GM/10ML	N76851 001	Aug 10, 2004	Aug	NEWA
----	--	------	----------	------------	--------------	-----	------

TABLET; ORAL

CARNITOR

>D>	+	SIGMA TAU	330MG	N18948 001	Dec 27, 1985	Sep	CFTG
-----	---	-----------	-------	------------	--------------	-----	------

>A>	AB	+	330MG	N18948 001	Dec 27, 1985	Sep	CFTG
-----	----	---	-------	------------	--------------	-----	------

>A>		LEVOCARNITINE					
-----	--	---------------	--	--	--	--	--

>A>	AB	COREPHARMA	330MG	N76858 001	Sep 20, 2004	Sep	NEWA
-----	----	------------	-------	------------	--------------	-----	------

LEVOFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

IQUIX

+	SANTEN	1.5%	N21571 001	Mar 01, 2004	Mar	NEWA
---	--------	------	------------	--------------	-----	------

LEVONORGESTREL

TABLET; ORAL

PLAN B

+	DURAMED	0.75MG	N21045 001	Jul 28, 1999	Feb	CAHN
---	---------	--------	------------	--------------	-----	------

LEVOTHYROXINE SODIUM*

TABLET; ORAL

LEVOLET

BX		VINTAGE	0.025MG	N21137 001	Jun 06, 2003	Jul	CAHN
----	--	---------	---------	------------	--------------	-----	------

BX			0.05MG	N21137 002	Jun 06, 2003	Jul	CAHN
----	--	--	--------	------------	--------------	-----	------

BX			0.075MG	N21137 003	Jun 06, 2003	Jul	CAHN
----	--	--	---------	------------	--------------	-----	------

BX			0.088MG	N21137 004	Jun 06, 2003	Jul	CAHN
----	--	--	---------	------------	--------------	-----	------

BX			0.1MG	N21137 005	Jun 06, 2003	Jul	CAHN
----	--	--	-------	------------	--------------	-----	------

BX			0.112MG	N21137 006	Jun 06, 2003	Jul	CAHN
----	--	--	---------	------------	--------------	-----	------

BX			0.125MG	N21137 007	Jun 06, 2003	Jul	CAHN
----	--	--	---------	------------	--------------	-----	------

BX			0.137MG	N21137 008	Jun 06, 2003	Jul	CAHN
----	--	--	---------	------------	--------------	-----	------

BX			0.15MG	N21137 009	Jun 06, 2003	Jul	CAHN
----	--	--	--------	------------	--------------	-----	------

BX			0.175MG	N21137 010	Jun 06, 2003	Jul	CAHN
----	--	--	---------	------------	--------------	-----	------

BX			0.2MG	N21137 011	Jun 06, 2003	Jul	CAHN
----	--	--	-------	------------	--------------	-----	------

BX			0.3MG	N21137 012	Jun 06, 2003	Jul	CAHN
----	--	--	-------	------------	--------------	-----	------

LEVO-T

AB2,		ALARA PHARM	0.025MG	N21342 001	Mar 01, 2002	Jun	CTEC
------	--	-------------	---------	------------	--------------	-----	------

AB3							
-----	--	--	--	--	--	--	--

AB2,			0.05MG	N21342 002	Mar 01, 2002	Jun	CTEC
------	--	--	--------	------------	--------------	-----	------

AB3							
-----	--	--	--	--	--	--	--

AB2,			0.075MG	N21342 003	Mar 01, 2002	Jun	CTEC
------	--	--	---------	------------	--------------	-----	------

AB3							
-----	--	--	--	--	--	--	--

* SEE PREFACE SECTION 1.4 LEVOTHYROXINE SODIUM

TABLET; ORAL

LEVO-T

AB2, AB3	ALARA PHARM	0.088MG	N21342 004	Mar 01, 2002	Jun	CTEC
AB2, AB3		0.1MG	N21342 005	Mar 01, 2002	Jun	CTEC
AB2, AB3		0.112MG	N21342 006	Mar 01, 2002	Jun	CTEC
AB2, AB3		0.125MG	N21342 007	Mar 01, 2002	Jun	CTEC
AB2, AB3		0.137MG	N21342 012	Dec 08, 2003	Jun	CTEC
AB2, AB3		0.15MG	N21342 008	Mar 01, 2002	Jun	CTEC
AB2, AB3		0.175MG	N21342 009	Mar 01, 2002	Jun	CTEC
AB2, AB3		0.2MG	N21342 010	Mar 01, 2002	Jun	CTEC
AB2, + AB3		0.3MG	N21342 011	Mar 01, 2002	Jun	CTEC

LEVOTHYROXINE SODIUM

AB1, AB2, AB3	MYLAN	0.025MG	N76187 001	Jun 05, 2002	Jun	CTEC
AB1, AB2, AB3		0.05MG	N76187 002	Jun 05, 2002	Jun	CTEC
AB1, AB2, AB3		0.075MG	N76187 003	Jun 05, 2002	Jun	CTEC
AB1, AB2, AB3		0.088MG	N76187 004	Jun 05, 2002	Jun	CTEC
AB1, AB2, AB3		0.1MG	N76187 005	Jun 05, 2002	Jun	CTEC
AB1, AB2, AB3		0.112MG	N76187 006	Jun 05, 2002	Jun	CTEC
AB1, AB2, AB3		0.125MG	N76187 007	Jun 05, 2002	Jun	CTEC
AB1, AB2, AB3		0.15MG	N76187 008	Jun 05, 2002	Jun	CTEC
AB1, AB2, AB3		0.175MG	N76187 009	Jun 05, 2002	Jun	CTEC
AB1, AB2, AB3		0.2MG	N76187 010	Jun 05, 2002	Jun	CTEC
AB1, AB2, AB3		0.3MG	N76187 011	Jun 05, 2002	Jun	CTEC

LEVOXYL

AB1, AB3	JONES PHARMA	0.025MG	N21301 001	May 25, 2001	Jun	CTEC
AB1, AB3		0.05MG	N21301 002	May 25, 2001	Jun	CTEC
AB1, AB3		0.075MG	N21301 003	May 25, 2001	Jun	CTEC
AB1, AB3		0.088MG	N21301 004	May 25, 2001	Jun	CTEC
AB1, AB3		0.1MG	N21301 005	May 25, 2001	Jun	CTEC
AB1, AB3		0.112MG	N21301 006	May 25, 2001	Jun	CTEC
AB1, AB3		0.125MG	N21301 007	May 25, 2001	Jun	CTEC
AB1, AB3		0.137MG	N21301 008	May 25, 2001	Jun	CTEC
AB3		0.137MG	N21301 008	May 25, 2001	Jul	CTEC

TABLET; ORAL

LEVOXYL

AB1, AB3	JONES PHARMA	0.15MG	N21301 009	May 25, 2001	Jun	CTEC
AB1, AB3		0.175MG	N21301 010	May 25, 2001	Jun	CTEC
AB1, AB3		0.2MG	N21301 011	May 25, 2001	Jun	CTEC
AB1, + AB3		0.3MG	N21301 012	May 25, 2001	Jun	CTEC

SYNTHROID

AB2	ABBOTT	0.025MG	N21402 001	Jul 24, 2002	Jun	CFTG
AB2		0.05MG	N21402 002	Jul 24, 2002	Jun	CFTG
AB2		0.075MG	N21402 003	Jul 24, 2002	Jun	CFTG
AB2		0.088MG	N21402 004	Jul 24, 2002	Jun	CFTG
AB2		0.1MG	N21402 005	Jul 24, 2002	Jun	CFTG
AB2		0.112MG	N21402 006	Jul 24, 2002	Jun	CFTG
AB2		0.125MG	N21402 007	Jul 24, 2002	Jun	CFTG
AB2		0.137MG	N21402 008	Jul 24, 2002	Jun	CFTG
AB2		0.15MG	N21402 009	Jul 24, 2002	Jun	CFTG
AB2		0.175MG	N21402 010	Jul 24, 2002	Jun	CFTG
AB2		0.2MG	N21402 012	Jul 24, 2002	Jun	CFTG
AB2 +		0.3MG	N21402 011	Jul 24, 2002	Jun	CFTG

UNITHROID

AB1, AB3	STEVENS J	0.025MG	N21210 001	Aug 21, 2000	Jun	CTEC
AB1, AB3		0.05MG	N21210 002	Aug 21, 2000	Jun	CTEC
AB1, AB3		0.075MG	N21210 003	Aug 21, 2000	Jun	CTEC
AB1, AB3		0.088MG	N21210 004	Aug 21, 2000	Jun	CTEC
AB1, AB3		0.1MG	N21210 005	Aug 21, 2000	Jun	CTEC
AB1, AB3		0.112MG	N21210 006	Aug 21, 2000	Jun	CTEC
AB1, AB3		0.125MG	N21210 007	Aug 21, 2000	Jun	CTEC
AB1, AB3		0.15MG	N21210 008	Aug 21, 2000	Jun	CTEC
AB1, AB3		0.175MG	N21210 009	Aug 21, 2000	Jun	CTEC
AB1, AB3		0.2MG	N21210 010	Aug 21, 2000	Jun	CTEC
AB1, + AB3		0.3MG	N21210 011	Aug 21, 2000	Jun	CTEC

LIDOCAINE

>D>	FILM, EXTENDED RELEASE; TOPICAL					
>D>	LIDODERM					
>D>	+ TEIKOKU PHARMA USA	700MG/12HR	N20612 001	Mar 19, 1999	Sep	CDFR
>A>	PATCH; TOPICAL					
>A>	LIDODERM					
>A>	+ TEIKOKU PHARMA USA	5%	N20612 001	Mar 19, 1999	Sep	CDFR

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

	LIDOCAINE HCL					
	@ BAXTER HLTHCARE	1%	N80407 001		Aug	CAHN
	@	2%	N80407 002		Aug	CAHN
AP	HOSPIRA	0.5%	N88328 001	May 17, 1984	May	CAHN
AP		1%	N40013 001	Jun 23, 1995	May	CAHN
AP		1%	N83158 001		May	CAHN

INJECTABLE; INJECTION

LIDOCAINE HCL

AP	HOSPIRA	1%	N88329 001	May 17, 1984	May	CAHN
	@	1.5%	N88330 001	May 17, 1984	May	CAHN
AP		2%	N40078 001	Jun 23, 1995	May	CAHN
AP		2%	N83158 002		May	CAHN
AP		2%	N88294 001	May 17, 1984	May	CAHN
AP		2%	N88331 001	May 17, 1984	May	CAHN
AP		20%	N83158 003		May	CAHN
	LIDOCAINE HCL 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER @ B BRAUN	200MG/100ML	N18967 001	Mar 30, 1984	Apr	DISC
	LIDOCAINE HCL 0.2% IN DEXTROSE 5%					
AP	HOSPIRA	200MG/100ML	N83158 005		May	CAHN
	LIDOCAINE HCL 0.2% IN DEXTROSE 5% IN PLASTIC CONTAINER					
AP	HOSPIRA	200MG/100ML	N18388 001		May	CAHN
	LIDOCAINE HCL 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER @ B BRAUN	400MG/100ML	N18967 002	Mar 30, 1984	Apr	DISC
	LIDOCAINE HCL 0.4% IN DEXTROSE 5%					
AP	HOSPIRA	400MG/100ML	N83158 006		May	CAHN
	LIDOCAINE HCL 0.4% IN DEXTROSE 5% IN PLASTIC CONTAINER					
AP	HOSPIRA	400MG/100ML	N18388 002		May	CAHN
	LIDOCAINE HCL 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER @ B BRAUN	800MG/100ML	N18967 003	Mar 30, 1984	Apr	DISC
	LIDOCAINE HCL 0.8% IN DEXTROSE 5% IN PLASTIC CONTAINER					
AP	HOSPIRA	800MG/100ML	N18388 003	Nov 05, 1982	May	CAHN
	LIDOCAINE HCL IN PLASTIC CONTAINER					
AP	HOSPIRA	0.5%	N88325 001	Jul 31, 1984	May	CAHN
AP		1%	N88299 001	Jul 31, 1984	May	CAHN
AP		1.5%	N88326 001	Jul 31, 1984	May	CAHN
AP		2%	N88327 001	Jul 31, 1984	May	CAHN
AP		10%	N88367 001	Jul 31, 1984	May	CAHN
AP		20%	N88368 001	Jul 31, 1984	May	CAHN
	LIDOCAINE HCL PRESERVATIVE FREE					
AP	HOSPIRA	1%	N80408 001		May	CAHN
AP		1.5%	N80408 002		May	CAHN
AP		4%	N88295 001	May 17, 1984	May	CAHN
	LIDOCAINE HCL PRESERVATIVE FREE IN PLASTIC CONTAINER					
AP	HOSPIRA	1%	N40302 001	Sep 28, 1998	May	CAHN
AP		2%	N40302 002	Sep 28, 1998	May	CAHN

INJECTABLE; SPINAL

LIDOCAINE HCL 5% AND DEXTROSE 7.5%

+	HOSPIRA	5%	N83914 001		May	CAHN
---	---------	----	------------	--	-----	------

SOLUTION; TOPICAL

LTA II KIT

AT	HOSPIRA	4%	N80409 001		May	CAHN
AT		4%	N88542 001	Jul 31, 1984	May	CAHN
	PEDIATRIC LTA KIT					
AT	HOSPIRA	2%	N85995 001		May	CAHN

LIDOCAINE HYDROCHLORIDE; OXYTETRACYCLINE

INJECTABLE; INJECTION

TERRAMYCIN

+	PFIZER	2%; 50MG/ML	N60567 001		Feb	CRLD
+		2%; 125MG/ML	N60567 002		Feb	CRLD

LITHIUM CARBONATE

CAPSULE; ORAL

LITHIUM CARBONATE

AB	ABLE	150MG	N76823 001	Jun 29, 2004	Jun	NEWA
AB		300MG	N76823 002	Jun 29, 2004	Jun	NEWA
AB		600MG	N76823 003	Jun 29, 2004	Jun	NEWA
AB	+ ROXANE	600MG	N17812 003	Jan 28, 1987	Jun	CFTG

TABLET, EXTENDED RELEASE; ORAL

LITHIUM CARBONATE

AB	ROXANE	450MG	N76691 001	Jan 05, 2004	Jan	NEWA
----	--------	-------	------------	--------------	-----	------

LITHOBID

>A>	AB	+ JDS PHARMS	300MG	N18027 001		Sep CAHN
>D>	AB	+ SOLVAY	300MG	N18027 001		Sep CAHN

LOPERAMIDE HYDROCHLORIDE

SOLUTION; ORAL

IMODIUM

@ JANSSEN PHARMA 1MG/5ML

N19037 001	Jul 31, 1984	Jul	CAHN
------------	--------------	-----	------

LORAZEPAM

INJECTABLE; INJECTION

LORAZEPAM

>D>	AP	BAXTER HLTHCARE	2MG/ML	N74496 001	Sep 28, 1998	Sep	DISC
>A>		@	2MG/ML	N74496 001	Sep 28, 1998	Sep	DISC
	AP		2MG/ML	N74496 001	Sep 28, 1998	Aug	CAHN
>D>	AP		4MG/ML	N74496 002	Sep 28, 1998	Sep	DISC
>A>		@	4MG/ML	N74496 002	Sep 28, 1998	Sep	DISC
	AP		4MG/ML	N74496 002	Sep 28, 1998	Aug	CAHN
	AP	HOSPIRA	2MG/ML	N74243 001	Apr 12, 1994	May	CAHN
	AP		2MG/ML	N74280 001	May 27, 1994	May	CAHN
	AP		2MG/ML	N74282 001	May 27, 1994	May	CAHN
	AP		2MG/ML	N74300 001	Apr 12, 1994	May	CAHN
	AP		4MG/ML	N74243 002	Apr 12, 1994	May	CAHN
	AP		4MG/ML	N74280 002	May 27, 1994	May	CAHN
	AP		4MG/ML	N74282 002	May 27, 1994	May	CAHN
	AP		4MG/ML	N74300 003	Mar 19, 1997	May	CAHN

TABLET; ORAL

LORAZEPAM

@ MUTUAL PHARM 0.5MG

N70472 001	Dec 10, 1985	Aug	CAHN
------------	--------------	-----	------

@ 1MG

N70473 001	Dec 10, 1985	Aug	CAHN
------------	--------------	-----	------

@ 2MG

N70474 001	Dec 10, 1985	Aug	CAHN
------------	--------------	-----	------

LOVASTATIN

TABLET, EXTENDED RELEASE; ORAL

ALTOPREV

>D>		ANDRX	10MG	N21316 001	Jun 26, 2002	Sep	CAHN
			10MG	N21316 001	Jun 26, 2002	Jul	CTNA
>D>			20MG	N21316 002	Jun 26, 2002	Sep	CAHN
			20MG	N21316 002	Jun 26, 2002	Jul	CTNA
>D>			40MG	N21316 003	Jun 26, 2002	Sep	CAHN
			40MG	N21316 003	Jun 26, 2002	Jul	CTNA
>D>		+	60MG	N21316 004	Jun 26, 2002	Sep	CAHN
		+	60MG	N21316 004	Jun 26, 2002	Jul	CTNA
>A>		ANDRX LABS LLC	10MG	N21316 001	Jun 26, 2002	Sep	CAHN
>A>			20MG	N21316 002	Jun 26, 2002	Sep	CAHN

TABLET, EXTENDED RELEASE; ORAL

ALTOPREV

>A>	ANDRX LABS LLC	40MG	N21316 003	Jun 26, 2002	Sep	CAHN
>A>	+	60MG	N21316 004	Jun 26, 2002	Sep	CAHN

LOVASTATIN; NIACIN

TABLET, EXTENDED RELEASE; ORAL

ADVICOR

+	KOS	20MG;500MG	N21249 001	Dec 17, 2001	Feb	CRLD
+		20MG;750MG	N21249 002	Dec 17, 2001	Feb	CRLD
	@	20MG;750MG	N21249 002	Dec 17, 2001	Jul	DISC

MAFENIDE ACETATE

FOR SOLUTION; TOPICAL

SULFAMYLON

+	MYLAN BERTEK	5%	N19832 003	Jun 05, 1998	Aug	CAHN
---	--------------	----	------------	--------------	-----	------

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION

NORMOSOL-R IN PLASTIC CONTAINER

	HOSPIRA	30MG/100ML;37MG/100ML;222MG/100ML; ;526MG/100ML;502MG/100ML	N17586 001		May	CAHN
--	---------	--	------------	--	-----	------

SOLUTION; IRRIGATION

PHYSIOSOL IN PLASTIC CONTAINER

	@ HOSPIRA	14MG/100ML;37MG/100ML;222MG/100ML; ;526MG/100ML;502MG/100ML	N18406 001		May	CAHN
		30MG/100ML;37MG/100ML;222MG/100ML; ;526MG/100ML;502MG/100ML	N17637 002	Jul 08, 1982	May	CAHN

PHYSIOSOL PH 7.4 IN PLASTIC CONTAINER

	HOSPIRA	30MG/100ML;37MG/100ML;222MG/100ML; ;526MG/100ML;502MG/100ML	N18406 002	Jul 08, 1982	May	CAHN
--	---------	--	------------	--------------	-----	------

MAGNESIUM SULFATE

INJECTABLE; INJECTION

MAGNESIUM SULFATE

AP	HOSPIRA	500MG/ML	N75151 001	Apr 25, 2000	May	CAHN
----	---------	----------	------------	--------------	-----	------

MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER

+	HOSPIRA	1GM/100ML	N20488 001	Jul 11, 1995	May	CAHN
+		2GM/100ML	N20488 002	Jul 11, 1995	May	CAHN

MAGNESIUM SULFATE IN PLASTIC CONTAINER

+	HOSPIRA	80MG/ML	N20309 002	Jun 24, 1994	May	CAHN
+		4GM/100ML	N20309 001	Jun 24, 1994	May	CAHN

MALATHION

LOTION; TOPICAL

OVIDE

+	TARO PHARMS NORTH	0.5%	N18613 001	Aug 02, 1982	Jun	CAHN
---	-------------------	------	------------	--------------	-----	------

MANGANESE CHLORIDE

INJECTABLE; INJECTION

MANGANESE CHLORIDE IN PLASTIC CONTAINER

	HOSPIRA	EQ 0.1MG MANGANESE/ML	N18962 001	Jun 26, 1986	May	CAHN
--	---------	-----------------------	------------	--------------	-----	------

MANNITOL

INJECTABLE; INJECTION

MANNITOL 10%

	@ HOSPIRA	10GM/100ML	N16269 002		May	CAHN
--	-----------	------------	------------	--	-----	------

INJECTABLE; INJECTION

	MANNITOL 10% IN PLASTIC CONTAINER					
AP	HOSPIRA	10GM/100ML	N19603 002	Jan 08, 1987	May	CAHN
	MANNITOL 15%					
	@ HOSPIRA	15GM/100ML	N16269 003		May	CAHN
	MANNITOL 15% IN PLASTIC CONTAINER					
AP	HOSPIRA	15GM/100ML	N19603 003	Jan 08, 1990	May	CAHN
	MANNITOL 20%					
	@ HOSPIRA	20GM/100ML	N16269 004		May	CAHN
	MANNITOL 20% IN PLASTIC CONTAINER					
AP	HOSPIRA	20GM/100ML	N19603 004	Jan 08, 1990	May	CAHN
	MANNITOL 25%					
	@ HOSPIRA	12.5GM/50ML	N16269 005		May	CAHN
AP		12.5GM/50ML	N16269 006	Aug 25, 1994	May	CAHN
	MANNITOL 5%					
	@ HOSPIRA	5GM/100ML	N16269 001		May	CAHN
	MANNITOL 5% IN PLASTIC CONTAINER					
AP	HOSPIRA	5GM/100ML	N19603 001	Jan 08, 1987	May	CAHN

MANNITOL; SORBITOL

SOLUTION; IRRIGATION

	SORBITOL-MANNITOL					
	@ HOSPIRA	540MG/100ML; 2.7GM/100ML	N80224 001		May	CAHN
	SORBITOL-MANNITOL IN PLASTIC CONTAINER					
AT	HOSPIRA	540MG/100ML; 2.7GM/100ML	N17636 001		May	CAHN
AT		540MG/100ML; 2.7GM/100ML	N18316 001		May	CAHN

MAPROTILINE HYDROCHLORIDE

TABLET; ORAL

	LUDIOMIL					
	@ NOVARTIS	25MG	N17543 001		Jun	DISC
	@	50MG	N17543 002		Jun	DISC
	@	75MG	N17543 003	Sep 30, 1982	Jun	DISC
	MAPROTILINE HCL					
AB	+ MYLAN	50MG	N72285 001	Oct 03, 1988	Jun	CRLD

MEDROXYPROGESTERONE ACETATE

INJECTABLE; INJECTION

	DEPO-PROVERA					
AB	+ PHARMACIA AND UPJOHN	150MG/ML	N20246 001	Oct 29, 1992	Jul	CFTG
	MEDROXYPROGESTERONE ACETATE					
AB	GENSIA SICOR PHARMS	150MG/ML	N76553 001	Jul 28, 2004	Jul	NEWA

MELOXICAM

SUSPENSION; ORAL

	MOBIC					
	+ BOEHRINGER INGELHEIM	7.5MG/5ML	N21530 001	Jun 01, 2004	Jun	NEWA

MENOTROPINS (FSH; LH)

INJECTABLE; INJECTION

	PERGONAL					
	@ SERONO	75 IU/AMP; 75 IU/AMP	N17646 001		May	DISC
	REPRONEX					
	+ FERRING	75 IU/VIAL; 75 IU/VIAL	N21047 001	Aug 27, 1999	May	CTEC

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

DEMEROL

AP	+	HOSPIRA	25MG/ML	N21171 001		May	CAHN
AP	+		50MG/ML	N21171 002		May	CAHN
AP	+		75MG/ML	N21171 003		May	CAHN
AP	+		100MG/ML	N21171 004		May	CAHN

MEPERIDINE HCL PRESERVATIVE FREE

AP	+	HOSPIRA	10MG/ML	N88432 001	Aug 16, 1984	May	CAHN
----	---	---------	---------	------------	--------------	-----	------

TABLET; ORAL

MEPERIDINE HCL

AA		MUTUAL PHARM	50MG	N80448 001		Aug	CAHN
AA			100MG	N80448 002		Aug	CAHN

MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CARBOCAINE

AP	+	HOSPIRA	1%	N12250 001		May	CAHN
AP	+		1.5%	N12250 005		May	CAHN
AP	+		2%	N12250 002		May	CAHN

MEPROBAMATE

TABLET; ORAL

MEPROBAMATE

@ MUTUAL PHARM

@

			200MG	N80699 001		Aug	CAHN
			400MG	N80699 002		Aug	CAHN

MERCAPTOPURINE

TABLET; ORAL

MERCAPTOPURINE

AB		PROMETHEUS LABS	50MG	N40461 001	Feb 11, 2004	Feb	NEWA
AB		ROXANE	50MG	N40528 001	Feb 13, 2004	Feb	NEWA
AB	+	TEVA	50MG	N09053 002		Feb	CFTG

MESALAMINE

CAPSULE, EXTENDED RELEASE; ORAL

PENTASA

SHIRE LABS

+

			250MG	N20049 001	May 10, 1993	Aug	CRLD
			500MG	N20049 002	Jul 08, 2004	Aug	NEWA

ENEMA; RECTAL

MESALAMINE

>A>	AB	CLAY PARK	4GM/60ML	N76751 001	Sep 17, 2004	Sep	NEWA
>A>	AB	TEVA	4GM/60ML	N76841 001	Sep 30, 2004	Sep	NEWA
>D>	+	SOLVAY	4GM/60ML	N19618 001	Dec 24, 1987	Sep	CFTG
>A>	AB	+	4GM/60ML	N19618 001	Dec 24, 1987	Sep	CFTG

MESNA

INJECTABLE; INTRAVENOUS

MESNA

AP		BEDFORD	100MG/ML	N75739 001	Jan 09, 2004	Jan	NEWA
----	--	---------	----------	------------	--------------	-----	------

MESORIDAZINE BESYLATE

CONCENTRATE; ORAL

SERENTIL

@ NOVARTIS

EQ 25MG BASE/ML

N16997 001

May DISC

TABLET; ORAL

SERENTIL

@ NOVARTIS

EQ 25MG BASE

N16774 002

May DISC

@

EQ 100MG BASE

N16774 004

May DISC

METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

FORTAMET

>D>	BX	ANDRX	500MG	N21574 001	Apr 27, 2004	Sep	CAHN
	BX		500MG	N21574 001	Apr 27, 2004	Apr	NEWA
>D>	+		1GM	N21574 002	Apr 27, 2004	Sep	CAHN
	+		1GM	N21574 002	Apr 27, 2004	Apr	NEWA
>A>	BX	ANDRX LABS LLC	500MG	N21574 001	Apr 27, 2004	Sep	CAHN
>A>	+		1GM	N21574 002	Apr 27, 2004	Sep	CAHN

GLUCOPHAGE XR

AB		BRISTOL MYERS SQUIBB	500MG	N21202 001	Oct 13, 2000	Jan	CFTG
----	--	----------------------	-------	------------	--------------	-----	------

METFORMIN HCL

AB		ANDRX PHARMS	500MG	N76172 001	Jun 16, 2004	Jun	NEWA
AB		IMPAX LABS	500MG	N76249 001	Jul 30, 2004	Jul	NEWA
AB		IVAX PHARMS	500MG	N76545 001	Dec 01, 2003	Jan	NEWA
AB		RANBAXY	500MG	N76413 001	Jun 18, 2004	Jun	NEWA
AB		TEVA	500MG	N76269 001	Jun 18, 2004	Jun	NEWA

METHADONE HYDROCHLORIDE

TABLET; ORAL

METHADONE HCL

		@ EON	5MG	N40241 001	May 29, 1998	Aug	DISC
AA		MALLINCKRODT	5MG	N40517 001	Apr 27, 2004	Apr	NEWA
AA			10MG	N40517 002	Apr 27, 2004	Apr	NEWA

METHAMPHETAMINE HYDROCHLORIDE

TABLET; ORAL

DESOXYN

AB	+	OVATION PHARMS	5MG	N05378 002		Feb	CFTG
----	---	----------------	-----	------------	--	-----	------

METHAMPHETAMINE HCL

AB		ABLE	5MG	N40529 001	Feb 25, 2004	Feb	NEWA
----	--	------	-----	------------	--------------	-----	------

METHENAMINE HIPPURATE

TABLET; ORAL

UREX

AB		VATRING PHARMS	1GM	N16151 001		Aug	CAHN
----	--	----------------	-----	------------	--	-----	------

METHIMAZOLE

TABLET; ORAL

TAPAZOLE

AB		KING PHARMS	5MG	N07517 002		Mar	CAHN
AB			10MG	N07517 004		Mar	CAHN

METHOCARBAMOL

TABLET; ORAL

METHOCARBAMOL

	@ MUTUAL PHARM	500MG	N84488 001		Aug	CAHN
	@	750MG	N84486 001		Aug	CAHN

METHOTREXATE SODIUM

INJECTABLE; INJECTION

METHOTREXATE

AP	BIGMAR BIOREN PHARMS	EQ 25MG BASE/ML	N40263 001	Feb 26, 1999	Jul	CAHN
----	----------------------	-----------------	------------	--------------	-----	------

METHOTREXATE PRESERVATIVE FREE

AP	BIGMAR BIOREN PHARMS	EQ 25MG BASE/ML	N40265 001	Feb 26, 1999	Jul	CAHN
----	----------------------	-----------------	------------	--------------	-----	------

AP		EQ 1GM BASE/VIAL	N40266 001	Feb 26, 1999	Jul	CAHN
----	--	------------------	------------	--------------	-----	------

METHYL AMINOLEVULINATE HYDROCHLORIDE

CREAM; TOPICAL

METHYL AMINOLEVULINATE

	+ PHOTOCURE ASA	16.8%	N21415 001	Jul 27, 2004	Jul	NEWA
--	-----------------	-------	------------	--------------	-----	------

METHYLDOPA

TABLET; ORAL

METHYLDOPA

	@ ACCORD HEALTH	125MG	N70070 003	Oct 15, 1985	Jun	CAHN
AB		250MG	N70084 001	Oct 15, 1985	Jun	CAHN
AB		500MG	N70085 001	Oct 15, 1985	Jun	CAHN
	@ MUTUAL PHARM	125MG	N70073 001	Oct 09, 1986	Aug	CAHN
	@	250MG	N70060 001	Oct 09, 1986	Aug	CAHN
	@	500MG	N70074 001	Oct 09, 1986	Aug	CAHN

METHYLDOPATE HYDROCHLORIDE

INJECTABLE; INJECTION

METHYLDOPATE HCL

AP	HOSPIRA	50MG/ML	N70698 001	Jun 15, 1987	May	CAHN
----	---------	---------	------------	--------------	-----	------

AP		50MG/ML	N70699 001	Jun 15, 1987	May	CAHN
----	--	---------	------------	--------------	-----	------

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

METADATE CD

BX	CELLTECH PHARMS	10MG	N21259 003	May 27, 2003	May	CTEC
----	-----------------	------	------------	--------------	-----	------

RITALIN LA

BX	NOVARTIS	10MG	N21284 004	Apr 10, 2004	May	CTEC
----	----------	------	------------	--------------	-----	------

		10MG	N21284 004	Apr 10, 2004	Apr	NEWA
--	--	------	------------	--------------	-----	------

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION

A-METHAPRED

AP	HOSPIRA	EQ 40MG BASE/VIAL	N85853 001		May	CAHN
AP		EQ 125MG BASE/VIAL	N85855 001		May	CAHN
AP		EQ 500MG BASE/VIAL	N85854 001		May	CAHN
AP		EQ 500MG BASE/VIAL	N89173 001	Aug 18, 1987	May	CAHN
AP		EQ 1GM BASE/VIAL	N85852 001		May	CAHN
AP		EQ 1GM BASE/VIAL	N89174 001	Aug 18, 1987	May	CAHN

METHYLPREDNISOLONE SODIUM SUCCINATE

AP	AM PHARM	EQ 40MG BASE/VIAL	N40583 001	Jul 30, 2004	Jul	NEWA
----	----------	-------------------	------------	--------------	-----	------

AP		EQ 125MG BASE/VIAL	N40583 002	Jul 30, 2004	Jul	NEWA
----	--	--------------------	------------	--------------	-----	------

INJECTABLE; INJECTION

METHYLPREDNISOLONE SODIUM SUCCINATE

AP	AM PHARM	EQ 1GM BASE/VIAL	N40612 001	Aug 12, 2004	Aug	NEWA
----	----------	------------------	------------	--------------	-----	------

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

METOCLOPRAMIDE HCL

AP	HOSPIRA	EQ 5MG BASE/ML	N70505 001	Jun 23, 1989	May	CAHN
	@	EQ 5MG BASE/ML	N70506 001	Jun 22, 1989	May	CAHN
AP		EQ 5MG BASE/ML	N73117 001	Jan 17, 1991	May	CAHN
AP		EQ 5MG BASE/ML	N73118 001	Jan 17, 1991	May	CAHN
AP		EQ 5MG BASE/ML	N74147 001	Aug 02, 1996	May	CAHN

TABLET; ORAL

METOCLOPRAMIDE HCL

@ MUTUAL PHARM

		EQ 10MG BASE	N70660 001	Feb 10, 1987	Aug	CAHN
--	--	--------------	------------	--------------	-----	------

METOLAZONE

TABLET; ORAL

METOLAZONE

AB	ROXANE	10MG	N76482 002	Apr 29, 2004	Apr	NEWA
AB	TEVA	2.5MG	N76600 001	Jan 06, 2004	Jan	NEWA
AB		5MG	N76833 001	Mar 01, 2004	Mar	NEWA
AB	WATSON LABS	10MG	N76891 001	Jul 21, 2004	Jul	NEWA
	MYKROX					
	@ CELLTECH PHARMS	0.5MG	N19532 001	Oct 30, 1987	Jan	DISC

METOPROLOL TARTRATE

INJECTABLE; INJECTION

METOPROLOL TARTRATE

AP	HOSPIRA	1MG/ML	N74133 001	Dec 21, 1993	May	CAHN
AP		1MG/ML	N75160 001	Jul 06, 1998	May	CAHN

TABLET; ORAL

LOPRESSOR

AB	NOVARTIS	100MG	N17963 002		Mar	CRLD
	METOPROLOL TARTRATE					
	CARACO	25MG	N76670 001	Jan 15, 2004	Jan	NEWA
AB		25MG	N76670 001	Jan 15, 2004	Mar	CTEC
+	MYLAN	25MG	N76704 001	Jan 16, 2004	Jan	NEWA
AB		25MG	N76704 001	Jan 16, 2004	Mar	CTEC
AB		50MG	N76704 002	Jan 16, 2004	Jan	NEWA
AB		100MG	N76704 003	Jan 16, 2004	Jan	NEWA
AB	+	100MG	N76704 003	Jan 16, 2004	Mar	CRLD

METRONIDAZOLE

CAPSULE; ORAL

METRONIDAZOLE

AB	KALI LABS	375MG	N76322 001	Jan 29, 2004	Jan	NEWA
----	-----------	-------	------------	--------------	-----	------

CREAM; TOPICAL

METROCREAM

AB	+	GALDERMA LABS LP	0.75%	N20531 001	Sep 20, 1995	May	CFTG
----	---	------------------	-------	------------	--------------	-----	------

METRONIDAZOLE

AB	ALTANA	0.75%	N76408 001	May 28, 2004	May	NEWA
----	--------	-------	------------	--------------	-----	------

INJECTABLE; INJECTION

METRONIDAZOLE IN PLASTIC CONTAINER

AP	+	HOSPIRA	500MG/100ML	N18890 002	Nov 18, 1983	May	CAHN
----	---	---------	-------------	------------	--------------	-----	------

TABLET; ORAL

METRONIDAZOLE

@ MUTUAL PHARM

250MG

N18818 001 Feb 16, 1983 Aug CAHN

@

500MG

N18818 002 Feb 16, 1983 Aug CAHN

MICONAZOLE

INJECTABLE; INJECTION

MONISTAT

@ JANSSSEN PHARMA

10MG/ML

N18040 001

Jul CAHN

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDAZOLAM HCL

@ HOSPIRA

EQ 1MG BASE/ML

N75293 001 Jun 20, 2000 May DISC

AP

EQ 1MG BASE/ML

N75409 002 Jun 20, 2000 May CAHN

AP

EQ 1MG BASE/ML

N75856 001 Jun 13, 2002 May CAHN

AP

+

EQ 1MG BASE/ML

N75857 001 Jul 22, 2002 May CAHN

@

EQ 5MG BASE/ML

N75293 002 Jun 20, 2000 May DISC

AP

EQ 5MG BASE/ML

N75409 001 Jun 20, 2000 May CAHN

AP

EQ 5MG BASE/ML

N75856 002 Jun 13, 2002 May CAHN

AP

+

EQ 5MG BASE/ML

N75857 002 Jul 22, 2002 May CAHN

AP

INTL MEDICATION

EQ 1MG BASE/ML

N76020 001 Jul 16, 2004 Jul NEWA

AP

EQ 5MG BASE/ML

N76020 002 Jul 16, 2004 Jul NEWA

MIDODRINE HYDROCHLORIDE

TABLET; ORAL

MIDODRINE HCL

AB

EON

10MG

N76514 003 Jul 02, 2004 Jul NEWA

AB

IMPAX PHARMS

2.5MG

N76449 001 May 27, 2004 May NEWA

AB

5MG

N76449 002 May 27, 2004 May NEWA

MILRINONE LACTATE

INJECTABLE; INJECTION

MILRINONE LACTATE

>A> AP

APOTEX

EQ 1MG BASE/ML

N76427 001 Sep 21, 2004 Sep NEWA

AP

HOSPIRA

EQ 1MG BASE/ML

N75884 001 May 28, 2002 May CAHN

MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP

B BRAUN

EQ 20MG BASE/100ML

N76414 001 Aug 18, 2004 Aug NEWA

AP

HOSPIRA

EQ 20MG BASE/100ML

N75885 001 May 28, 2002 May CAHN

MINOCYCLINE HYDROCHLORIDE

TABLET; ORAL

MINOCYCLINE HCL

AB

MEDICIS

EQ 50MG BASE

N65131 001 Apr 16, 2003 Jan CFTG

AB

EQ 75MG BASE

N65131 002 Apr 16, 2003 Jan CFTG

AB

+

EQ 100MG BASE

N65131 003 Apr 16, 2003 Jan CFTG

AB

RANBAXY

EQ 50MG BASE

N65156 001 Jan 06, 2004 Jan NEWA

AB

EQ 75MG BASE

N65156 002 Jan 06, 2004 Jan NEWA

AB

EQ 100MG BASE

N65156 003 Jan 06, 2004 Jan NEWA

MIRTAZAPINE

TABLET; ORAL

MIRTAZAPINE

CARACO

7.5MG

N76541 004 Apr 22, 2004 Apr NEWA

AB

15MG

N76541 001 Apr 22, 2004 Apr NEWA

AB

30MG

N76541 002 Apr 22, 2004 Apr NEWA

	TABLET; ORAL							
	MIRTAZAPINE							
AB	CARACO	45MG		N76541 003	Apr 22, 2004	Apr	NEWA	
	<u>MOLINDONE HYDROCHLORIDE</u>							
	CONCENTRATE; ORAL							
	MOBAN							
	@ ENDO PHARMS	20MG/ML		N17938 001		May	DISC	
	TABLET; ORAL							
	MOBAN							
	@ ENDO PHARMS	100MG		N17111 008		May	DISC	
	<u>MORPHINE SULFATE</u>							
	INJECTABLE, LIPOSOMAL; EPIDURAL							
	DEPODUR							
	SKYEPHARMA	10MG/ML		N21671 001	May 18, 2004	May	NEWA	
		15MG/1.5ML (10MG/ML)		N21671 002	May 18, 2004	May	NEWA	
	+	20MG/2ML (10MG/ML)		N21671 003	May 18, 2004	May	NEWA	
	INJECTABLE; INJECTION							
	MORPHINE SULFATE							
AP	+	HOSPIRA	0.5MG/ML	N19917 001	Oct 30, 1992	May	CAHN	
AP			0.5MG/ML	N71849 001	May 11, 1988	May	CAHN	
AP			0.5MG/ML	N73509 001	Sep 30, 1992	May	CAHN	
AP	+		1MG/ML	N19916 001	Oct 30, 1992	May	CAHN	
AP			1MG/ML	N71850 001	May 11, 1988	May	CAHN	
AP			1MG/ML	N73510 001	Sep 30, 1992	May	CAHN	
	TABLET, EXTENDED RELEASE; ORAL							
	MORPHINE SULFATE							
AB	KV PHARM	15MG		N76733 001	May 19, 2004	May	NEWA	
AB		60MG		N76720 001	May 19, 2004	May	NEWA	
	ORAMORPH SR							
BC	+	AAIPHARMA	60MG	N19977 002	Aug 15, 1991	Mar	CRLD	
	<u>MYCOPHENOLIC ACID</u>							
	TABLET, EXTENDED RELEASE; ORAL							
	MYFORTIC							
	NOVARTIS	180MG		N50791 001	Feb 27, 2004	Feb	NEWA	
	+	360MG		N50791 002	Feb 27, 2004	Feb	NEWA	
	<u>NABILONE</u>							
	CAPSULE; ORAL							
	CESAMET							
	@ VALEANT	1MG		N18677 001	Dec 26, 1985	Jan	CAHN	
	<u>NAFCILLIN SODIUM</u>							
	INJECTABLE; INJECTION							
	NAFCILLIN SODIUM							
	+	SANDOZ	EQ 500MG BASE/VIAL	N62527 001	Aug 02, 1984	Jun	CAHN	
AP			EQ 1GM BASE/VIAL	N62527 002	Aug 02, 1984	Jun	CAHN	
AP			EQ 2GM BASE/VIAL	N62527 003	Aug 02, 1984	Jun	CAHN	
AP			EQ 10GM BASE/VIAL	N62527 004	Aug 02, 1984	Jun	CAHN	
	<u>NAFTIFINE HYDROCHLORIDE</u>							
	CREAM; TOPICAL							
	NAFTIN							
	MERZ PHARMS	1%		N19599 001	Feb 29, 1988	Jul	CAHN	

GEL; TOPICAL

NAFTIN

+	MERZ PHARMS	1%	N19356 001	Jun 18, 1990	Jul	CAHN
---	-------------	----	------------	--------------	-----	------

NALBUPHINE HYDROCHLORIDE

INJECTABLE; INJECTION

NALBUPHINE HCL

AP	HOSPIRA	10MG/ML	N70914 001	Feb 03, 1989	May	CAHN
AP		10MG/ML	N70915 001	Feb 03, 1989	May	CAHN
AP		20MG/ML	N70916 001	Feb 03, 1989	May	CAHN
AP		20MG/ML	N70918 001	Feb 03, 1989	May	CAHN
	@ KING PHARMS	10MG/ML	N74471 001	Mar 19, 1998	Mar	DISC

NALIDIXIC ACID

TABLET; ORAL

NALIDIXIC ACID

@ MUTUAL PHARM

@

@

250MG

500MG

1GM

N70270 001 Jun 29, 1988 Aug CAHN

N70271 001 Jun 29, 1988 Aug CAHN

N70272 001 Jun 29, 1988 Aug CAHN

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

NALOXONE

@ BAXTER HLTHCARE

@

NALOXONE HCL

		0.4MG/ML	N70298 001	Sep 24, 1986	Aug	CAHN
		0.4MG/ML	N70299 001	Sep 24, 1986	Aug	CAHN
AP	HOSPIRA	0.02MG/ML	N70171 001	Sep 24, 1986	May	CAHN
AP		0.02MG/ML	N70252 001	Jan 16, 1987	May	CAHN
AP		0.02MG/ML	N70253 001	Jan 16, 1987	May	CAHN
	@	0.4MG/ML	N70172 001	Sep 24, 1986	May	CAHN
AP		0.4MG/ML	N70254 001	Jan 07, 1987	May	CAHN
AP		0.4MG/ML	N70255 001	Jan 07, 1987	May	CAHN
AP		0.4MG/ML	N70256 001	Jan 07, 1987	May	CAHN
AP		0.4MG/ML	N70257 001	Jan 07, 1987	May	CAHN

NAPROXEN

TABLET; ORAL

NAPROXEN

@ BAXTER HLTHCARE

@

@

250MG

375MG

500MG

AB	WESTWARD	250MG	N74105 001	Dec 21, 1993	Aug	DISC
			N74105 002	Dec 21, 1993	Aug	DISC
			N74105 003	Dec 21, 1993	Aug	DISC
AB		250MG	N76494 001	Jan 14, 2004	Jan	NEWA
AB		375MG	N76494 002	Jan 14, 2004	Jan	NEWA
AB		500MG	N76494 003	Jan 14, 2004	Jan	NEWA

NAPROXEN SODIUM

TABLET, EXTENDED RELEASE; ORAL

NAPRELAN

AB	+	STAT TRADE	EQ 375MG BASE	N20353 001	Jan 05, 1996	Jun	CAHN
AB	+		EQ 500MG BASE	N20353 002	Jan 05, 1996	Jun	CAHN
		@	EQ 750MG BASE	N20353 003	Jan 05, 1996	Jun	CAHN

NEDOCROMIL SODIUM

AEROSOL, METERED; INHALATION

TILADE

+	KING PHARMS	1.75MG/INH	N19660 001	Dec 30, 1992	Jan	CAHN
---	-------------	------------	------------	--------------	-----	------

NEFAZODONE HYDROCHLORIDE

TABLET; ORAL

NEFAZODONE HCL

@ ROXANE	50MG	N76196 001	Sep 16, 2003	Jul	DISC
@	100MG	N76196 002	Sep 16, 2003	Jul	DISC
@	150MG	N76196 003	Sep 16, 2003	Jul	DISC
@	200MG	N76196 004	Sep 16, 2003	Jul	DISC
@	250MG	N76196 005	Sep 16, 2003	Jul	DISC

NIACIN

TABLET; ORAL

NIACIN

@ MK LABS	500MG	N83525 001		Feb	DISC
@ TABLICAPS	500MG	N84237 001		Feb	DISC
NIACOR					
AA + UPSHER SMITH	500MG	N40378 001	May 03, 2000	Feb	CRLD

NIFEDIPINE

TABLET, EXTENDED RELEASE; ORAL

NIFEDIPINE

AB2 MARTEC	90MG	N75414 003	Mar 23, 2004	Mar	NEWA
AB2 + PROCARDIA XL					
PFIZER	90MG	N19684 003	Sep 06, 1989	Mar	CFTG

NITAZOXANIDE

TABLET; ORAL

ALINIA

+ ROMARK	500MG	N21497 001	Jul 21, 2004	Jul	NEWA
----------	-------	------------	--------------	-----	------

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

NITROFURANTOIN

@ MYLAN	100MG	N74967 002	Jul 09, 1997	Aug	DISC
AB	100MG	N77025 001	Aug 18, 2004	Aug	NEWA

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

MACROBID

AB + PROCTER AND GAMBLE	75MG;25MG	N20064 001	Dec 24, 1991	Mar	CFTG
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)					
AB MYLAN	EQ 75MG BASE;25MG	N76648 001	Mar 22, 2004	Mar	NEWA
AB	75MG;25MG	N76648 001	Mar 22, 2004	Apr	CPOT

NITROGLYCERIN

FILM, EXTENDED RELEASE; TRANSDERMAL

NITROGLYCERIN

AB1 KREMERS URBAN	0.2MG/HR	N75115 001	Aug 10, 2004	Aug	NEWA
AB1	0.4MG/HR	N75115 002	Aug 10, 2004	Aug	NEWA

INJECTABLE; INJECTION

NITROGLYCERIN

AP + HOSPIRA	5MG/ML	N18531 001		May	CAHN
NITROGLYCERIN IN DEXTROSE 5%					
AP HOSPIRA	0.1MG/ML	N74083 001	Oct 26, 1994	May	CAHN
AP	10MG/100ML	N71846 001	Aug 31, 1990	May	CAHN
AP	20MG/100ML	N71847 001	Aug 31, 1990	May	CAHN

INJECTABLE; INJECTION

NITROGLYCERIN IN DEXTROSE 5%

AP	HOSPIRA	40MG/100ML	N71848 001	Aug 31, 1990	May	CAHN
----	---------	------------	------------	--------------	-----	------

NIZATIDINE

SOLUTION; ORAL

AXID

+	RELIANT PHARMS	15MG/ML	N21494 001	May 25, 2004	May	NEWA
---	----------------	---------	------------	--------------	-----	------

NOREPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

LEVOPHED

AP	+	HOSPIRA	EQ 1MG BASE/ML	N07513 001		May	CAHN
----	---	---------	----------------	------------	--	-----	------

NOREPINEPHRINE BITARTRATE

>A>	AP	PHARMAFORCE		N40522 001	Sep 30, 2004	Sep	NEWA
-----	----	-------------	--	------------	--------------	-----	------

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE; ORAL

AVENTYL HCL

@ LILLY

EQ 10MG BASE

N14684 001

Jun

DISC

@

EQ 25MG BASE

N14684 002

Jun

DISC

NYSTATIN

PASTILLE; ORAL

MYCOSTATIN

@ BRISTOL MYERS SQUIBB 200,000 UNITS

N50619 001

Apr 09, 1987

Jun

DISC

POWDER; TOPICAL

NYSTATIN

AT		KALI LABS	100,000 UNITS/GM	N65138 001	Jul 23, 2004	Jul	NEWA
----	--	-----------	------------------	------------	--------------	-----	------

AT		TANON	100,000 UNITS/GM	N65203 001	Jul 15, 2004	Jul	NEWA
----	--	-------	------------------	------------	--------------	-----	------

SUSPENSION; ORAL

MYCOSTATIN

@ APOTHECON 100,000 UNITS/ML

N61533 001

Aug

DISC

NILSTAT

AA	+	GLENMARK PHARMA	100,000 UNITS/ML	N50299 001		Jul	CAHN
----	---	-----------------	------------------	------------	--	-----	------

NYSTATIN

@ BAUSCH AND LOMB 100,000 UNITS/ML

N64042 001

Feb 28, 1994

Aug

DISC

AA	+	MORTON GROVE	100,000 UNITS/ML	N62512 001	Oct 29, 1984	Aug	CRLD
----	---	--------------	------------------	------------	--------------	-----	------

AA		VISTAPHARM	100,000 UNITS/ML	N64142 001	Jun 25, 1998	Aug	CAHN
----	--	------------	------------------	------------	--------------	-----	------

NYSTEX

@ SAVAGE LABS 100,000 UNITS/ML

N62519 001

Jul 06, 1984

Aug

DISC

OPFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

OCUFLOX

AT	+	ALLERGAN	0.3%	N19921 001	Jul 30, 1993	May	CFTG
----	---	----------	------	------------	--------------	-----	------

OPFLOXACIN

AT		ALCON	0.3%	N76231 001	May 14, 2004	May	NEWA
----	--	-------	------	------------	--------------	-----	------

AT		BAUSCH AND LOMB	0.3%	N76622 001	May 14, 2004	May	NEWA
----	--	-----------------	------	------------	--------------	-----	------

AT		HI TECH PHARMA	0.3%	N76615 001	May 14, 2004	May	NEWA
----	--	----------------	------	------------	--------------	-----	------

AT		NOVEX	0.3%	N76513 001	May 14, 2004	May	NEWA
----	--	-------	------	------------	--------------	-----	------

SOLUTION/DROPS; OTIC

FLOXIN OTIC

+	DAIICHI	0.3%	N20799 001	Dec 16, 1997	Jun	CTNA
---	---------	------	------------	--------------	-----	------

SOLUTION; OPHTHALMIC

OPFLOXACIN

AT		PHARMAFORCE	EQ 0.3% BASE	N76830 001	Aug 31, 2004	Aug	NEWA
----	--	-------------	--------------	------------	--------------	-----	------

OLANZAPINE

INJECTABLE; INTRAMUSCULAR

ZYPREXA

+ LILLY 10MG/VIAL N21253 001 Mar 29, 2004 Mar NEWA

OLSALAZINE SODIUM

CAPSULE; ORAL

DIPENTUM

+ CELLTECH PHARMS 250MG N19715 001 Jul 31, 1990 Jun CAHN

OMEPRAZOLE

FOR SUSPENSION; ORAL

ZEGERID

+ SANTARUS 20MG/PACKET N21636 001 Jun 15, 2004 Jun NEWA

OXACILLIN SODIUM

INJECTABLE; INJECTION

OXACILLIN SODIUM

AP	+	APOTHECON	EQ 250MG BASE/VIAL	N61490 001		Mar	CRLD
AP	+		EQ 2GM BASE/VIAL	N61490 004		Mar	NEWA
AP			EQ 2GM BASE/VIAL	N62737 002	Dec 23, 1986	Mar	CRLD
AP	+	SANDOZ	EQ 250MG BASE/VIAL	N61490 001		Jun	CAHN
AP	+		EQ 500MG BASE/VIAL	N61490 002		Jun	CAHN
AP	+		EQ 1GM BASE/VIAL	N61490 003		Jun	CAHN
AP	+		EQ 2GM BASE/VIAL	N61490 004		Jun	CAHN
AP	+		EQ 10GM BASE/VIAL	N61490 006	May 09, 1991	Jun	CAHN

OXAMNIQUINE

CAPSULE; ORAL

VANSIL

@ PFIZER

250MG N18069 001 Mar DISC

OXAPROZIN

TABLET; ORAL

OXAPROZIN

>A> AB APOTEX 600MG N75987 001 Sep 02, 2004 Sep NEWA

>D> OXAPROZIN POTASSIUM

>D> TABLET; ORAL

>D> DAYPRO ALTA

>A> @ GD SEARLE 600MG N20776 001 Oct 17, 2002 Sep DISC

>D> + PHARMACIA 600MG N20776 001 Oct 17, 2002 Sep DISC

OXAZEPAM

CAPSULE; ORAL

OXAZEPAM

@ MUTUAL PHARM

10MG N70957 001 Aug 10, 1987 Aug CAHN

@

15MG N71025 001 Aug 10, 1987 Aug CAHN

@

30MG N71026 001 Aug 10, 1987 Aug CAHN

SERAX

@ ALPHARMA

15MG N15539 004 Aug DISC

TABLET; ORAL

OXAZEPAM

@ MUTUAL PHARM

15MG N70683 001 Jan 16, 1987 Aug CAHN

OXYCODONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

OXYCODONE HCL

AB	ENDO PHARMS	10MG	N75923 001	Mar 23, 2004	Mar	NEWA	
AB		20MG	N75923 002	Mar 23, 2004	Mar	NEWA	
AB		40MG	N75923 003	Mar 23, 2004	Mar	NEWA	
>A>	AB	80MG	N75923 004	Sep 29, 2004	Sep	NEWA	
>A>	AB	IMPAX LABS	80MG	N76318 001	Sep 27, 2004	Sep	NEWA
AB	TEVA	80MG	N76168 001	Mar 23, 2004	Mar	NEWA	

OXYCONTIN

AB	PURDUE PHARMA LP	10MG	N20553 001	Dec 12, 1995	Mar	CFTG
AB		20MG	N20553 002	Dec 12, 1995	Mar	CFTG
AB	+	40MG	N20553 003	Dec 12, 1995	Mar	CFTG
AB	+	80MG	N20553 004	Jan 06, 1997	Mar	CFTG
AB		80MG	N20553 004	Jan 06, 1997	Jun	CRLO

TABLET; ORAL

OXYCODONE HCL

AB	AMIDE PHARM	15MG	N76636 001	Feb 06, 2004	Feb	NEWA
AB		30MG	N76636 002	Feb 06, 2004	Feb	NEWA
AB	MALLINCKRODT	15MG	N76758 001	Jun 30, 2004	Jun	NEWA
AB		30MG	N76758 002	Jun 30, 2004	Jun	NEWA

ROXICODONE

AB	+	AAIPHARMA	15MG	N21011 001	Aug 31, 2000	Feb	CFTG
AB			30MG	N21011 002	Aug 31, 2000	Feb	CFTG

PANCURONIUM BROMIDE

INJECTABLE; INJECTION

PANCURONIUM BROMIDE

AP	HOSPIRA	1MG/ML	N72320 001	Jan 19, 1989	May	CAHN
AP		2MG/ML	N72321 001	Jan 19, 1989	May	CAHN

PARICALCITOL

INJECTABLE; INJECTION

ZEMPLAR

	ABBOTT	0.002MG/ML	N20819 002	Feb 01, 2000	Mar	NEWA
--	--------	------------	------------	--------------	-----	------

PAROXETINE HYDROCHLORIDE

TABLET; ORAL

PAROXETINE HCL

AB	ALPHAPHARM	EQ 10MG BASE	N75716 001	Mar 08, 2004	Mar	NEWA
AB		EQ 20MG BASE	N75716 002	Mar 08, 2004	Mar	NEWA
AB		EQ 30MG BASE	N75716 003	Mar 08, 2004	Mar	NEWA
AB		EQ 40MG BASE	N75716 004	Mar 08, 2004	Mar	NEWA
AB	SANDOZ	EQ 10MG BASE	N75566 001	Mar 08, 2004	Mar	NEWA
AB		EQ 20MG BASE	N75566 002	Mar 08, 2004	Mar	NEWA
AB		EQ 30MG BASE	N75566 003	Mar 08, 2004	Mar	NEWA
AB		EQ 40MG BASE	N75566 004	Mar 08, 2004	Mar	NEWA

FEMETREXED DISODIUM

INJECTABLE; IV (INFUSION)

ALIMTA

+	LILLY	EQ 500MG BASE/VIAL	N21462 001	Feb 04, 2004	Feb	NEWA
---	-------	--------------------	------------	--------------	-----	------

PENTAMIDINE ISETHIONATE

INJECTABLE; INJECTION
PENTAMIDINE ISETHIONATE

AP HOSPIRA 300MG/VIAL N73479 001 Jun 30, 1992 May CAHN

PENTAZOCINE LACTATE

INJECTABLE; INJECTION
TALWIN

+ HOSPIRA EQ 30MG BASE/ML N16194 001 May CAHN

PENTETATE CALCIUM TRISODIUM

SOLUTION; INHALATION, INTRAVENOUS
PENTETATE CALCIUM TRISODIUM

+ HAMELN PHARMS EQ 1GM/5ML(EQ 200MG/ML) N21749 001 Aug 11, 2004 Aug NEWA

PENTETATE ZINC TRISODIUM

SOLUTION; INHALATION, INTRAVENOUS
PENTETATE ZINC TRISODIUM

+ HAMELN PHARMS EQ 1GM/5ML(EQ 200MG/ML) N21751 001 Aug 11, 2004 Aug NEWA

PENTOBARBITAL SODIUM

CAPSULE; ORAL
NEMBUTAL SODIUM

@ OVATION PHARMS 30MG N84095 001 May DISC

@ 100MG N83245 001 May DISC

SODIUM PENTOBARBITAL

+ VALEANT PHARM INTL 100MG N83264 001 May CRLD

PENTOSAN POLYSULFATE SODIUM

CAPSULE; ORAL
ELMIRON

+ ORTHO MCNEIL PHARM 100MG N20193 001 Sep 26, 1996 Jun CAHN

PHENDIMETRAZINE TARTRATE

TABLET; ORAL
BONTRIL PDM

AA VALEANT 35MG N85272 001 Aug CAHN

PHENYL BUTAZONE

CAPSULE; ORAL
PHENYL BUTAZONE
@ MUTUAL PHARM

100MG N88994 001 Dec 04, 1985 Aug CAHN

TABLET; ORAL
PHENYL BUTAZONE
@ MUTUAL PHARM

100MG N88863 001 Dec 04, 1985 Aug CAHN

PHENYTOIN

SUSPENSION; ORAL
PHENYTOIN

AB TARO 125MG/5ML N40521 001 Mar 08, 2004 Mar NEWA

PHENYTOIN SODIUM

CAPSULE; ORAL
DILANTIN

+ PARKE DAVIS 30MG EXTENDED N84349 001 Aug MAGC

CAPSULE; ORALDILANTIN

AB	+	PARKE DAVIS	100MG EXTENDED	N84349 002		Aug	MAGC
----	---	-------------	----------------	------------	--	-----	------

DIPHENYLAN SODIUM@ LANNETT@

			30MG PROMPT	N80857 001		Aug	MAGC
			100MG PROMPT	N80857 002		Aug	MAGC

EXTENDED PHENYTOIN SODIUM

AB		BARR	100MG EXTENDED	N40435 001	Jun 20, 2003	Aug	MAGC
----	--	------	----------------	------------	--------------	-----	------

AB		MYLAN	100MG EXTENDED	N40298 001	Dec 28, 1998	Aug	MAGC
----	--	-------	----------------	------------	--------------	-----	------

@ PLIVAPHENYTEK

	+	MYLAN	200MG EXTENDED	N40298 002	Dec 06, 2001	Aug	MAGC
--	---	-------	----------------	------------	--------------	-----	------

	+		300MG EXTENDED	N40298 003	Dec 06, 2001	Aug	MAGC
--	---	--	----------------	------------	--------------	-----	------

PHENYTEX@ WATSON LABSPHENYTOIN SODIUM@ PHARMERAL@ WATSON LABS

			100MG PROMPT	N85435 001		Aug	MAGC
			100MG PROMPT	N85894 001		Aug	MAGC

PROMPT PHENYTOIN SODIUM

EX	+	IVAX PHARMS	100MG PROMPT	N80259 001		Aug	MAGC
----	---	-------------	--------------	------------	--	-----	------

@ WATSON LABSINJECTABLE; INJECTIONPHENYTOIN SODIUM@ HOSPIRA@

			50MG/ML	N89521 001	Mar 17, 1987	May	CAHN
			50MG/ML	N89744 001	Dec 18, 1987	May	CAHN

PHYTONADIONEINJECTABLE; INJECTIONVITAMIN K1

BF		HOSPIRA	1MG/0.5ML	N87954 001	Jul 25, 1983	May	CAHN
----	--	---------	-----------	------------	--------------	-----	------

BF			10MG/ML	N87955 001	Jul 25, 1983	May	CAHN
----	--	--	---------	------------	--------------	-----	------

@

			10MG/ML	N87956 001	Jul 25, 1983	May	CAHN
--	--	--	---------	------------	--------------	-----	------

PIPERACILLIN SODIUMINJECTABLE; INJECTIONPIPERACILLIN

	+	AM PHARM	EQ 40GM BASE/VIAL	N65157 001	Jul 12, 2004	Jul	NEWA
--	---	----------	-------------------	------------	--------------	-----	------

PIPERAZINE CITRATESYRUP; ORALMULTIFUGE@ BLULINE

			EQ 500MG BASE/5ML	N09452 001		Jul	DISC
--	--	--	-------------------	------------	--	-----	------

PODOFILOXSOLUTION; TOPICALCONDYLOX

>A>	AT	+	OCLASSEN	0.5%	N19795 001	Dec 13, 1990	Sep	CAHN
-----	----	---	----------	------	------------	--------------	-----	------

>D>	AT	+	PADDOCK	0.5%	N19795 001	Dec 13, 1990	Sep	CAHN
-----	----	---	---------	------	------------	--------------	-----	------

POLYETHYLENE GLYCOL 3350FOR SOLUTION; ORALGLYCOLAX

AA		SCHWARZ PHARMA	17GM/SCOOPFUL	N76652 001	Jul 02, 2004	Jul	NEWA
----	--	----------------	---------------	------------	--------------	-----	------

MIRALAX

AA	+	BRAINTREE	17GM/SCOOPFUL	N20698 001	Feb 18, 1999	Jul	CFTG
----	---	-----------	---------------	------------	--------------	-----	------

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION; ORAL

NULYTELY

AA	+	BRAINTREE	420GM/BOT;1.48GM/BOT;5.72GM/BOT;1 1.2GM/BOT	N19797 001	Apr 22, 1991	Feb	CFTG
----	---	-----------	--	------------	--------------	-----	------

NULYTELY-FLAVORED

AA	+	BRAINTREE	420GM/BOT;1.48GM/BOT;5.72GM/BOT;1 1.2GM/BOT	N19797 002	Nov 18, 1994	Feb	CFTG
----	---	-----------	--	------------	--------------	-----	------

TRILYTE

AA		SCHWARZ PHARMA	420GM/BOT;1.48GM/BOT;5.72GM/BOT;1 1.2GM/BOT	N76491 001	Feb 05, 2004	Feb	NEWA
----	--	----------------	--	------------	--------------	-----	------

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE

SOLUTION; ORAL

OCL

+	HOSPIRA	6GM/100ML;75MG/100ML;168MG/100ML; 146MG/100ML;1.29GM/100ML	N19284 001	Apr 30, 1986	May	CAHN
---	---------	---	------------	--------------	-----	------

POTASSIUM ACETATE

INJECTABLE; INJECTION

POTASSIUM ACETATE IN PLASTIC CONTAINER

+	HOSPIRA	2MEQ/ML	N18896 001	Jul 20, 1984	May	CAHN
---	---------	---------	------------	--------------	-----	------

POTASSIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE

	@	HOSPIRA	1MEQ/ML	N80205 003		May	CAHN
	@		1MEQ/ML	N83345 003		May	CAHN
	+		1.5MEQ/ML	N83345 001		May	CAHN
AP	+		2MEQ/ML	N80205 001		May	CAHN
AP			2MEQ/ML	N83345 002		May	CAHN
	@		2.4MEQ/ML	N80205 004		May	CAHN
	@		3.2MEQ/ML	N80205 005		May	CAHN

POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER

	@	HOSPIRA	14.9MG/ML	N20161 005	Nov 30, 1992	May	CAHN
	@		745MG/100ML	N20161 001	Nov 30, 1992	May	CAHN

POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER

AP	+	HOSPIRA	29.8MG/ML	N20161 006	Aug 11, 1998	May	CAHN
	@		1.49GM/100ML	N20161 002	Nov 30, 1992	May	CAHN

POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER

AP	+	HOSPIRA	2.24GM/100ML	N20161 003	Aug 11, 1998	May	CAHN
----	---	---------	--------------	------------	--------------	-----	------

POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER

AP	+	HOSPIRA	2.98GM/100ML	N20161 004	Aug 11, 1998	May	CAHN
----	---	---------	--------------	------------	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL

POTASSIUM CHLORIDE

AB		EURAND	20MEQ	N76368 001	Aug 18, 2004	Aug	NEWA
----	--	--------	-------	------------	--------------	-----	------

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 20MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP		HOSPIRA	149MG/100ML;900MG/100ML	N19686 001	Oct 17, 1988	May	CAHN
----	--	---------	-------------------------	------------	--------------	-----	------

POTASSIUM CHLORIDE 40MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP		HOSPIRA	298MG/100ML;900MG/100ML	N19686 002	Oct 17, 1988	May	CAHN
----	--	---------	-------------------------	------------	--------------	-----	------

POTASSIUM CHLORIDE; SODIUM CHLORIDE; TROMETHAMINE

INJECTABLE; INJECTION

THAM-E

@ HOSPIRA	370MG/VIAL;1.75GM/VIAL;36GM/VIAL	N13025 001	May	CAHN
-----------	----------------------------------	------------	-----	------

PREDNISOLONE

TABLET; ORAL

PREDNISOLONE

@ EVERYLIFE	2.5MG	N84439 002	May	DISC
-------------	-------	------------	-----	------

@	5MG	N84439 003	May	DISC
---	-----	------------	-----	------

@ SPERTI	1MG	N80358 001	May	DISC
----------	-----	------------	-----	------

@	2.5MG	N80358 002	May	DISC
---	-------	------------	-----	------

@	5MG	N80358 003	May	DISC
---	-----	------------	-----	------

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION; ORAL

PREDNISOLONE SODIUM PHOSPHATE

AA	PADDOCK	EQ 5MG BASE/5ML	N75988 001	May 25, 2004	May	NEWA
----	---------	-----------------	------------	--------------	-----	------

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC

VASOCIDIN

AT	+	NOVARTIS	EQ 0.23% PHOSPHATE;10%	N18988 001	Aug 26, 1988	Aug	CAHN
----	---	----------	------------------------	------------	--------------	-----	------

PREDNISONE

TABLET; ORAL

DELTASONE

>D>	AB	+	PHARMACIA AND UPJOHN	2.5MG	N09986 005	Sep	DISC
-----	----	---	----------------------	-------	------------	-----	------

>A>			@	2.5MG	N09986 005	Sep	DISC
-----	--	--	---	-------	------------	-----	------

>D>	AB	+		10MG	N09986 006	Sep	DISC
-----	----	---	--	------	------------	-----	------

>A>			@	10MG	N09986 006	Sep	DISC
-----	--	--	---	------	------------	-----	------

			@	20MG	N09986 007	Jul	DISC
--	--	--	---	------	------------	-----	------

PREDNISONE

@ MUTUAL PHARM

			@	5MG	N80701 001	Aug	CAHN
--	--	--	---	-----	------------	-----	------

			@	10MG	N86595 001	Aug	CAHN
--	--	--	---	------	------------	-----	------

			@	20MG	N84634 001	Aug	CAHN
--	--	--	---	------	------------	-----	------

			@	50MG	N86596 001	Aug	CAHN
--	--	--	---	------	------------	-----	------

AB	+	ROXANE	20MG	N87342 001	Jul	CRLD
----	---	--------	------	------------	-----	------

		@ SANDOZ	20MG	N85813 001	Aug	DISC
--	--	----------	------	------------	-----	------

AB		WEST WARD	2.5MG	N40538 001	Jan 08, 2004	Jan	NEWA
----	--	-----------	-------	------------	--------------	-----	------

PROCAINAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

PROCAINAMIDE HCL

AP		HOSPIRA	100MG/ML	N89069 001	Feb 12, 1986	May	CAHN
----	--	---------	----------	------------	--------------	-----	------

AP			500MG/ML	N89070 001	Feb 12, 1986	May	CAHN
----	--	--	----------	------------	--------------	-----	------

AP			500MG/ML	N89537 001	Aug 25, 1987	May	CAHN
----	--	--	----------	------------	--------------	-----	------

PROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

NOVOCAIN

AP	+	HOSPIRA	1%	N85362 003	May	CAHN
----	---	---------	----	------------	-----	------

AP	+		2%	N85362 004	May	CAHN
----	---	--	----	------------	-----	------

		+	10%	N86797 001	May	CAHN
--	--	---	-----	------------	-----	------

INJECTABLE; INJECTION

PROCAINE HCL

AP	HOSPIRA	1%		N80416 001		May	CAHN
AP		2%		N80416 002		May	CAHN

PROCHLORPERAZINE EDISYLATE

INJECTABLE; INJECTION

PROCHLORPERAZINE EDISYLATE

AP	BAXTER HLTHCARE	EQ 5MG BASE/ML		N89903 001	Aug 29, 1989	Aug	CAHN
AP	BEDFORD	EQ 5MG BASE/ML		N40540 001	May 28, 2004	May	NEWA
AP	HOSPIRA	EQ 5MG BASE/ML		N89703 001	Apr 07, 1988	May	CAHN

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

PROMETHAZINE HCL

AP	BEDFORD LABS	25MG/ML		N40524 001	Mar 17, 2004	Mar	NEWA
AP		50MG/ML		N40524 002	Mar 17, 2004	Mar	NEWA
>A>	BIONICHE PHARMA	25MG/ML		N40471 001	Nov 21, 2002	Sep	CAHN
AP	HOSPIRA	25MG/ML		N40372 001	Jun 08, 2000	May	CAHN
AP		50MG/ML		N40372 002	Jun 08, 2000	May	CAHN
AP		50MG/ML		N83838 002		May	CAHN
>D>	PHARMAFORCE	25MG/ML		N40471 001	Nov 21, 2002	Sep	CAHN

SYRUP; ORAL

PROMETH PLAIN

@ ALPHARMA

6.25MG/5ML

N85953 001

Feb DISC

PROMETHAZINE HCL

AA + HI TECH PHARMA

6.25MG/5ML

N40026 001

Sep 25, 1998 Feb CRLD

AA

6.25MG/5ML

N40026 001

Sep 25, 1998 May CRLD

PROMETHAZINE PLAIN

AA + MORTON GROVE

6.25MG/5ML

N87953 001

Nov 15, 1982 May CRLD

TABLET; ORAL

PHENERGAN

>D> AB WYETH PHARMS INC

12.5MG

N07935 002

Sep DISC

>A> @

12.5MG

N07935 002

Sep DISC

AB 12.5MG

N07935 002

Jul CFTG

AB 25MG

N07935 003

Jul CTEC

AB + 50MG

N07935 004

Jul CTEC

PROMETHAZINE HCL

AB ABLE

12.5MG

N40558 001

Jul 01, 2004 Jul NEWA

AB 25MG

N40558 002

Jul 01, 2004 Jul NEWA

AB 50MG

N40558 003

Jul 01, 2004 Jul NEWA

@ MUTUAL PHARM

12.5MG

N84555 001

Aug CAHN

@

25MG

N84554 001

Aug CAHN

@

50MG

N84557 001

Aug CAHN

PROPAPENONE HYDROCHLORIDE

TABLET; ORAL

PROPAPENONE HCL

AB PLIVA

150MG

N76550 001

Apr 23, 2004 Apr NEWA

AB 225MG

N76550 002

Apr 23, 2004 Apr NEWA

AB 300MG

N76550 003

Apr 23, 2004 Apr NEWA

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

DARVON

@ AAIPHARMA LLC

32MG

N10997 001

Aug DISC

	CAPSULE; ORAL							
	PROPOXYPHENE HCL							
	@ MUTUAL PHARM	65MG		N83186 001			Aug	CAHN
	<u>PROPRANOLOL HYDROCHLORIDE</u>							
	INJECTABLE; INJECTION							
	PROPRANOLOL							
AP	AM PHARM PARTNERS	1MG/ML		N75826 001	Aug 31, 2001	Jan		NEWA
	TABLET; ORAL							
	PROPRANOLOL HCL							
	@ MUTUAL PHARM	10MG		N70319 001	Oct 22, 1985	Aug		CAHN
	@	20MG		N70320 001	Oct 22, 1985	Aug		CAHN
	@	40MG		N70103 001	Oct 22, 1985	Aug		CAHN
	@	60MG		N70321 001	Sep 24, 1986	Aug		CAHN
	@	80MG		N70322 001	Aug 04, 1986	Aug		CAHN
	<u>PROPYLTHIOURACIL</u>							
	TABLET; ORAL							
	PROPYLTHIOURACIL							
	@ MUTUAL PHARM	50MG		N83982 001		Aug		CAHN
	<u>PROTAMINE SULFATE</u>							
	INJECTABLE; INJECTION							
	PROTAMINE SULFATE							
+	AM PHARM PARTNERS	10MG/ML		N89454 001	Apr 07, 1987	Mar		CRLD
	@ LILLY	10MG/ML		N06460 002		Mar		DISC
	<u>PROTRIPTYLINE HYDROCHLORIDE</u>							
	TABLET; ORAL							
	VIVACTIL							
	@ ODYSSEY PHARMS	5MG		N16012 001		Jun		CAHN
	@	10MG		N16012 002		Jun		CAHN
	<u>RANITIDINE HYDROCHLORIDE</u>							
	TABLET, EFFERVESCENT; ORAL							
	ZANTAC 25							
	GLAXOSMITHKLINE	EQ 25MG BASE		N20251 003	Apr 01, 2004	Apr		NEWA
	<u>RIBAVIRIN</u>							
	CAPSULE; ORAL							
	REBETOL							
AB	+ SCHERING PLOUGH RES	200MG		N20903 002	Jul 25, 2001	Apr		CFTG
	RIBASPHERE							
AB	THREE RIVERS PHARMS	200MG		N76203 001	Apr 06, 2004	Apr		NEWA
	RIBAVIRIN							
AB	SANDOZ	200MG		N76192 001	Apr 06, 2004	Apr		NEWA
	<u>RIFAXIMIN</u>							
	TABLET; ORAL							
	XIFAXAN							
+	SALIX PHARMS	200MG		N21361 001	May 25, 2004	May		NEWA
	<u>RISPERIDONE</u>							
	INJECTABLE; INTRAMUSCULAR							
	RISPERDAL CONSTA							
	JANSSEN PHARMA	25MG/VIAL		N21346 001	Oct 29, 2003	Jul		CAHN

INJECTABLE; INTRAMUSCULAR

RISPERDAL CONSTA

JANSSEN PHARMA	37.5MG/VIAL	N21346 002	Oct 29, 2003	Jul	CAHN
+	50MG/VIAL	N21346 003	Oct 29, 2003	Jul	CAHN
TABLET, ORALLY DISINTEGRATING; ORAL					
RISPERDAL					
JANSSEN PHARMA	0.5MG	N21444 001	Apr 02, 2003	Jun	CAHN
+	1MG	N21444 002	Apr 02, 2003	Jun	CAHN
	2MG	N21444 003	Apr 02, 2003	Jun	CAHN

RITODRINE HYDROCHLORIDE

INJECTABLE; INJECTION

RITODRINE HCL

+ HOSPIRA	10MG/ML	N71618 001	Feb 28, 1991	May	CAHN
+	15MG/ML	N71619 001	Feb 28, 1991	May	CAHN
RITODRINE HCL IN DEXTROSE 5% IN PLASTIC CONTAINER					
+ HOSPIRA	30MG/100ML	N71438 001	Jan 22, 1991	May	CAHN

ROCURONIUM BROMIDE

INJECTABLE; INJECTION

ZEMURON

ORGANON USA INC	10MG/ML	N20214 002	Mar 17, 1994	Jun	CMFD
@	10MG/ML	N20214 002	Mar 17, 1994	Jul	DISC
ZEMURON (P/F)					
+ ORGANON USA INC	50MG/5ML (10MG/ML)	N20214 001	Mar 17, 1994	Jul	CPOT
+	100MG/10ML (10MG/ML)	N20214 003	Mar 17, 1994	Jul	NEWA

>D> ROFECOXIB

>D> SUSPENSION; ORAL

>D> VIOXX

>D> MERCK	12.5MG/5ML	N21052 001	May 20, 1999	Sep	DISC
>A> @	12.5MG/5ML	N21052 001	May 20, 1999	Sep	DISC
>D> +	25MG/5ML	N21052 002	May 20, 1999	Sep	DISC
>A> @	25MG/5ML	N21052 002	May 20, 1999	Sep	DISC

>D> TABLET; ORAL

>D> VIOXX

>D> MERCK	12.5MG	N21042 001	May 20, 1999	Sep	DISC
>A> @	12.5MG	N21042 001	May 20, 1999	Sep	DISC
>D>	25MG	N21042 002	May 20, 1999	Sep	DISC
>A> @	25MG	N21042 002	May 20, 1999	Sep	DISC
>D> +	50MG	N21042 003	Feb 25, 2000	Sep	DISC
>A> @	50MG	N21042 003	Feb 25, 2000	Sep	DISC

ROPINIROLE HYDROCHLORIDE

TABLET; ORAL

REQUIP

GLAXOSMITHKLINE	EQ 5MG BASE	N20658 005	Sep 19, 1997	May	CRLD
-----------------	-------------	------------	--------------	-----	------

SAFFLOWER OIL; SOYBEAN OIL

INJECTABLE; INJECTION

LIPOSYN II 10%

+ HOSPIRA	5%;5% (5GM/100ML)	N18997 001	Aug 27, 1984	May	CAHN
LIPOSYN II 20%					
+ HOSPIRA	10%;10% (10GM/100ML)	N18991 001	Aug 27, 1984	May	CAHN

SECRETIN SYNTHETIC HUMAN

FOR SOLUTION; INTRAVENOUS

>A>	CHIRHOSTIM						
>A>	+ CHIRHOCLIN	16UGM/VIAL	N21256	001	Apr 09, 2004	Sep	CTNA
>D>	HUMAN SECRETIN						
>D>	+ CHIRHOCLIN	16UGM/VIAL	N21256	001	Apr 09, 2004	Sep	CTNA
	+	16UGM/VIAL	N21256	001	Apr 09, 2004	Apr	NEWA

SECRETIN SYNTHETIC PORCINE

FOR SOLUTION; INTRAVENOUS

SECREMAX

+ CHIRHOCLIN	16UGM/VIAL	N21136	001	Apr 04, 2002	Jul	CAIN
--------------	------------	--------	-----	--------------	-----	------

SELEGILINE HYDROCHLORIDE

TABLET; ORAL

SELEGILINE HCL

@ SOMERSET

5MG	N19334	001	Jun 05, 1989	Aug	DISC
-----	--------	-----	--------------	-----	------

SEVELAMER HYDROCHLORIDE

CAPSULE; ORAL

RENAGEL

@ GENZYME

403MG	N20926	001	Oct 30, 1998	Jun	DISC
-------	--------	-----	--------------	-----	------

SIROLIMUS

TABLET; ORAL

RAPAMUNE

WYETH PHARMS INC

2MG	N21110	002	Aug 22, 2002	Feb	CRLD
-----	--------	-----	--------------	-----	------

+

5MG	N21110	003	Feb 23, 2004	Feb	NEWA
-----	--------	-----	--------------	-----	------

SODIUM ACETATE, ANHYDROUS

INJECTABLE; INJECTION

SODIUM ACETATE IN PLASTIC CONTAINER

+ HOSPIRA	2MEQ/ML	N18893	001	May 04, 1983	May	CAHN
-----------	---------	--------	-----	--------------	-----	------

SODIUM CHLORIDE

INJECTABLE; INJECTION

BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AF + HOSPIRA	9MG/ML	N18800	001	Oct 29, 1982	May	CAHN
--------------	--------	--------	-----	--------------	-----	------

SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AF HOSPIRA	450MG/100ML	N18090	001		May	CAHN
------------	-------------	--------	-----	--	-----	------

AF	450MG/100ML	N19759	001	Jun 08, 1988	May	CAHN
----	-------------	--------	-----	--------------	-----	------

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AF HOSPIRA	9MG/ML	N18803	001	Oct 29, 1982	May	CAHN
------------	--------	--------	-----	--------------	-----	------

AF +	9MG/ML	N19217	001	Jul 13, 1984	Jul	CRLD
------	--------	--------	-----	--------------	-----	------

AF	9MG/ML	N19217	001	Jul 13, 1984	May	CAHN
----	--------	--------	-----	--------------	-----	------

AF	9MG/ML	N19465	002	Jul 15, 1985	May	CAHN
----	--------	--------	-----	--------------	-----	------

AF	900MG/100ML	N16366	001		May	CAHN
----	-------------	--------	-----	--	-----	------

AF	900MG/100ML	N19465	001	Jul 15, 1985	May	CAHN
----	-------------	--------	-----	--------------	-----	------

AF	900MG/100ML	N19480	001	Sep 17, 1985	May	CAHN
----	-------------	--------	-----	--------------	-----	------

SODIUM CHLORIDE IN PLASTIC CONTAINER

HOSPIRA

2.5MEQ/ML	N18897	001	Jul 20, 1984	May	CAHN
-----------	--------	-----	--------------	-----	------

SOLUTION; IRRIGATION

SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AT HOSPIRA	450MG/100ML	N17670	001		May	CAHN
------------	-------------	--------	-----	--	-----	------

@

450MG/100ML	N18380	001		May	CAHN
-------------	--------	-----	--	-----	------

SOLUTION; IRRIGATION							
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER							
AT	HOSPIRA	900MG/100ML		N17514 001		May	CAHN
AT		900MG/100ML		N18314 001		May	CAHN
<u>SODIUM FERRIC GLUCONATE COMPLEX</u>							
INJECTABLE; INJECTION							
FERRLECIT							
+	WATSON PHARMS	62.5MG/5ML		N20955 001	Feb 18, 1999	Feb	CAHN
<u>SODIUM IODIDE, I-131</u>							
SOLUTION; ORAL							
SODIUM IODIDE I 131							
	@ CIS	50mCi/ML		N17315 001		Apr	DISC
<u>SODIUM LACTATE</u>							
INJECTABLE; INJECTION							
SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER							
AP	HOSPIRA	1.87GM/100ML		N18249 001		May	CAHN
SODIUM LACTATE IN PLASTIC CONTAINER							
	HOSPIRA	5MEQ/ML		N18947 001	Sep 05, 1984	May	CAHN
<u>SODIUM NITROPRUSSIDE</u>							
INJECTABLE; INJECTION							
NITROPRESS							
AP	+	HOSPIRA	25MG/ML	N71961 001	Aug 01, 1988	May	CAHN
	+		50MG/VIAL	N70566 001	Jun 09, 1986	May	CAHN
<u>SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS</u>							
INJECTABLE; INJECTION							
SODIUM PHOSPHATES IN PLASTIC CONTAINER							
	HOSPIRA	142MG/ML;276MG/ML		N18892 001	May 10, 1983	May	CAHN
<u>SOMATROPIN RECOMBINANT</u>							
INJECTABLE; INJECTION							
SAIZEN							
	@ SERONO	6MG/VIAL		N19764 001	Oct 08, 1996	May	DISC
SEROSTIM							
BX	SERONO	4MG/VIAL		N20604 003	Jul 25, 1997	Jan	CTEC
	@	8.8MG/VIAL		N20604 004	Sep 06, 2001	Jan	DISC
ZORBTIVE							
	@ SERONO INC	4MG/VIAL		N21597 001	Dec 01, 2003	May	DISC
	@	5MG/VIAL		N21597 002	Dec 01, 2003	May	DISC
	@	6MG/VIAL		N21597 003	Dec 01, 2003	May	DISC
<u>SOTALOL HYDROCHLORIDE</u>							
TABLET; ORAL							
SOTALOL HCL							
AB2	MUTUAL PHARM	80MG		N76576 001	Apr 08, 2004	Apr	NEWA
AB2		120MG		N76576 002	Apr 08, 2004	Apr	NEWA
AB2		160MG		N76576 003	Apr 08, 2004	Apr	NEWA
AB2	TEVA	80MG		N76883 001	Jul 26, 2004	Jul	NEWA
AB2		120MG		N76883 002	Jul 26, 2004	Jul	NEWA
AB2		160MG		N76883 003	Jul 26, 2004	Jul	NEWA

SOYBEAN OIL

	INJECTABLE; INJECTION				
	LIPOSYN III 10%				
AP	+	HOSPIRA	10%	N18969 001	Sep 24, 1984 May CAHN
		LIPOSYN III 20%			
AP	+	HOSPIRA	20%	N18970 001	Sep 25, 1984 May CAHN
		LIPOSYN III 30%			
AP	+	HOSPIRA	30%	N20181 001	Jan 13, 1998 May CAHN

SPARFLOXACIN

TABLET; ORAL

ZAGAM

@ MYLAN

200MG

N20677 001 Dec 19, 1996 Mar DISC

SPIRONOLACTONE

TABLET; ORAL

SPIRONOLACTONE

AB MUTUAL PHARM

25MG

N87265 001 Aug CAHN

STAVUDINE

CAPSULE, EXTENDED RELEASE; ORAL

ZERIT XR

@ BRISTOL MYERS SQUIBB 37.5MG

N21453 001 Dec 31, 2002 Jun DISC

@ 50MG

N21453 002 Dec 31, 2002 Jun DISC

@ 75MG

N21453 003 Dec 31, 2002 Jun DISC

@ 100MG

N21453 004 Dec 31, 2002 Jun DISC

SUCCINYLCHOLINE CHLORIDE

INJECTABLE; INJECTION

ANECTINE

AP + SABEX 2002

20MG/ML

N08453 002

Jul CAHN

@ 50MG/ML

N08453 003

Jul CAHN

+ 500MG/VIAL

N08453 001

Jul CAHN

+ 1GM/VIAL

N08453 004

Jul CAHN

QUELICIN

AP + HOSPIRA

20MG/ML

N08845 006

May CAHN

QUELICIN PRESERVATIVE FREE

AP + HOSPIRA

20MG/ML

N08845 001

May CAHN

@ 50MG/ML

N08845 002

May CAHN

+ 100MG/ML

N08845 004

May CAHN

SUCRALFATE

TABLET; ORAL

CARAFATE

AB + AXCAN SCANDIPHARM

1GM

N18333 001

Feb CAHN

SUFENTANIL CITRATE

INJECTABLE; INJECTION

SUFENTANIL CITRATE

AP BAXTER HLTHCARE

EQ 0.05MG BASE/ML

N74413 001 Dec 15, 1995 Aug CAHN

SUFENTANIL CITRATE

AP HOSPIRA

EQ 0.05MG BASE/ML

N74534 001 Dec 11, 1996 May CAHN

SULFACETAMIDE SODIUMSOLUTION/DROPS; OPHTHALMIC
SULF-10

AT NOVARTIS 10% N80025 001 Mar CMFD

SULFACYTINETABLET; ORAL
RENOQUID

@ GLENWOOD 250MG N17569 001 Aug DISC

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE; INJECTION

SULFAMETHOXAZOLE AND TRIMETHOPRIM

>D> AP BAXTER HLTHCARE 80MG/ML;16MG/ML N70627 001 Dec 29, 1987 Sep DISC

>A> @ 80MG/ML;16MG/ML N70627 001 Dec 29, 1987 Sep DISC

AP 80MG/ML;16MG/ML N70627 001 Dec 29, 1987 Aug CAHN

AP 80MG/ML;16MG/ML N70628 001 Dec 29, 1987 Aug CAHN

AP HOSPIRA 80MG/ML;16MG/ML N73199 001 Sep 11, 1992 May CAHN

TABLET; ORAL

>D> SULFAMETHOPRIM-DS

>D> AB PAR PHARM 800MG;160MG N70032 001 Feb 15, 1985 Sep DISC

>A> @ 800MG;160MG N70032 001 Feb 15, 1985 Sep DISC

SULFAMETHOXAZOLE AND TRIMETHOPRIM

@ MUTUAL PHARM 400MG;80MG N70006 001 Nov 14, 1984 Aug CAHN

>D> AB SANDOZ 400MG;80MG N70889 001 Nov 13, 1986 Sep DISC

>A> @ 400MG;80MG N70889 001 Nov 13, 1986 Sep DISC

SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH

@ MUTUAL PHARM 800MG;160MG N70007 001 Nov 14, 1984 Aug CAHN

TECHNETIUM TC-99M APCITIDE

INJECTABLE; INJECTION

ACUTECT

BERLEX LABS N/A N20887 001 Sep 14, 1998 Jun CAHN

TECHNETIUM TC-99M DEPREOTIDE

INJECTABLE; INJECTION

NEO TECT KIT

+ BERLEX LABS N/A N21012 001 Aug 03, 1999 Jun CAHN

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE; INJECTION

DRAXIMAGE MDP

AP + DRAXIMAGE N/A N18035 001 May CTNA

TECHNETIUM TC-99M OXIDRONATE KIT

INJECTABLE; INJECTION

TECHNESCAN

>A> + MALLINCKRODT N/A N18321 001 Sep CRLD

TECHNESCAN HDP

>D> MALLINCKRODT N/A N18321 001 Sep CRLD

TECHNETIUM TC-99M SESTAMIBI KIT

INJECTABLE; INJECTION

CARDIOLITE

+ BRISTOL MYERS SQUIBB N/A N19785 001 Dec 21, 1990 Jul CRLD

TELITHROMYCIN

TABLET; ORAL

KETEK

+ AVENTIS PHARMS 400MG N21144 001 Apr 01, 2004 Apr NEWA

TEMAZEPAM

CAPSULE; ORAL

TEMAZEPAM

@ MUTUAL PHARM 15MG N71174 001 Jul 10, 1986 Aug CAHN

@ 30MG N71175 001 Jul 10, 1986 Aug CAHN

TERBINAFINE

GEL; TOPICAL

LAMISIL

NOVARTIS 1% N20846 001 Apr 29, 1998 Jan CMFD

TERBUTALINE SULFATE

INJECTABLE; INJECTION

BRETHINE

AP + AAIPHARMA LLC 1MG/ML N18571 001 Apr CFTG

TERBUTALINE SULFATE

AP AM PHARM 1MG/ML N76887 001 May 26, 2004 May NEWA

AP BEDFORD 1MG/ML N76770 001 Apr 23, 2004 Apr NEWA

AP SICOR PHARMS 1MG/ML N76853 001 Jul 20, 2004 Jul NEWA

TERCONAZOLE

CREAM; VAGINAL

TERAZOL 3

AB + ORTHO MCNEIL PHARM 0.8% N19964 001 Feb 21, 1991 Apr CFTG

TERCONAZOLE

AB TARO 0.8% N75953 001 Apr 06, 2004 Apr NEWA

TESTOSTERONE

FILM, EXTENDED RELEASE; TRANSDERMAL

ANDRODERM

+ WATSON LABS 5MG/24HR N20489 002 May 02, 1997 Aug CTEC

TESTODERM

@ ALZA 4MG/24HR N19762 001 Oct 12, 1993 Aug DISC

@ 6MG/24HR N19762 002 Oct 12, 1993 Aug DISC

TESTODERM TTS

@ ALZA 5MG/24HR N20791 001 Dec 18, 1997 Aug DISC

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL

TETRACYCLINE HCL

AB MUTUAL PHARM 250MG N60736 001 Aug CAHN

AB 500MG N60736 002 Aug CAHN

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL

AEROLATE III

@ FLEMING PHARMS 65MG N85075 003 Nov 24, 1986 Jun DISC

AEROLATE JR

@ FLEMING PHARMS 130MG N85075 002 Nov 24, 1986 Jun DISC

CAPSULE, EXTENDED RELEASE; ORAL

AEROLATE SR

@ FLEMING PHARMS 260MG

N85075 001 Nov 24, 1986 Jun DISC

INJECTABLE; INJECTION

THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP + HOSPIRA 4MG/ML

N19211 007 Dec 14, 1984 May CAHN

AP + 40MG/100ML

N19211 001 Dec 14, 1984 May CAHN

AP + 80MG/100ML

N19211 002 Dec 14, 1984 May CAHN

AP + 160MG/100ML

N19211 003 Dec 14, 1984 May CAHN

AP + 200MG/100ML

N19211 004 Dec 14, 1984 May CAHN

AP + 320MG/100ML

N19211 006 Jan 20, 1988 May CAHN

AP + 400MG/100ML

N19211 005 Dec 14, 1984 May CAHN

SOLUTION; ORAL

AEROLATE

@ FLEMING PHARMS 150MG/15ML

N89141 001 Dec 03, 1986 Jun DISC

TABLET, EXTENDED RELEASE; ORAL

THEOLAIR-SR

@ 3M 200MG

N88369 001 Jul 16, 1987 Jun DISC

@ 250MG

N86363 002 Jul 16, 1987 Jun DISC

@ 300MG

N88364 001 Jul 16, 1987 Jun DISC

@ 500MG

N89132 001 Jul 16, 1987 Jun DISC

THEOPHYLLINE

AB ABLE 300MG

N40548 001 Apr 30, 2004 Apr NEWA

AB 400MG

N40543 001 Apr 27, 2004 Apr NEWA

AB 450MG

N40546 001 Apr 30, 2004 Apr NEWA

AB 600MG

N40539 001 Apr 27, 2004 Apr NEWA

UNIPHYL

AB + PURDUE FREDERICK 400MG

N87571 001 Sep 01, 1982 Apr CFTG

AB + 600MG

N40086 001 Apr 15, 1996 Apr CFTG

THIAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

THIAMINE HCL

AP BAXTER HLTCARE 100MG/ML

N80575 001 Aug CAHN

AP HOSPIRA 100MG/ML

N40079 001 May 03, 1996 May CAHN

THIORIDAZINE HYDROCHLORIDE

TABLET; ORAL

THIORIDAZINE HCL

@ MUTUAL PHARM 10MG

N88375 001 Nov 18, 1983 Aug CAHN

@ 15MG

N88461 001 Nov 18, 1983 Aug CAHN

@ 25MG

N87264 001 Nov 18, 1983 Aug CAHN

AB 50MG

N88370 001 Nov 18, 1983 Aug CAHN

@ 100MG

N88379 001 Nov 16, 1983 Aug CAHN

@ 150MG

N88737 001 Sep 26, 1984 Aug CAHN

@ 200MG

N88738 001 Oct 16, 1984 Aug CAHN

TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

ISTALOL

>A> BT + ISTA PHARMS EQ 0.5% BASE

N21516 001 Jun 04, 2004 Sep CTEC

>D> + SENJU EQ 0.5% BASE

N21516 001 Jun 04, 2004 Sep CTEC

+ EQ 0.5% BASE

N21516 001 Jun 04, 2004 Jun NEWA

TIMOLOL MALEATE

AT HI TECH PHARMA EQ 0.5% BASE

N75163 001 Sep 10, 2002 Jun CDFR

TINIDAZOLE

TABLET; ORAL

TINDAMAX

PRESUTTI LABS

250MG

N21618 001 May 17, 2004 May NEWA

+

500MG

N21618 002 May 17, 2004 May NEWA

TIOTROPIUM BROMIDE MONOHYDRATE

CAPSULE; INHALATION

SPIRIVA

+ BOEHRINGER INGELHEIM EQ 0.018MG BASE

N21395 001 Jan 30, 2004 Jan NEWA

TIZANIDINE HYDROCHLORIDE

CAPSULE; ORAL

ZANAFLEX

ACORDA

EQ 2MG BASE

N21447 001 Aug 29, 2002 Aug CAHN

EQ 4MG BASE

N21447 002 Aug 29, 2002 Aug CAHN

+

EQ 6MG BASE

N21447 003 Aug 29, 2002 Aug CAHN

TABLET; ORAL

TIZANIDINE HCL

>A> AB IVAX PHARMS

EQ 2MG BASE

N76321 001 Sep 30, 2004 Sep NEWA

>A> AB

EQ 4MG BASE

N76321 002 Sep 30, 2004 Sep NEWA

AB TORPHARM

EQ 2MG BASE

N76533 001 Jan 16, 2004 Jan NEWA

AB

EQ 4MG BASE

N76533 002 Jan 16, 2004 Jan NEWA

ZANAFLEX

AB ACORDA

EQ 2MG BASE

N20397 002 Feb 04, 2000 Aug CAHN

AB +

EQ 4MG BASE

N20397 001 Nov 27, 1996 Aug CAHN

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION

NEBCIN

@ LILLY

EQ 10MG BASE/ML

N50477 005 Jun DISC

@

EQ 10MG BASE/ML

N62008 004 Jun DISC

@

EQ 10MG BASE/ML

N62707 001 Apr 29, 1987 Jun DISC

@

EQ 40MG BASE/ML

N62008 001 Jun DISC

@

EQ 1.2GM BASE/VIAL

N50519 001 Jun DISC

TOBRAMYCIN

AM PHARM

EQ 1.2GM BASE/VIAL

N50789 001 Jul 13, 2004 Jul NEWA

AP + PHARMA TEK

EQ 1.2GM BASE/VIAL

N65013 001 Aug 17, 2001 Jun CRLD

+

EQ 1.2GM BASE/VIAL

N65013 001 Aug 17, 2001 Jul CTEC

TOBRAMYCIN SULFATE

AP + HOSPIRA

EQ 10MG BASE/ML

N63080 001 Apr 30, 1991 Jun CRLD

AP

EQ 10MG BASE/ML

N63080 001 Apr 30, 1991 May CAHN

AP

EQ 10MG BASE/ML

N63112 001 Apr 30, 1991 May CAHN

AP

EQ 40MG BASE/ML

N63111 001 Apr 30, 1991 May CAHN

AP +

EQ 40MG BASE/ML

N63116 001 May 18, 1992 May CAHN

AP

EQ 40MG BASE/ML

N63161 001 May 29, 1991 May CAHN

TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

+ HOSPIRA

EQ 1.2MG BASE/ML

N63081 003 Jul 31, 1990 May CAHN

+

EQ 1.6MG BASE/ML

N63081 006 Jun 02, 1993 May CAHN

+

EQ 80MG BASE/100ML

N63081 001 Jul 31, 1990 May CAHN

TOLAZAMIDE

TABLET; ORAL

TOLAZAMIDE

@ WATSON LABS

100MG

N70513 001 Jan 09, 1986 Aug DISC

TOLCAPONE

TABLET; ORAL

TASMAR

VALEANT

100MG

N20697 001 Jan 29, 1998 Aug CAHN

+

200MG

N20697 002 Jan 29, 1998 Aug CAHN

TOLMETIN SODIUM

CAPSULE; ORAL

TOLMETIN SODIUM

TEVA

EQ 400MG BASE

N73519 001 May 29, 1992 Sep DISC

>D> AB

@

EQ 400MG BASE

N73519 001 May 29, 1992 Sep DISC

>A>

TOPIRAMATE

CAPSULE; ORAL

TOPAMAX SPRINKLE

ORTHO MCNEIL PHARM

15MG

N20844 001 Oct 26, 1998 Jul CAHN

+

25MG

N20844 002 Oct 26, 1998 Jul CAHN

@

50MG

N20844 003 Oct 26, 1998 Jul CAHN

TABLET; ORAL

TOPAMAX

ORTHO MCNEIL PHARM

50MG

N20505 005 Dec 24, 1996 Jun CMFD

TRAVOPROST

SOLUTION/DROPS; OPHTHALMIC

TRAVATAN

ALCON

0.004%

N21257 001 Mar 16, 2001 May CAHN

TRETINOIN

CREAM; TOPICAL

AVITA

MYLAN BERTEK

0.025%

N20404 003 Jan 14, 1997 Aug CAHN

AB

GEL; TOPICAL

AVITA

MYLAN BERTEK

0.025%

N20400 001 Jan 29, 1998 Aug CAHN

BT

TRIAMCINOLONE

TABLET; ORAL

ARISTOCORT

FUJISAWA HLTHCARE

4MG

N11161 007

Jun CRLD

BF

KENACORT

@ BRISTOL MYERS SQUIBB

8MG

N11283 010

Jun DISC

TRIAMCINOLONE

@ WATSON LABS

4MG

N84270 001

Jun DISC

TRIAMCINOLONE ACETONIDE

AEROSOL, METERED; INHALATION

AZMACORT

KOS

0.1MG/INH

N18117 001 Apr 23, 1982 Apr CAHN

SPRAY, METERED; NASAL

NASACORT HFA

AVENTIS PHARMS

0.055MG/SPRAY

N20784 001 Apr 07, 2004 Apr NEWA

+

TRIAMCINOLONE DIACETATE

INJECTABLE; INJECTION

ARISTOCORT

@ SABEX 2002

25MG/ML

N11685 003

Jun DISC

@

40MG/ML

N12802 001

Jun DISC

TRIMETHOBENZAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

TRIMETHOBENZAMIDE HCL

AP HOSPIRA

100MG/ML

N88804 001 Apr 03, 1987 May CAHN

TRIMETHOPRIM

TABLET; ORAL

TRIMETHOPRIM

@ MUTUAL PHARM

100MG

N70494 001 Jan 22, 1986 Aug CAHN

@

200MG

N70495 001 Sep 24, 1986 Aug CAHN

TRIMIPRAMINE MALEATE

CAPSULE; ORAL

SURMONTIL

ODYSSEY PHARMS

EQ 25MG BASE

N16792 001

Jun CAHN

EQ 50MG BASE

N16792 002

Jun CAHN

+

EQ 100MG BASE

N16792 003 Sep 15, 1982 Jun CAHN

TRIPTORELIN PAMOATE

INJECTABLE; INTRAMUSCULAR

TRELSTAR

>D> + PHARMACIA AND UPJOHN 11.25MG/VIAL

N21288 001 Jun 29, 2001 Sep CAHN

>A> + WATSON PHARMS 11.25MG/VIAL

N21288 001 Jun 29, 2001 Sep CAHN

TRELSTAR DEPOT

>D> + PHARMACIA AND UPJOHN EQ 3.75MG BASE/VIAL

N20715 001 Jun 15, 2000 Sep CAHN

>A> + WATSON PHARMS EQ 3.75MG BASE/VIAL

N20715 001 Jun 15, 2000 Sep CAHN

TROLAMINE POLYPEPTIDE OLEATE CONDENSATE

SOLUTION/DROPS; OTIC

CERUMENEX

@ PURDUE FREDERICK

10%

N11340 002

May DISC

TROMETHAMINE

INJECTABLE; INJECTION

THAM

+ HOSPIRA

3.6GM/100ML

N13025 002

May CAHN

TROSPIMUM CHLORIDE

TABLET; ORAL

SANCTURA

+ INDEVUS

20MG

N21595 001 May 28, 2004 May NEWA

TROVAFLOXACIN MESYLATE

TABLET; ORAL

TROVAN

@ PFIZER

EQ 100MG BASE

N20759 001 Dec 18, 1997 Jun DISC

@

EQ 200MG BASE

N20759 002 Dec 18, 1997 Jun DISC

TUBOCURARINE CHLORIDE

	INJECTABLE; INJECTION						
	TUBOCURARINE CHLORIDE						
	+ BRISTOL MYERS SQUIBB	3MG/ML		N05657	001	Jun	CTEC
	@	3MG/ML		N05657	001	Jul	DISC
AP	+ HOSPIRA	3MG/ML		N06095	001	May	CAHN
	@	3MG/ML		N06095	001	Jun	DISC

UNOPROSTONE ISOPROPYL

SOLUTION/DROPS; OPHTHALMIC

RESCULA

	+ NOVARTIS	0.15%		N21214	001	Aug 03, 2000	Aug	CAHN
--	------------	-------	--	--------	-----	--------------	-----	------

UREA

INJECTABLE; INJECTION

STERILE UREA

	@ HOSPIRA	40GM/VIAL		N17698	001		May	CAHN
--	-----------	-----------	--	--------	-----	--	-----	------

UREAPHIL

	+ HOSPIRA	40GM/VIAL		N12154	001		May	CAHN
--	-----------	-----------	--	--------	-----	--	-----	------

URSODIOL

TABLET; ORAL

URSO 250

	AXCAN SCANDIPHARM	250MG		N20675	001	Dec 10, 1997	Jul	CTNA
--	-------------------	-------	--	--------	-----	--------------	-----	------

>A>

URSO FORTE

>A>

	+ AXCAN SCANDIPHARM	500MG		N20675	002	Jul 21, 2004	Sep	CTNA
--	---------------------	-------	--	--------	-----	--------------	-----	------

>D>

ORSODIOL

>D>

	+ AXCAN SCANDIPHARM	500MG		N20675	002	Jul 21, 2004	Sep	CTNA
--	---------------------	-------	--	--------	-----	--------------	-----	------

	+ AXCAN SCANDIPHARM	500MG		N20675	002	Jul 21, 2004	Jul	NEWA
--	---------------------	-------	--	--------	-----	--------------	-----	------

VALACYCLOVIR HYDROCHLORIDE

TABLET; ORAL

VALTREX

	+ GLAXOSMITHKLINE	EQ 1GM BASE		N20487	002	Jun 23, 1995	Feb	CRLD
--	-------------------	-------------	--	--------	-----	--------------	-----	------

VANCOMYCIN HYDROCHLORIDE

FOR SOLUTION; ORAL

VANCOCIN HCL

	@ LILLY	EQ 250MG BASE/5ML		N61667	002	Jul 13, 1983	Jun	DISC
--	---------	-------------------	--	--------	-----	--------------	-----	------

	@	EQ 500MG BASE/6ML		N61667	001		Jun	DISC
--	---	-------------------	--	--------	-----	--	-----	------

INJECTABLE; INJECTION

VANCOCIN HCL

	@ LILLY	EQ 500MG BASE/VIAL		N60180	001		Jun	DISC
--	---------	--------------------	--	--------	-----	--	-----	------

	@	EQ 500MG BASE/VIAL		N62476	001	Mar 15, 1984	Jun	DISC
--	---	--------------------	--	--------	-----	--------------	-----	------

	@	EQ 500MG BASE/VIAL		N62716	001	Mar 13, 1987	Jun	DISC
--	---	--------------------	--	--------	-----	--------------	-----	------

	@	EQ 500MG BASE/VIAL		N62812	001	Nov 17, 1987	Jun	DISC
--	---	--------------------	--	--------	-----	--------------	-----	------

	@	EQ 1GM BASE/VIAL		N60180	002	Mar 21, 1986	Jun	DISC
--	---	------------------	--	--------	-----	--------------	-----	------

	@	EQ 1GM BASE/VIAL		N62476	002	Mar 21, 1986	Jun	DISC
--	---	------------------	--	--------	-----	--------------	-----	------

	@	EQ 1GM BASE/VIAL		N62716	002	Mar 13, 1987	Jun	DISC
--	---	------------------	--	--------	-----	--------------	-----	------

	@	EQ 1GM BASE/VIAL		N62812	002	Nov 17, 1987	Jun	DISC
--	---	------------------	--	--------	-----	--------------	-----	------

	@	EQ 10GM BASE/VIAL		N62812	003	Nov 17, 1987	Jun	DISC
--	---	-------------------	--	--------	-----	--------------	-----	------

VANCOMYCIN HCL

AP	HOSPIRA	EQ 500MG BASE/VIAL		N62911	001	Aug 04, 1988	May	CAHN
----	---------	--------------------	--	--------	-----	--------------	-----	------

AP		EQ 500MG BASE/VIAL		N62931	001	Oct 29, 1992	May	CAHN
----	--	--------------------	--	--------	-----	--------------	-----	------

AP		EQ 1GM BASE/VIAL		N62912	001	Aug 04, 1988	May	CAHN
----	--	------------------	--	--------	-----	--------------	-----	------

INJECTABLE; INJECTION

VANCOMYCIN HCL

AP	HOSPIRA	EQ 1GM BASE/VIAL	N62933 001	Oct 29, 1992	May	CAHN
AP		EQ 5GM BASE/VIAL	N63076 001	Dec 21, 1990	May	CAHN

VECURONIUM BROMIDE

INJECTABLE; INJECTION

VECURONIUM BROMIDE

	+ ABBOTT	4MG/VIAL	N75558 001	Sep 11, 2001	Apr	CAHN
	+ HOSPIRA	4MG/VIAL	N75558 001	Sep 11, 2001	May	CAHN
AP		10MG/VIAL	N75164 001	Oct 21, 1999	May	CAHN
AP		20MG/VIAL	N75164 002	Oct 21, 1999	May	CAHN

VENLAFAXINE HYDROCHLORIDE

TABLET; ORAL

EFFEXOR

WYETH PHARMS INC

		EQ 50MG BASE	N20151 003	Dec 28, 1993	May	CRLD
--	--	--------------	------------	--------------	-----	------

	+	EQ 100MG BASE	N20151 005	Dec 28, 1993	May	CRLD
--	---	---------------	------------	--------------	-----	------

VERAPAMIL HYDROCHLORIDE

INJECTABLE; INJECTION

VERAPAMIL HCL

AP	HOSPIRA	2.5MG/ML	N70577 001	Feb 02, 1987	May	CAHN
AP		2.5MG/ML	N70737 001	May 06, 1987	May	CAHN
AP		2.5MG/ML	N70738 001	May 06, 1987	May	CAHN
AP		2.5MG/ML	N70739 001	May 06, 1987	May	CAHN
AP		2.5MG/ML	N70740 001	May 06, 1987	May	CAHN
AP		2.5MG/ML	N75136 001	Oct 20, 1998	May	CAHN

TABLET, EXTENDED RELEASE; ORAL

VERAPAMIL HCL

AB	BARR	120MG	N75072 001	May 25, 1999	May	CMFD
AB		240MG	N75072 003	May 25, 1999	May	CMFD
AB	KALI LABS	120MG	N75072 001	May 25, 1999	Aug	CAHN
AB		240MG	N75072 003	May 25, 1999	Aug	CAHN

TABLET; ORAL

VERAPAMIL HCL

@ MUTUAL PHARM

@

		80MG	N70482 001	Sep 24, 1986	Aug	CAHN
--	--	------	------------	--------------	-----	------

		120MG	N70483 001	Sep 24, 1986	Aug	CAHN
--	--	-------	------------	--------------	-----	------

VINCRISTINE SULFATE

INJECTABLE; INJECTION

ONCOVIN

@ LILLY

		1MG/ML	N14103 003	Mar 07, 1984	Mar	DISC
--	--	--------	------------	--------------	-----	------

VINORELBINE TARTRATE

INJECTABLE; INJECTION

VINORELBINE TARTRATE

AP	BAXTER HLTHCARE	EQ 10MG BASE/ML	N75992 001	Jun 10, 2003	Aug	CAHN
----	-----------------	-----------------	------------	--------------	-----	------

VITAMIN A PALMITATE

INJECTABLE; INJECTION

AQUASOL A

	+ MAYNE PHARMA USA	EQ 50,000 UNITS BASE/ML	N06923 001		Apr	CAHN
--	--------------------	-------------------------	------------	--	-----	------

WARFARIN SODIUM

TABLET; ORAL

WARFARIN SODIUM

>A>	AB	GENPHARM	1MG	N40415 001	Sep 27, 2004	Sep	NEWA
>A>	AB		2MG	N40415 002	Sep 27, 2004	Sep	NEWA
>A>	AB		2.5MG	N40415 003	Sep 29, 2004	Sep	NEWA
>A>	AB		3MG	N40415 004	Sep 27, 2004	Sep	NEWA
>A>	AB		4MG	N40415 005	Sep 27, 2004	Sep	NEWA
>A>	AB		5MG	N40415 006	Sep 27, 2004	Sep	NEWA
>A>	AB		6MG	N40415 007	Sep 27, 2004	Sep	NEWA
>A>	AB		7.5MG	N40415 008	Sep 27, 2004	Sep	NEWA
>A>	AB		10MG	N40415 009	Sep 27, 2004	Sep	NEWA

WATER FOR INJECTION, STERILE

LIQUID; N/A

BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER

AF		HOSPIRA	100%	N18802 001	Oct 27, 1982	May	CAHN
AF		HOSPIRA	100%	N19077 001	Mar 02, 1984	May	DISC
AF		HOSPIRA	100%	N18233 001		May	CAHN
AF			100%	N18801 001	Oct 27, 1982	May	CAHN
AF			100%	N19869 001	Dec 26, 1989	May	CAHN

WATER FOR IRRIGATION, STERILE

LIQUID; IRRIGATION

STERILE WATER IN PLASTIC CONTAINER

AT		HOSPIRA	100%	N17513 001		May	CAHN
AT			100%	N18313 001		May	CAHN

XENON, XE-133

GAS; INHALATION

XENON XE 133

>D>		GEN ELECTRIC	5-100 CI/CYLINDER	N17550 001		Sep	DISC
>A>		@	5-100 CI/CYLINDER	N17550 001		Sep	DISC
>D>			0.25-5 CI/AMP	N17550 003		Sep	DISC
>A>		@	0.25-5 CI/AMP	N17550 003		Sep	DISC

ZIDOVUDINE

SYRUP; ORAL

RETROVIR

+		GLAXOSMITHKLINE	50MG/5ML	N19910 001	Sep 28, 1989	Jul	CRLD
---	--	-----------------	----------	------------	--------------	-----	------

ZILEUTON

TABLET; ORAL

ZYFLO

		@ CRITICAL	300MG	N20471 001	Dec 09, 1996	Jul	CAHN
+			600MG	N20471 003	Dec 09, 1996	Jul	CAHN

ZINC CHLORIDE

INJECTABLE; INJECTION

ZINC CHLORIDE IN PLASTIC CONTAINER

+		HOSPIRA	EQ 1MG ZINC/ML	N18959 001	Jun 26, 1986	May	CAHN
---	--	---------	----------------	------------	--------------	-----	------

ZIPRASIDONE HYDROCHLORIDE

CAPSULE; ORAL

GEODON

>D>	PFIZER	20MG	N20825 001	Feb 05, 2001	Sep	CRLD
>A>	+	20MG	N20825 001	Feb 05, 2001	Sep	CRLD
>D>	+	80MG	N20825 004	Feb 05, 2001	Sep	CRLD
>A>		80MG	N20825 004	Feb 05, 2001	Sep	CRLD

ZOLPIDEM TARTRATE

TABLET; ORAL

AMBIEN

	SANOFI SYNTHELABO	5MG	N19908 001	Dec 16, 1992	Apr	CAHN
+		10MG	N19908 002	Dec 16, 1992	Apr	CAHN

PRESCRIPTION DRUG PRODUCT LIST - 24TH EDITION

OTC DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 9 - September 2004

2-1

ANTAZOLINE PHOSPHATE; NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

VASOCON-A

+ NOVARTIS 0.5%;0.05% N18746 002 Jul 11, 1994 Feb CAHN

BUTOCONAZOLE NITRATE

CREAM; VAGINAL

FEMSTAT 3

+ BAYER 2% N20421 001 Dec 21, 1995 Jun CAHN

CHLORHEXIDINE GLUCONATE

SOLUTION; TOPICAL

HIBICLENS

>A> + REGENT 4% N17768 001 Sep CAHN

>D> + SSL INTL 4% N17768 001 Sep CAHN

HIBISTAT

>A> + REGENT 0.5% N18300 001 Sep CAHN

>D> + SSL INTL 0.5% N18300 001 Sep CAHN

SPONGE; TOPICAL

HIBICLENS

>A> + REGENT 4% N18423 001 Sep CAHN

>D> + SSL INTL 4% N18423 001 Sep CAHN

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SPONGE; TOPICAL

CHLORAPREP ONE-STEP FREPP

+ MEDI FLEX HOSP 2%;70% N20832 001 Jul 14, 2000 Jun CTNA

SWAB; TOPICAL

CHLORAPREP ONE-STEP SEPP

+ MEDI FLEX HOSP 2%;70% N21555 001 Oct 07, 2002 Jun CAIN

CHLORPHENIRAMINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL

CHLORPHENIRAMINE MALEATE

@ SANDOZ 12MG

N70797 001 Aug 12, 1988 Apr DISC

TABLET, EXTENDED RELEASE; ORAL

CHLOR-TRIMETON

>D> + SCHERING PLOUGH 8MG N07638 001 Sep DISC

>A> @ 8MG N07638 001 Sep DISC

EFIDAC 24 CHLORPHENIRAMINE MALEATE

>D> + ALZA 16MG N19746 002 Nov 18, 1994 Sep DISC

>D> @ 16MG N19746 002 Nov 18, 1994 Sep DISC

>A> + 16MG N19746 002 Nov 18, 1994 Mar CRLD

CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

SUSPENSION; ORAL

CHILDREN'S ADVIL ALLERGY SINUS

+ WYETH CONS 1MG/5ML;100MG/5ML;15MG/5ML N21587 001 Feb 24, 2004 Feb NEWA

DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN

TABLET, EXTENDED RELEASE; ORAL

MUCINEX DM

ADAMS LABS

30MG;600MG

N21620 002 Apr 29, 2004 Apr NEWA

TABLET, EXTENDED RELEASE; ORAL

MUCINEX DM						
+ ADAMS LABS	60MG;1.2GM	N21620	001	Apr 29, 2004	Apr	NEWA

DOXYLAMINE SUCCINATE

TABLET; ORAL

DOXYLAMINE SUCCINATE						
LNK	25MG	N40564	001	Aug 27, 2004	Aug	NEWA

GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

MUCINEX D						
ADAMS	600MG;60MG	N21585	001	Jun 22, 2004	Jun	NEWA
+	1.2GM;120MG	N21585	002	Jun 22, 2004	Jun	NEWA

IBUPROFEN

SUSPENSION; ORAL

CHILDREN'S ELIXSURE						
TARO	100MG/5ML	N21604	001	Jan 07, 2004	Jan	NEWA

TABLET, CHEWABLE; ORAL

IBUPROFEN						
FERRIGO	50MG	N76359	001	Jan 16, 2004	Jan	NEWA
	100MG	N76359	002	Jan 16, 2004	Jan	NEWA

TABLET; ORAL

IBUPROFEN						
LNK	100MG	N76741	001	Jun 17, 2004	Jun	NEWA
@ MUTUAL PHARM	200MG	N70493	001	Dec 24, 1985	Aug	CAHN
@	200MG	N70908	001	Sep 26, 1986	Aug	CAHN
@	200MG	N71462	001	Oct 02, 1986	Aug	CAHN

IBUPROFEN POTASSIUM; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE; ORAL

ADVIL COLD AND SINUS						
+ WYETH CONS	200MG;30MG	N21374	001	May 30, 2002	Mar	CAHN

LORATADINE

SYRUP; ORAL

LORATADINE						
MORTON GROVE	1MG/ML	N75815	001	Aug 20, 2004	Aug	NEWA
FERRIGO	1MG/ML	N75728	001	Aug 20, 2004	Aug	NEWA
RANBAXY	1MG/ML	N76529	001	Aug 20, 2004	Aug	NEWA
TARO	1MG/ML	N76805	001	Aug 20, 2004	Aug	NEWA

TABLET; ORAL

LORATADINE						
FERRIGO	10MG	N21512	001	Jun 24, 2004	Jun	NEWA
	10MG	N76301	001	Jun 25, 2004	Jun	NEWA

LORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

CLARITIN-D						
@ SCHERING	5MG;120MG	N19670	002	Nov 27, 2002	Aug	DISC
LORATADINE AND PSEUDOEPHEDRINE SULFATE						
ANDRX PHARMS	5MG;120MG	N76208	001	Jan 28, 2004	Jan	NEWA
+ IMPAX LABS	5MG;120MG	N76050	001	Jan 30, 2003	Aug	CRLD
	10MG;240MG	N75989	001	Mar 04, 2004	Mar	NEWA
RANBAXY	10MG;240MG	N76557	001	Sep 22, 2004	Sep	NEWA

MICONAZOLE NITRATE

CREAM, SUPPOSITORY; TOPICAL, VAGINAL

MICONAZOLE 7 COMBINATION PACK

G AND W LABS 2%, 100MG

N76585 001 Mar 26, 2004 Mar NEWA

CREAM; TOPICAL, VAGINAL

MICONAZOLE 3 COMBINATION PACK

PERRIGO 2%, 4%

N76357 001 Mar 30, 2004 Mar NEWA

MONISTAT 3 COMBINATION PACK

PERSONAL PRODS 2%, 4%

N21261 003 Jun 17, 2003 Aug CRLD

MINOXIDIL

SOLUTION; TOPICAL

THEROXIDIL

HARMONY LABS 5%

N76239 001 Aug 24, 2004 Aug NEWA

NAPROXEN SODIUM; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

NAPROXEN SODIUM AND PSEUDOEPHEDRINE HCL

PERRIGO EQ 200MG BASE; 120MG

N76518 001 Mar 17, 2004 Mar NEWA

NICOTINE POLACRILEX

GUM, CHEWING; BUCCAL

NICOTINE POLACRILEX

PERRIGO EQ 2MG BASE

N76775 001 Sep 16, 2004 Sep NEWA

EQ 4MG BASE

N76789 001 Sep 16, 2004 Sep NEWA

WATSON LABS EQ 2MG BASE

N76568 001 Jul 29, 2004 Jul NEWA

EQ 2MG BASE

N76569 001 Jul 29, 2004 Jul NEWA

EQ 4MG BASE

N76568 002 Jul 29, 2004 Jul NEWA

EQ 4MG BASE

N76569 002 Jul 29, 2004 Jul NEWA

NICOTINE POLACRILEX (MINT)

PERRIGO EQ 2MG BASE

N76777 001 Sep 16, 2004 Sep NEWA

EQ 4MG BASE

N76779 001 Sep 16, 2004 Sep NEWA

NICOTINE POLACRILEX (ORANGE)

PERRIGO EQ 2MG BASE

N76776 001 Sep 16, 2004 Sep NEWA

EQ 4MG BASE

N76778 001 Sep 16, 2004 Sep NEWA

RANITIDINE HYDROCHLORIDE

TABLET; ORAL

ZANTAC 150

+ PFIZER CONS HLTHCARE EQ 150MG BASE

N21698 001 Aug 31, 2004 Aug NEWA

ZANTAC 75

WARNER LAMBERT EQ 75MG BASE

N20520 001 Dec 19, 1995 Aug CRLD

TERBINAFINE HYDROCHLORIDE

SPRAY; TOPICAL

LAMISIL AT

+ NOVARTIS 1%

N21124 002 Mar 17, 2000 Feb NEWA

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE
CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 9 SEPTEMBER 2004

NO SEPTEMBER 2004 APPROVALS

**This data is provided to the Office of Generic Drugs from
the Office of Orphan Products Development and it is not edited prior to publication.**

Orphan Products Designations and Approvals List
September 2004

Generic Name:	Indication Designated:
Trade Name (if present): A10 & AS2-1 Antineoplaston	Treatment for patients with brain stem glioma
Date Designated: 9/3/2004	Sponsor and Address Burzynski Research Institute, Inc. 9432 Old Katy Road Houston TX 77055
Marketing Exclusivity Date:	

Generic Name: (1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-	Indication Designated: Treatment of chronic lymphocytic leukemia and related leukemias to imino-D-ribose hydrochloride include prolymphocytic leukemia, adult T-cell leukemia, and hairy cell leukemia
Trade Name (if present):	Sponsor and Address BioCryst Pharmaceuticals, Inc. 2190 Parkway Lake Drive Birmingham AL 35244
Date Designated: 8/10/2004	
Marketing Exclusivity Date:	

Generic Name: (1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-1,4- imino-D-ribose hydrochloride	Indication Designated: Treatment of acute lymphoblastic leukemia.
Trade Name (if present):	Sponsor and Address BioCryst Pharmaceuticals, Inc. 2190 Parkway Lake Drive Birmingham AL 35244
Date Designated: 8/13/2004	
Marketing Exclusivity Date:	

Generic Name: (1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-1,4- imino-D-ribose hydrochloride	Indication Designated: Treatment of T-cell non-Hodgkin's lymphoma
Trade Name (if present):	Sponsor and Address BioCryst Pharmaceuticals, Inc. 2190 Parkway Lake Drive Birmingham AL 35244
Date Designated: 1/29/2004	
Marketing Exclusivity Date:	

Orphan Products Designations and Approvals List

September 2004

<p>Generic Name: (3-[5-(2-fluoro-phenyl)-[1,2,4]oxadiazole-3-yl]-benzoic acid</p> <p>Trade Name (if present):</p> <p>Date Designated: 9/1/2004</p> <p>Marketing Exclusivity Date:</p>	<p>Indication Designated: For use in the treatment of cystic fibrosis resulting from a nonsense (premature stopcodon) mutation in the cystic fibrosis transmembrane conductance regulatory gene.</p> <p>Sponsor and Address PTC Therapeutics 100 Corporate Court South Plainfield NJ 07080</p>
---	--

<p>Generic Name: (6R,S)5,10-methylene-tetrahydrofolic acid</p> <p>Trade Name (if present): CoFactor</p> <p>Date Designated: 8/13/2004</p> <p>Marketing Exclusivity Date:</p>	<p>Indication Designated: For use in combination with 5-fluorouracil for the treatment of patients with pancreatic cancer</p> <p>Sponsor and Address Adventrx Pharmaceuticals, Inc. 6725 Mesa Ridge Road Suite 100 San Diego CA 92121</p>
--	---

<p>Generic Name: 17-allylamino-17-demethoxygeldanamycin (17-AGG)</p> <p>Trade Name (if present):</p> <p>Date Designated: 9/9/2004</p> <p>Marketing Exclusivity Date:</p>	<p>Indication Designated: Treatment of multiple myeloma.</p> <p>Sponsor and Address Kosan Biosciences, Inc 3832 Bay Center Place Hayward CA 94545</p>
--	---

<p>Generic Name: 17-allylamino-17-demethoxygeldanamycin (17-AGG)</p> <p>Trade Name (if present):</p> <p>Date Designated: 9/3/2004</p> <p>Marketing Exclusivity Date:</p>	<p>Indication Designated: For the treatment of Chronic Myelogenous Leukemia</p> <p>Sponsor and Address Kosan Biosciences, Inc. 3832 Bay Center Place Hayward CA 94545</p>
--	---

Orphan Products Designations and Approvals List

September 2004

Generic Name:
1-Deoxygalactonojirimycin

Indication Designated:
Treatment of Fabry Disease

Trade Name (if present):

Sponsor and Address
Amicus Therapeutics, Inc.
675 US Route 1
North Brunswick NJ 08902

Date Designated: 2/25/2004

Marketing Exclusivity Date:

Generic Name:
5-methyl-1-phenyl-2-(1H)-pyridone(CAS 53179-13-8)

Indication Designated:
Treatment of idiopathic pulmonary fibrosis

Trade Name (if present):
Pirfenidone

Sponsor and Address
InterMune, Inc.
3280 Bayshore Blvd
Brisbane CA 94005

Date Designated: 3/5/2004

Marketing Exclusivity Date:

Generic Name:
90Y-hPAMA4

Indication Designated:
Treatment of pancreatic cancer

Trade Name (if present):
PAN-Cide

Sponsor and Address
Immunomedics, Inc.
300 American Road
Morris Plains NJ 07950

Date Designated: 1/29/2004

Marketing Exclusivity Date:

Generic Name:
Allogeneic retinal epithelial cells transfected with plasmid vector expressing ciliary neurotrophic growth factor

Indication Designated:
Treatment of retinitis pigmentosa

Trade Name (if present):

Sponsor and Address
Neurotech USA, Inc.
6 Blackstone Valley Place
Lincoln RI 02865

Date Designated: 9/1/2004

Marketing Exclusivity Date:

Orphan Products Designations and Approvals List

September 2004

<p>Generic Name: alpha-1-acid glycoprotein</p> <p>Trade Name (if present):</p> <p>Date Designated: 3/5/2004</p> <p>Marketing Exclusivity Date:</p>	<p>Indication Designated: Treatment of cocaine overdose</p> <p>Sponsor and Address Bio Products Laboratory Dagger Lane, Elstree Hertfordshire</p> <p>UNITED KINGDOM</p>

<p>Generic Name: Alpha-1-acid glycoprotein</p> <p>Trade Name (if present):</p> <p>Date Designated: 3/17/2004</p> <p>Marketing Exclusivity Date:</p>	<p>Indication Designated: Treatment of tricyclic antidepressant poisoning</p> <p>Sponsor and Address Bio Products Laboratory Dagger Lane Elstree, Hertfordshire</p> <p>UNITED KINGDOM</p>

<p>Generic Name: Alpha1-Proteinase Inhibitor (Human) [API]</p> <p>Trade Name (if present): ARC-API</p> <p>Date Designated: 9/1/2004</p> <p>Marketing Exclusivity Date:</p>	<p>Indication Designated: Treatment of Cystic Fibrosis</p> <p>Sponsor and Address Kamada Ltd. Kiryat Weizmann</p> <p>ISRAEL</p>

<p>Generic Name: Ambrisentan</p> <p>Trade Name (if present):</p> <p>Date Designated: 7/16/2004</p> <p>Marketing Exclusivity Date:</p>	<p>Indication Designated: Treatment of pulmonary arterial hypertension</p> <p>Sponsor and Address Myogen, Inc. 7575 West 103rd Avenue Suite 102 Westminister CO 80021-5426</p>

Orphan Products Designations and Approvals List

September 2004

Generic Name: antivenin crotaline (pit-viper) equine immune F(ab)2
 Indication Designated: Treatment of envenomation by Crotaline snakes

Trade Name (if present): Antivipmyn

Sponsor and Address
 Rare Disease Therapeutics, Inc.
 1101 Kermit Drive,
 Suite 608
 Nashville TN 37217

Date Designated: 1/29/2004

Marketing Exclusivity Date:

Generic Name: Aplidin
 Indication Designated: Treatment of Acute Lymphoblastic Leukemia

Trade Name (if present):

Sponsor and Address
 PharmaMar USA, Inc
 320 Putnam Avenue
 Cambridge MA 02139

Date Designated: 6/18/2004

Marketing Exclusivity Date:

Generic Name: Autologous incubated macrophage
 Indication Designated: Therapy to improve the motor and sensory neurological outcome in acute cases of spinal cord injury

Trade Name (if present):

Sponsor and Address
 Proneuron Biotechnologies, Inc.
 Weizmann Science Park
 P. O. Box 277
 Ness-Ziona 74101
 ISRAEL

Date Designated: 9/3/2004

Marketing Exclusivity Date:

Generic Name: Buffered Ursodeoxycholic Acid
 Indication Designated: For the treatment of pruritus in patients with Alagille Syndrome

Trade Name (if present): Ursocarb

Sponsor and Address
 Digestive Care, Inc.
 1120 Win Drive
 Bethlehem PA 18017

Date Designated: 9/3/2004

Marketing Exclusivity Date:

Orphan Products Designations and Approvals List September 2004

Generic Name: C1 esterase inhibitor (human)
Indication Designated: Treatment of Angioedema

Trade Name (if present):

Sponsor and Address
Lev Pharmaceuticals, Inc.
236 Old Lancaster Road
Merion Station PA 19066

Date Designated: 7/16/2004

Marketing Exclusivity Date:

Generic Name: chenodeoxycholic acid
Indication Designated: Treatment of cerebrotendinous xanthomatosis

Trade Name (if present):
Chenofalk

Sponsor and Address
Dr. Falk Pharma GmbH
Leinenweberstrasse 5
Postfach 6529

Date Designated: 1/29/2004

Marketing Exclusivity Date:

GERMANY

Generic Name: Coagulation factor VIIa (recombinant)
Indication Designated: Prevention of bleeding episodes in patients with acquired inhibitors to Factor VIII or Factor IX

Trade Name (if present):
NovoSeven

Sponsor and Address
Novo Nordisk Pharmaceuticals, Inc.
100 College Road West
Princeton NJ 08540

Date Designated: 7/21/2004

Marketing Exclusivity Date:

Generic Name: Coagulation factor VIIa (recombinant)
Indication Designated: Prevention of bleeding episodes in Glanzmann's thrombasthenia

Trade Name (if present):
NovoSeven

Sponsor and Address
Novo Nordisk Pharmaceuticals, Inc.
100 College Road West
Princeton NJ 08540

Date Designated: 6/18/2004

Marketing Exclusivity Date:

Orphan Products Designations and Approvals List

September 2004

Generic Name: Coagulation factor VIIa (recombinant) Indication Designated: Prevention of bleeding episodes in patients with congenital Factor VII deficiency

Trade Name (if present):
NovoSeven

Sponsor and Address
Novo Nordisk Pharmaceuticals, Inc.
100 College Road West
Princeton NJ 08540

Date Designated: 9/10/2004
Marketing Exclusivity Date:

Generic Name: Coagulation Factor VIIa (Recombinant) Indication Designated: Treatment of bleeding episodes in patients with acquired inhibitors to Factor VIII or Factor IX

Trade Name (if present):
NovoSeven

Sponsor and Address
Novo Nordisk Pharmaceuticals, Inc.
100 College Road West
Princeton NJ 08540

Date Designated: 7/16/2004
Marketing Exclusivity Date:

Generic Name: Coagulation factor VIIa (recombinant) Indication Designated: Prevention of bleeding episodes in patients with hemophilia A or B, with or without inhibitors

Trade Name (if present):
NovoSeven

Sponsor and Address
Novo Nordisk Pharmaceuticals, Inc.
100 College Road West
Princeton NJ 08540

Date Designated: 6/18/2004
Marketing Exclusivity Date:

Generic Name: Coagulation factor VIIa (Recombinant) Indication Designated: Treatment of bleeding episodes in Glanzmann's thrombasthenia

Trade Name (if present):
NovoSeven

Sponsor and Address
Novo Nordisk Pharmaceuticals, Inc.
100 College Road West
Princeton NJ 08540

Date Designated: 6/18/2004
Marketing Exclusivity Date:

Orphan Products Designations and Approvals List

September 2004

<p>Generic Name: Coagulation factor VIIa (recombinant)</p> <p>Trade Name (if present): NovoSeven</p> <p>Date Designated: 9/10/2004</p> <p>Marketing Exclusivity Date:</p>	<p>Indication Designated: Treatment of bleeding episodes in patients with congenital factor VII deficiency</p> <p>Sponsor and Address Novo Nordisk Pharmaceuticals, Inc. 100 College Road West Princeton NJ 08540</p>
---	---

<p>Generic Name: DEAE-rebeccamycin</p> <p>Trade Name (if present):</p> <p>Date Designated: 3/1/2004</p> <p>Marketing Exclusivity Date:</p>	<p>Indication Designated: Treatment of bile duct tumors</p> <p>Sponsor and Address Exelixis, Inc. 170 Harbor Way South San Francisco CA 94083-0511</p>
--	--

<p>Generic Name: Deferitron</p> <p>Trade Name (if present):</p> <p>Date Designated: 4/14/2004</p> <p>Marketing Exclusivity Date:</p>	<p>Indication Designated: For the treatment of iron overload</p> <p>Sponsor and Address Genzyme Corporation 153 Second Avenue Waltham MA 02451</p>
--	--

<p>Generic Name: Dehydrodideminin B</p> <p>Trade Name (if present): Aplidin</p> <p>Date Designated: 9/30/2004</p> <p>Marketing Exclusivity Date:</p>	<p>Indication Designated: Treatment of multiple myeloma</p> <p>Sponsor and Address PharmaMar USA, Inc. 320 Putnam Avenue Cambridge MA 02139-4616</p>
--	--

Orphan Products Designations and Approvals List

September 2004

Generic Name: Depsipeptide
 Indication Designated: Treatment of cutaneous T-cell lymphoma

Trade Name (if present):

Sponsor and Address
 Gloucester Pharmaceuticals, Inc.
 One Broadway
 Cambridge MA 02142

Date Designated: 9/30/2004

Marketing Exclusivity Date:

Generic Name: dexanabinol
 Indication Designated: For the attenuation or amelioration of the long-term neurological sequelae associated with moderate and severe traumatic brain injury

Trade Name (if present):

Sponsor and Address
 Pharmos Corporation
 99 Wood Avenue
 Suite 311
 Iselin NJ 08830

Date Designated: 8/11/2004

Marketing Exclusivity Date:

Generic Name: Dexrazoxane
 Indication Designated: Treatment of anthracycline extravasation during chemotherapy

Trade Name (if present):

Sponsor and Address
 Topo Target A/S
 Fruebjergvej 3, 2100
 Copenhagen

Date Designated: 3/25/2004

Marketing Exclusivity Date:

DENMARK

Generic Name: diethylenetriaminepentaacetate (DPTA)
 Indication Designated: For treatment of patients with known or suspected internal contamination with plutonium, americium or curium to increase the rates of elimination.

Trade Name (if present):

Sponsor and Address
 CIS-US
 10 DeAngelo Drive
 Bedford MA 01730

Date Designated: 4/14/2004

Marketing Exclusivity Date:

Orphan Products Designations and Approvals List

September 2004

<p>Generic Name: Diethylenetriaminepentaacetic acid (DTPA)</p> <p>Trade Name (if present):</p> <p>Date Designated: 4/28/2004</p> <p>Marketing Exclusivity Date:</p>	<p>Indication Designated: Treatment of patients with known or suspected internal contamination with plutonium, americium, or curium to increase the rates of elimination.</p> <p>Sponsor and Address Hameln Pharmaceuticals gmbh Langes Feld 13 Hameln</p> <p>GERMANY</p>
---	---

<p>Generic Name: Diethylnorspermine (DENSPM)</p> <p>Trade Name (if present):</p> <p>Date Designated: 5/25/2004</p> <p>Marketing Exclusivity Date:</p>	<p>Indication Designated: Treatment for hepatocellular carcinoma</p> <p>Sponsor and Address Genzyme Corporation 153 Second Avenue Waltham MA 02451</p>
---	--

<p>Generic Name: Doripenem</p> <p>Trade Name (if present):</p> <p>Date Designated: 7/16/2004</p> <p>Marketing Exclusivity Date:</p>	<p>Indication Designated: Treatment of bronchopulmonary infection in patients with cystic fibrosis who are colonized with Pseudomonas aeruginosa or Burkholderia cepacia.</p> <p>Sponsor and Address Peninsula Pharmaceuticals, Inc. 1751 Harbor Bay Parkway Alameda CA 94502</p>
---	---

<p>Generic Name: efaproxiral</p> <p>Trade Name (if present):</p> <p>Date Designated: 7/28/2004</p> <p>Marketing Exclusivity Date:</p>	<p>Indication Designated: An adjunct to whole brain radiation therapy for the treatment of brain metastases in patients with breast cancer.</p> <p>Sponsor and Address Allos Therapeutics, Inc. 11080 CirclePoint Road Suite 200 Westminster CO 80020</p>
---	---

Orphan Products Designations and Approvals List

September 2004

<p>Generic Name: heat killed Mycobacterium w immunomodulator</p> <p>Trade Name (if present): CADI Mw</p> <p>Date Designated: 9/3/2004</p> <p>Marketing Exclusivity Date:</p>	<p>Indication Designated: To be used as an adjuvant to chemotherapy for multi drug resistant tuberculosis.</p> <p>Sponsor and Address CPL, Inc. 16020 Swingley Ridge Road Chesterfield MO 63017</p>
--	---

<p>Generic Name: Human anti-CD30 monoclonal antibody</p> <p>Trade Name (if present):</p> <p>Date Designated: 9/27/2004</p> <p>Marketing Exclusivity Date:</p>	<p>Indication Designated: Treatment of Hodgkin's Disease</p> <p>Sponsor and Address Medarex, Inc. 519 Route 173 West Bloomsbury NJ 08804</p>
---	--

<p>Generic Name: human anti-CD4 monoclonal antibody</p> <p>Trade Name (if present): HuMax-CD4</p> <p>Date Designated: 8/13/2004</p> <p>Marketing Exclusivity Date:</p>	<p>Indication Designated: Treatment of mycosis fungoides</p> <p>Sponsor and Address Genmab A/S Tolbodgade 33 DK-1253 Copenhagen K</p> <p>DENMARK</p>
--	--

<p>Generic Name: human anti-transforming growth factor-B1,2,3</p> <p>Trade Name (if present):</p> <p>Date Designated: 7/9/2004</p> <p>Marketing Exclusivity Date:</p>	<p>Indication Designated: Treatment of idiopathic pulmonary fibrosis</p> <p>Sponsor and Address Genzyme Corporation 500 Kendall Street Cambridge MA 02142</p>
---	---

Orphan Products Designations and Approvals List

September 2004

Generic Name: human immunoglobulin (IgG1k)antiCTLA-4 monoclonal antibody

Indication Designated: Treatment of high risk Stage II, Stage III, and Stage IV melanoma

Trade Name (if present):

Sponsor and Address
Medarex, Inc.
519 Route 173 West
Bloomsbury NJ 08804

Date Designated: 6/3/2004

Marketing Exclusivity Date:

Generic Name: hydralazine

Indication Designated: Treatment of severe intrapartum hypertension (diastolic blood pressure greater than or equal to 110 or systolic blood pressure less than or equal to 160) associated with severe reeclampsia/eclampsia of pregnancy

Trade Name (if present):

Sponsor and Address
Esp Pharma, Inc.
2035 Lincoln Hwy.
Suite 2150
Edison NJ 08817

Date Designated: 4/9/2004

Marketing Exclusivity Date:

Generic Name: Icatibant acetate

Indication Designated: Treatment of burn patients hospitalized with burn-induced edema

Trade Name (if present):

Sponsor and Address
Jerini AG
Invalidenstr, 130
10115 Berlin

Date Designated: 5/5/2004

Marketing Exclusivity Date:

GERMANY

Generic Name: Idebenone (INN)

Indication Designated: Treatment of cardiomyopathy associated with Friedreich's ataxia

Trade Name (if present):

Sponsor and Address
MyoContract Ltd.
Hammerstrasse 25
CH-4410 Liestal

Date Designated: 3/25/2004

Marketing Exclusivity Date:

SWITZERLAND

Orphan Products Designations and Approvals List

September 2004

Generic Name: Iloprost inhalation solution
 Indication Designated: Treatment of pulmonary arterial hypertension

Trade Name (if present):
 Ventavis

Sponsor and Address
 CoTherix, Inc.
 5000 Shoreline Court
 South San Francisco CA 94080

Date Designated: 8/12/2004

Marketing Exclusivity Date:

Generic Name: Immortalized human liver cells found in the extracorporeal liver assist device
 Indication Designated: Treatment of fulminant hepatic failure (acute liver failure)

Trade Name (if present):
 ELAD

Sponsor and Address
 Vital Therapies, Inc.
 15222 Avenue of Science
 Suite C
 San Diego CA 92128

Date Designated: 7/16/2004

Marketing Exclusivity Date:

Generic Name: Immune Globulin (Human)
 Indication Designated: Treatment of chronic inflammatory demyelinating polyneuropathy

Trade Name (if present):
 Gamunex

Sponsor and Address
 Bayer Corporation
 800 Dwight Way
 Berkley CA 94701-1986

Date Designated: 7/27/2004

Marketing Exclusivity Date:

Generic Name: Immune Globulin (Human) containing high titers of West Nile virus antibodies
 Indication Designated: Treatment of the West Nile virus infection

Trade Name (if present):
 Omr-IgG-am (tm) 5% (WNV)

Sponsor and Address
 OMRIX Biopharmaceuticals, Ltd.
 Plasma Fractionation Institute
 Ramat Gan 52621

Date Designated: 3/17/2004

Marketing Exclusivity Date:

ISRAEL

Orphan Products Designations and Approvals List

September 2004

Generic Name: Immune Globulin Intravenous (human) Indication Designated: Treatment for Guillain Barre Syndrome

Trade Name (if present): Carimune NF

Sponsor and Address
ZLB Bioplasma AG
Wankdorfstrasse 10
CH-3000 Bern 22

Date Designated: 5/4/2004

Marketing Exclusivity Date:

SWITZERLAND

Generic Name: Immune Globulin Subcutaneous (Human)

Indication Designated: Treatment of patients with primary immune deficiency (PID) that are intolerant to immune globulin intravenous (IGIV) due to severe adverse events or poor venous access

Trade Name (if present): Vivaglobin P (proposed)

Sponsor and Address
Aventis Behring, L.L.C.
1020 First Avenue
P.O. Box 61501
King of Prussia PA 19406-0901

Date Designated: 9/22/2004

Marketing Exclusivity Date:

Generic Name: Implitapide

Indication Designated: Treatment of homozygous familial hypercholesterolemia

Trade Name (if present):

Sponsor and Address
Medical Research Laboratories International
2 Tesseneer Drive
Highland Heights KY 41076

Date Designated: 8/13/2004

Marketing Exclusivity Date:

Generic Name: Implitapide

Indication Designated: Treatment of patients with Fredrickson type I or V hyperlipoproteinemia

Trade Name (if present):

Sponsor and Address
Medical Research Laboratories International
2 Tesseneer Drive
Highland Heights KY 41076

Date Designated: 8/18/2004

Marketing Exclusivity Date:

Orphan Products Designations and Approvals List

September 2004

Generic Name:
Lenalidomide

Indication Designated:
Treatment of myelodysplastic syndromes

Trade Name (if present):
Revimid

Sponsor and Address
Celgene Corporation
7 Powder Horn Drive
Warren NJ 07059

Date Designated: 1/29/2004
Marketing Exclusivity Date:

Generic Name:
Liarozole

Indication Designated:
The treatment of congenital ichthyosis

Trade Name (if present):

Sponsor and Address
Barrier Therapeutics, Inc
600 College Road East
Princeton NJ 08540

Date Designated: 6/18/2004
Marketing Exclusivity Date:

Generic Name:
L-tyrosine-L-serine-L-leucine

Indication Designated:
Treatment of hepatocellular carcinoma.

Trade Name (if present):
CMS-024

Sponsor and Address
Pepfarm R&D Limited
Room 1404, 14th Floor
#39 Healthy Street East

Date Designated: 9/10/2004
Marketing Exclusivity Date:

North Point
HONG KONG

Generic Name:
mannopentaose phosphate sulfate

Indication Designated:
Treatment of high-risk Stage II, Stage III, and Stage IV melanoma

Trade Name (if present):

Sponsor and Address
Progen Industries Limited
P. O. Box 28
Richlands 4077

Date Designated: 4/27/2004
Marketing Exclusivity Date:

AUSTRALIA

Orphan Products Designations and Approvals List

September 2004

Generic Name:
meclorothamine or nitrogen mustard

Indication Designated:
Treatment of mycosis fungoides.

Trade Name (if present):

Sponsor and Address
Yaupon Therapeutics, Inc.
259 Radnor Chester Road
Radnor PA 19087

Date Designated: 8/12/2004

Marketing Exclusivity Date:

Generic Name:
Melatonin

Indication Designated:
Treatment of non-24-hour sleep-wake disorder in blind individuals
without light perception

Trade Name (if present):
Circadin

Sponsor and Address
Neurim Pharmaceuticals, Ltd.
8 Hanechoshet St.
Tel-Aviv

Date Designated: 7/9/2004

Marketing Exclusivity Date:

ISRAEL

Generic Name:
mepolizumab

Indication Designated:
For first-line treatment in patients with hypereosinophilic
syndrome

Trade Name (if present):

Sponsor and Address
GlaxoSmithKline Pharmaceuticals
P.O. Box 7929
Philadelphia PA 19101

Date Designated: 5/28/2004

Marketing Exclusivity Date:

Generic Name:
Multi-ligand somatostatin analogue

Indication Designated:
Treatment of patients with functional gastroenteropancreatic (GEP)
neuroendocrine tumors (specifically, carcinoid, insulinoma,
gastrinoma, somastatinoma, GRFoma, VIPoma and glucagonoma.

Trade Name (if present):

Sponsor and Address
Novartis Pharmaceuticals Corporation
One Health Plaza
East Hanover NJ 07936-1080

Date Designated: 7/27/2004

Marketing Exclusivity Date:

Orphan Products Designations and Approvals List

September 2004

<p>Generic Name: multi-vitiam infusion without vitamin K</p> <p>Trade Name (if present): M.V.I.-12</p> <p>Date Designated: 3/8/2004</p> <p>Marketing Exculsivity Date:</p>	<p>Indication Designated: Prevention of vitamin deficiency and thromboembolic complications in people receiving home parenteral nutrition and warfarin-type anticoagulant therapy</p> <p>Sponsor and Address Mayne Pharma (USA) Inc. Mack-Cali Centre II Second Floor 9/9/2004 Paramus NJ 07652</p>
--	--

<p>Generic Name: N-[2-[(4-hydroxyphenyl)amino]-3-pyridinyl]-4-methoxybenzenesulfonamide</p> <p>Trade Name (if present):</p> <p>Date Designated: 9/30/2004</p> <p>Marketing Exculsivity Date:</p>	<p>Indication Designated: Treatment of neuroblastoma</p> <p>Sponsor and Address Abbott Laboratories Pharmaceuticals Products Division D-491, AP30-1E Abbott Park II. 60064-6157</p>
--	---

<p>Generic Name: N-[4-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide</p> <p>Trade Name (if present):</p> <p>Date Designated: 8/13/2004</p> <p>Marketing Exculsivity Date:</p>	<p>Indication Designated: Treatment of stages IIB-IV melanoma</p> <p>Sponsor and Address 3M Pharmaceuticals 3M Center Building 270-3A-08 St. Paul MN 55144-1000</p>
---	---

<p>Generic Name: nelarabine</p> <p>Trade Name (if present):</p> <p>Date Designated: 8/10/2004</p> <p>Marketing Exculsivity Date:</p>	<p>Indication Designated: Treatment of acute lymphoblastic leukemia and lymphoblastic lymphoma</p> <p>Sponsor and Address GlaxoSmithKline One Franklin Plaza Phildelphia PA 19101</p>
--	---

Orphan Products Designations and Approvals List

September 2004

Generic Name: Nitric oxide
 Indication Designated: To reduce the risk of chronic lung disease in premature neonates

Trade Name (if present): INOmax

Sponsor and Address
 INO Therapeutics
 6 Route 173
 Clinton NJ 08809

Date Designated: 9/27/2004

Marketing Exclusivity Date:

Generic Name: Nucleic acid aptamer binding to tumor cell nucleolin
 Indication Designated: Treatment of pancreatic cancer

Trade Name (if present):

Sponsor and Address
 Aptamera, Inc.
 640 S. Fourth Street
 Louisville KY 40202

Date Designated: 8/11/2004

Marketing Exclusivity Date:

Generic Name: oral unfractionated heparin
 Indication Designated: Treatment of sickle cell disease

Trade Name (if present):

Sponsor and Address
 TRF Technologies, Inc.
 108 Eagle Trace Drive
 Half Moon Bay CA 94019

Date Designated: 1/29/2004

Marketing Exclusivity Date:

Generic Name: pentetate trisodium
 Indication Designated: Treatment of patients with known or suspected internal contamination with plutonium, americium, or curium.

Trade Name (if present): diethylenetriaminepentaacetate

Sponsor and Address
 Heyl Chemisch-Pharmazeutische Fabrik GMBH & Co. KG
 Goerzallee 253
 Fedderal of Republic of Germany

Date Designated: 4/12/2004

Marketing Exclusivity Date:

GERMANY

Orphan Products Designations and Approvals List September 2004

Generic Name:
posaconazole

Indication Designated:
Treatment of zygomycosis

Trade Name (if present):
Posoril

Sponsor and Address
Schering Corporation
2000 Galloping Hill Road
Kenilworth NJ 07033

Date Designated: 7/16/2004
Marketing Exclusivity Date:

Generic Name:
PR1 Vaccine

Indication Designated:
Treatment of myelodysplastic syndromes (MDS) requiring therapy.

Trade Name (if present):

Sponsor and Address
The Vaccine Company
P. O. Box 93921
Carmel CA 93921

Date Designated: 9/3/2004
Marketing Exclusivity Date:

Generic Name:
PR1 Vaccine

Indication Designated:
Treatment of acute myelogenous leukemia

Trade Name (if present):

Sponsor and Address
The Vaccine Company
P. O. Box 93921
Carmel CA 93921

Date Designated: 9/3/2004
Marketing Exclusivity Date:

Generic Name:
PR1 Vaccine

Indication Designated:
Treatment of chronic myelogenous leukemia.

Trade Name (if present):

Sponsor and Address
The Vaccine Company
P. O. Box 93921
Carmel CA 93921

Date Designated: 9/3/2004
Marketing Exclusivity Date:

Orphan Products Designations and Approvals List

September 2004

Generic Name:
Quinine Sulfate

Indication Designated:
Treatment of malaria

Trade Name (if present):

Sponsor and Address
Mutual Pharmaceutical Company, Inc.
1100 Orthodox Street
Philadelphia PA 19124

Date Designated: 6/3/2004

Marketing Exclusivity Date:

Generic Name:
recombinant human fibroblast growth factor-20

Indication Designated:
Treatment of radiation induced oral mucositis

Trade Name (if present):

Sponsor and Address
CuraGen Corporation
322 East Main Street
Branford CT 06405

Date Designated: 1/29/2004

Marketing Exclusivity Date:

Generic Name:
Recombinant Porcine Factor VIII, B-domain

Indication Designated:
Treatment and prevention of episodic bleeding in patients with
Inhibitor Deleted antibodies to human coagulation factor VIII

Trade Name (if present):

Sponsor and Address
Ipsen Limited
190 Bath Road
Berkshire S11 3XE

Date Designated: 3/16/2004

Marketing Exclusivity Date:

UNITED KINGDOM

Generic Name:
rh-microplasmin

Indication Designated:
Adjunct to surgery in cases of pediatric vitrectomy

Trade Name (if present):

Sponsor and Address
ThromboGenics Ltd
Unit 14
Bridgecourt Office Park
Dublin 12
IRELAND

Date Designated: 3/16/2004

Marketing Exclusivity Date:

Orphan Products Designations and Approvals List

September 2004

Generic Name:
SGN-40 (anti-CD40 antibody)

Indication Designated:
Treatment of multiple myeloma.

Trade Name (if present):

Sponsor and Address
Seattle Genetics, Inc.
21823 30th Drive Southeast
Bothell WA 98021

Date Designated: 8/13/2004

Marketing Exclusivity Date:

Generic Name:
sodium thiosulfate

Indication Designated:
Prevention of platinum-induced ototoxicity in pediatric patients

Trade Name (if present):

Sponsor and Address
Adherex Technologies, Inc.
600 Peter Morand Crescent
Ottawa, Ontario

Date Designated: 3/17/2004

Marketing Exclusivity Date:

CANADA

Generic Name:
somatropin

Indication Designated:
Treatment of patients with HIV-associated adipose redistribution syndrome

Trade Name (if present):
Serostim

Sponsor and Address
Serono, Inc.
One Technology Place
Rockland MA 02370

Date Designated: 3/16/2004

Marketing Exclusivity Date:

Generic Name:
Staphylococcus aureus Immune Globulin (Human)

Indication Designated:
Prophylaxis against Staphylococcus aureus infections in low birth weight neonates

Trade Name (if present):
Altastaph

Sponsor and Address
Nabi Biopharmaceuticals
12276 Wilkins Avenue
Rockville MD 20852

Date Designated: 1/29/2004

Marketing Exclusivity Date:

Orphan Products Designations and Approvals List

September 2004

Generic Name:
Suberoylanilide Hydroxamic Acid

Indication Designated:
Treatment of mesothelioma

Trade Name (if present):

Sponsor and Address
Merck & Co., Inc.
P. O. Box 2000, RY 32-605
Rahway NJ 07065-0900

Date Designated: 3/17/2004

Marketing Exclusivity Date:

Generic Name:
Suberoylanilide Hydroxamic Acid (SAHA)

Indication Designated:
Treatment of T-cell non-Hodgkin's lymphoma

Trade Name (if present):

Sponsor and Address
Merck & Co., Inc.
P. O. Box 2000, RY 32-605
Rahway NJ 07065-0900

Date Designated: 3/16/2004

Marketing Exclusivity Date:

Generic Name:
temocillin sodium

Indication Designated:
Treatment of pulmonary infections caused by Burkholderia cepacia

Trade Name (if present):
Negaban

Sponsor and Address
Belpharma N.V.
67 Winston Churchill Avenue
Brussels

Date Designated: 4/21/2004

Marketing Exclusivity Date:

BELGIUM

Generic Name:
tetrahydrobiopterin

Indication Designated:
For treatment of hyperphenylalaninemia

Trade Name (if present):

Sponsor and Address
Biomarin Pharmaceutical Inc.
371 Bel Marin Blvd.
Novato CA 94949

Date Designated: 1/29/2004

Marketing Exclusivity Date:

Orphan Products Designations and Approvals List

September 2004

Generic Name: Indication Designated:
Thalidomide Treatment of Myelodysplastic Syndrome

Trade Name (if present):
Thalomid

Sponsor and Address
Celgene Corporation
7 Powder Horn Drive
Warren NJ 07059

Date Designated: 9/27/2004

Marketing Exclusivity Date:

Generic Name: Indication Designated:
Thymosin Beta 4 Treatment of Epidermolysis Bullosa

Trade Name (if present):

Sponsor and Address
RegeneRx Biopharmaceuticals, Inc.
3 Bethesda Metro Center
Suite 700
Bethesda MD 20814

Date Designated: 5/28/2004

Marketing Exclusivity Date:

Generic Name: Indication Designated:
Tipifarnib Treatment of acute myeloid leukemia

Trade Name (if present):
Zarnestra

Sponsor and Address
Johnson & Johnson Pharmaceutical Research & Dev.
920 U.S. Highway 202
Raritan NJ 08869

Date Designated: 7/6/2004

Marketing Exclusivity Date:

Generic Name: Indication Designated:
trabectedin Treatment of soft tissue sarcoma.

Trade Name (if present):
Yondelis

Sponsor and Address
Johnson & Johnson Pharmaceutical Research & Dev.
920 US Highway 202
Raritan NJ 08869

Date Designated: 9/30/2004

Marketing Exclusivity Date:

Orphan Products Designations and Approvals List

September 2004

<p>Generic Name: Trisodium zinc Diethylenetriaminepentaacetate</p> <p>Trade Name (if present):</p> <p>Date Designated: 2/27/2004</p> <p>Marketing Exclusivity Date:</p>	<p>Indication Designated: Treatment of patients with known or suspected internal contamination with plutonium, americium, or curium to increase the rate of elimination.</p> <p>Sponsor and Address CustomCare Pharmacy 5710 Hoover Blvd Tampa FL 33634</p>
---	---

<p>Generic Name: Ubiquinol</p> <p>Trade Name (if present): Ubi-Q-Nol, Li-Q-Nol</p> <p>Date Designated: 4/12/2004</p> <p>Marketing Exclusivity Date:</p>	<p>Indication Designated: Treatment of Huntington's Disease</p> <p>Sponsor and Address Gel-Tec Division of Tishcon Corp P. O. Box 331 Westbury NY 11590</p>
---	---

<p>Generic Name: ubiquinol, coenzyme Q10, ubiquinone</p> <p>Trade Name (if present): UBI-Q-NOL</p> <p>Date Designated: 4/12/2004</p> <p>Marketing Exclusivity Date:</p>	<p>Indication Designated: Treatment of pediatric congestive heart failure</p> <p>Sponsor and Address Gel-Tec, Division of TISHCON Corporation 30 New York Avenue P.O. Box 331 Westbury NY 11590</p>
---	---

<p>Generic Name: Vaccinia Immune Globulin (Human) Intravenous</p> <p>Trade Name (if present): CNJ-016</p> <p>Date Designated: 6/18/2004</p> <p>Marketing Exclusivity Date:</p>	<p>Indication Designated: Treatment of complications of vaccinia vaccination</p> <p>Sponsor and Address Cangene Corporation 104 Chancellor Matheson Road Winnipeg, Manitoba R3T 5Y3</p> <p>CANADA</p>
--	---

Orphan Products Designations and Approvals List September 2004

Generic Name:
Vaccinia Immune Globulin (Human) Intravenous

Indication Designated:
Treatment of severe complications from the smallpox vaccine

Trade Name (if present):

Sponsor and Address
DynPort Vaccine Company LLC
64 Thomas Johnson Drive
Frederick MD 21702

Date Designated: 6/18/2004

Marketing Exclusivity Date:

Generic Name:
vapeotide

Indication Designated:
Treatment of symptomatic carcinoid tumors

Trade Name (if present):
Sanvar

Sponsor and Address
H3 Pharma, Inc.
666 Sherbrooke Street West Suite 1400
Montreal, Quebec,

Date Designated: 4/6/2004

Marketing Exclusivity Date:

CANADA

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY
IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO SEPTEMBER 2004 ADDITIONS

PRESCRIPTION AND OTC DRUG PRODUCT
 PATENT AND EXCLUSIVITY DATA
 See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	021652 001	ABACAVIR SULFATE;EPZ1COM	5034394	DEC 18, 2011	DS DP	
>ADD>			5089500	JUN 26, 2009	U257	
>ADD>			6294540	MAY 14, 2018	DS DP U257	
>ADD>			5047407	NOV 17, 2009	DS DP U257	
>ADD>			5905082	MAY 18, 2016	DS DP	
>ADD>			6417191	MAR 28, 2016	DP U257	
>ADD>			6180639	JAN 30, 2018	DP U257	
	020977 001	ABACAVIR SULFATE;ZIAGEN				D-40
	020978 001	ABACAVIR SULFATE;ZIAGEN				D-40
	021320 001	ABARELIX;PLENAXIS	5968895	DEC 11, 2016	DP	AUG 02, 2007
			6180608	DEC 11, 2016	DP U549	AUG 02, 2007
			6423686	JUN 07, 2015	DS	
			6455499	JUN 07, 2015	U549	
			5843901	DEC 01, 2015	DS DP	
			6699833	DEC 11, 2016	DP	
	021431 001	ACAMPROSATE CALCIUM;CAMPRAL				NCE
	021539 001	ACETYLCYSTEINE;ACETADOTE				ODE
	021449 001	ADEFOVIR DIPIVOXIL;HEPSERA	6451340	JUL 23, 2018	DS DP U470	JUL 29, 2009
			5663159	SEP 02, 2014	DS DP U470	JAN 23, 2011
			6635278	DEC 15, 2018	DS DP	
	020899 001	ALBUMIN HUMAN;OPTISON	6723303	APR 20, 2021	DP	
	020949 001	ALBUTEROL SULFATE;ACCUNEB	6702997	DEC 28, 2021	U558	
	020949 002	ALBUTEROL SULFATE;ACCUNEB	6702997	DEC 28, 2021	U558	
	020983 001	ALBUTEROL SULFATE;VENTOLIN HFA	6315173	DEC 23, 2017	DP	
			6510969	DEC 23, 2017	DP	
			6131566	APR 14, 2015	DP U589	
			6532955	APR 14, 2015	DP U590	
	020560 005	ALENDRONATE SODIUM;FOSAMAX				D-87
	021575 001	ALENDRONATE SODIUM;FOSAMAX				D-87
	020886 001	ALITRETINOIN; PANRETIN	5932622	AUG 03, 2016	U562	APR 16, 2007
>ADD>	021727 001	AMLEXANOX;AMLEXANOX				NDF
	021540 001	AMLODIPINE BESYLATE;CADUET	5273995	DEC 28, 2010	DS DP U162	SEP 29, 2007
			5273995*PED	JUN 28, 2011		JAN 30, 2007
			6455574	AUG 11, 2018	U552	
			5969156	JUL 08, 2016	DS	
			5969156*PED	JAN 08, 2017		
			5686104	NOV 11, 2014	DP U213	
			5686104*PED	MAY 11, 2015		
			6126971	JAN 19, 2013	DP	
			6126971*PED	JUL 19, 2013		
			4681893	SEP 24, 2009	DS DP U161	
			4681893*PED	MAR 24, 2010		
			4879303	MAR 25, 2007	DS DP	
			4879303*PED	SEP 25, 2007		
			4572909	JUL 31, 2006	DS DP U3	
			4572909*PED	JAN 31, 2007		
	021540 002	AMLODIPINE BESYLATE;CADUET	4681893	SEP 24, 2009	DS DP U161	NC
			4681893*PED	MAR 24, 2010		JAN 30, 2007
			4879303	MAR 25, 2007	DS DP	
			4879303*PED	SEP 25, 2007		
			4572909	JUL 31, 2006	DS DP U3	
			4572909*PED	JAN 31, 2007		
			5273995	DEC 28, 2010	DS DP U162	
			5273995*PED	JUN 28, 2011		
			6455574	AUG 11, 2018	U552	
			5969156	JUL 08, 2016	DS	

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE (S)	EXCLUS CODE	EXCLUS EXPIRES
021540 003	AMLODIPINE BESYLATE; CADUET	5969156*PED	JAN 08, 2017			
		5686104	NOV 11, 2014	DP U213		
		5686104*PED	MAY 11, 2015			
		6126971	JAN 19, 2013	DP		
		6126971*PED	JUL 19, 2013			
		4681893	SEP 24, 2009	DS DP U161	NC	JAN 30, 2007
		4681893*PED	MAR 24, 2010			
		4879303	MAR 25, 2007	DS DP		
		4879303*PED	SEP 25, 2007			
		4572909	JUL 31, 2006	DS DP U3		
		4572909*PED	JAN 31, 2007			
		5273995	DEC 28, 2010	DS DP U162		
		5273995*PED	JUN 28, 2011			
		6455574	AUG 11, 2018	U552		
		5969156	JUL 08, 2016	DS		
021540 004	AMLODIPINE BESYLATE; CADUET	5969156*PED	JAN 08, 2017			
		5686104	NOV 11, 2014	DP U213		
		5686104*PED	MAY 11, 2015			
		6126971	JAN 19, 2013	DP		
		6126971*PED	JUL 19, 2013			
		4681893	SEP 24, 2009	DS DP U161	NC	JAN 30, 2007
		4681893*PED	MAR 24, 2010			
		4879303	MAR 25, 2007	DS DP		
		4879303*PED	SEP 25, 2007			
		4572909	JUL 31, 2006	DS DP U3		
		4572909*PED	JAN 31, 2007			
		5273995	DEC 28, 2010	DS DP U162		
		5273995*PED	JUN 28, 2011			
		6455574	AUG 11, 2018	U552		
		5969156	JUL 08, 2016	DS		
021540 005	AMLODIPINE BESYLATE; CADUET	5969156*PED	JAN 08, 2017			
		5686104	NOV 11, 2014	DP U213		
		5686104*PED	MAY 11, 2015			
		6126971	JAN 19, 2013	DP		
		6126971*PED	JUL 19, 2013			
		4681893	SEP 24, 2009	DS DP U161	NC	JAN 30, 2007
		4681893*PED	MAR 24, 2010			
		4879303	MAR 25, 2007	DS DP		
		4879303*PED	SEP 25, 2007			
		4572909	JUL 31, 2006	DS DP U3		
		4572909*PED	JAN 31, 2007			
		5273995	DEC 28, 2010	DS DP U162		
		5273995*PED	JUN 28, 2011			
		6455574	AUG 11, 2018	U552		
		5969156	JUL 08, 2016	DS		
021540 006	AMLODIPINE BESYLATE; CADUET	5969156*PED	JAN 08, 2017			
		5686104	NOV 11, 2014	DP U213		
		5686104*PED	MAY 11, 2015			
		6126971	JAN 19, 2013	DP		
		6126971*PED	JUL 19, 2013			
		4681893	SEP 24, 2009	DS DP U161	NC	JAN 30, 2007
		4681893*PED	MAR 24, 2010			
		4879303	MAR 25, 2007	DS DP		
		4879303*PED	SEP 25, 2007			
		4572909	JUL 31, 2006	DS DP U3		
		4572909*PED	JAN 31, 2007			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE (S)	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	021540 010	AMLODIPINE BESYLATE; CADUET	4681893	SEP 24, 2009	DS DP U161	NC JAN 30, 2007
>ADD>			4681893*PED	MAR 24, 2010		
>ADD>			4879303	MAR 25, 2007	DS DP	
>ADD>			4879303*PED	SEP 25, 2007		
>ADD>			4572909	JUL 31, 2006	DS DP U3	
>ADD>			4572909*PED	JAN 31, 2007		
>ADD>			5273995	DEC 28, 2010	DS DP U162	
>ADD>			5273995*PED	JUN 28, 2011		
>ADD>			6455574	AUG 11, 2018	U552	
>ADD>			5969156	JUL 08, 2016	DS	
>ADD>			5969156*PED	JAN 08, 2017		
>ADD>			5686104	NOV 11, 2014	DP U213	
>ADD>			5686104*PED	MAY 11, 2015		
>ADD>			6126971	JAN 19, 2013	DP	
>ADD>			6126971*PED	JUL 19, 2013		
>ADD>	021540 011	AMLODIPINE BESYLATE; CADUET	4681893	SEP 24, 2009	DS DP U161	NC JAN 30, 2007
>ADD>			4681893*PED	MAR 24, 2010		
>ADD>			4879303	MAR 25, 2007	DS DP	
>ADD>			4879303*PED	SEP 25, 2007		
>ADD>			4572909	JUL 31, 2006	DS DP U3	
>ADD>			4572909*PED	JAN 31, 2007		
>ADD>			5273995	DEC 28, 2010	DS DP U162	
>ADD>			5273995*PED	JUN 28, 2011		
>ADD>			6455574	AUG 11, 2018	U552	
>ADD>			5969156	JUL 08, 2016	DS	
>ADD>			5969156*PED	JAN 08, 2017		
>ADD>			5686104	NOV 11, 2014	DP U213	
>ADD>			5686104*PED	MAY 11, 2015		
>ADD>			6126971	JAN 19, 2013	DP	
>ADD>			6126971*PED	JUL 19, 2013		
	021007 001	AMPRENAVIR; AGENERASE	6730679	NOV 11, 2017	DP	
	021007 002	AMPRENAVIR; AGENERASE	6730679	NOV 11, 2017	DP	
	020333 001	ANAGRELIDE HYDROCHLORIDE; AGRYLIN				ODE MAR 14, 2004
						PED SEP 14, 2004
						ODE MAR 14, 2004
						PED SEP 14, 2004
						NCE APR 20, 2009
						NCE APR 20, 2009
						I-437 SEP 29, 2007
						I-437 SEP 29, 2007
						I-437 SEP 29, 2007
						I-437 SEP 29, 2007
						I-437 SEP 29, 2007
						I-437 SEP 29, 2007
						I-437 SEP 29, 2007
	021264 001	APOMORPHINE HYDROCHLORIDE; APOKYN				ODE SEP 09, 2011
	021264 002	APOMORPHINE HYDROCHLORIDE; APOKYN				D-89 JUL 06, 2007
>ADD>	021436 001	ARIPIPRAZOLE; ABILIFY				D-89 JUL 06, 2007
>ADD>	021436 002	ARIPIPRAZOLE; ABILIFY				D-89 JUL 06, 2007
>ADD>	021436 003	ARIPIPRAZOLE; ABILIFY				D-89 JUL 06, 2007
>ADD>	021436 004	ARIPIPRAZOLE; ABILIFY				D-89 JUL 06, 2007
>ADD>	021436 005	ARIPIPRAZOLE; ABILIFY				D-89 JUL 06, 2007
>ADD>	021436 006	ARIPIPRAZOLE; ABILIFY				I-434 JUL 30, 2007
	021248 001	ARSENIC TRIOXIDE; TRISENOX	6723351	NOV 10, 2018	U573	
>ADD>	008809 006	ASCORBIC ACID; M.V.I. -12 (WITHOUT V				ODE SEP 09, 2011
	021567 001	ATAZANAVIR SULFATE; REYATAZ				D-89 JUL 06, 2007
	021567 002	ATAZANAVIR SULFATE; REYATAZ				D-89 JUL 06, 2007
	021567 003	ATAZANAVIR SULFATE; REYATAZ				D-89 JUL 06, 2007
	020702 001	ATORVASTATIN CALCIUM; LIPITOR	4681893	SEP 24, 2009	DS DP U161	I-434 JUL 30, 2007
			5273995	DEC 28, 2010	DS DP U162	M-36 JUL 30, 2007
			5686104	NOV 11, 2014	DP U213	
			5969156	JUL 08, 2016	DS	
			6126971	JAN 19, 2013	DP	

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020702 002	ATORVASTATIN CALCIUM;LIPITOR	4681893	SEP 24, 2009	DS DP U161	I-434	JUL 30, 2007
		5273995	DEC 28, 2010	DS DP U162	M-36	JUL 30, 2007
		5686104	NOV 11, 2014	DP U213		
		5969156	JUL 08, 2016	DS		
		6126971	JAN 19, 2013	DP		
020702 003	ATORVASTATIN CALCIUM;LIPITOR	4681893	SEP 24, 2009	DS DP U161	I-434	JUL 30, 2007
		5273995	DEC 28, 2010	DS DP U162	M-36	JUL 30, 2007
		5686104	NOV 11, 2014	DP U213		
		5969156	JUL 08, 2016	DS		
		6126971	JAN 19, 2013	DP		
020702 004	ATORVASTATIN CALCIUM;LIPITOR	4681893	SEP 24, 2009	DS DP U161	I-434	JUL 30, 2007
		5273995	DEC 28, 2010	DS DP U162	M-36	JUL 30, 2007
		5686104	NOV 11, 2014	DP U213		
		5969156	JUL 08, 2016	DS		
		6126971	JAN 19, 2013	DP		
020114 001	AZELASTINE HYDROCHLORIDE;ASTELIN	5164194	NOV 01, 2010	DP U207		
		5164194*PED	MAY 01, 2011			
020610 001	BALSALAZIDE DISODIUM;COLAZAL	4412992	JUL 08, 2006			
019851 001	BENAZEPRIL HYDROCHLORIDE;LOTENSIN				M-30	MAR 02, 2007
					PED	SEP 02, 2007
019851 002	BENAZEPRIL HYDROCHLORIDE;LOTENSIN				M-30	MAR 02, 2007
					PED	SEP 02, 2007
019851 003	BENAZEPRIL HYDROCHLORIDE;LOTENSIN				M-30	MAR 02, 2007
					PED	SEP 02, 2007
019851 004	BENAZEPRIL HYDROCHLORIDE;LOTENSIN				M-30	MAR 02, 2007
					PED	SEP 02, 2007
021551 001	BISACODYL;HALFLYTELY				NP	MAY 10, 2007
021602 001	BORTEZOMIB;VELCADE	6713446	JAN 25, 2022	DP		
		6747150	OCT 28, 2014	DP		
020746 001	BUDESONIDE;RHINOCORT	6686346	APR 29, 2017	DP U557		
020746 002	BUDESONIDE;RHINOCORT	6686346	APR 29, 2017	DP U557		
019880 001	CARBOPLATIN;PARAPLATIN	4657927	APR 14, 2004	U175		
		4657927*PED	OCT 14, 2004			
019880 002	CARBOPLATIN;PARAPLATIN	4657927	APR 14, 2004	U175		
		4657927*PED	OCT 14, 2004			
019880 003	CARBOPLATIN;PARAPLATIN	4657927	APR 14, 2004	U175		
		4657927*PED	OCT 14, 2004			
020452 001	CARBOPLATIN;PARAPLATIN	4657927	APR 14, 2004	DP U175		
		4657927*PED	OCT 14, 2004			
020452 002	CARBOPLATIN;PARAPLATIN	4657927	APR 14, 2004	DP U175		
		4657927*PED	OCT 14, 2004			
020452 003	CARBOPLATIN;PARAPLATIN	4657927	APR 14, 2004	DP U175		
		4657927*PED	OCT 14, 2004			
020452 004	CARBOPLATIN;PARAPLATIN	4657927	APR 14, 2004	DP U175		
		4657927*PED	OCT 14, 2004			
>ADD>	020637 001	CARMUSTINE;GLIADEL			ODE	FEB 25, 2010
>ADD>	021227 001	CASPOFUNGIN ACETATE;CANCIDAS			I-438	SEP 29, 2007
>ADD>	021227 002	CASPOFUNGIN ACETATE;CANCIDAS			I-438	SEP 29, 2007
	021621 001	CETIRIZINE HYDROCHLORIDE;ZYRTEC	4525358	JUN 25, 2007	DS DP U565	
		4525358*PED	DEC 25, 2007			
		6455533	JUL 02, 2018	DP		
	021621 002	CETIRIZINE HYDROCHLORIDE;ZYRTEC	4525358	JUN 25, 2007	DS DP U565	
		4525358*PED	DEC 25, 2007			
		6455533	JUL 02, 2018	DP		

PRESCRIPTION AND OTC DRUG PRODUCT
 PATENT AND EXCLUSIVITY DATA
 See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PBD EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020989 002	CEVIMELINE HYDROCHLORIDE;EVOXAC	5340821	JUL 07, 2013	U309		
021587 001	CHLORPHENIRAMINE MALEATE;CHILDREN'S ADVIL ALL				NP	FEB 24, 2007
>ADD> 021149 002	CHORIOGONADOTROPIN ALFA;OVIDREL	5767251	JUN 16, 2015	DS		
		6706681	MAR 16, 2021	DP		
021688 001	CINACALCET HYDROCHLORIDE;SENSIPAR	6031003	DEC 14, 2016	U559	ODE	MAR 08, 2011
		6211244	OCT 23, 2015	DS DP U560	NCE	MAR 08, 2009
		6313146	DEC 14, 2016	DS DP		
		6011068	DEC 14, 2016	DS DP		
021688 002	CINACALCET HYDROCHLORIDE;SENSIPAR	6031003	DEC 14, 2016		ODE	MAR 08, 2011
		6211244	OCT 23, 2015	DS DP U560	NCE	MAR 08, 2009
		6313146	DEC 14, 2016	DS DP		
		6011068	DEC 14, 2016	DS DP		
021688 003	CINACALCET HYDROCHLORIDE;SENSIPAR	6031003	DEC 14, 2016	U559	ODE	MAR 08, 2011
		6211244	OCT 23, 2015	DS DP U560	NCE	MAR 08, 2009
		6313146	DEC 14, 2016	DS DP		
		6011068	DEC 14, 2016	DS DP		
019537 001	CIPROFLOXACIN HYDROCHLORIDE;CIPRO				I-421	MAR 25, 2007
					PED	SEP 25, 2007
019537 002	CIPROFLOXACIN HYDROCHLORIDE;CIPRO				I-421	MAR 25, 2007
					PED	SEP 25, 2007
019537 003	CIPROFLOXACIN HYDROCHLORIDE;CIPRO				I-421	MAR 25, 2007
					PED	SEP 25, 2007
019537 004	CIPROFLOXACIN HYDROCHLORIDE;CIPRO				I-421	MAR 25, 2007
					PED	SEP 25, 2007
020805 001	CIPROFLOXACIN HYDROCHLORIDE;CIPRO HC	5965549	JUN 06, 2015	DP		
>ADD> 075593 002	CIPROFLOXACIN HYDROCHLORIDE;CIPROFLOXACIN				PC	FEB 05, 2005
019847 001	CIPROFLOXACIN;CIPRO				I-421	MAR 25, 2007
					PED	SEP 25, 2007
020780 001	CIPROFLOXACIN;CIPRO				I-421	MAR 25, 2007
					PED	SEP 25, 2007
020780 002	CIPROFLOXACIN;CIPRO				I-421	MAR 25, 2007
					PED	SEP 25, 2007
019857 001	CIPROFLOXACIN;CIPRO IN DEXTROSE 5%				I-421	MAR 25, 2007
					PED	SEP 25, 2007
019858 001	CIPROFLOXACIN;CIPRO IN SODIUM CHLO	4670444	DEC 09, 2003			
		4705789	NOV 10, 2004			
		4957922	SEP 18, 2007			
		4808583	FEB 28, 2006			
		4670444*PED	JUN 09, 2004			
		4705789*PED	MAY 10, 2005			
		4808583*PED	AUG 28, 2006			
		4957922*PED	MAR 18, 2008			
021473 002	CIPROFLOXACIN;CIPRO XR	4670444	DEC 09, 2003	DS DP U555	NS	AUG 28, 2006
		4670444*PED	JUN 09, 2004		PED	FEB 28, 2007
					NDF	FEB 05, 2007
021644 001	CLOBETASOL PROPIONATE;CLOBEX	4659716	APR 21, 2005	U427		
021165 001	DESLORATADINE;CLARINEX	4659716*PED	OCT 21, 2005	U427		
		4659716	APR 21, 2005	U427		
021312 001	DESLORATADINE;CLARINEX	4659716*PED	OCT 21, 2005	U427		
		6716867	MAR 31, 2019	U572		
021038 001	DEXMEDETOMIDINE;PRECEDEX	6528530	DEC 04, 2015	DS DP		
021278 001	DEXMETHYLPHENIDATE HYDROCHLORIDE;FOCALIN	6528530	DEC 04, 2015	DS DP		
021278 002	DEXMETHYLPHENIDATE HYDROCHLORIDE;FOCALIN	6528530	DEC 04, 2015	DS DP		

PRESCRIPTION AND OTC DRUG PRODUCT
 PATENT AND EXCLUSIVITY DATA
 See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES	
021278 003	DEXMETHYLPHENIDATE HYDROCHLORIDE; FOCALIN	6528530	DEC 04, 2015	DS DP			
021392 001	DILTIAZEM HYDROCHLORIDE; CARDIZEM LA				I-133	APR 09, 2007	
021392 002	DILTIAZEM HYDROCHLORIDE; CARDIZEM LA				I-133	APR 09, 2007	
021392 003	DILTIAZEM HYDROCHLORIDE; CARDIZEM LA				I-133	APR 09, 2007	
021392 004	DILTIAZEM HYDROCHLORIDE; CARDIZEM LA				I-133	APR 09, 2007	
021392 005	DILTIAZEM HYDROCHLORIDE; CARDIZEM LA				I-133	APR 09, 2007	
021392 006	DILTIAZEM HYDROCHLORIDE; CARDIZEM LA				I-133	APR 09, 2007	
021168 001	DIVALPROEX SODIUM; DEPAKOTE ER	6528090	DEC 18, 2018	DP			
		6713086	DEC 18, 2018	DP U579			
		5212326	JAN 29, 2008	DS DP			
		6528091	DEC 18, 2018	U106			
021168 002	DIVALPROEX SODIUM; DEPAKOTE ER	6528090	DEC 18, 2018	DP			
		6713086	DEC 18, 2018	DP U579			
		5212326	JAN 29, 2008	DS DP			
020449 001	DOCETAXEL; TAXOTERE				I-429	MAY 19, 2007	
					I-436	AUG 18, 2007	
020931 001	DOFETILIDE; TIKOSYN	4959366	SEP 25, 2007				
020931 002	DOFETILIDE; TIKOSYN	4959366	SEP 25, 2007				
020931 003	DOFETILIDE; TIKOSYN	4959366	SEP 25, 2007				
020869 001	DORZOLAMIDE HYDROCHLORIDE; COSOPT	6316443	APR 17, 2011	DP U561			
020408 001	DORZOLAMIDE HYDROCHLORIDE; TRUSOPT	4797413	APR 28, 2008	DS DP U103			
		4619939	OCT 28, 2003	DP U104			
020862 001	DOXERCALCIFEROL; HECTOROL				I-424	APR 23, 2007	
020862 002	DOXERCALCIFEROL; HECTOROL	5869473	AUG 02, 2008	U278	I-424	APR 23, 2007	
018651 001	DRONABINOL; MARINOL	6703418	FEB 26, 2011	U563			
018651 002	DRONABINOL; MARINOL	6703418	FEB 26, 2011	U563			
018651 003	DRONABINOL; MARINOL	6703418	FEB 26, 2011	U563			
021098 001	DROSPIRENONE; YASMIN	6787531	AUG 31, 2020	DP			
>ADD>	021427 001	DULOXETINE HYDROCHLORIDE; CYMBALTA	5023269	JUN 11, 2008	DS DP U605	NCE	AUG 03, 2009
>ADD>			5508276	JUL 18, 2014	DP		
>ADD>	021427 002	DULOXETINE HYDROCHLORIDE; CYMBALTA	5023269	JUN 11, 2008	DS DP U605	NCE	AUG 03, 2009
>ADD>			5508276	JUL 18, 2014	DP		
>ADD>	021427 004	DULOXETINE HYDROCHLORIDE; CYMBALTA	5023269	JUN 11, 2008	DS DP U605	NCE	AUG 03, 2009
>ADD>			5508276	JUL 18, 2014	DP		
>ADD>	021733 001	DULOXETINE HYDROCHLORIDE; CYMBALTA				NCE	AUG 03, 2009
>ADD>						NDF	SEP 03, 2007
>ADD>	021733 002	DULOXETINE HYDROCHLORIDE; CYMBALTA				NCE	AUG 03, 2009
>ADD>						NDF	SEP 03, 2007
>ADD>	021733 004	DULOXETINE HYDROCHLORIDE; CYMBALTA				NCE	AUG 03, 2009
>ADD>						NDF	SEP 03, 2007
021500 001	EMTRICITABINE; EMTRIVA	6703396	MAR 09, 2021	DS DP			
021504 001	EPINEPHRINE; LIDOSITE TOPICAL SYS	5246418	SEP 30, 2013	DS DP	NP	MAY 04, 2007	
		5873850	SEP 30, 2013	DS DP			
		6377847	SEP 30, 2013	DS DP			
		6385488	SEP 30, 2013	DS DP			
		6629968	JUN 30, 2020	DS DP			
		6635045	JUN 29, 2021	DS DP			
021437 001	EPLERENONE; INSPRA	6747020	NOV 05, 2019	U587			
021437 002	EPLERENONE; INSPRA	6747020	NOV 05, 2019	U587			
021437 003	EPLERENONE; INSPRA	6747020	NOV 05, 2019	U587			
021633 001	ESTRADIOL ACETATE; FEMTRACE				NDF	AUG 20, 2007	
021633 002	ESTRADIOL ACETATE; FEMTRACE				NDF	AUG 20, 2007	

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
021633 003	ESTRADIOL ACETATE; FEMTRACE				NDF	AUG 20, 2007
021371 001	ESTRADIOL HEMIHYDRATE; ESTRASORB	5629021	JAN 31, 2015	DP	NDF	OCT 09, 2006
021166 001	ESTRADIOL; ESTROGEL				NDF	FEB 09, 2007
021674 001	ESTRADIOL; MENOSTAR	5891868	NOV 21, 2017	DP U594	NP	JUN 08, 2007
		6692763	NOV 21, 2017	DP U594		
		5223261	JUN 29, 2010	DP U594		
		6747019	MAR 20, 2020	U311		
021040 001	ESTRADIOL; PREFEST					
020992 002	ESTROGENS, CONJUGATED SYNTHETIC A; CENESTIN				D-85	FEB 05, 2007
020992 003	ESTROGENS, CONJUGATED SYNTHETIC A; CENESTIN				D-85	FEB 05, 2007
020992 004	ESTROGENS, CONJUGATED SYNTHETIC A; CENESTIN				D-85	FEB 05, 2007
020992 006	ESTROGENS, CONJUGATED SYNTHETIC A; CENESTIN				NS	FEB 05, 2007
					D-85	FEB 05, 2007
021443 003	ESTROGENS, CONJUGATED SYNTHETIC B; ENJUVIA				NP	MAY 10, 2007
021443 004	ESTROGENS, CONJUGATED SYNTHETIC B; ENJUVIA				NP	MAY 10, 2007
021490 001	ETHINYL ESTRADIOL; OVCON-35	6667050	JUN 12, 2021	DP U1		
021687 001	EZETIMIBE; VYTORIN	4444784	DEC 23, 2005	DS DP U592	NCE	OCT 25, 2007
		5846966	SEP 21, 2013	DP U593		
		RE37721	JUN 16, 2015	DS DP		
021687 002	EZETIMIBE; VYTORIN	4444784	DEC 23, 2005	DS DP U592	NCE	OCT 25, 2007
		5846966	SEP 21, 2013	DP U593		
		RE37721	JUN 16, 2015	DS DP		
021687 003	EZETIMIBE; VYTORIN	4444784	DEC 23, 2005	DS DP U592	NCE	OCT 25, 2007
		5846966	SEP 21, 2013	DP U593		
		RE37721	JUN 16, 2015	DS DP		
021687 004	EZETIMIBE; VYTORIN	4444784	DEC 23, 2005	DS DP U592	NCE	OCT 25, 2007
		5846966	SEP 21, 2013	DP U593		
		RE37721	JUN 16, 2015	DS DP		
020363 001	FAMCICLOVIR; FAMVIR	5840763	SEP 01, 2015	U96		
		5866581	OCT 04, 2014	U96		
		5916893	SEP 01, 2015	U96		
		6124304	OCT 04, 2014	U96		
020363 002	FAMCICLOVIR; FAMVIR	5840763	SEP 01, 2015	U96		
		5866581	OCT 04, 2014	U96		
		5916893	SEP 01, 2015	U96		
		6124304	OCT 04, 2014	U96		
020363 003	FAMCICLOVIR; FAMVIR	5840763	SEP 01, 2015	U96		
		5866581	OCT 04, 2014	U96		
		5916893	SEP 01, 2015	U96		
		6124304	OCT 04, 2014	U96		
019922 001	FENOLDOPAM MESYLATE; CORLOPAM				I-422	APR 01, 2007
020180 001	FINASTERIDE; PROSCAR	4760071	JUN 19, 2006	DS DP U262		
		5886184	NOV 19, 2012	DS		
		6046183	MAR 20, 2011	DP U577		
019949 001	FLUCONAZOLE; DIFLUCAN	4404216	JAN 29, 2004			
		4404216*PED	JUL 29, 2004			
019949 002	FLUCONAZOLE; DIFLUCAN	4404216	JAN 29, 2004			
		4404216*PED	JUL 29, 2004			
019949 003	FLUCONAZOLE; DIFLUCAN	4404216	JAN 29, 2004			
		4404216*PED	JUL 29, 2004			
019949 004	FLUCONAZOLE; DIFLUCAN	4404216	JAN 29, 2004			
		4404216*PED	JUL 29, 2004			
020090 001	FLUCONAZOLE; DIFLUCAN	4404216	JAN 29, 2004			
		4404216*PED	JUL 29, 2004			

PRESCRIPTION AND OTC DRUG PRODUCT
 PATENT AND EXCLUSIVITY DATA
 See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020090 002	FLUCONAZOLE;DIFLUCAN	4404216	JAN 29, 2004			
019950 003	FLUCONAZOLE;DIFLUCAN IN DEXTROSE	4404216*PED	JUL 29, 2004			
019950 005	FLUCONAZOLE;DIFLUCAN IN DEXTROSE	4404216	JAN 29, 2004			
019950 001	FLUCONAZOLE;DIFLUCAN IN SODIUM C	4404216*PED	JUL 29, 2004			
019950 002	FLUCONAZOLE;DIFLUCAN IN SODIUM C	4404216	JAN 29, 2004			
019950 004	FLUCONAZOLE;DIFLUCAN IN SODIUM C	4404216*PED	JUL 29, 2004			
020985 001	FLUOROURACIL;CARAC	6670335	JUN 02, 2021	DP U68		
021235 001	FLUOXETINE HYDROCHLORIDE;PROZAC WEEKLY	5910319	MAY 29, 2017	U396		
		5985322	MAY 29, 2017	U397		
021077 001	FLUTICASONE PROPIONATE;ADVAIR DISKUS 100/50	6170717	DEC 23, 2017	DP	M-33	APR 21, 2007
021433 001	FLUTICASONE PROPIONATE;FLOVENT HFA	6315173	DEC 23, 2017	DP	NP	MAY 14, 2007
		6510969	DEC 23, 2017	DP		
		6743413	JUN 01, 2021	DP U581		
		6253762	APR 14, 2015	DP U582		
		6546928	APR 14, 2015	DP U583		
021433 002	FLUTICASONE PROPIONATE;FLOVENT HFA	6170717	DEC 23, 2017	DP	NP	MAY 14, 2007
		6315173	DEC 23, 2017	DP		
		6510969	DEC 23, 2017	DP		
		6743413	JUN 01, 2021	DP U581		
		6253762	APR 14, 2015	DP U582		
		6546928	APR 14, 2015	DP U583		
021433 003	FLUTICASONE PROPIONATE;FLOVENT HFA	6170717	DEC 23, 2017	DP	NP	MAY 14, 2007
		6315173	DEC 23, 2017	DP		
		6510969	DEC 23, 2017	DP		
		6743413	JUN 01, 2021	DP U581		
		6253762	APR 14, 2015	DP U582		
		6546928	APR 14, 2015	DP U583		
021211 001	FOLLITROPIN ALFA/BETA;FOLLISTIM AQ	5929028	JAN 14, 2018	DP U567		
		5767251	JUN 16, 2015	DS		
		4589402	JUL 26, 2004	U568		
		4589402	JUL 26, 2004	U569		
		4589402	JUL 26, 2004	U570		
021211 002	FOLLITROPIN ALFA/BETA;FOLLISTIM AQ	5929028	JAN 14, 2018	DP U567		
		4589402	JUL 26, 2004	U568		
		5767251	JUN 16, 2015	DS		
		4589402	JUL 26, 2004	U569		
		4589402	JUL 26, 2004	U570		
>ADD>	020378 001	FOLLITROPIN ALFA/BETA;GONAL-F	5767251	JUN 16, 2015	DS	
>ADD>	020378 002	FOLLITROPIN ALFA/BETA;GONAL-F	5767251	JUN 16, 2015	DS	
>ADD>	020378 003	FOLLITROPIN ALFA/BETA;GONAL-F	5767251	JUN 16, 2015	DS	
>ADD>	020378 004	FOLLITROPIN ALFA/BETA;GONAL-F	5767067	JUN 16, 2015	DS	ODE MAY 24, 2007
>ADD>			5767251	JUN 16, 2015	DS	
>ADD>	020378 005	FOLLITROPIN ALFA/BETA;GONAL-F	5767251	JUN 16, 2015	DS	ODE MAY 24, 2007
			5767067	JUN 16, 2015	DS	
>ADD>	021765 001	FOLLITROPIN ALFA/BETA;GONAL-F	5767251	JUN 16, 2015	DS	NP MAR 25, 2007

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES	
>ADD>	021765 002	FOLLITROPIN ALFA/BETA;GONAL-F	5767251	JUN 16, 2015	DS	NP	MAR 25, 2007
			5767067	JUN 16, 2015	DS		
>ADD>	021765 003	FOLLITROPIN ALFA/BETA;GONAL-F	5767251	JUN 16, 2015	DS	NP	MAR 25, 2007
>ADD>	021684 001	FOLLITROPIN ALFA/BETA;GONAL-F RFF PEN	5767251	JUN 16, 2015	DS		
			5767067	JUN 16, 2015	DS		
>ADD>	021684 002	FOLLITROPIN ALFA/BETA;GONAL-F RFF PEN	5767251	JUN 16, 2015	DS		
			5767067	JUN 16, 2015	DS		
>ADD>	021684 003	FOLLITROPIN ALFA/BETA;GONAL-F RFF PEN	5767251	JUN 16, 2015	DS		
			5767067	JUN 16, 2015	DS		
	021345 001	FONDAPARINUX SODIUM;ARIXTRA				I-426	MAY 31, 2007
						I-427	MAY 31, 2007
	021345 002	FONDAPARINUX SODIUM;ARIXTRA				I-426	MAY 31, 2007
						NCE	DEC 07, 2006
						I-397	JUN 17, 2006
						NS	MAY 31, 2007
	021345 003	FONDAPARINUX SODIUM;ARIXTRA				I-427	MAY 31, 2007
						I-426	MAY 31, 2007
						NCE	DEC 07, 2006
						I-397	JUN 17, 2006
						NS	MAY 31, 2007
	021345 004	FONDAPARINUX SODIUM;ARIXTRA				I-427	MAY 31, 2007
						I-426	MAY 31, 2007
						NCE	DEC 07, 2006
						I-397	JUN 17, 2006
						NS	MAY 31, 2007
						I-427	MAY 31, 2007
	021344 001	FULVESTRANT;FASLODEX	6774122	JAN 09, 2021		U596	
	076017 001	GABAPENTIN;GABAPENTIN				PC	FEB 14, 2005
	076017 002	GABAPENTIN;GABAPENTIN				PC	FEB 14, 2005
	076017 003	GABAPENTIN;GABAPENTIN				PC	FEB 14, 2005
	021061 001	GATIFLOXACIN;TEQUIN				I-432	JUN 30, 2007
	021061 002	GATIFLOXACIN;TEQUIN				I-432	JUN 30, 2007
	021062 001	GATIFLOXACIN;TEQUIN				I-432	JUN 30, 2007
	021062 002	GATIFLOXACIN;TEQUIN				I-432	JUN 30, 2007
	021062 003	GATIFLOXACIN;TEQUIN				I-432	JUN 30, 2007
	021062 004	GATIFLOXACIN;TEQUIN				I-432	JUN 30, 2007
>ADD>	021678 001	GATIFLOXACIN;TEQUIN	4980470	DEC 25, 2007	DS	NCE	DEC 17, 2004
>ADD>			5880283	DEC 05, 2015	DS	I-329	OCT 17, 2005
>ADD>			6589955	MAY 09, 2022	DS	U603	
	021493 001	GATIFLOXACIN; ZYMAR	4980470	DEC 25, 2007			
			6333045	AUG 20, 2019		DP	
	020509 001	GEMCITABINE HYDROCHLORIDE;GEMZAR	4808614	MAY 15, 2010	DS	I-428	MAY 19, 2004
	020509 002	GEMCITABINE HYDROCHLORIDE;GEMZAR	4808614	MAY 15, 2010	DS	I-428	MAY 19, 2007
	021158 001	GEMIFLOXACIN MESYLATE;FACTIVE	6723734	MAR 20, 2018	DS DP		
	021667 001	GLUTAMINE;NUTRESTORE				NCE	JUN 10, 2009
	076345 001	GLYBURIDE;GLYBURIDE AND METFOR				PC	OCT 31, 2004
	076345 002	GLYBURIDE;GLYBURIDE AND METFOR				PC	OCT 31, 2004
	076345 003	GLYBURIDE;GLYBURIDE AND METFOR				PC	OCT 31, 2004
	021640 001	HYALURONIDASE;VITRASE				NP	MAY 05, 2007
	020758 001	HYDROCHLOROTHIAZIDE;AVALIDE	5270317	SEP 30, 2011			
			5994348	JUN 07, 2015			
			5270317*PED	MAR 30, 2012			
			5994348*PED	DEC 07, 2015			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE (S)	EXCLUS CODE	EXCLUS EXPIRES
020758 002	HYDROCHLOROTHIAZIDE; AVALIDE	5270317 5994348 5270317*PED	SEP 30, 2011 JUN 07, 2015 MAR 30, 2012			
020758 003	HYDROCHLOROTHIAZIDE; AVALIDE	5994348*PED 5270317 5994348 5270317*PED 5994348*PED	DEC 07, 2015 SEP 30, 2011 JUN 07, 2015 MAR 30, 2012 DEC 07, 2015			
076604 001	HYDROCODONE BITARTRATE; HYDROCODONE BITARTRA				PC	OCT 11, 2004
>ADD>	021044 001				NDF	SEP 24, 2007
>ADD>	021044 002				NDF	SEP 24, 2007
>ADD>	021044 003				NDF	SEP 24, 2007
>ADD>	021044 004				NDF	SEP 24, 2007
	021604 001				NP	JAN 07, 2007
	076478 001				PC	JUL 29, 2004
	020723 001				I-420 I-433	MAR 02, 2007 JUL 14, 2007
	020685 001	6689761	FEB 10, 2021	U554		
	020685 003	6689761	FEB 10, 2021	U554		
	020685 005	6689761	FEB 10, 2021	U554		
	020685 006	6689761	FEB 10, 2021	U554		
	021629 001	6221633	JUN 18, 2018	DS DP U471	NCE	APR 16, 2009
	020563 001				D-86	JUN 02, 2007
	020563 002				D-86	JUN 02, 2007
	021425 003	4364921	MAR 06, 2005	DS DP U113		
	020757 001	5270317 6342247 5270317*PED 6342247*PED	SEP 30, 2011 JUN 07, 2015 MAR 30, 2012 DEC 07, 2015		I-373 PED	SEP 17, 2005 MAR 17, 2006
>ADD>	020757 002	5270317*PED 6342247*PED	MAR 30, 2012 DEC 07, 2015		I-373 PED	SEP 17, 2005 MAR 17, 2006
>ADD>	020757 003	5270317*PED	MAR 30, 2012		I-373 PED	SEP 17, 2005 MAR 17, 2006
>ADD>	020571 001	4604463 6403569 4604463*PED 6403569*PED	AUG 20, 2007 APR 28, 2020 FEB 20, 2008 OCT 28, 2020	U449	M-34 PED	JUN 24, 2007 DEC 24, 2007
	021066 001	6777429 6774137 6776982	JAN 13, 2019 JAN 13, 2019 JAN 13, 2019		DP U599 DP	
	021281 001				M-12	AUG 30, 2005
	021281 002				M-12	AUG 30, 2005
	021428 001				M-12	AUG 30, 2005
	021428 002				M-12	AUG 30, 2005
	021566 001				NDF	MAY 27, 2007
	020905 001				M-32 PED	MAR 05, 2007 SEP 05, 2007
	020905 002				M-32 PED	MAR 05, 2007 SEP 05, 2007
	020905 003				M-32 PED	MAR 05, 2007 SEP 05, 2007
	020837 004	6083993 6451289 5362755 5547994 5760090	JAN 05, 2010 MAR 21, 2021 NOV 08, 2011 AUG 20, 2013 JAN 05, 2010	U332 DP U332 U332 U332		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES	
020182 001	LEVOCARNITINE; CARNITOR	5844002	JAN 05, 2010	US			
021571 001	LEVOPLOXACIN; IQUIX	6696493	JAN 18, 2021	U433			
021225 001	LEVONORGESTREL; MIRENA	5053407	DEC 20, 2010	DS DP U600	NP	MAR 01, 2007	
021451 001	LIDOCAINE; ORAQIX	5785053	DEC 05, 2015	DP			
021130 001	LINEZOLID; ZYVOX	6031007	APR 01, 2017	DP U553			
		5688792	NOV 18, 2014	DS U319	I-431	JUN 23, 2007	
		6559305	JAN 29, 2021	DS			
021130 002	LINEZOLID; ZYVOX	5688792	NOV 18, 2014	DS U319	I-431	JUN 23, 2007	
		6559305	JAN 29, 2021	DS			
021131 001	LINEZOLID; ZYVOX	6559305	JAN 29, 2021	DS	I-431	JUN 23, 2007	
021132 001	LINEZOLID; ZYVOX	5688792	NOV 18, 2014	DS U319	I-431	JUN 23, 2007	
		6559305	JAN 29, 2021	DS			
021226 001	LOPINAVIR; KALETRA	6703403	JUN 26, 2016	U257			
021251 001	LOPINAVIR; KALETRA	6703403	JUN 26, 2016	U257			
075505 001	LORATADINE; LORATADINE				PC	AUG 20, 2004	
020386 001	LOSARTAN POTASSIUM; COZAAR				NPP	MAR 11, 2007	
					PED	SEP 11, 2007	
020386 002	LOSARTAN POTASSIUM; COZAAR				NPP	MAR 11, 2007	
					PED	SEP 11, 2007	
020386 003	LOSARTAN POTASSIUM; COZAAR				NPP	MAR 11, 2007	
					PED	SEP 11, 2007	
020803 001	LOTEPREDNOL ETABONATE; ALREX	5747061	OCT 25, 2013	DP U576			
020583 001	LOTEPREDNOL ETABONATE; LOTEMAX	5747061	OCT 25, 2013	DP U575			
021249 001	LOVASTATIN; ADVICOR	6676967	SEP 20, 2013	U548			
		5746691	SEP 20, 2013	U586			
021249 002	LOVASTATIN; ADVICOR	6676967	SEP 20, 2013	U548			
		6746691	SEP 20, 2013	U586			
021249 003	LOVASTATIN; ADVICOR	6676967	SEP 20, 2013	U548			
		6746691	SEP 20, 2013	U586			
020938 001	MELOXICAM; MOBIC				I-430	JUL 16, 2007	
020938 002	MELOXICAM; MOBIC				I-430	JUL 16, 2007	
021530 001	MELOXICAM; MOBIC	6184220	MAR 25, 2019	DP	I-430	JUL 16, 2007	
					NCE	APR 13, 2005	
013217 001	METAXALONE; SKELAXIN	6683102	DEC 03, 2021	U189			
013217 003	METAXALONE; SKELAXIN	6683102	DEC 03, 2021	U189			
>ADD>	021574 001	METFORMIN HYDROCHLORIDE; FORTAMET	6790459	MAR 17, 2021	U604	NP	APR 27, 2007
>ADD>			6495162	MAR 20, 2018	DP		
>ADD>			6099859	MAR 20, 2018	DP		
>ADD>	021574 002	METFORMIN HYDROCHLORIDE; FORTAMET	6790459	MAR 17, 2021	U604	NP	APR 27, 2007
>ADD>			6495162	MAR 20, 2018	DP		
>ADD>			6099859	MAR 20, 2018	DP		
076172 001	METFORMIN HYDROCHLORIDE; METFORMIN HCL				PC	DEC 14, 2004	
076545 001	METFORMIN HYDROCHLORIDE; METFORMIN HCL				PC	MAY 29, 2004	
021415 001	METHYL AMINOLEVULINATE HYDROCHLORIDE; METHYL AMINOLEVULINA				NE	JUL 27, 2007	
021284 001	METHYLPHENIDATE HYDROCHLORIDE; RITALIN LA	5837284	DEC 04, 2015	DP			
		6635284	DEC 04, 2015	DP U591			
021284 002	METHYLPHENIDATE HYDROCHLORIDE; RITALIN LA	5837284	DEC 04, 2015	DP			
		6635284	DEC 04, 2015	DP U591			
021284 003	METHYLPHENIDATE HYDROCHLORIDE; RITALIN LA	5837284	DEC 04, 2015	DP			
		6635284	DEC 04, 2015	DP U591			
021284 004	METHYLPHENIDATE HYDROCHLORIDE; RITALIN LA	5837284	DEC 04, 2015	DP			
		6635284	DEC 04, 2015	DP U591			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
021308 001	MICONAZOLE NITRATE;MONISTAT 1 COMBINATI				RTO	JUN 29, 2004
>ADD>					D-90	OCT 01, 2007
076307 001	MIRTAZAPINE;MIRTAZAPINE				PC	JUN 14, 2004
076307 002	MIRTAZAPINE;MIRTAZAPINE				PC	JUN 14, 2004
020762 001	MOMETASONE FUROATE MONOHYDRATE;NASONEX	6723713	JAN 27, 2014	U574		
		6723713*PED	JUL 27, 2014			
021671 001	MORPHINE SULFATE;DEPODUR	5723147	MAR 03, 2015	DP U584		
		5807572	SEP 15, 2015	DP		
		5891467	JAN 31, 2017	DP		
		5931089	JUL 14, 2015	U584		
		5997899	SEP 01, 2016	DP		
		5962016	JAN 31, 2017	DP U584		
		6071534	FEB 18, 2008			
		6171613	OCT 01, 2016	DP		
		6193998	SEP 01, 2016	DP		
		6241999	SEP 01, 2016	DP		
021671 002	MORPHINE SULFATE;DEPODUR	5723147	MAR 03, 2015	DP U584		
		5807572	SEP 15, 2015	DP		
		5891467	JAN 31, 2017	DP		
		5931089	JUL 14, 2015	U584		
		5997899	SEP 01, 2016	DP		
		5962016	JAN 31, 2017	DP U584		
		6071534	FEB 18, 2008			
		6171613	OCT 01, 2016	DP		
		6193998	SEP 01, 2016	DP		
		6241999	SEP 01, 2016	DP		
021671 003	MORPHINE SULFATE;DEPODUR	5723147	MAR 03, 2015	DP U584		
		5807572	SEP 15, 2015	DP		
		5891467	JAN 31, 2017	DP		
		5931089	JUL 14, 2015	U584		
		5997899	SEP 01, 2016	DP		
		5962016	JAN 31, 2017	DP U584		
		6071534	FEB 18, 2008			
		6171613	OCT 01, 2016	DP		
		6193998	SEP 01, 2016	DP		
		6241999	SEP 01, 2016	DP		
021598 001	MOXIFLOXACIN HYDROCHLORIDE;VIGAMOX	6716830	SEP 20, 2019	DP	NCE	DEC 10, 2004
		6716830*PED	MAR 29, 2020		PED	JUN 10, 2005
020381 001	NIACIN;NIASPAN	6746691	SEP 20, 2013	U586		
020381 002	NIACIN;NIASPAN	6676967	SEP 20, 2013	U548		
		6746691	SEP 20, 2013	U586		
020381 003	NIACIN;NIASPAN	6676967	SEP 20, 2013	U548		
		6746691	SEP 20, 2013	U586		
020381 004	NIACIN;NIASPAN	6676967	SEP 20, 2013	U548		
		6746691	SEP 20, 2013	U586		
020381 005	NIACIN;NIASPAN TITRATION ST	6746691	SEP 20, 2013	U586		
021497 001	NITAZOXANIDE;ALINIA				NDF	JUL 21, 2007
					NCE	NOV 22, 2007
					ODE	NOV 22, 2009
021498 001	NITAZOXANIDE;ALINIA				NPP	JUL 21, 2007
					ODE	NOV 22, 2009
076648 001	NITROFURANTOIN;NITROFURANTOIN (MONO				PC	SEP 19, 2004

PRESCRIPTION AND OTC DRUG PRODUCT
 PATENT AND EXCLUSIVITY DATA
 See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
021494 001	NIZATIDINE;AXID				NDF	MAY 25, 2007
020592 001	OLANZAPINE; ZYPREXA	5229382	APR 23, 2011	DS DP U149	I-417	JAN 14, 2007
		5229382	APR 23, 2001	U547		
020592 002	OLANZAPINE; ZYPREXA	5229382	APR 23, 2011	DS DP U149	I-417	JAN 14, 2007
		5229382	APR 23, 2011	U547		
020592 003	OLANZAPINE; ZYPREXA	5229382	APR 23, 2011	DS DP U149	I-417	JAN 14, 2007
		5229382	APR 23, 2011	U547		
020592 004	OLANZAPINE; ZYPREXA	5229382	APR 23, 2011	DS DP U149	I-417	JAN 14, 2007
		5229382	APR 23, 2011	U547		
020592 005	OLANZAPINE; ZYPREXA	5229382	APR 23, 2011	DS DP U149	I-417	JAN 14, 2007
		5229382	APR 23, 2011	U547		
020592 006	OLANZAPINE; ZYPREXA	5229382	APR 23, 2011	DS DP U149	I-417	JAN 14, 2007
		5229382	APR 23, 2011	DS DP U547		
021253 001	OLANZAPINE; ZYPREXA	5229382	APR 23, 2011	DS DP U571	NDF	MAR 29, 2007
					NP	MAR 29, 2007
021086 001	OLANZAPINE; ZYPREXA ZYDIS				I-417	JAN 14, 2007
					I-400	JUL 10, 2006
021086 002	OLANZAPINE; ZYPREXA ZYDIS				I-417	JAN 14, 2007
					I-400	JUL 10, 2006
021086 003	OLANZAPINE; ZYPREXA ZYDIS				I-417	JAN 14, 2007
					I-400	JUL 10, 2006
021086 004	OLANZAPINE; ZYPREXA ZYDIS				I-417	JAN 14, 2007
					I-400	JUL 10, 2006
021636 001	OMEPRAZOLE; ZEGERID	5840737	JUL 16, 2016		U588	
		6645988	JUL 16, 2016	DS DP		
		6489346	JUL 16, 2016	DS DP	U588	
		6699885	JUL 16, 2016		U588	
		6780882	JUL 16, 2016	DS DP		
021087 001	OSELTAMIVIR PHOSPHATE; TAMIFLU	5763483	DEC 27, 2016		NCE	OCT 27, 2004
		5866601	FEB 02, 2016		PED	APR 27, 2005
		5952375	FEB 02, 2016			
		5763483*PED	JUN 27, 2017			
		5866601*PED	AUG 02, 2016			
		5952375*PED	AUG 02, 2016			
021246 001	OSELTAMIVIR PHOSPHATE; TAMIFLU	5866601	FEB 02, 2016		NCE	OCT 27, 2004
		5952375	FEB 02, 2016		PED	APR 27, 2005
		5763483	DEC 27, 2016	U376		
		5763483*PED	JUN 27, 2017			
		5866601*PED	AUG 02, 2016			
		5952375*PED	AUG 02, 2016			
021492 001	OXALIPLATIN; ELOXATIN				I-425	JAN 09, 2007
021492 002	OXALIPLATIN; ELOXATIN				I-425	JAN 09, 2007
013718 001	OXANDROLONE; OXANDRIN	5872147	DEC 05, 2017		U585	
		6670351	OCT 20, 2012		U585	
		6576659	DEC 05, 2017		U585	
		6090799	JUL 18, 2017		U585	
013718 002	OXANDROLONE; OXANDRIN	5872147	DEC 05, 2017		U585	
		6670351	OCT 20, 2012		U585	
		6576659	DEC 05, 2017		U585	
		6090799	JUL 18, 2017		U585	
021351 002	OXYBUTYNIN; OXYTROL	6743441	APR 26, 2020	DP	U318	
076168 001	OXYCODONE HYDROCHLORIDE; OXYCODONE HCL				PC	SEP 26, 2004

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
>ADD> 020988 001	PANTOPRAZOLE SODIUM;PROTONIX IV	6780881	NOV 17, 2021	DP		
020819 001	PARICALCITOL;ZEMPLAR				M-31	MAR 31, 2007
020819 002	PARICALCITOL;ZEMPLAR	5246925	APR 17, 2012		PED	OCT 01, 2007
		5246925*PED	OCT 17, 2012	U314	M-31	MAR 31, 2007
		5587497	DEC 24, 2013		PED	OCT 01, 2007
		5587497*PED	JUN 24, 2014			
		6136799	APR 08, 2018			
		6136799*PED	OCT 08, 2019			
		6361758	APR 08, 2018	DP		
		6361758*PED	OCT 08, 2018			
021462 001	PEMETREXED DISODIUM;ALIMTA	5217974	MAR 29, 2011	U551	NCE	FEB 04, 2009
		5344932	SEP 06, 2011	DS DP	ODE	FEB 04, 2011
020629 001	PENCICLOVIR SODIUM;DENAVIR	5840763	SEP 01, 2015	U501		
		5866581	SEP 04, 2014	U501		
		5916893	SEP 01, 2015	U501		
		6124304	SEP 04, 2014	U501		
021749 001	PENTETATE CALCIUM TRISODIUM;PENTETATE CALCIUM TR				NCE	AUG 11, 2009
021751 001	PENTETATE ZINC TRISODIUM;PENTETATE ZINC TRISO				NCE	AUG 11, 2009
021073 001	PIOGLITAZONE HYDROCHLORIDE;ACTOS				M-35	NOV 26, 2006
021073 002	PIOGLITAZONE HYDROCHLORIDE;ACTOS				M-35	NOV 26, 2006
021073 003	PIOGLITAZONE HYDROCHLORIDE;ACTOS				M-35	NOV 26, 2006
020639 001	QUETIAPINE FUMARATE;SEROQUEL	4879288	SEP 26, 2011	DS DP U550	I-419	JAN 12, 2007
					I-418	JAN 12, 2007
020639 002	QUETIAPINE FUMARATE;SEROQUEL	4879288	SEP 26, 2011	DS DP U550	I-419	JAN 12, 2007
					I-418	JAN 12, 2007
020639 003	QUETIAPINE FUMARATE;SEROQUEL	4879288	SEP 26, 2011	DS DP U550	I-419	JAN 12, 2007
					I-418	JAN 12, 2007
020639 004	QUETIAPINE FUMARATE;SEROQUEL	4879288	SEP 26, 2011	DS DP U550	I-419	JAN 12, 2007
					I-418	JAN 12, 2007
020639 005	QUETIAPINE FUMARATE;SEROQUEL	4879288	SEP 26, 2011	DS DP U550	I-419	JAN 12, 2007
					I-418	JAN 12, 2007
>ADD> 020815 001	RALOXIFENE HYDROCHLORIDE;EVISTA	6797719	MAR 10, 2017	DP		
>ADD> 021698 001	RANITIDINE HYDROCHLORIDE;ZANTAC 150				NP	AUG 31, 2007
020741 001	REPAGLINIDE;PRANDIN	6677358	JUN 12, 2018	DS DP U546		
020741 002	REPAGLINIDE;PRANDIN	6677358	JUN 12, 2018	DS DP U546		
020741 003	REPAGLINIDE;PRANDIN	6677358	JUN 12, 2018	DS DP U546		
020903 002	RIBAVIRIN;REBETOL	6177074	NOV 01, 2016	U454		
		6177074*PED	MAY 01, 2017	U454		
		6461605	NOV 01, 2016	U478		
		6461605*PED	MAY 01, 2017	U478		
		6472373	SEP 21, 2017	U479		
		6472373*PED	MAR 21, 2018	U479		
		6524570	NOV 01, 2016	U499		
		6524570*PED	MAY 01, 2017	U499		
076203 001	RIBAVIRIN;RIBASPHERE				PC	OCT 03, 2004
076192 001	RIBAVIRIN;RIBAVIRIN				PC	OCT 03, 2004
021361 001	RIFAXIMIN;XIFAXAN				NCE	MAY 25, 2009
020835 003	RISEDRONATE SODIUM;ACTONEL	6465443	AUG 14, 2018	DP		
		6432932	JUL 17, 2018	U595		
020659 001	RITONAVIR;NORVIR	6703403	JUN 26, 2016	U564		
020945 001	RITONAVIR;NORVIR	6703403	JUN 26, 2016	U564		

PRESCRIPTION AND OTC DRUG PRODUCT
 PATENT AND EXCLUSIVITY DATA
 See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES		
>ADD>	021042 001	ROFECOXIB;VIOXX	5474995	JUN 24, 2013	DS DP U602	NCE	MAY 20, 2004	
>ADD>			6063811	MAY 06, 2017	U602	I-353	APR 11, 2005	
>ADD>			6239173	JUN 24, 2013	DS DP U602	M-27	AUG 06, 2006	
			5691374	MAY 18, 2015		PED	NOV 20, 2004	
			5474995*PED	DEC 24, 2013		PED	OCT 11, 2005	
			5691374*PED	NOV 18, 2015		PED	FEB 06, 2007	
			6063811*PED	NOV 06, 2017		I-423	MAR 26, 2007	
			6239173*PED	DEC 24, 2013				
>ADD>	021042 002	ROFECOXIB;VIOXX	5474995	JUN 24, 2013	DS DP U602	NCE	MAY 20, 2004	
>ADD>			6063811	MAY 06, 2017	U602	I-353	APR 11, 2005	
>ADD>			6239173	JUN 24, 2013	DS DP U602	M-27	AUG 06, 2006	
			5691374	MAY 18, 2015		PED	NOV 20, 2004	
			5474995*PED	DEC 24, 2013		PED	OCT 11, 2005	
			5691374*PED	NOV 18, 2015		PED	FEB 06, 2007	
			6063811*PED	NOV 06, 2017		I-423	MAR 26, 2007	
			6239173*PED	DEC 24, 2013				
>ADD>	021042 003	ROFECOXIB;VIOXX	6239173	JUN 24, 2013	DS DP U602	NCE	MAY 20, 2004	
>ADD>			5474995	JUN 24, 2013	DS DP U602	I-353	APR 11, 2005	
>ADD>			6063811	MAY 06, 2017	U602	M-27	AUG 06, 2006	
			5691374	MAY 18, 2015		PED	NOV 20, 2004	
			5474995*PED	DEC 24, 2013		PED	OCT 11, 2005	
			5691374*PED	NOV 18, 2015		PED	FEB 06, 2007	
			6063811*PED	NOV 06, 2017		I-423	MAR 26, 2007	
			6239173*PED	DEC 24, 2013				
	021052 001	ROFECOXIB;VIOXX	5474995	JUN 24, 2013		U266	NCE	MAY 20, 2004
			5691374	MAY 18, 2015			I-353	APR 11, 2005
			6063811	MAY 06, 2017		U266	M-27	AUG 06, 2006
			6239173	JUN 24, 2013			PED	NOV 20, 2004
			5474995*PED	DEC 24, 2013			PED	FEB 06, 2007
			5691374*PED	NOV 18, 2015			PED	OCT 11, 2005
			6063811*PED	NOV 06, 2017				
			6239173*PED	DEC 24, 2013				
	021052 002	ROFECOXIB;VIOXX	5474995	JUN 24, 2013		U266	NCE	MAY 20, 2004
			5691374	MAY 18, 2015			I-353	APR 11, 2005
			6063811	MAY 06, 2017		U266	M-27	AUG 06, 2006
			6239173	JUN 24, 2013			PED	NOV 20, 2004
			5474995*PED	DEC 24, 2013			PED	FEB 06, 2007
			5691374*PED	NOV 18, 2015			PED	OCT 11, 2005
			6063811*PED	NOV 06, 2017				
			6239173*PED	DEC 24, 2013				
	021256 001	SECRETIN SYNTHETIC HUMAN;CHIRHOSTIM					ODE	APR 04, 2009
							NCE	APR 09, 2009
	020990 001	SERTRALINE HYDROCHLORIDE;ZOLOFT	6727283	OCT 11, 2019	DE US80			
	020926 001	SEVELAMER HYDROCHLORIDE;RENAGEL	6509013	AUG 11, 2013				
	021179 001	SEVELAMER HYDROCHLORIDE;RENAGEL	6509013	AUG 11, 2013				
>ADD>	020632 001	SIBUTRAMINE HYDROCHLORIDE;MERIDIA	4746680	JUN 11, 2007				
>ADD>			4929629	MAY 29, 2007				
>ADD>			5436272	JUL 25, 2012		U439		
>ADD>			4746680*PED	DEC 11, 2007				
>ADD>			4929629*PED	NOV 29, 2007				
>ADD>			5436272*PED	JAN 25, 2013				
>ADD>	020632 002	SIBUTRAMINE HYDROCHLORIDE;MERIDIA	4746680	JUN 11, 2007				
>ADD>			4929629	MAY 29, 2007				
>ADD>			5436272	JUL 25, 2012		U439		
>ADD>			4746680*PED	DEC 11, 2007				
>ADD>			4929629*PED	NOV 29, 2007				

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
>ADD>		5436272*PED	JAN 25, 2013			
>ADD>	020632 003 SIBUTRAMINE HYDROCHLORIDE;MERIDIA	4746680	JUN 11, 2007			
>ADD>		4929629	MAY 29, 2007			
>ADD>		5436272	JUL 25, 2012	U439		
>ADD>		4746680*PED	DEC 11, 2007			
>ADD>		4929629*PED	NOV 29, 2007			
>ADD>		5436272*PED	JAN 25, 2013			
021110 003	SIROLIMUS;RAPAMUNE				NCE	SEP 15, 2004
					I-386	APR 11, 2006
020955 001	SODIUM FERRIC GLUCONATE COMPLEX;FERRLECIT				NPP	AUG 13, 2007
					PED	FEB 13, 2008
021196 001	SODIUM OXYBATE;XYREM	6780889	DEC 22, 2019	DP		
020280 004	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	4968299	JUN 28, 2008	DP		
020168 001	SOMATROPIN RECOMBINANT;NUTROPIN	5096885	MAR 17, 2009	DP		
020168 002	SOMATROPIN RECOMBINANT;NUTROPIN	5096885	MAR 17, 2009	DP		
020522 001	SOMATROPIN RECOMBINANT;NUTROPIN AQ	5763394	JUN 09, 2015	DP		
020522 002	SOMATROPIN RECOMBINANT;NUTROPIN AQ PEN	5763394	JUN 09, 2015	DP		
020080 001	SUMATRIPTAN SUCCINATE;IMITREX	4816470	DEC 28, 2006	U72		
		5037845	AUG 06, 2008	U72		
		4816470*PED	JUN 28, 2007			
		5037845*PED	FEB 06, 2009			
020132 001	SUMATRIPTAN SUCCINATE;IMITREX	4816470	DEC 28, 2006	U72		
		5037845	AUG 06, 2008	U72		
		6368627	MAR 02, 2012	U444		
		5863559	JAN 26, 2016	U72		
		6020001	MAR 02, 2012	U444		
		6020001*PED	SEP 02, 2012			
		6368627*PED	SEP 02, 2012			
		4816470*PED	JUN 28, 2007			
		5037845*PED	FEB 06, 2009			
		5863559*PED	JUL 26, 2016			
020132 002	SUMATRIPTAN SUCCINATE;IMITREX	4816470	DEC 28, 2006	U72		
		5037845	AUG 06, 2008	U72		
		6368627	MAR 02, 2012	U444		
		5863559	JAN 26, 2016	U72		
		6020001	MAR 02, 2012	U444		
		6020001*PED	SEP 02, 2012			
		6368627*PED	SEP 02, 2012			
		4816470*PED	JUN 28, 2007			
		5037845*PED	FEB 06, 2009			
		5863559*PED	JUL 26, 2016			
020132 003	SUMATRIPTAN SUCCINATE;IMITREX	5037845	AUG 06, 2008	U72		
		4816470	DEC 28, 2006	U72		
		6368627	MAR 02, 2012	U444		
		5863559	JAN 26, 2016	U72		
		6020001	MAR 02, 2012	U444		
		6020001*PED	SEP 02, 2012			
		6368627*PED	SEP 02, 2012			
		4816470*PED	JUN 28, 2007			
		5037845*PED	FEB 06, 2009			
		5863559*PED	JUL 26, 2016			
020626 001	SUMATRIPTAN;IMITREX	4816470	DEC 28, 2006	U72		
		5037845	AUG 06, 2008			
		5307953	DEC 02, 2012			
		5554639	SEP 10, 2013	U232		
		5705520	DEC 10, 2011	U232		

PRESCRIPTION AND OTC DRUG PRODUCT
 PATENT AND EXCLUSIVITY DATA
 See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES		
020626 002	SUMATRIPTAN; IMITREX	5554639*PED	MAR 10, 2014					
		5705520*PED	JUN 10, 2012					
		4816470*PED	JUN 28, 2007					
		5037845*PED	FEB 06, 2009					
		5307953*PED	JUN 02, 2013					
		4816470	DEC 28, 2006	U72				
		5037845	AUG 06, 2008					
		5307953	DEC 02, 2012					
		5554639	SEP 10, 2013	U232				
		5705520	DEC 10, 2011	U232				
		5554639*PED	MAR 10, 2014					
		5705520*PED	JUN 10, 2012					
		4816470*PED	JUN 28, 2007					
		5037845*PED	FEB 06, 2009					
020626 003	SUMATRIPTAN; IMITREX	5307953*PED	JUN 02, 2013					
		4816470	DEC 28, 2006	U72				
		5037845	AUG 06, 2008					
		5307953	DEC 02, 2012					
		5554639	SEP 10, 2013	U232				
		5705520	DEC 10, 2011	U232				
		5554639*PED	MAR 10, 2014					
		5705520*PED	JUN 10, 2012					
		4816470*PED	JUN 28, 2007					
		5037845*PED	FEB 06, 2009					
		5307953*PED	JUN 02, 2013					
		5859006	JAN 12, 2016	DS DP				
		6140329	JUL 11, 2016	DP U155				
		021368 001	TADALAFIL; CIALIS	5859006	JAN 12, 2016	DS DP		
6140329	JUL 11, 2016			DP U155				
5859006	JAN 12, 2016			DS DP				
021368 002	TADALAFIL; CIALIS	6140329	JUL 11, 2016	DP U155				
		5859006	JAN 12, 2016	DS DP				
		6140329	JUL 11, 2016	DP U155				
021368 003	TADALAFIL; CIALIS	5859006	JAN 12, 2016	DS DP				
		6140329	JUL 11, 2016	DP U155				
		5859006	JAN 12, 2016	DS DP				
021388 001	TALC; TALC				ODE	DEC 24, 2004		
020372 001	TECHNETIUM TC-99M TETROFOSMIN KIT; MYOVIEW	5045302	FEB 09, 2010					
021200 001	TEGASEROD MALEATE; ZELNORM				I-435	AUG 21, 2007		
021200 002	TEGASEROD MALEATE; ZELNORM				I-435	AUG 21, 2007		
021144 001	TELITHROMYCIN; KETEK	D459798	SEP 24, 2015	DP	NCE	APR 01, 2009		
021124 002	TERBINAFINE HYDROCHLORIDE; LAMISIL AT	5635485	APR 21, 2015	DS DP U578				
		5681849	OCT 28, 2014					
		4755534	DEC 30, 2006	U73				
		4680291	JUL 14, 2004	U73				
		6121314	MAY 18, 2012	U504				
		5681849	OCT 28, 2014	DP				
		6121314	MAY 18, 2012	DP U504				
		6121314	MAY 18, 2012	DP U540				
020846 001	TERBINAFINE; LAMISIL	6121314	MAY 18, 2012	DP U502				
		6005001	MAY 18, 2012	DP U540				
		6005001	MAY 18, 2012	U502				
		6005001	MAY 18, 2012	U504				
		5856355	MAY 18, 2012	DP U502				
		5856355	MAY 18, 2012	U504				
		5856355	MAY 18, 2012	U540				
		6770623	DEC 08, 2018	DP U597				
		021318 001	TERIPARATIDE RECOMBINANT HUMAN; FORTEO					

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES	
020785 001	THALIDOMIDE; THALOMID	6755784	SEP 23, 2020	U371			
020785 002	THALIDOMIDE; THALOMID	6755784	SEP 23, 2020	U371			
020785 003	THALIDOMIDE; THALOMID	6755784	SEP 23, 2020	U371			
020898 001	THYROTROPIN ALFA; THYROGEN	6365127	NOV 24, 2015	DS DP U556			
021618 001	TINIDAZOLE; TINDAMAX				NCE	MAY 17, 2009	
021618 002	TINIDAZOLE; TINDAMAX				NCE	MAY 17, 2009	
>ADD>	021395 001	TIOTROPIUM BROMIDE MONOHYDRATE; SPIRIVA	6777423	JAN 30, 2023	DS DP	NCE	JAN 30, 2009
		5610163	MAR 11, 2014	DS DP U566			
>ADD>	020912 001	TIROFIBAN HYDROCHLORIDE; AGGRASTAT	5658929	SEP 27, 2010			
>ADD>	020913 001	TIROFIBAN HYDROCHLORIDE; AGGRASTAT	5658929	SEP 27, 2010			
	021228 001	TOLTERODINE TARTRATE; DETROL LA	6770295	AUG 26, 2019	DP U544		
		6770295*PED	FEB 26, 2020				
	021228 002	TOLTERODINE TARTRATE; DETROL LA	6770295	AUG 26, 2019	DP U544		
		6770295*PED	FEB 26, 2020				
	020505 001	TOPIRAMATE; TOPAMAX	4513006	SEP 26, 2008	DS DP U83	D-88	DEC 16, 2006
		5998380	SEP 13, 2015	U598			
		6503884	OCT 13, 2015	U598			
	020505 002	TOPIRAMATE; TOPAMAX	4513006	SEP 26, 2008	DS DP U83	D-88	DEC 16, 2006
		5998380	SEP 13, 2015	U598			
		6503884	OCT 13, 2015	U598			
	020505 003	TOPIRAMATE; TOPAMAX	4513006	SEP 26, 2008	DS DP U83	D-88	DEC 16, 2006
		5998380	SEP 13, 2015	U598			
		6503884	OCT 13, 2015	U598			
	020505 004	TOPIRAMATE; TOPAMAX	4513006	SEP 26, 2008	DS DP U83	D-88	DEC 16, 2006
		5998380	SEP 13, 2015	U598			
		6503884	OCT 13, 2015	U598			
	020505 005	TOPIRAMATE; TOPAMAX	4513006	SEP 26, 2008	DS DP U83	D-88	DEC 16, 2006
		5998380	SEP 13, 2015	U598			
		6503884	OCT 13, 2015	U598			
	020505 006	TOPIRAMATE; TOPAMAX	4513006	SEP 26, 2008	DS DP U83	D-88	DEC 16, 2006
		5998380	SEP 13, 2015	U598			
		6503884	OCT 13, 2015	U598			
>ADD>	020844 001	TOPIRAMATE; TOPAMAX SPRINKLE	6503884	OCT 13, 2015	U598	D-88	DEC 16, 2006
		4513006	SEP 26, 2008	DS DP U83			
		5998380	SEP 13, 2015	U598			
>ADD>	020844 002	TOPIRAMATE; TOPAMAX SPRINKLE	6503884	OCT 13, 2015	U598	D-88	DEC 16, 2006
		4513006	SEP 26, 2008	DS DP U83			
		5998380	SEP 13, 2015	U598			
>ADD>	020844 003	TOPIRAMATE; TOPAMAX SPRINKLE	6503884	OCT 13, 2015	U598	D-88	DEC 16, 2006
		4513006	SEP 26, 2008	DS DP U83			
		5998380	SEP 13, 2015	U598			
	021257 001	TRAVOPROST; TRAVATAN	6011062	DEC 22, 2014	DP		
		5849792	DEC 22, 2014	DP U383			
		5889052	DEC 02, 2014	DP U383			
		5510383	AUG 03, 2013	DP U383			
	021272 001	TREPROSTINIL SODIUM; REMODULIN	6765117	OCT 24, 2017	DS		
	021272 002	TREPROSTINIL SODIUM; REMODULIN	6765117	OCT 24, 2017	DS		
	021272 003	TREPROSTINIL SODIUM; REMODULIN	6765117	OCT 24, 2017	DS		
	021272 004	TREPROSTINIL SODIUM; REMODULIN	6765117	OCT 24, 2017	DS		
	021595 001	TROSPIDIUM CHLORIDE; SANCTURA				NCE	MAY 28, 2009
	020675 001	URSODIOL; URSO 250	4859660	NOV 19, 2007			
	021630 001	VORICONAZOLE; VFEND	5116844	AUG 11, 2009	DP U540	NCE	MAY 24, 2007
		5364938	NOV 15, 2011	DS	I-409	NOV 14, 2006	
		5567817	OCT 22, 2013	DS DP U540			
		5773443	JAN 25, 2011	DS DP U540			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020825 001	ZIPRASIDONE HYDROCHLORIDE;GEODON	4831031	MAR 02, 2007	DS DP		
		5312925	SEP 01, 2012	DS DP		
		6150366	MAY 27, 2019	DP		
		6245766	DEC 18, 2018		U601	
020825 002	ZIPRASIDONE HYDROCHLORIDE;GEODON	4831031	MAR 02, 2007	DS DP		
		6150366	MAY 27, 2019	DP		
		6245766	DEC 18, 2018		U601	
		5312925	SEP 01, 2012	DS DP		
020825 003	ZIPRASIDONE HYDROCHLORIDE;GEODON	4831031	MAR 02, 2007	DS DP		
		5312925	SEP 01, 2012	DS DP		
		6150366	MAY 27, 2019	DP		
		6245766	DEC 18, 2018		U601	
020825 004	ZIPRASIDONE HYDROCHLORIDE;GEODON	4831031	MAR 02, 2007	DS DP		
		5312925	SEP 01, 2012	DS DP		
		6150366	MAY 27, 2019	DP		
		6245766	DEC 18, 2018		U601	
021450 004	ZOLMITRIPTAN;ZOMIG	6750237	NOV 28, 2020	DP		
		6750237*PED	MAY 28, 2021			

Footnote:

- Patents are published upon receipt by the Orange Book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(c)(3)(5).
- Patents submitted on FDA Form 3542 and listed after August 18, 2003 will have one to three patent codes indicating specific patent claims as submitted by the sponsor:
DS = Drug Substance claim
DP = Drug Product claim
U and number = Method of Use claim (may be multiple). Specific Method of use claims are listed at <http://www.fda.gov/cder/orange/patex.htm>
- Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.
- *PED and PED represent pediatric exclusivity. Patents with pediatric exclusivity granted after August 18, 2003 will be indicated with *PED as was done prior to August 18, 2003. Patents with *PED added after August 18, 2003 will not contain any information relative to the patent itself other than the *PED extension. Information related specifically to the patent will be conveyed on the original patent only.

PATENT AND EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE PATENT AND EXCLUSIVITY COLUMNS, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. PLEASE REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 24TH EDITION FOR A FULL LISTING OF PATENT AND EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). THE CUMULATIVE SUPPLEMENT WILL LIST NEW CODES ADDED SINCE THE LAST ANNUAL EDITION. THE MOST CURRENT COMPLETE LIST OF ALL PATENT AND EXCLUSIVITY TERMS IS AVAILABLE AT [HTTP://WWW.FDA.GOV/CDER/ORANGE/PATEX.HTM](http://www.fda.gov/cder/orange/patex.htm).

PATENT & EXCLUSIVITY ABBREVIATIONS

W EXCLUSIVITY ON THIS APPLICATION EXPIRING ON THIS DATE HAS BEEN WAIVED BY SPONSOR - SEE SECTION 1.8 OF ORANGE BOOK PREFACE WAIVED EXCLUSIVITY

EXCLUSIVITY DOSING SCHEDULE

D-85 LOWER RECOMMENDED STARTING DOSE GUIDELINES FOR TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH THE MENOPAUSE
 D-86 FOR USE IN SELECT EXTERNAL INSULIN PUMPS
 D-87 ADDITION OF ONCE-WEEKLY DOSING FOR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
 D-88 NEW DOSING RANGE OF 200-400MG PER DAY IN TWO DIVIDED DOSES FOR ADULTS WITH PARTIAL
 D-89 USE OF REYATAZ 300 MG/RITONAVIR 100 MG ONCE DAILY FOR TREATMENT IN HIV-INFECTED ANTIRETROVIRAL-EXPERIENCED PATIENTS
 D-90 ADDITION OF DAYTIME ADMINISTRATION TO TREAT VULVOVAGINAL CANDIDIASIS

EXCLUSIVITY INDICATION

I-417 USE IN THE LONG TERM TREATMENT OF BIPOLAR I DISORDER
 I-418 ADJUNCTIVE THERAPY W/ MOOD STABILIZERS (LITHIUM OR DIVALPROEX) IN THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDERS
 I-419 MONOTHERAPY IN THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
 I-420 TOPICAL TREATMENT OF CLINICALLY TYPICAL, NONHYPERKERATOTIC, NONHYPERTROPHIC ACTINIC KERATOSES ON THE FACE OR SCALP IN IMMUNOCOMPETENT ADULTS
 I-421 TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS AND PYELONEPHRITIS DUE TO E.COLI FOR PED PATIENTS (1-17) NOT AS FIRST CHOICE
 I-422 INDICATED FOR THE IN-HOSPITAL SHORT-TERM (UP TO 4 HOURS) REDUCTION IN BLOOD PRESSURE IN PEDIATRIC PATIENTS
 I-423 ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS
 I-424 MANAGEMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH MODERATE TO SEVERE CHRONIC RENAL INSUFFICIENCY NOT YET ON DIALYSIS
 I-425 FLOXATIN IN COMBINATION WITH INFUSIONAL 5-FLUOROURACIL (5-FU) AND LEUCOVORIN (LV) FOR THE TREATMENT OF PATIENTS PREVIOUSLY UNTREATED FOR ADVANCED COLORECTAL CANCER
 I-426 TREATMENT OF ACUTE PULMONARY EMBOLISM WHEN ADMINISTERED IN CONJUNCTION WITH WARFARIN SODIUM
 I-427 TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITHOUT PULMONARY EMBOLISM WHEN ADMINISTERED IN CONJUNCTION WITH WARFARIN SODIUM
 I-428 FOR USE IN COMBINATION WITH PACLITAXEL FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR ANTHRACYCLINE CONTAINING ADJUVANT CHEMOTHERAPY UNLESS ANTHRACYCLINES WERE CLINICALLY CONTRAINDICATED
 I-429 FOR USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH ANDROGEN INDEPENDENT (HORMONE REFRACTORY) METASTATIC PROSTATE CANCER
 I-430 FOR USE IN THE RELIEF OF THE SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS IN ADULTS
 I-431 NOSOCOMIAL PNEUMONIA AND COMMUNITY-ACQUIRED PNEUMONIA CAUSED BY STREPTOCOCCUS PNEUMONIAE INDICATION EXPANDED TO INCLUDE MULTI-DRUG RESISTANT STRAINS

- I-432 TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA CAUSED BY MULTI-DRUG RESISTANT STREPTOCOCCUS PNEUMONIAE
- I-433 TREATMENT OF BIOPSY-CONFIRMED, PRIMARY SUPERFICIAL BASAL CELL CARCINOMA IN IMMUNOCOMPETENT ADULTS, WITH A MAXIMUM TUMOR DIAMETER OF 2.0CM, LOCATED ON THE TRUNK (EXCLUDING ANOGENITAL SKIN), NECK, OR EXTREMITIES (EXCLUDING HANDS AND FEET)
- I-434 PREVENTION OF CARDIOVASCULAR DISEASE IN ADULT PATIENTS WITHOUT CLINICALLY EVIDENT HEART DISEASE, BUT WITH MULTIPLE RISK FACTORS FOR CORONARY HEART DISEASE TO REDUCE RISK OF MI AND RISK FOR REVASCLARIZATION PROCEDURES AND ANGINA
- I-435 CHRONIC IDIOPATHIC CONSTIPATION
- I-436 FOR USE IN COMBINATION WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE FOR THE ADJUVANT TREATMENT OF PATIENTS WITH OPERABLE NODE-POSITIVE BREAST CANCER
- I-437 TREATMENT OF ACUTE MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR DISORDER
- I-438 EMPIRICAL THERAPY FOR PRESUMED FUNGAL INFECTIONS IN FEBRILE, NEUTROPENIC PATIENTS

EXCLUSIVITY MISCELLANEOUS

- M-30 CHANGES TO CLINICAL PHARMACOLOGY, PRECAUTIONS, AND DOSAGE AND ADMINISTRATION SECTIONS OF LABELING CONCERNING USE OF LOTENSIN IN PEDIATRIC PATIENTS WITH HYPERTENSION
- M-31 INFORMATION FOR USE IN PEDIATRIC PATIENTS WITH CHRONIC KIDNEY DISEASE STAGE 5 (END-STAGE RENAL DISEASE)
- M-32 ADDITIONAL LANGUAGE TO CLINICAL PHARMACOLOGY AND CLINICAL STUDIES
- M-33 INFORMATION FOR USE OF ADVAIR DISKUS 100/50 IN CHILDREN 4 TO 11 YEARS OF AGE WITH ASTHMA
- M-34 EXPANDED INFORMATION TO PEDIATRIC USE SUBSECTION OF LABELING IN RESPONSE TO PEDIATRIC WRITTEN REQUEST
- M-35 ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES DONE WITH ACTOS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, OR INSULIN ADDED TO CLINICAL PHARMACOLOGY
- M-36 ADDITION OF INFORMATION TO CLINICAL STUDIES REGARDING PREVENTION OF CARDIOVASCULAR DISEASE

PATENT USE

- U-546 USE OF REPAGLINIDE IN COMBINATION WITH METFORMIN TO LOWER BLOOD GLUCOSE
- U-547 MAINTENANCE MONOTHERAPY FOR BIPOLAR DISORDER
- U-548 A METHOD OF REDUCING FLUSH IN AN INDIVIDUAL BEING TREATED FOR A LIPIDEMIC DISORDER AND EFFECTIVELY TREATING THE LIPIDEMIC DISORDER
- U-549 USE IN THE TREATMENT OF MEN WITH ADVANCED SYMPTOMATIC PROSTATE CANCER
- U-550 TREATMENT OF BIPOLAR MANIA AND SCHIZOPHRENIA
- U-551 METHOD FOR REDUCING TOXICITY OF ALIMTA TREATED PATIENTS BY ADMINISTERING FOLIC ACID
- U-552 TREATMENT OF HYPERTENSION AND HYPERLIPIDEMIA WITH A SINGLE COMPOSITION
- U-553 MANAGEMENT OF PAIN AND DISCOMFORT ASSOCIATED WITH PERIDONTAL SCALING AND ROOT PLANNING PROCEDURES BY APPLICATION OF AN EUTECTIC MIXTURE OF LOCAL ANESTHETICS TO PERIDONTAL POCKETS
- U-554 TREATING HIV INFECTION WITH INDINAVIR SULFATE IN COMBINATION WITH ANTIRETROVIRAL AGENTS
- U-555 TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS AND ACUTE UNCOMPLICATED PYELONEPHRITIS
- U-556 USE AS ADJUNCT DIAGNOSTIC FOR SERUM THYROGLOBULIN (TG) TESTING
- U-557 NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS
- U-558 INDICATED FOR THE RELIEF OF BRONCHOSPASM IN PATIENTS 2-12 YEARS OF AGE WITH ASTHMA (REVERSIBLE OBSTRUCTIVE AIRWAY DISEASE)
- U-559 METHOD OF DECREASING OR REDUCING PARATHYROID HORMONE LEVEL; METHOD OF MODULATING PARATHYROID HORMONE SECRETION; METHOD OF TREATING HYPERPARATHYROIDISM; METHOD OF REDUCING SERUM IONIZED CALCIUM LEVEL
- U-560 METHOD OF DECREASING PARATHYROID HORMONE LEVEL; METHOD OF TREATING HYPERPARATHYROIDISM
- U-561 COSOPT IS INDICATED FOR THE REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION WHO ARE INSUFFICIENTLY RESPONSIVE TO BETA BLOCKERS
- U-562 TOPICAL TREATMENT OF CUTANEOUS LESIONS IN PATIENTS WITH AIDS-RELATED KAPOSI'S SARCOMA
- U-563 MARINOL IS INDICATED FOR, INTER ALIA, ANOREXIA ASSOCIATED WITH WEIGHT LOSS IN PATIENTS WITH AIDS
- U-564 TREATMENT OF HIV IN CONCOMITANT THERAPY
- U-565 TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS, AND CHRONIC URTICARIA
- U-566 FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND

- EMPHYSEMA
- U-567 METHOD OF TREATING INFERTILITY
 - U-568 METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION
 - U-569 METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION AND WHEREIN THEREAFTER AN OVULATORY INDUCING AMOUNT OF HCG IS ADMINISTERED
 - U-570 METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION AND WHEREIN THE DAILY AMOUNT OF FSH IS ABOUT 5-10 IU/KG
 - U-571 TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA AND BIPOLAR I MANIA
 - U-572 INTENSIVE CARE UNIT SEDATION
 - U-573 TREATMENT OF ACUTE PROMYELOGENOUS LEUKEMIA (APL)
 - U-574 PROPHYLAXIS AND TREATMENT OF THE NASAL SYMPTOMS OF SEASONAL ALLERGIC RHINITIS AND TREATMENT OF THE NASAL SYMPTOMS OF PERENNIAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
 - U-575 LOTEMAX IS INDICATED FOR STEROID-RESPONSIVE INFLAMMATORY OCULAR CONDITIONS FOR WHICH A CORTICOSTEROID IS INDICATED AND WHERE SUPERFICIAL BACTERIAL OCULAR INFECTION OR A RISK OF BACTERIAL OCULAR INFECTION EXISTS
 - U-576 ALREX IS INDICATED FOR STEROID-RESPONSIVE INFLAMMATORY OCULAR CONDITIONS FOR WHICH A CORTICOSTEROID IS INDICATED AND WHERE SUPERFICIAL BACTERIAL OCULAR INFECTION OR A RISK OF BACTERIAL OCULAR INFECTION EXISTS.
 - U-577 TREATMENT OF BENIGN PROSTATIC HYPERTROPHY WITH FINASTERIDE IN COMBINATION WITH DOXAZOSIN
 - U-578 TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA, ACUTE EXACERBATION OF CHRONIC BRONCHITIS, AND ACUTE BACTERIAL SINUSITIS CAUSED BY SUSCEPTIBLE STRAINS OF DESIGNATED MICROORGANISMS IN PATIENTS 18 YEARS AND OLDER.
 - U-579 TREATMENT OF EPILEPSY AND/OR MIGRAINE.
 - U-580 TREATMENT OF DISORDERS OF THE SEROTONERGIC SYSTEM SUCH AS DEPRESSION AND ANXIETY-RELATED DISORDERS
 - U-581 METHOD OF TREATING A CONDITION CAPABLE OF TREATMENT BY INHALATION, E.G. ASTHMA, COMPRISING ADMINISTRATION OF A FORMULATION CLAIMED IN US PATENT NO. 6743413
 - U-582 METHOD FOR THE TREATMENT OF A RESPIRATORY DISORDER, E.G. ASTHMA, COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF AN AEROSOL COMPOSITION TO A PATIENT FROM A METERED DOSE INHALER SYSTEM AS CLAIMED IN US PATENT NO. 6253762
 - U-583 METHOD FOR THE TREATMENT OF A RESPIRATORY DISORDER, E.G. ASTHMA, COMPRISING ADMINISTERING TO A PATIENT BY INHALATION, A METERED AEROSOL DOSE OF A DRUG FORMULATION FROM THE METERED DOSE INHALER SYSTEM CLAIMED IN US 6546928
 - U-584 SINGLE-DOSE ADMINISTRATION BY THE EPIDURAL ROUTE, AT THE LUMBAR LEVEL, FOR THE TREATMENT OF PAIN FOLLOWING MAJOR SURGERY
 - U-585 TO PROMOTE WEIGHT GAIN AFTER WEIGHT LOSS IN CERTAIN TYPES OF PATIENTS
 - U-586 AN INTERMEDIATE RELEASE NICOTINIC ACID FORMULATION SUITABLE FOR ORAL ADMINISTRATION ONCE-A-DAY AS A SINGLE DOSE FOR TREATING HYPERLIPIDEMIA WITHOUT CAUSING DRUG-INDUCED HEPATOTOXICITY OR ELEVATIONS IN URIC ACID OR GLUCOSE OR BOTH
 - U-587 USE OF EPLERENONE IN COMBINATION WITH AN ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITOR (AND OPTIONALLY A DIURETIC) FOR TREATING CONGESTIVE HEART FAILURE AND HYPERTENSION
 - U-588 SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER; TREATMENT OF HEARTBURN AND OTHER SYMPTOMS ASSOCIATED WITH GERD; SHORT-TERM TREATMENT OF EROSIIVE ESOPHAGITIS; MAINTENANCE OF HEALING OF EROSIIVE ESOPHAGITIS
 - U-589 METHOD FOR TREATMENT OF A RESPIRATORY DISORDER, E.G., BRONCHOSPASM, COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF AN AEROSOL COMPOSITION TO A PATIENT FROM A METERED DOSE INHALER SYSTEM AS CLAIMED IN U.S. PATENT NO. 6131966
 - U-590 METHOD FOR TREATMENT OF A RESPIRATORY DISORDER, E.G., BRONCHOSPASM, COMPRISING ADMINISTERING TO A PATIENT BY ORAL OR NASAL INHALATION A DRUG FORMULATION BY USING THE METERED DOSE INHALER SYSTEM AS CLAIMED IN US PATENT NO.6532955
 - U-591 TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER USING A DOSAGE FORM WHICH PROVIDES ONCE-DAILY ORAL ADMINISTRATION OF A PHENIDATE DRUG
 - U-592 TREATMENT OF PRIMARY HYPERCHOLESTEROLEMIA, MIXED HYPERLIPIDEMIA AND/OR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFA)
 - U-593 TREATMENT OF PRIMARY HYPERCHOLESTEROLEMIA, MIXED HYPERLIPIDEMIA AND/OR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH)
 - U-594 PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
 - U-595 35 MG ORALLY ONCE A WEEK FOR PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN; 35 MG ORALLY ONCE A WEEK FOR TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
 - U-596 TREATMENT OF HORMONE RECEPTOR POSITIVE METASTATIC BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH DISEASE PROGRESSION FOLLOWING ANTIESTROGEN THERAPY
 - U-597 FORTEO IS INDICATED FOR THE TREATMENT OF POST MENOPAUSAL WOMEN WITH OSTEOPOROSIS WHO ARE AT HIGH RISK FOR FRACTURE
 - U-598 PROPHYLACTIC TREATMENT OF MIGRAINE
 - U-599 METHOD FOR TREATING ALLERGIC CONJUNCTIVITIS

- U-600 A METHOD OF TREATING A PATIENT IN NEED OF OPHTHALMIC ANTIMICROBIAL THERAPY WITH LEVOFLOXACIN
- U-601 TREATMENT OF BIPOLAR DISORDERS
- U-602 SIGNS AND SYMPTOMS OF OSTEOARTHRITIS, RHEUMATOID ARTHRITIS IN ADULTS, AND/OR PAUCIARTICULAR OR POLYARTICULAR COURSE JUVENILE RHEUMATOID ARTHRITIS, ACUTE PAIN IN ADULTS; PRIMARY DYSMENORRHEA; AND/OR ACUTE MIGRAINE ATTACKS IN ADULTS
- U-603 METHOD OF TREATING INFECTIONS COMPRISING ORALLY ADMINISTERING AN EFFECTIVE AMOUNT OF THE FDA APPROVED ORAL SUSPENSION
- U-604 METHOD OF LOWERING BLOOD GLUCOSE BY ONCE DAILY ADMINISTRATION
- U-605 TREATMENT OF MAJOR DEPRESSIVE DISORDER(MDD);ALTHOUGH THE MECHANISM OF THE ANTIDEPRESSANT ACTION OF DULOXETINE IN HUMANS IS UNKNOWN, IT IS BELIEVED TO BE RELATED TO ITS POTENTIATION OF SERATONERGIC AND NORADRENERGIC ACTIVITY IN THE CNS

